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Abstract 
 
Background  
Asthma is a public health problem in Latin America, where asthmatic children are 
mainly treated at emergency rooms during acute attacks. These attacks result in 
loss of lung function and quality of life for the asthmatic child and family, risk of 
death and high direct and indirect economic costs. In order to improve paediatric 
asthma management in Esmeraldas, Ecuador, we aimed to identify predictors of 
recurrent asthma attacks requiring emergency care and to explore the caregivers’ 
(CGs) and health care workers’ (HCWs) perceptions of barriers and facilitators to 
asthma health and home care access. 
Methods  
First, a systematic review and meta-analysis of published studies analysing 
predictors for emergency department (ED) re-attendance or hospital 
readmission for acute asthma in children was performed. Second, a prospective 
cohort study of children treated for an asthma attack at an emergency room in 
Esmeraldas, Ecuador, was undertaken to define the characteristics of these 
children, determine the rate of ED re-attendance for acute asthma and identify 
the predictors for this to occur. Third, a qualitative study to explore acute asthma 
significance and perceived barriers and facilitators for health and home care 
access from the asthmatic children’s CGs’ and HCWs’ perspective was performed. 
Results 
In both the meta-analysis and prospective cohort study, children of a younger age 
and a history of severe asthma attacks during the previous year were at a greater 
risk of ED re-attendance for acute asthma. Forty six percent of the children 
                                                                          
XI 
 
recruited during the prospective cohort suffered a subsequent asthma attack 
requiring emergency care in the following 6 months. Other identified predictors 
of ED re-attendance for acute asthma were: existing asthma diagnosis (AOR: 2.17, 
95% CI: 1.19-3.94; AHR: 1.66, 95% CI: 1.15-2.39); food triggers (AOR: 1.99, 95% 
CI: 1.11-3.55); existing eczema diagnosis (AOR: 4.22, 95% CI 1.02-17.54); and 
urban residence as protective (AHR: 0.69, 95% CI: 0.50-0.95). 
Twelve HCWs and 20 CGs participated in the in-depth interviews and focus group 
discussions, expressing a differing significance of asthma attacks. This difference 
was also observed between experienced and inexperienced HCWs.  Multiple 
barriers and several facilitators were identified by HCWs and CGs that affect 
health and home care access for asthmatic children. When shown the predictors 
of ED-reattendance for acute asthma combined in a risk-assessment tool, both 
HCWs and CGs reported finding the tool easy to use and understand, as well as a 
useful aid in the decision-making process concerning asthma treatment and 
follow-up. 
Conclusion 
A combination of several question-based predictors may result in an effective and 
simple risk-assessment tool to be used at the ED to identify asthmatic children at 
a higher risk of recurrent severe asthma attacks. Increasing CGs’ and HCWs’ 
asthma knowledge as well as HCWs’ communication skills, to establish a patient-
centred approach with a shared decision-making process could mean a difference 
in the quality of the asthma care in this setting. The use of the described 
recurrent risk assessment tool could prove useful in this process, as reported by 
the participants in this study. 
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1. Introduction 
Over 330 million people are affected by asthma worldwide, according to the 
latest Global Asthma Report. Asthma is the most common chronic disease in 
children, and up to 14% of the world’s children have experienced asthma 
symptoms in the last year1. Although asthma prevalence may have reached a 
plateau in developed countries with high rates, such as the UK or New Zealand, 
global asthma prevalence is still rising, mainly due to a more recent increase in 
developing countries2. This is the case of some Latin American countries, such as 
Brazil or Costa Rica, where current asthma rates are now as high as in 
traditionally high prevalence countries2. 
 
Traditionally asthma severity has been classified according to daily symptom 
control, and questionnaires have been developed and validated to assess this, 
such as the Asthma Control Test3, which has been also adapted for children (C-
ACT)4. Consequently, daily symptoms are the focus of treatment guidelines, and 
physicians have used asthma control questionnaires to make treatment 
adjustments. However, current guidelines5,6 have included the concept of ‘future 
risk’ to define asthma severity and control, referring to the risk of adverse events 
such as acute exacerbations and loss of lung function. Children with well-
controlled asthma are still at risk of developing severe, life-threatening, acute 
asthma attacks7. 
An asthmatic exacerbation is an acute or subacute worsening of respiratory 
symptoms and lung function. It can be either mild or severe, the latter defined in 
the last American Thoracic Society (ATS) and European Respiratory Society 
(ERS) 2009 statement, as an event that requires systemic corticosteroids (for at 
1.1 Background
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least 3 days) and emergency department attendance or hospital admission8. 
Asthma exacerbations are still common9 and are associated with high healthcare 
costs 10 as well as missed school and workdays. These acute events are especially 
relevant among children in whom they are extremely common, often following a 
viral respiratory tract infection11,12. Asthma acute attacks are also a cause of great 
anxiety in patients13 due to the potential severe complications, risk of death and 
long-term effects such as loss of lung function14. 
  
Asthma attacks are generally preventable, either by avoiding previously 
identified triggers (acute respiratory infections, aeroallergen exposure, etc.) or 
by appropriate preventive treatment. Although exacerbations may occur despite 
the use of inhaled corticosteroids15, these may still reduce the number of overall 
exacerbations by 40% when compared to other anti-inflammatory treatments 
such as leukotriene receptor antagonist7, as well as attenuate the decline in lung 
function associated with acute exacerbations16. It is therefore important to be 
able to identify patients at risk of further attacks and hospital admission to 
provide additional education and support or adjustments to treatment. Strategies 
to reduce such risks among underprivileged populations through the provision of 
inhaled corticosteroids through the public health system have been done with 
considerable success in research programmes such as Pro-AR in Salvador, 
Brazil17. 
Even though uncontrolled symptoms are a risk factor for asthma exacerbations18, 
the adequate management of daily symptoms does not guarantee an absence of 
acute attacks19. Therefore, asthma control questionnaires based on daily 
symptoms, such as those previously mentioned, have limited utility for the 
prediction of individual risk of exacerbations20; for example, a study including 
more than 7000 patients found current control was not associated with the risk 
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of a future asthma attack after controlling for potential confounders in a 
multivariable model21. In addition, health care workers may not rely on 
subjective evaluations of asthma control, as airflow obstruction perception varies 
between patients22. A tool to enable clinicians to identify asthmatic children at a 
greater risk of suffering repeated acute exacerbations would be extremely useful 
to optimise treatment strategies and address modifiable risk factors. This is 
especially relevant when treating patients with discordant manifestations of 
asthma, such as few daily symptoms but evidence of active eosinophilic 
inflammation in the airways and therefore a high risk of exacerbations, and vice 
versa23. All in all, individualised therapies reduce the patient’s risk of adverse 
reactions from asthma medications they may not even need. This fact is even 
more important in resource poor settings, where access to specialised health care 
and treatment is limited24. 
 
Asthma has been described as a public health problem in Latin America25, not 
only due to its high prevalence, but also to the significant associated morbidity 
and mortality. There is an important under-diagnosis of asthma because of the 
limited availability of clinical expertise and lung function measurements outside 
private health care in the main urban centres. As for asthma treatment, essential 
drugs are not usually available or affordable, and long-term medications are 
rarely prescribed26,27. These factors are aggravated by a low rate of compliance 
with medication. Finally, adequate follow-up of diagnosed asthma is 
uncommon28. As a result, asthmatic patients are treated mainly in emergency 
health services during their acute attacks, with a poor control of daily symptoms 
and exacerbations. The lack of appropriate asthma management causes an 
1.2 Starting points 
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increase of indirect (e.g. loss of hours from work and school) and direct (e.g. use 
of emergency services and quick-relief medications) costs24.  
There is scarce data regarding asthma prevalence in Ecuador. In the 2004 GINA 
burden report, 16% of the Ecuadorian population had self-reported current 
asthma symptoms29, while 0.8% prevalence of recent wheezing amongst children 
aged 8-12 years old was found in a rural setting in the ISAAC phase II study30.  As 
described in other Latin American countries31,32, asthma cases in Ecuador may be 
concentrated in growing and overpopulated cities such as the city of Esmeraldas, 
while rural populations may have  a much lower prevalence33. 
Esmeraldas is the capital city of the province of Esmeraldas, one of the poorest 
provinces in Ecuador situated on the northern coast. There is an important lack 
of adequate asthma management and control in Ecuador, as reflected in a pilot 
study we carried out in Esmeraldas city: only 20% of 60 cases recruited from the 
emergency department with an acute asthma attack had visited a doctor during 
the last year for a regular review of their asthma, whilst 86% had attended the 
emergency department at least once in this same period34. None of these children 
were receiving long-term inhaled corticosteroids, even though 53% had 4 or 
more acute exacerbations in the previous year34.  
 
1.3.1. Hypothesis  
We hypothesised that a risk assessment tool could be designed that encompassed 
those parameters shown to be associated with future risk of emergency care re-
attendance due to an asthma attack in a low resource setting. Such a tool should 
be simple to administer and should be of direct benefit to patients and clinicians, 
guiding shared decision-making about subsequent lifestyle and therapeutic 
1.3. Hypothesis, aims and objectives 
                                                                          Chapter 1 | Introduction 
5 
 
choices. It could also be useful as a standardised measure of future risk for 
asthma control in children living in other low and middle-income countries in the 
near future. 
1.3.2. Aims  
The overall aims of this thesis were to investigate the factors associated with 
emergency care re-attendance for acute asthma exacerbations in children in the 
city of Esmeraldas (Ecuador), to combine these factors into a risk score that 
provided an individual-level assessment of the likelihood of future emergency 
attendances with acute asthma, as well as to explore the meanings of acute 
asthma, the barriers and facilitators for asthma health care access and the 
behaviours and beliefs towards the use of such a risk score, from the caregivers 
and health care workers perspective. 
1.3.3. Objectives 
The specific objectives of the study are: 
- To describe and critically appraise study designs and methods that have 
been used to analyse factors associated with subsequent asthma exacerbations 
that require emergency care amongst children. 
- To identify factors related to a future risk of re-attendance to emergency 
care due to asthma exacerbations, and to quantify their influence. 
- To describe the characteristics of children attending emergency care 
with bronchodilator-responsive wheeze in Esmeraldas, Ecuador. 
- To estimate the proportion of children attending emergency care with 
bronchodilator-responsive wheeze who recur with a subsequent severe asthma 
exacerbation requiring emergency care in the following 6 months in Esmeraldas, 
Ecuador. 
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- To determine the factors associated with emergency care re-attendance 
for later asthmatic exacerbations in children, in Esmeraldas, Ecuador. 
 - To use this cohort of children to design an instrument to provide an 
assessment of the risk of future asthma exacerbations requiring emergency care 
re-attendance in Esmeraldas, Ecuador, and thus assist with decision-making 
regarding lifestyle modifications, medication use, and tertiary referral. 
- To explore the meanings of acute asthma attacks and their recurrence, 
in children from the caregivers’ and health care workers’ perspective, in 
Esmeraldas, Ecuador. 
- To describe the barriers that limit health care access and home care and 
facilitators, in children with recurrent asthma exacerbations, from the caregivers’ 
and health care workers’ perspective, in Esmeraldas, Ecuador.  
- To describe behaviours and beliefs towards the use of a recurrent 
asthma attack risk assessment tool in asthmatic children with recurrent asthma 
attacks, from the caregivers’ and health care workers’ perspective, in Esmeraldas, 
Ecuador. 
 
Chapter 1 holds the project’s starting points, aims and objectives. In Chapter 2, an 
extensive review of the literature concerning asthma and its management, acute 
asthma attacks, and Ecuadorian health system, is introduced. Chapter 3 includes 
a Systematic Review and Meta-analysis of predictors of emergency care re-
attendance for acute asthma.  
Chapter 4 describes a prospective cohort study analysing predictors for 
emergency care re-attendance for acute asthma in Esmeraldas, Ecuador. Chapter 
1.4. Outline of thesis
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5 refers to a qualitative study of acute asthma significance, barriers and 
facilitators for health care access for asthmatic children and opinions regarding 
the use of a recurrent asthma attack risk assessment tool, from the health care 
workers’ and caregivers’ perspective.  
In Chapter 6, the potential implementation and intervention strategies and main 
conclusions are discussed. 
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2. Literature review 
The term asthma derives from the Greek word for ‘panting’ (ἅσθμα), originally 
used by Hippocrates to describe a specific respiratory problem in 450 B.C35. 
Asthma is a chronic inflammatory disease of the airways characterised by the 
presence of respiratory symptoms, reversible airflow obstruction and airway 
hyperresponsiveness6,36. The respiratory symptoms include cough, wheeze, 
shortness of breath and chest tightness37. These symptoms, together with the 
characteristic expiratory airflow limitation, are highly variable in intensity and 
time, depending on the exposure to certain environmental factors (such as viral 
respiratory infections, allergens, irritants and cold temperatures) or exercise37. 
An important characteristic of asthma is the partial or total reversibility of the 
airflow obstruction either spontaneously or in response to treatment6. The 
interaction between the main features of asthma (symptoms, airway obstruction, 
hyperresponsiveness and inflammation) may determine the severity and clinical 
manifestations, as well as the response to treatment6. Common to all forms of 
asthma are episodes of acute worsening of respiratory symptoms and lung 
function that are normally referred to as acute asthma exacerbations or asthma 
attacks. 
 
 
2.1. Definition of asthma
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2.2.1. Prevalence 
According to the 2014 Global Burden of Disease study, undertaken in 2008-2010, 
an estimated 334 million people have asthma1 and 14% of the world’s children 
suffer asthma symptoms38. Even though there is a high variability in asthma 
prevalence between different regions37 (1-18%,) it is no longer considered a 
disease of high-income countries. 
There has been a growing interest in defining asthma prevalence over recent 
decades, with multiple studies conducted worldwide. However, definitions used 
to assess asthma prevalence varied greatly between studies, precluding adequate 
comparisons39. To overcome these limitations, the International Study of Asthma 
and Allergy in Childhood (ISAAC) was undertaken. The study comprised 
standardised definitions and methodology and was carried out in 155 centres in 
56 countries in 1992-6 (Phase I), including a total of 463 801 children 13-14 
years old and 257 800 children 6-7 years old40. This worldwide study was 
followed by a Phase III completed 5-10 years later (2000-2003) in 106 centres in 
56 countries with 304 679 13-14-year-old children, and in 66 centres in 37 
countries with 193 404 6-7-year-old children2. The main definitions used were: 
current wheeze (“wheezing in the last 12 months’’), lifetime asthma (“ever had 
asthma”) and severe asthma (≥4 attacks of wheezing in the previous 12 
months”)39. To date, these have been the most extensive international surveys 
performed to assess asthma symptom prevalence in childhood. 
 
 
 
2.2. Global burden of asthma
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Figure 2.1: World map of prevalence of clinical asthma (2004) 
 
Source: Masoli et al, Allergy, 200429.  
Key findings from the ISAAC Phase I, revealed a high asthma prevalence in 
Anglophone countries (United Kingdom, Australia, New Zealand and US) and 
Western Europe, as expected40. More surprising were the high asthma symptoms 
rates found in certain Latin American countries, such as, Peru, Costa Rica and 
Brazil40. Prevalence of asthma symptoms was much lower in Africa, Eastern 
Europe and Asia, except for more industrialised countries like Japan and 
Singapore. Phase III enabled a time-trend analysis of asthma prevalence, 
revealing a slight worldwide increase (from 13.2% to 13.7%)2 . Highly relevant 
were the different regional patterns found, with a slight decrease in the regions 
with the previous highest rates, like Oceania, and an increase in some of the low 
prevalence regions. Exceptions to these were countries such as Albania and India, 
which remained low throughout the two phases of the study, and certain Latin 
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American countries with a relatively high prevalence in Phase I and an important 
increase in Phase III (Costa Rica, Panama, Mexico, Argentina and Chile)2. We may 
therefore conclude that the global burden of asthma in children is still rising 
while differences between regions are lessening.    
The use of current wheeze as a proxy for asthma has been widely validated41 and 
has a sensitivity of 0.58-0.88 and specificity of 0.64-0.95 for doctor’s diagnosis of 
asthma in children35. Nevertheless, it may represent certain limitations related to 
differences in understating or translation of the term ‘wheeze’ as was reflected in 
the discrepancies found between the written and the video questionnaire results 
in the ISAAC study, with lower positive responses in the latter2. However, this 
may not affect global and regional patterns, especially as there was a good 
correlation between ‘current wheeze’ and ‘severe asthma’2,38.  On the other hand, 
given the diverse access to health care in different countries, ‘current wheeze’ 
may be a more consistent definition to use compared to physician-diagnosed 
asthma.  
As wheezing may be present in other respiratory diseases and self-reported 
current mild wheezing may not be diagnostic of clinical asthma, Masoli et al29 
used an arbitrary figure to estimate ‘clinical asthma’ prevalence in children of 
50% of the prevalence of ‘current wheeze’. This figure appears to be the best 
current estimate and seems to correlate well with certain findings, e.g., the 
prevalence of a positive response to the video sequence of wheezing was around 
50% of ‘current wheeze’ in the written ISAAC questionnaire29. All in all, ‘current 
wheeze’ has been globally accepted as the most accurate term to use in 
epidemiological studies analysing asthma prevalence.   
The location of the participating centres in epidemiological studies is also 
something to bear in mind, given the higher asthma prevalence in urban versus 
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rural settings. Countries with only one centre may not be representative of the 
national prevalence29. Another limitation associated with multi-national studies 
is the difference in expertise in developing large population surveys between 
centres and collaborators2.  
Over-diagnosis of asthma is an issue that should be adequately addressed, now 
that access to health care and diagnosis is increasing worldwide. A recent study 
from Canada revealed that one third of adults with physician-diagnosed asthma 
were misdiagnosed and could be weaned from their asthma medications42. 
Similarly, studies from primary care have shown that around one third of adults 
with an asthma diagnosis do not present evidence of airflow obstruction or 
bronchial hyperresponsiveness43,44. This should also be considered when 
evaluating asthma prevalence worldwide. 
Updated large international population surveys are needed to assess the current 
prevalence of asthma both regionally and worldwide, as the data previously 
described is already more than 10 years old. The Global Asthma Network is 
planning to undertake these studies, which will hopefully contribute to a better 
understanding of the evolution of this important disease.  
2.2.2. Morbidity and mortality 
An estimated 489 000 deaths worldwide were caused by asthma in 2013 (8 age-
standardised deaths per 100.000), 0.89% of all-cause global deaths45.  
Asthma is not only a cause of mortality, but of morbidity, and a standard way to 
measure the loss of quality of life together with mortality due to a disease is the 
‘disability adjusted life-year (DALY). This measure is the sum of the years lived 
with disability (YLD) and the years of life lost to premature death (YLL), and one 
DALY is equivalent to the loss of one year of healthy life.  
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Figure 2.2: Components of disability adjusted life years (DALYs): years lived 
with disability (YLD) and years of life lost (YLL) per 100,000 population 
attributed to asthma by age group. Global population, 2010.  
 
 
 
 
 
 
Source: Global Asthma Network, Global Asthma Report, 20141. 
 
The number of DALYs lost due to asthma worldwide has been estimated to be 
currently about 22 million per year (326.4 age-standardised DALYs per 
100.000)45. This represents a 1% of the total DALYs for all causes and is similar to 
that caused by meningitis, protein-energy malnutrition or hypertensive heart 
disease45. However, children are one of the most affected age groups: asthma 
represents 1.79% of total DALY’s for all causes in the 5-14 years old group45 
(Figure 2.2). As represented on Figure 2.2, disability is the most important 
component of asthma burden in children and young adults. It is estimated that 
asthma is the 14th most important disorder accounting for years lived with 
disability, and this affects children and adolescents (5-19-year-old) above all age 
groups1.  This burden of disease due to asthma is, nevertheless, unequally 
distributed, with a greater burden in high prevalence regions such as Australia, as 
well some low and middle-income regions with a lower prevalence (Figure 2.3). 
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Figure 2.3. Disability adjusted life years (DALYs) per 100,000 population 
attributed to asthma by country, both sexes, 2010. 
 
 
 
 
 
 
 
 
Source: Global Asthma Network, Global Asthma Report, 20141. 
 
It is important to highlight that around 75-90% of asthma morbidity and 
mortality appears easily preventable with an adequate management that includes 
medical treatment and lifestyle modifications7. However, physicians treating 
asthmatic patients are identifying rather poorly who is at risk of asthma 
morbidity and mortality46 and basic recorded features do not seem to assist in 
the identification of mortality risk due to asthma47.  
During the last three decades, asthma prevalence has increased worldwide48, 
currently affecting over 300 million people29. Asthma is a highly complex disease, 
as a result of an intricate gene-environment interaction. An extensive number of 
risk factors for the development of asthma have been analysed over the last 30 
years, in the search for primary interventions to reduce the burden of asthma. 
However, these associations are not always straightforward when studying 
2.3. Risk factors
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asthma, showing contradictory results49. This might be in part due to the 
different asthma phenotypes and its complex natural history, which complicates 
the study of individual risk factors50.  
Asthma risk factors may be divided into different groups, according to the 
moment in life they may play a role (intra-uterus, early life, childhood or 
adulthood) as well as to their characteristics. As shown in Figure 2.4 they may 
include genetic, epigenetic, environmental and behavioural factors. The risk of 
developing asthma may vary over time depending on the different risk factors 
they are exposed to. 
Figure 2.4: Schematic illustrating risk of developing symptomatic asthma 
trajectories for two individuals  
 
 
 
 
 
 
 
 
 
 The crosses indicate the risk for each influence, and the arrows indicate the 
individual’s total risk. One individual is shown in red, the other in blue.  
Source: Modified from Blakey et al, Clinical & Experimental Allergy, 201451 
 
2.3.1. Genetics and epigenetics 
There exists a clear genetic predisposition (family history of asthma) for asthma 
risk, though the specific genetic transmission is still not well understood. Asthma 
genetics is highly complex, and for the moment, more than 100 genes have been 
described as possible contributors to asthma manifestations52-54. These genes are 
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involved in different aspects of the disease, such as primary disease conferring 
risk, severity and treatment response55. 
Epigenetics encompasses all the mechanisms that affect or regulate gene 
expression. The term was first introduced in the 1950’s by C.H. Wadding to 
describe the mechanisms involved in cell differentiation from pluripotent stem 
cells56. Epigenetics regulates inflammation in asthma and specific mechanisms 
have been described, such as DNA methylation and histone modifications at the 
Th2 locus control region, which may be responsible for the Th1/Th2 imbalance57. 
These epigenetic mechanisms may be induced by environmental exposures and it 
may alter the epigenome enabling its transmission through generations, what is 
known as transgenerational inheritance of epigenetic traits57. For example, 
tobacco smoke and airway pollution have been shown to cause DNA 
methylation58,59. This would explain how a persistent change in an environmental 
exposure increases the baseline risk of asthma exponentially, as it induces 
transmittable epigenetic changes inducing an amplification of the phenotypes at 
each generation57 (Figure 2.5). Epigenetics is therefore the bridge between 
genetic and environmental risk factors for asthma. 
Figure 2.5: Epigenetic transgenerational inheritance model  
 
 
 
 
 
Source: Begin et al, Allergy, Asthma & Clinical Immunology, 201457 
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2.3.2. Environmental 
Hygiene hypothesis  
Until the 1990’s this increased asthma rate was mainly seen in industrialised 
countries, and it was explained by what is known as the ‘hygiene hypothesis’. 
According to this hypothesis a diminished exposure to certain microorganisms 
during the early years of life, may increase the risk of developing allergic 
diseases60. It was first described in 1989 when Strachan et al.61 demonstrated a 
reduced rate of hay fever amongst families with a higher number of siblings, and 
it has been used for many years to explain the lower rates of asthma in rural 
populations and farming environments62. 
The immunological mechanisms underlying the hygiene hypothesis are still 
under debate. The original concept pictured a skewed T cell differentiation 
towards a T helper 2 (Th2) pro-allergic response because of a diminished T 
helper 1 (Th1) stimulus, caused by certain bacteria and viruses63. However, this 
did not explain the increase in prevalence of other chronic inflammatory Th1-
mediated diseases such as Type 1 diabetes or multiple sclerosis, or the protective 
effect of helminth infestation, associated to a Th2-type response63. Advances in 
immunology have identified certain immunoregulatory cells such as regulatory T 
cells (Treg) and regulatory cytokines such as IL-10 and TGF-B, which may exert 
negative feedback over Th1 and Th2 cells. A defect in this feedback circuit could 
induce either a Th1- or Th2-mediated inflammatory chronic disorder64. 
Therefore, another possible explanation for the hygiene hypothesis is that certain 
environmental organisms, such as those present in the gut microbiota, nasal 
colonizers or intestinal helminths, are responsible for driving Treg cells and 
consequently, a reduced or altered exposure to these microorganisms may lead 
to chronic inflammatory diseases64. In addition, inflammation caused by other 
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diseases such as obesity or metabolic syndrome, may drive changes in the 
microbiome, worsening the severity of asthma symptoms. 
Even though the hygiene hypothesis may not be the only explanation for 
increasing asthma prevalence, it is reasonable to blame changes in environmental 
exposures for the increase in asthma prevalence occurred over such a short 
period of time, as well as an improved diagnosis and greater access to health 
care. Several studies have demonstrated a reduced risk of atopy and allergic 
diseases associated to farming environments65, helminth infestations66and having 
older siblings67 In a similar way, endotoxin exposure was found to increase the 
risk for wheeze in younger children but act as a protective factor for asthma in 
older children in a recent meta-analysis of observational studies from developed 
countries68.  
Recent findings by Stein et al.69 have shown that the high endotoxin levels found 
in Amish house dust may partly explain the low prevalence of asthma and allergic 
sensitization among this population. Airways hyperreactivity was significantly 
inhibited in mice after instillation of dust extracts from Amish homes. The same 
did not happen when using dust extracts from Hutterite homes, an agricultural 
population very similar to the Amish population, except that they use 
industrialized farming practices with limited contact with farm animals and that 
they present high rates of asthma and allergic sensitization, comparable to the 
rest of the US population. This study showed that the protective effect of the 
Amish environment required the activation of innate immune signalling and 
suggested that asthma susceptibility may be increased as a consequence of a 
weak innate immune stimulation69. This study is highly relevant to better 
understand the main role of the innate immune system in the development of 
asthma. 
                                                                          Chapter 2 | Literature review 
19 
 
Intra-utero and peri-natal exposures  
Peri-natal factors such as pre-term birth or low birth weight70 and being born by 
caesarean section71 have been associated with an increased asthma risk. 
Together with this, there is now increasing evidence that in-utero exposure to 
certain environmental exposures such as tobacco smoke, antibiotics72, 
paracetamol73 or maternal stress74 may also increase the risk of asthma in 
offspring.  
Early-life exposures  
Multiple environmental factors in early life have been associated with asthma 
risk: exposure to tobacco75 and biomass smoke76, health inequalities due to low 
socioeconomic status leading to poorer health and higher stress77, early-life 
respiratory viral infections (especially Respiratory Syncytial Virus (RSV) and 
rhinovirus)78, body-mass index79,80, sedentary lifestyle80, diet (salt, trans fatty 
acids and fast-foods)81,82, exposure to dampness and mould83, rhinitis and 
sinusitis84,85. Urbanisation has been linked to an increased risk of asthma, 
especially in developing countries86,87, though it is probably due to the combined 
effect of various factors such as lifestyle, diet, socio-economic and housing 
changes.  This may as well be the case of the association of asthma with certain 
ethnic groups88.  
Other factors are still under debate, such as allergen exposure in early life89 or 
the protective effect on asthma risk of a diet rich in fruits and vegetables81,82. 
There are also contradictory findings concerning the effect of breastfeeding on 
the later development of asthma90. 
Some of these environmental factors may alter the child’s microbiome, such as 
the use of antibiotics, caesarean section or living in an urban environment with 
no animal exposure. There is a growing interest in the study of how the 
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microbiome (both in the gastrointestinal and respiratory tract) may affect the 
development of the immune system, and therefore the risk of developing certain 
inflammatory diseases like asthma91. There are now studies that have associated 
dysbiosis in the bacterial microbiota of the gut, respiratory tract and skin with 
the development of allergic diseases91. For example, Arrieta et al.92 showed that 
microbiota and bacterial metabolic products during early life could alter the risk 
of childhood asthma. The next question to be answered is how to alter the 
microbiome both to prevent the development of asthma in high-risk populations 
and to treat asthmatic patients. 
Adulthood exposures  
Some adults may develop new-onset asthma when exposed to asthmagens at 
their place of work while others suffer exacerbations of their illness93. These are 
both defined as occupational asthma. Asthmagens are agents that are causally 
related to the development of asthma, and may include organic dusts that may 
sensitize the airways (such as wood, flour or animal dander), or chemicals that 
irritate the respiratory tract (such as cyanates or glutaraldehyde)94. A recent 
study from Australia (Australian Workplace Exposure Study-Asthma) estimated 
that 47% of men and 40% of women are exposed to at least one asthmagen at 
their workplace95. Occupational asthma may account for around 16-17% of adult-
onset asthma96 and it is highly relevant, given its possibility of prevention. 
2.3.3. Behavioural 
Diverse behavioural and mental health problems such as anxiety, depression and 
personality disorders, have been associated with asthma risk. Studies from Brazil 
have shown an association between the presence of behavioural problems in 
children or community violence and occurrence of asthma symptoms in 
children97,98.  
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However, this not only includes the patient’s own behaviour, but also his or her 
family’s behaviour, especially the mother’s.  Maternal mental disorders have been 
associated with wheezing (both atopic and non-atopic)99,100. According to a 
recent study101 there is not a critical exposure period for maternal mental 
disorders or distress, but it is rather the cumulative exposure that determines the 
increased risk of asthma in the offspring. 
Some other risk factors that we have already mentioned, such as smoking, 
exposure to pets or cold dry air in skiers, could also be interpreted as behavioural 
aspects that may influence the development and/or severity of the disease. 
2.3.4. Atopy 
Atopy has been described as one of the most important risk factors associated 
with asthma. However, the proportion of asthma cases attributable to atopy 
varies greatly between regions, increasing with economic development30.  
The more widely used classification of asthma into atopic and non-atopic asthma 
(see below) may reflect different underlying mechanisms and therefore different 
associated environmental exposures50. This fact highlights the importance of 
analysing the risk factors for each asthma phenotype separately, for example, 
atopic and non-atopic asthma. However, until now, most studies have used a 
combination of different comparison groups making it difficult to define which 
are the risk factor for atopy, and which for asthma (both atopic and non-
atopic)RW.ERROR - Unable to find reference:239, and have not analysed risk factors for atopic 
and non-atopic asthma in the same population, using appropriate control groups.  
In European and North American studies, atopic asthma has been associated with 
family history of asthma, male gender, a higher body mass index (BMI), and 
presence of eczema or rhinitis, while a higher endotoxin load in the house, having 
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pets at home, and higher mean poverty income ratio have been described as 
protective102-109. On the other hand, non-atopic asthma in developed countries 
has been associated with male gender, family history of asthma, dampness at 
home, smoking in parents, breastfeeding less than 3 months, a higher endotoxin 
load at home, a higher BMI, early life infections, recurrent chest infections in 
infancy and a dirty school, with contradictory results regarding parental 
educational level102-109. Overall, underlying mechanisms and risk factors for both 
atopic and non-atopic asthma are not well understood, resulting in a lack of any 
preventive strategy to reduce asthma burden prevalence. 
2.3.5. Other 
There are some other factors that are difficult to classify into either genetics or 
exposures. This is the case of the metabolic or hormonal environment, such as 
the influence of sex on asthma risk. This effect is age-dependant, as it is the male 
sex that increases asthma risk until adolescence, after which it is the female sex 
that increases the risk110. The reason for this variation over time has not yet been 
clarified. 
Asthma is a complex and heterogeneous111-113 disease and encompasses a wide 
spectrum of disease characteristics111,114,115. Given its heterogeneity, scientists 
have tried to classify asthma into different subgroups with similar characteristics 
to study the disease and search for specific and more efficient treatments. 
However, this has proven to be challenging and there is still no international 
consensus on the classification of asthma. Multiple studies have been now 
published in an attempt to classify asthma into phenotypes (according to 
2.4. Asthma phenotypes and endotypes
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observable characteristics) and endotypes (according to specific underlying 
biologic mechanisms). 
2.4.1. Asthma phenotypes 
Phenotypes are identified by a set of outward manifestations of the disease, 
including clinical, physiologic and immunological features55, which may be 
studied using cluster analysis approaches. These characteristics correspond to 
certain underlying genetics and each phenotype may also be associated with a 
different underlying pathogenetic process. The importance of defining asthma 
phenotypes lies in their different response to asthma treatments and the search 
for phenotype-specific treatments. 
Diverse cluster analyses of asthmatic patients have identified different sets of 
asthma phenotypes116-118. The most commonly used characteristics that have 
been used include: age, sex, age of onset, atopy, lung function, airflow obstruction 
reversibility, and obesity. The last GINA report, describes one possible phenotype 
classification37:  
a. Allergic asthma: Also referred to as ‘atopic asthma’. It is the best-known 
form of asthma, with an early onset during childhood and an association with a 
personal or family history of allergic diseases (food or drug allergies, eczema and 
allergic rhinitis). Eosinophils are responsible for the airway inflammation in 
these patients, they have a greater risk of exacerbations and they respond well to 
corticosteroid treatment. 
b. Non-allergic asthma: Or non-atopic asthma. These patients have no 
history of allergic diseases and may not respond well to corticosteroid treatment. 
Both neutrophils and eosinophils may predominate in induced sputum. 
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c. Late-onset asthma: This phenotype is more common among women, 
and is characterised for appearing during adult life.  
d. Asthma with fixed airflow limitation: Different asthma phenotypes can 
evolve into this phenotype due to airway wall remodelling causing a fixed airflow 
obstruction. 
e. Asthma with obesity: Obese asthmatic patients may present a poor 
response to corticosteroid treatment, with notable daily symptoms that may limit 
their everyday life. Scarce eosinophilic inflammation is also characteristic of this 
asthma phenotype. 
Nevertheless, there are many other possible classifications, according to different 
characteristics, as shown on Table 2.1. 
Table 2.1: Example of different asthma phenotypes according to various 
characteristics  
 
 
 
 
 
 
 
Source: Beasley et al, Lancet, 201550. 
 
 
Cluster analysis of asthma phenotypes allows for more objective analysis of 
asthma subgroups with consistent patterns of disease. It uses mathematical 
algorithms to group asthmatic patients into clusters based on the similarity 
between them according to multiple pre-specified variables. As an example, 
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Haldar et al.23  performed a cluster analysis using two different asthma 
populations (primary and secondary care asthma) and based on multiple socio-
demographic, inflammation markers, lung function, treatment and behavioural 
factors. As a result, they obtained 5 distinct asthma phenotypes illustrated in 
Figure 2.6. They then classified these phenotypes into concordant (symptom and 
inflammation expression agree) and discordant, showing that patients in 
secondary care, with refractory asthma are more prone to discordant 
manifestations of asthma, and would therefore benefit from inflammation 
monitoring for treatment adjustments23. This is an example of how asthma 
phenotyping may be used to improve clinical management. 
Figure 2.6: Clinical phenotypes of asthma. 
 
A summary of phenotypes identified using cluster analysis in primary- and secondary-care 
asthma populations. The clusters are plotted according to their relative expression of 
symptoms and inflammation because these are the two clinically pertinent and modifiable 
dimensions of the disease. The plot highlights greater discordance to be a feature of 
secondary-care asthma. Although reasons for this dissociation are unclear, the use of 
measures of airway inflammation in these subgroups is clinically informative. BMI = body 
mass index. 
Source: Haldar et al, Am J Respir Crit Care Med, 200823. 
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Similar techniques have been used in paediatric populations to assess childhood 
asthma and wheeze phenotypes. Two separate birth cohorts, the Avon 
Longitudinal Study of Parents and Children (ALSPAC)119, and the Prevention and 
Incidence of Asthma and Mite Allergy (PIAMA)120 were used to study wheeze 
phenotypes in children, obtaining comparable subgroups: never/infrequent, 
transient early, prolonged early (only in ALSPAC), intermediate-onset, late-onset 
and persistent wheeze (Figure 2.7)121.  
Figure 2.7: Estimated prevalence of wheeze at each time point from birth to age 8 
years for each wheezing phenotype in ALSPAC free 6-class model (N= 5760) and 
PIAMA optimal 5-class model (N = 2810). 
 
 
 
 
 
 
 
 
  
 
 
 
 
Source: Savenije et al, J Allergy Clin Immunol, 2011121 
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Savenije et al.121 fitted the results of the PIAMA cohort to the ALSPAC 6-class 
wheezing phenotypes, obtaining similar proportions. Even though these are 
wheeze and not asthma phenotypes, the persistent, late-onset and intermediate-
onset wheeze phenotypes were strongly associated with doctor-diagnosed 
asthma at age 8 years in the PIAMA cohort, all of which are non-transient 
phenotypes121. 
However, cluster analysis should be taken with caution, as it is a mathematical 
discovery tool and does not confirm the truth of the phenotypes identified. It is 
the person undertaking the analysis who selects the variables included in the 
model, and therefore they offer relatively little new insight beyond what we 
already observe, and they may be radically modified by adding in other variables. 
As they are defined by the things we have already measured, they always sound 
plausible even though they may not be true. 
Since 2010 a new research project called ‘Unbiased Biomarkers for the Prediction 
of Respiratory Disease Outcomes’ (U-BIOPRED) has brought together scientists 
from academia, biopharma industry, patients or care organisations, small 
companies and multinational industry across Europe. One of their aims was to 
identify different phenotypes of severe asthma by collecting various samples and 
information from the 893 adults and children with mild-moderate or severe 
asthma that participated, and use advanced mathematics to produce what they 
defined as a ‘handprint’ of severe asthma122-124. These phenotype handprints are 
more molecular-based than clinical feature-based, enabling classifications of 
patients by the underlying cause of their asthma. For this, they collected blood, 
sputum, exhaled breath, throat swabs and urine samples and performed ‘omics’ 
studies at different levels (genomics, transcriptomics, proteomics and 
metabolomics) (Figure 2.8). These were then combined with clinical data and 
lung function parameters from the patients122,123. 
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Figure 2.8: Different types of information collected from the trial participants 
(black text) used to identify the subtypes of severe asthma in the U-BIOPRED 
project. 
 
 
 
 
 
 
Source: UBIOPRED webpage124 http://www.europeanlung.org/en/projects-and-
research/projects/u-biopred/news-and-events/news/u-biopred-on-course-to-
create-a-handprint-of-severe-asthma 
 
The classification of patients with severe asthma into these different phenotype 
handprints should facilitate the selection of the specific treatment for each 
patient, evolving into a personalized medicine that may increase efficacy and 
reduce side effects of asthma drugs. So far, the 4 adult severe asthma phenotypes 
they have identified coincide with those described by the American Severe 
Asthma Research Program (SARP) consortia, and are associated with different 
pathobiological pathways123 (Figure 2.9). 
Figure 2.9: Adult severe asthma phenotypes identified by the U-BIOPRED 
consortium 
Source: Lefaudeux et al, J Allergy Clin Immunol 2017123. 
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P: Phenotype; E: Endotype 
Source: Skloot et al, Curr Opin Pulm Med, 201555. 
 
Figure 2.10 Schematic representation of the 
asthma syndrome and its phenotypes and 
endotypes. 
 
2.4.2. Asthma endotypes   
Endotypes provide some insight 
into the underlying biological 
mechanisms. These mechanisms 
may be common for different 
phenotypes (that is, there can be 
more than one phenotype sharing a 
common endotype), as there may 
also be more than one endotype for 
the same phenotype, as 
represented in Figure 2.1055. 
 
The most common endotypes proposed by different experts are shown in Table 
2.2 and are based on 7 characteristics: genetics, physiology, clinical 
characteristics, biomarkers, histopathology and epidemiology, as well as 
response to treatment125.  
Table 2.2: Selected endotypes and their characteristics 
 
 
 
 
 
 
 
ABPM: allergic bronchopulmonary mycosis: CF: cystic fibrosis; FeNO: Fractional exhaled 
nitric oxide; HLA: Human leukocyte antigens; PMNs: polymorphonucleocytes.  
Source: Skloot et al, Curr Opin Pulm Med, 201555. 
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2.4.3. Treatable traits 
Given the complexity of asthma and to enable the development of personalised 
and precision medicine for asthmatic patients, a different management strategy 
has been proposed. This strategy moves away from the “diagnostic labels”, to 
concentrate on ‘treatable traits’ of a particular patient126. These treatable traits 
include aspects of the patient’s phenotype, endotype and comorbidities, and they 
are non-mutually exclusive. A list of possible treatable traits based on current 
knowledge, and how each of them should be treated and managed, was collected 
in a paper by Agusti et al126. Examples of these treatable traits are: airflow 
limitation, eosinophilic airway inflammation, airway bacterial colonisation, 
obesity, gastro-oesophageal reflux, rhino-sinusitis, psychiatric disorders, 
smoking, exposure to sensitising agents or pollution, adherence to treatment, or 
poor inhalation technique. Each of these traits should be addressed separately 
with a specific and adequate treatment. 
Recently, Pavord et al.127 have called for a more pragmatic approach, proposing 
to use the term ‘asthma’ as a descriptive label for a collection of symptoms, such 
as we do with the term ‘arthritis’. It is just the beginning of the diagnostic 
process, that should be followed by the questions: What asthma does this patient 
have? How should I treat it?127. This way, we should focus on traits that are 
treatable by dissecting a patient’s airway disease into its component parts and 
offering an individualised and precise approach127. 
Asthma diagnosis is based on three main pillars: detailed medical history, 
physical examination and lung function testing. These three elements are 
necessary for an adequate asthma diagnosis, given that some other pulmonary 
2.5. Diagnosis
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diseases may mimic its symptoms and examination (chronic pulmonary disease, 
cystic fibrosis, bronchiectasis, vocal cord dysfunction, etc.), and therefore an 
accurate history and physical examination may not be sufficient to obtain an 
accurate asthma diagnosis128. The aim is to ascertain the presence of episodic 
symptoms of airflow obstruction that is at least partially reversible, and to 
exclude alternative diagnoses6. 
2.5.1. Personal history 
Risk factors for asthma including personal and family history of allergic diseases 
(atopic dermatitis, allergic rhinitis, food allergies, etc.), increase the probability of 
asthma diagnosis37. 
A comprehensive history is necessary to search for the presence of intermittent 
respiratory symptoms such as cough, shortness of breath, chest tightness and/or 
wheezing. They are usually present more than one at a time, though children may 
present isolated coughing which is accompanied by wheezing and difficulty 
breathing only during acute exacerbations. These symptoms may present 
spontaneously or triggered by exercise, allergens, cold air, laughter, airborne 
irritants or respiratory viral infections. They characteristically vary in intensity 
and over time, and particularly worsen at night6,37. 
On the other hand, there are several clinical features which are not suggestive of 
asthma such as chest pain, difficulty breathing together with dizziness or 
paresthesias, and/or chronic production of sputum. 
2.5.2. Physical examination  
The most frequent abnormal finding in asthmatic patients during physical 
examination is the expiratory wheezing on auscultation or a prolonged phase of 
forced exhalation6,37. However, this is often not present between attacks, and 
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therefore physical examination may be perfectly normal. During asthma 
exacerbations, physical signs of difficulty breathing may appear (nasal flaring, 
intercostal retractions, etc.) together with wheezing (both inspiratory and 
expiratory if severe), though this latter may be absent in severe exacerbations 
(silent chest) because of severely reduced airflow. Apparent wheezing may also 
appear in other conditions, such as respiratory infections, inhaled foreign body, 
tracheomalacia, upper airway dysfunction or chronic obstructive pulmonary 
disease (COPD). 
Other physical findings during examination in asthma are hyper expansion of the 
thorax and chest deformity (especially in children). There may also be other 
accompanying allergic conditions, like atopic dermatitis or allergic rhinitis 
(increased nasal secretion, mucosal swelling and nasal polyps)6. 
2.5.3. Lung function testing 
Medical history and physical examination are not sufficient to exclude alternative 
diagnoses and assess lung impairment severity. Perception of airflow obstruction 
is dependent on the patient’s subjectivity, and therefore highly variable. There 
are several studies showing that an important proportion of patients are under 
or over-classified according to symptoms, when compared to the results of 
pulmonary function tests129,130. Therefore, every child over the age of 5 should 
have spirometry measures both before and after short acting bronchodilator, to 
assess the presence of airflow obstruction, its severity, reversibility and 
variation6,37. The most important spirometry measures used are the Forced Vital 
Capacity, or FVC, which is the maximal volume of air forcibly exhaled from the 
point of maximal inhalation, and the Forced Expiratory Volume in the first 
second, or FEV1, which is the volume of air exhaled during the first second of this 
manoeuvre6. 
                                                                          Chapter 2 | Literature review 
33 
 
Spirometry is also recommended over peak expiratory flow (PEF) 
measurements, given the variability in the latter depending on the brand of the 
peak flow meter131. Thus, PEF measurements would be confined to monitoring 
purposes rather than initial diagnosis6. Nevertheless, spirometry should be 
undertaken following international guidelines recommendations with adequately 
maintained and calibrated equipment131,132 and by trained professionals131. The 
patients should also perform the test at its maximal effort to avoid diagnostic 
errors. In addition, appropriate standard values should be used according to the 
populations’ characteristics (ethnicity, age, location, etc.). Both FEV1 and FVC may 
be expressed as a proportion of the predicted values for the patient’s age and 
size.  
Figure 2.11: Theoretical spirometric 
tracings in asthmatic patients  
Source: GINA 2017 Slide Teaching Set133 
 
 
Asthma is characterized by airflow obstruction which translates into a reduced 
FEV1 and FEV1/FVC ratio. FEV1 values may show an excessive variability 
(improvement or deterioration) in asthma, either during the day or between 
days, or even between seasons.  They will also show reversibility, which is a rapid 
improvement after the use of a rapid acting bronchodilator, such as a β2- agonist 
(salbutamol). This improvement or deterioration of FEV1 should be of at least 
>12% or >200ml from baseline in adults to be considered diagnostic131. These 
variations in FEV1 values may be evidenced either by administration of a 
bronchodilator or controller treatment (a trial of inhaled corticosteroids (ICS) for 
example), after exercise or bronchial provocation test (with methacholine, for 
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example), or by repeated measurements over time. The specific GINA criteria for 
the different procedures are summarised in Table 2.3.  
Table 2.3: Diagnostic criteria for asthma in adults, adolescents, and children 6-11 
years  
DIAGNOSTIC FEATURE CRITERIA FOR MAKING THE DIAGNOSIS OF 
ASTHMA 
Documented excessive variability 
in lung function* (one or more of 
the tests below) 
AND documented airflow 
limitation* 
The greater the variations, or the more occasions 
excess variation is seen, the more confident the 
diagnosis. 
At least once during diagnostic process when FEV1 is 
low, confirm that FEV1/FVC is reduced (normally 
>0.75–0.80 in adults, >0.90 in children) 
Positive bronchodilator (BD) 
reversibility test* (more likely to 
be positive if BD medication is 
withheld before test: SABA ≥4 
hours, LABA ≥15 hours) 
Adults: increase in FEV1 of >12% and >200 mL from 
baseline, 10–15 minutes after 200–400 mcg albuterol 
or equivalent (greater confidence if increase is >15% 
and >400 mL). 
Children: increase in FEV1 of >12% predicted 
Excessive variability in twice-daily 
PEF over 2 weeks* 
Adults: average daily diurnal PEF variability >10%** 
Children: average daily diurnal PEF variability >13%** 
Significant increase in lung 
function after 4 weeks of anti-
inflammatory treatment 
Adults: increase in FEV1 by >12% and >200 mL (or PEF† 
by >20%) from baseline after 4 weeks of treatment, 
outside respiratory infections 
Positive exercise challenge test* Adults: fall in FEV1 of >10% and >200 mL from baseline 
Children: fall in FEV1 of >12% predicted, or PEF >15% 
Positive bronchial challenge test 
(usually only performed in adults) 
Fall in FEV1 from baseline of ≥20% with standard doses 
of methacholine or histamine, or ≥15% with 
standardized hyperventilation, hypertonic saline or 
mannitol challenge 
Excessive variation in lung 
function between visits* (less 
reliable) 
Adults: variation in FEV1 of >12% and >200 mL 
between visits, outside of respiratory infections 
Children: variation in FEV1 of >12% in FEV1 or >15% in 
PEF† between visits (may include respiratory 
infections) 
BD: bronchodilator (short-acting SABA or rapid-acting LABA); FEV1: forced expiratory 
volume in 1 second; LABA: long-acting beta2-agonist; PEF: peak expiratory flow (highest 
of three readings); SABA: short-acting beta2-agonist.  
*These tests can be repeated during symptoms or in the early morning. **Daily diurnal 
PEF variability is calculated from twice daily PEF as ([day’s highest minus day’s lowest] / 
mean of day’s highest and lowest), and averaged over one week. †For PEF, use the same 
meter each time, as PEF may vary by up to 20% between different meters. BD 
reversibility may be lost during severe exacerbations or viral infections. If bronchodilator 
reversibility is not present at initial presentation, the next step depends on the 
availability of other tests and the urgency of the need for treatment. In a situation of 
clinical urgency, asthma treatment may be commenced, and diagnostic testing arranged 
within the next few weeks, but other conditions that can mimic asthma should be 
considered, and the diagnosis of asthma confirmed as soon as possible. 
 
Source: GINA 201737 
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The FVC and the response to bronchodilators may decrease with time in certain 
patients, because of a reduced lung function in chronic asthma6. On the other 
hand, variability may also decrease with treatment, as inflammation diminishes, 
and lung function improves37. Therefore, it is recommended to assess lung 
function at the initial diagnosis, before starting treatment. The extent of 
reversibility depends on the eosinophilic inflammation134, and therefore patients 
with greater response to short-acting β-agonists (SABA) are also at a higher risk 
of reduced lung function and fixed airflow obstruction in the long term135 . 
Finally, response to SABA may be reduced during viral respiratory infections or 
when using SABA during the previous hours. 
2.5.4. Additional tests 
On some occasions, further tests are necessary to rule out other respiratory 
diseases which may mimic asthma. As explained, the asthmatic symptoms may be 
present in other conditions, and some asthmatic patients may be asymptomatic 
during physical examination. Similarly, there may be no airflow obstruction or 
reversibility present. These are the different additional tests we may undertake 
to confirm the asthma diagnosis: 
Chest X-ray  
To exclude other diagnoses such as malformations, chronic infections 
(tuberculosis), or foreign body. Other imaging investigations may be necessary. 
Allergy testing  
As described, not all asthma is atopic, however the diagnosis of atopy may 
facilitate the diagnosis of atopic asthma. There are two methods to diagnose 
atopy: skin prick test (SPT) and the measurement of allergen specific 
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immunoglobulin E (sIgE). Skin prick test has a high sensitivity when performed 
by an experienced professional, it is simple, quick and cheap. However, sIgE 
measurement may be have a higher sensitivity, though require a specialised 
laboratory, take a longer time to obtain the results, and is more expensive37. It is 
important to confirm the positive findings of the SPT and sIgE with the patient’s 
history, as not all diagnosed atopy is symptomatic.  
Inflammation biomarkers 
Blood, nasal and sputum eosinophilia: These may be studied to assess the 
patient’s inflammatory profile (eosinophilic vs neutrophilic) which may affect 
treatment response to certain drugs such as ICS. 
Fraction of Exhaled Nitric Oxide (FENO): FENO measurements correlate with 
eosinophilic inflammation of the airways, thus may be increased in atopic 
asthma, as well as eosinophilic bronchitis and allergic rhinitis37. Several studies 
have shown that high FENO values are associated with a positive response to 
inhaled corticosteroids136. The 2017 GINA guidelines37 do not currently 
recommended FeNO measurements for either diagnosis or control of asthmatic 
patients. However, the NICE 2015 guidelines128 do recommend offering a FeNO 
test in adults when considering an asthma diagnosis and to children (5-16 years 
old) in case of an uncertain asthma diagnosis due to a normal spirometry or 
obstructive spirometry with negative bronchodilator reversibility. 
2.5.5. Asthma diagnosis in children 
 Children under 5 years old (and some under 8) may not be able to perform an 
adequate spirometry manoeuvre, thus diagnosis should be based on medical 
history and physical examination, together with additional tests results (see 
above) or even a therapeutic trial6. Diagnosis may be therefore challenging in this 
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age group, resulting in under-diagnosis of asthma in early childhood. One of the 
reasons for this, is the variations in the natural history of asthma in the early 
stages137, resulting in even more phenotypes of asthma in preschool children.  
Table 2.4: Classic Asthma Phenotypes in children with wheeze from the Tucson 
study, based on their natural history in the long term.  
Transient Early Wheeze 
- Start before 1 year old, disappear around 3 years old. 
- Negative sIgE and SPT, no atopic features or family history. 
- Decreased lung function at birth, normal at 16 years of age. 
- Negative bronchial hyperresponsiveness or PEF variability at age of 11. 
- Risk factors: maternal smoking during pregnancy, male, prematurity, 
having older siblings and/or attending childcare.  
Persistent Wheeze 
- Generally appear before the age of 1 and persist at the age of 6. 
- No gender differences. 
- Negative sIgE and SPT, no atopic features or family history. 
- Normal lung function at birth and decreased at age of 6 and 11. 
- Bronchial hyperresponsiveness that decreased with age. 
- Normally disappears during adolescence. 
Late-onset Wheeze 
- First episode after the age of 1 and is predominant among males. 
- Positive sIgE and/or SPT, with atopic features and/or family history. 
- Normal lung function at birth, decreased at age of 6, followed by an 
onward stabilization below average. 
- Bronchial hyperresponsiveness present. 
- Normally persists during adolescence. 
Source: Stein et al, Paediatr Respir Rev., 200469 
 
The first description of childhood wheeze phenotypes emerged from the Tucson 
study69 (Table 2.4) and even though there have been other prospective studies 
(birth cohorts)138,139 and complex statistical analysis of various study 
populations140, there is still no clinically-useful asthma phenotype classification 
available for children.  
As seen, this classification is based on parental reporting of ‘wheeze’, which is 
rather unreliable and unspecific137. Parents understand the term wheeze 
differently141 and often fail to recognise it142.  
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Another added difficulty is the lack of evidence-based consensus on standard 
definitions, diagnosis and management137 In order to facilitate asthma diagnosis 
in pre-school children and predict the future risk of asthma in late childhood and 
adulthood, various tools have been developed though only few have been 
validated. The most widely used is the Asthma Predictive Index (API) (Table 2.5), 
developed from the Tucson cohort143 and which was later modified144.  
Table 2.5: Original and Modified Asthma Predictive Index for children 0-3 years of 
age  
Original Asthma Predictive Index Modified Asthma Predictive Index 
A history of ≥3 wheezing episodes during 
the first 3 years of life 
 
A history of ≥4 wheezing episodes in the 
past year with ≥1 physician’s diagnosis. 
In addition, the child must meet ≥1 of the major criteria or ≥2 of the minor criteria: 
Major Criteria 
 Parental history of asthma 
 Doctor-diagnosed atopic dermatitis 
 Parental history of asthma 
 Doctor-diagnosed atopic dermatitis 
 Allergic sensitization to ≥1 
aeroallergen 
Minor Criteria 
 Doctor-diagnosed allergic rhinitis 
 Blood eosinophils ≥4% 
 Allergic sensitization to milk, egg, or 
peanut 
 Wheezing unrelated to colds 
 Blood eosinophils ≥4% 
 
Source: Castro-Rodriguez et al, Am.J.Respir.Crit.Care Med., 2000143 and Bacharier et  
al,  J Allergy Clin Immunol.  2012144. 
 
2.5.6. Classification 
There exist multiple different classifications and definitions of asthma severity 
according to each country or organisation, and they are continuously changing 
over the years. We will now introduce some of the most widely used 
classifications. 
Initial asthma severity classification 
Asthmatic patients may be classified at initial diagnosis, before starting baseline 
treatment, according to the frequency and severity of their symptoms. There 
have been different classifications used by diverse organisations.  
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Below is the NHLBI classification which includes 2 main components: 
impairment and risk. The impairment component consists of all the respiratory 
symptoms present during the day or night, as well as the use of relievers 
(salbutamol) and the lung function.  
Table 2.6: Asthma Severity in Treatment Naïve Patients  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: National Asthma Education and Prevention Program, 20076 
 
Given that asthma severity assessed by daily asthma symptoms does not exactly 
correlate with future risk of serious adverse outcomes46,47, they added a new 
component to the initial asthma severity classification. This is the risk 
component, which recollects the future risk of suffering acute severe asthma 
exacerbation.  
The 2017 GINA guidelines37 do not include a classification of asthma severity for 
treatment naïve patients, as the initial symptoms do not predict the response to 
treatment and therefore it is not useful from a practical and clinical point of view. 
However, some other international (such as the NHLBI6) and national guidelines 
(Spanish145, Brazilian) still include this initial classification of asthmatic patients 
(Table 2.6). Even though learned institutions do not agree on severity 
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classification of asthma, it is now more widely accepted to define asthma severity 
based on the treatment required to gain adequate control. 
Table 2.7: Initial classification of asthma severity in children  
 Intermittent 
Occasional 
Intermittent 
Frequent 
Persistent 
Moderate 
Persistent 
Severe 
Episodes -Few hours/days 
duration 
- <1 every 10-12 
weeks 
- Max 4-5 per 
year 
- <1 every 5-6 
weeks 
- Max 6-8 per 
year 
< 1 every 4-5 
weeks 
Frequent 
Symptoms 
between 
episodes 
Asymptomatic 
Good tolerance 
to exercise 
Asymptomatic Mild Frequent 
Wheezing - With intensive 
efforts 
With moderate 
efforts 
With minimum 
efforts 
Night-time 
symptoms 
- - ≤2 nights per 
week 
>2 nights per 
week 
SABA use - - ≤3 days per 
week 
3 days per 
week 
Lung function 
- FEV1 
- PEF variability 
 
>80% 
<20% 
 
>80% 
<20% 
 
<70% - <80% 
>20% -<30% 
 
<70% 
>30% 
FEV1: Forced Expiratory Volume 1st second; PEF: Peak Expiratory Flow; SABA: Short Acting β-Agonists 
Source: GEMA, 2015145. 
 
On the other hand, there are several national guidelines which differentiate the 
adult from the children’s initial classification. This is the case of the Spanish 
guideline145 -Guía Española para el Manejo del Asma (GEMA, Spanish Guide for 
Asthma Management)- and the Ecuadorian ‘Consensus’146. Both guidelines use 
the above classification for adults, though they acknowledge the existence of 2 
types of intermittent asthma in children: occasional and frequent, according to 
the frequency of the episodes, though both are symptom-free in-between the 
acute episodes and have normal lung function145 (Table 2.7). The justification for 
this difference, is the frequent episodic presentation of asthmatic symptoms with 
scarce impairment between acute episodes in children, compared to adults. 
Likewise, this classification does not present a ‘Mild Persistent Asthma’ group, as 
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persistent asthma in children should at least be considered as moderate147. 
According to this line of thought, the number of acute worsening of respiratory 
symptoms in children is highly relevant, regardless the presence or absence of 
daily impairment. 
Asthma control 
Asthma control may be classified as controlled, partly controlled or uncontrolled 
according to the 2017 GINA guidelines37 based on the current clinical 
characteristics of the patient. However, the assessment of future risk is also 
considered, including the risk of side effects from medication, of loss of lung 
function, of instability, together with the risk of suffering future exacerbations. 
Table 2.8: Levels of asthma control  
A. Assessment of current clinical control (preferably 4 weeks) 
Characteristics Controlled (All of 
the following) 
Partly Controlled 
(Any measure 
presented) 
Uncontrolled 
Daytime symptoms None (≤2/week) >2/week Three of more 
features of partly 
controlled asthma*† 
Limitation of activities None Any 
Nocturnal 
symptoms/awaking 
None Any 
Need for reliever/ 
rescue inhaler 
None (≤2/week) >2/week 
Lung function (PEF or 
FEV1) ‡ 
Normal <80% predicted or 
personal best (if 
known) 
B. Assessment of Future Risk (risk of exacerbations, instability, rapid decline in lung 
function, side effects) 
Features that are associated with increased risk of adverse events in the future include: 
Poor clinical control, frequent exacerbations in the past year*, ever admission to critical 
care for asthma, low FEV1, exposure to cigarette smoke, high dose medications. 
*Any exacerbation should prompt review of maintenance treatment to ensure that it is 
adequate 
† By deϐinition, an exacerbation in any week makes that an uncontrolled asthma week 
‡ Without administration of bronchodilator 
Lung function is not a reliable test for children 5 years and younger. 
Source: GINA 201737 
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Other national and international guidelines use slightly modified classifications of 
the level of asthma control, including up to 4 groups: complete, good, partial and 
bad. The items of the impairment section, however, are the same, as those of the 
future risk component, though the latter is also quantified (using the number of 
acute exacerbations in the previous year and none vs. variable medication 
adverse effects). 
The main way to evaluate the level of control of asthma is through regular 
medical visits during follow-up. During these visits the health care worker should 
evaluate the presence of symptoms, measure the lung function (spirometry) and 
enquire about possible exacerbations and emergency care visits. In addition, the 
impact on the patient’s everyday life and activity should also be explored, as well 
as side effects of the medications and adherence to baseline treatment. Different 
tests have been validated which may facilitate and standardise the measurement 
of asthma control. The most used are the Asthma Control Test (ACT)3 and the 
Asthma Control Questionnaire (ACQ)148. The ACT has been specially validated to 
be used at the clinic during the routine visits, with defined cut points: a score 
equal to or above 20 is consistent with a well-controlled asthma, a score between 
16 and 19 with a partially or not well-controlled asthma and equal to or below 15 
with an uncontrolled asthma136,149. Similarly, an ACQ score equal to or below 0.75 
is a well-controlled asthma, and a score of 1.5 or above is an uncontrolled 
asthma150. However, studies carried out in different settings, such as Spain, have 
shown different cut points151. Nevertheless, the overall reliability of both tests to 
detect uncontrolled asthma is poor152, so they should not be used in isolation to 
assess asthma control. As commented before, poor control of daily asthma 
symptoms does not necessarily increase a person’s risk of suffering severe acute 
asthma attacks. 
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Severe asthma definition 
Given the lack of consensus of severe asthma definition, whether it should be 
based on symptom severity or the type or dose of medication needed to control 
those symptoms, the American Thoracic Society (ATS) and the European 
Respiratory Society (ERS) organised a Task Force in 2013153 addressing this 
problem. The definition for severe asthma they finally agreed upon is: 
“Asthma which requires treatment with guidelines suggested medications for 
GINA steps 4–5 asthma (high dose ICS and LABA or leukotriene 
modifier/theophylline) for the previous year or systemic CS for ≥50% of the 
previous year to prevent it from becoming ‘‘uncontrolled’’ or which remains 
‘‘uncontrolled” despite this therapy. 
- Uncontrolled asthma defined as at least one of the following: 
1) Poor symptom control: Asthma Control Questionnaire (ACQ) 
consistently >1.5, Asthma Control Test (ACT) <20 (or ‘‘not well controlled’’ by 
National Asthma Education and Prevention Programme or GINA guidelines) 
2) Frequent severe exacerbations: two or more bursts of systemic CS (>3 
days each) in the previous year. 
3) Serious exacerbations: at least one hospitalisation, ICU stay or 
mechanical ventilation in the previous year. 
4) Airflow limitation: after appropriate bronchodilator withhold FEV1 
<80% predicted (in the face of reduced FEV1/FVC defined as less than the lower 
limit of normal). 
- Controlled asthma that worsens on tapering of these high doses of ICS or 
systemic CS (or additional biologics).”153 
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As shown, this definition of severe asthma combines both the level of control of 
the disease and the medication needed to achieve it. It also includes those 
patients with uncontrolled asthma due to incomplete treatment of 
comorbidities153. Most of the guidelines and medical professionals have accepted 
this ATS/ERS definition, reaching an international consensus. However, this 
statement is based on experts’ opinion and the cut-off values they used could be 
altered. There is still a strong debate around the definition of severe asthma, 
given the lack of supportive evidence for a severe asthma distinct phenotype and 
the heterogeneity of the disease154. On the other hand, those patients with 
uncontrolled asthma due to inadequate or inappropriate treatment or poor 
adherence should be considered as suffering ‘difficult to treat asthma’37. 
The main aim of asthmatic treatment is to achieve and maintain control of the 
disease as soon as possible, together with preventing acute exacerbations and 
chronic airflow obstruction, and reduce mortality145. Adequate treatment should 
control daily symptoms, prevent exacerbations and loss of lung function, as well 
as cause the least damage possible. To attain this, a global and individualized 
long-term strategy is necessary based on an optimal pharmacological therapy 
and supervision, environmental control measures and education on asthma155. 
2.6.1. Pharmacological treatment 
Medication should be adjusted according to the level of control, using the most 
effective, safe, affordable and acceptable for the patient145. Pharmacological 
treatment of asthma is not static, as it should be modified to adjust to the 
changing circumstances of the condition. As explained above (Classification 
section) both the current control of daily symptoms and the future risk domains 
2.6. Asthma treatment
                                                                          Chapter 2 | Literature review 
45 
 
should be taken into consideration when deciding upon asthma medication, given 
the different response they may show to treatment19,156. 
To enable this continuous adjustment, asthma treatment is now modified 
following a stepwise approach. Before explaining the different steps, I will 
introduce a brief description of the different medications available. 
Reliever medications  
They are also called rescue medications and include the drugs that are used to 
treat acute bronchoconstriction rapidly. The main two are: 
 - Inhaled short acting β-agonists (SABA): The most commonly used are 
salbutamol (or albuterol) and terbutaline, which may be used in inhalation, 
nebulized or oral. They are the first line treatment for acute asthma, as they are 
the most effective to rapidly reverse the airway obstruction. Their effect starts 
just 3-5 minutes after inhalation and lasts for around 3-4 hours. They may cause 
tachycardia, muscle tremor, hypokalaemia, increased lactic acid, headache and 
hypoglycaemia as side effects. 
 - Inhaled anticholinergic: Ipratropium bromide is used in combination 
with a SABA to treat moderate or severe acute asthma exacerbations, especially 
in children, given its synergistic effect. It may be used as an inhaler or nebulized. 
It should only be used alone as a reliever drug, in case of allergy or intolerance to 
SABA37. It may cause certain side effects such as blurry vision, dry mouth, urinary 
retention and bronchospasms. 
Controller medications  
They are also called maintenance or long-term baseline treatment. They should 
be used daily during long-term periods and include: 
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 - Inhaled (ICS) or systemic corticosteroids: They are the most effective 
maintenance therapy for asthma, either for controlling daily symptoms or to 
decrease the risk of future exacerbations157-159. There are different types of ICS 
such as: beclomethasone, budesonide, ciclesonide, fluticasone and mometasone. 
ICS may cause coughing, dysphonia, oropharyngeal candidiasis, growth 
retardation in children and increase the risk of fractures160-164. They are the first 
step treatment for persistent asthma, as an inhaler, though they are sometimes 
prescribed orally to treat severe persistent asthma or to gain control rapidly (for 
example, during an acute exacerbation).  
Systemic corticosteroids may produce much more serious side effects, especially 
if used over long periods. These include: diabetes, hypertension, skin atrophy, 
osteoporosis, cataracts, muscle weakness, moon face, peptic ulcer, 
immunosuppression, aseptic necrosis of the femoral head and mood swings. 
Additionally, when suspended abruptly, they may induce an acute adrenal failure 
or unmask an underlying condition such as the Churg-Strauss Syndrome. 
 -  Leukotriene Receptor Antagonists (LTRAs): Montelukast and zafirlukast 
are an alternative to ICS165 for persistent asthma, though in the long-term, ICS 
have been shown to be superior to LTRAs165,166, as patients who are well 
controlled with low-dose ICS, do not obtain the same degree of control when 
using montelukast167.  They are therefore indicated as an alternative to ICS in 
patients who do not wish to use or do not tolerate well ICS, who have difficulties 
with the inhaling technique or who present with concomitant allergic rhinitis168. 
On the other hand, they are mostly used as complementary therapy associated 
with ICS in patients who do not achieve good control of symptoms on ICS alone. 
When compared to the combination of ICS and long-acting β-agonists (LABA), 
patients using LTRAs as add-on therapy to ICS have a higher median adherence 
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to therapy169, an advantage of oral treatments. LTRAs may produce weakness, 
epigastralgia, diarrhoea, dizziness, headache and mouth pain. 
 - Long-acting β-agonists (LABA): Formoterol and salmeterol are used 
together with ICS as maintenance therapy, and they should not be used in 
monotherapy for asthma. There exist specific combinations of ICS and LABA 
(inhalers). Formoterol is a LABA, but with a rapid effect (3-5 minutes) so it may 
be used in combination with ICS during an acute exacerbation. Their effects last 
for around 12 hours, and salmeterol starts to show an effect after 20-45 minutes. 
Their side effects include cardiovascular stimulation, muscular tremor, 
hypokalaemia and tachyphylaxis.  
 - Tiotropium: It is a long-acting inhaled anticholinergic which may be 
added to other maintenance treatment (ICS and LABA) in patients with moderate 
or severe persistent asthma who do not achieve an adequate control. It has 
shown to be efficacious in reducing the number of asthma attacks and improving 
asthma control in school-age children with moderate-to severe asthma, as well as 
being well tolerated170. 
 - Monoclonal antibodies  
Anti-IgE, Omalizumab: It is used subcutaneously and as for 
tiotropium is indicated for patients with moderate or severe persistent 
asthma who do not achieve an adequate control with ICS. Side effects that 
have been described with omalizumab include pain and bruising at the 
injection site, anaphylaxis and malignant neoplasms, though the 
relationship with the medication in latter case is unclear6.  
Anti-IL5, mepolizumab: Anti-IL5: Various new treatments are 
now becoming available, such as mepolizumab that has been just recently 
included in the 2017 GINA guidelines, to be used in the last step of 
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treatment (see Figure 2.13) as an add-on therapy for patients older than 
12 years old, with severe eosinophilic asthma37. Other examples are 
reslizumab (approved by the U.S. Food and Drug Administration in March 
2016 and by the European Medicines Agency in June 2016) and 
benralizumab (approved by the US FDA in November 2017)171. 
 - Theophylline: It is a weaker bronchodilator, when compared to LABA, 
though it also has a modest anti-inflammatory effect at low doses. It is available 
in sustained-release formulae to be taken once or twice a day, with an overall 
weak efficacy in asthma172-174. It may be used as an add-on therapy for patients 
who do not achieve an adequate control with ICS and LABA. However, it has 
common side effects, such as nausea and vomiting, arrhythmias, convulsions and 
even death at high doses175. 
 - Azithromycin: Low dose azithromycin during several months may play a 
role as an add-on therapy for patients with severe non-eosinophilic asthma and 
frequent exacerbations176,177. However, it is not currently recommended in 
international asthma guidelines37,128. 
Stepwise treatment 
Figure 2.12: The control-based asthma management cycle 
 
 
 
 
 
Source: GINA 2017 Teaching Slides133 
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The strategy used for the stepwise treatment, is to increase or decrease the 
number and doses of controller drugs used to treat asthma, in relation to the 
patient’s degree of control. This may be done using the GINA classification in 
controlled, partly controlled or uncontrolled asthma (see above, Table 2.8). 
According to the 2017 GINA guidelines, asthma management should be a 
continuous process following the steps: assess, adjust (both pharmacological and 
non-pharmacological treatment) and review the response37 (Figure 2.12). 
Figure 2.13: Stepwise approach to control symptoms and minimise risk 
 
 
 
 
 
 
 
 
 
ICS: inhaled corticosteroids; LABA: long acting beta2-agonist; med: medium dose; OCS: oral 
corticosteroids; SLIT: sublingual immunotherapy. *: Not for <12 years; ** For 6-11 years, the 
preferred Step 3 is medium dose ICS; #: Low dose ICS/formoterol is the reliever medication 
for patients prescribed low dose budesonide/formoterol or low dose 
beclomethasone/formoterol maintenance and reliever therapy. ᵻ: Tiotropium by mist 
inhaler is an add-on treatment for patients with a history of exacerbations; not indicated for 
<12 years. 
 Source: GINA 2017 Teaching Slides 133 
 
The different drugs recommended by GINA37 at each step are described in Figure 
2.13. The first step is the use of SABA as needed, with no maintenance therapy. 
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This should be only used for patients with infrequent symptoms (<2 times per 
month), of short duration and with no risk factors for exacerbations37. 
Steps 2 to 5 include maintenance therapy together with SABA as a rescue 
medication. Step 2 begins with low dose ICS as preferred therapy. In the next 
steps, other drugs are added to the ICS and/or the dose of the ICS is increased. 
The other drugs added are LABA, LTRAs, tiotropium, theophylline, omalizumab 
and mepolizumab.  The last step includes the use of low dose oral 
corticosteroids37. Before upgrading patients to the next step, it is always 
necessary to assess adherence and correct inhaler technique. Similarly, it is 
recommended to refer the patient for specialist investigation before moving on to 
Step 5. At this stage, it may be advisable to use sputum-guided treatment. 
Combinations of ICS and fast-acting LABA exist as maintenance and reliever 
therapy (MART) in a single inhaler that may be used for both daily maintenance 
therapy and the relief of symptoms as required.  
During follow-up visits, patients who have been well controlled and have stable 
lung function during ≥3 months, should be considered to try to step down their 
treatment37. This should always be done under close supervision and engaging 
the patient in the process by providing understandable information and self-
monitoring guidance. The 2017 GINA guidelines37 include specific options on how 
to step down depending on the current medication and dose. 
Table 2.9: Instructions for stepping down treatment once asthma is well controlled  
General principles of stepping down asthma treatment 
 Consider stepping down when asthma symptoms have been well controlled and 
lung function has been stable for 3 or more months. If the patient has risk 
factors for exacerbations or fixed airflow limitation, do not step down without 
close supervision.  
 Choose an appropriate time (no respiratory infection, patient not travelling, not 
pregnant).  
 Approach each step as a therapeutic trial. Engage the patient in the process; 
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document their asthma status (symptom control, lung function and risk factors; 
provide clear instructions; provide written asthma action plan and ensure 
patient has sufficient medication to resume their previous dose if necessary; 
monitor symptoms and/or PEF; and schedule a follow-up visit.  
 Stepping down ICS doses by 25-50% at 3 month intervals is feasible and safe for 
most patients.  
Curr 
ent 
step 
Current medication and dose Options for stepping down 
Step  
5 
 
High dose ICS/LABA plus oral 
corticosteroids (OCS) 
  
 
 
 
High dose ICS/LABA plus 
other add-on agents  
 Continue high dose ICS/LABA and reduce OCS 
dose 
 Use sputum-guided approach to reducing OCS 
 Alternate-day OCS treatment 
 Replace OCS with high dose ICS 
 
 Refer for expert advice  
 
Step  
4 
 
Moderate to high dose 
ICS/LABA maintenance 
treatment  
 
 
Medium dose 
ICS/formoterol* as 
maintenance and reliever 
 
High dose ICS plus second 
controller  
 Continue combination ICS/LABA with 50% 
reduction in ICS component, by using available 
formulations  
 Discontinuing LABA may lead to deterioration 
 
 Reduce maintenance ICS/formoterol* to low 
dose, and continue as- needed low dose 
ICS/formoterol* reliever  
 
 Reduce ICS dose by 50% and continue second 
controller 
Step  
3 
 
Low dose ICS/LABA 
maintenance  
 
Low dose ICS/formoterol* as 
maintenance and reliever 
 
 
Moderate- or high-dose ICS  
 Reduce ICS/LABA to once daily  
 Discontinuing LABA may lead to deterioration 
 
 Reduce maintenance ICS/formoterol* dose to 
once daily and continue as-needed low dose 
ICS/formoterol* reliever  
 
 Reduce ICS dose by 50% 
Step  
2 
 
Low dose ICS 
 
 
 
Low dose ICS or LTRA  
 
 
 Once-daily dosing (budesonide, ciclesonide, 
mometasone)  
 Adding LTRA may allow ICS dose to be stepped 
down 
 Insufficient evidence to support step-down to as-
needed ICS with SABA 
 
 Consider stopping controller treatment only if 
there have been no symptoms for 6–12 months, 
and patient has no risk factors.  
 Provide a written asthma action plan, and 
monitor closely. Complete cessation of ICS in 
adults is not advised as the risk of exacerbations 
is increased 
BDP: beclometasone dipropionate; ICS: inhaled corticosteroids; LABA: long-acting beta2-
agonist; LTRA: leukotriene receptor antagonist; OCS: oral corticosteroids.  
*ICS/formoterol maintenance and reliever treatment can be prescribed with low dose 
budesonide/formoterol or BDP/formoterol.                  Source: GINA 201737 
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2.6.2. Other treatments 
Environmental exposure control 
Smoking and exposure to tobacco smoke (ETS) worsens asthmatic symptoms and 
the response to treatment with ICS, even in mild asthmatics178 and may produce a 
rapid lung function decrease179, making it necessary to step-up the treatment 
needed180. Additionally, longitudinal studies have associated tobacco smoke with 
the development of asthma in adults, adolescents181 and infants182, and ETS may 
also worsen respiratory symptoms in asthmatic children. It is therefore one of 
the most important environmental exposures which should be addressed during 
asthma follow-up visits, informing about the most effective smoking cessation 
interventions183.  
Certain asthmatic patients may develop acute exacerbations when treated with 
acetylsalicylic acid or nonsteroidal anti-inflammatory drugs (NSAIDs), especially 
those with concomitant nasal polyps. These reactions may be severe or even 
fatal184, therefore early diagnosis in these patients by medical history or oral 
provocation is essential185,186. These patients should avoid taking these drugs.  
In the case of proven allergies, certain specific measures should be taken into 
consideration. The most effective are those which imply a marked reduction in 
the level of exposure to the specific allergen, such as occurs in occupational 
asthma, animal dander allergy (by removing the animal) and cockroach (by 
eliminating the cockroaches from the house)187-191. However, individual isolated 
measures, like the use of acaricides or mattress covers, have not proven to be as 
effective, even in decreasing the allergen exposure level192-194. On the other hand, 
the application of a combination of specific interventions has been shown to 
significantly reduce the level of allergen exposure and therefore the clinical 
efficacy195-197. Two different meta-analysis concluded that the efficacy of isolated 
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environmental mite control measures is limited in patients with rhinitis187, and 
null in asthmatic patients194, though a more recent systematic review analysing a 
combination of these measure showed more promising results198.  
Allergen immunotherapy 
Subcutaneous allergen immunotherapy is an efficient treatment for well-
controlled allergic asthma in the 2-4th step of treatment, as long as IgE mediated 
sensitization has been shown to common aeroallergens and is clinically relevant, 
well characterized and standardized extracts are used199,200, and complex 
mixtures are not applied201. It should not be prescribed to patients with severe or 
uncontrolled asthma, as it is ineffective and implies a high risk of severe adverse 
reactions which could be fatal202,203. Given this risk, the efficacy of other safer and 
more convenient alternatives have been studied, such as sublingual 
immunotherapy. Two systematic reviews concluded that sublingual 
immunotherapy may significantly reduce clinical bronchial manifestations in 
children and adolescents with allergic asthma204,205, as well as in adults206. Most 
clinical trials which demonstrated the efficacy of this method used well 
characterized extracts and at higher doses than those usually prescribed for 
subcutaneous immunotherapy. Sublingual immunotherapy is well tolerated, and 
no fatal reactions have been described206. 
To my knowledge, there have been no comparative cost-effectiveness studies of 
immunotherapy vs. conventional pharmacotherapy, and they may well not be 
any, given the complexity of the study design. Nevertheless, immunotherapy has 
some additional advantages over pharmacotherapy, such as the maintained 
clinical improvement up to several years after stopping treatment207,208 or the 
ability to halt the progression of rhinoconjunctivitis to asthma208. Finally, 
immunotherapy has been shown to be a cost-effective treatment for patients with 
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coexistent rhinoconjunctivitis and asthma, when compared to exclusive 
pharmacological treatment209,210. 
Flu and Pneumococcal Vaccination  
Vaccination against seasonal flu211,212 and Streptococcus pneumoniae213 have not 
been shown to prevent asthma exacerbations. However, given the high risk of 
complications in patients with chronic diseases214,215, vaccination against 
seasonal flu should be considered in patients with moderate to severe asthma, 
both adults and children. 
Other methods  
Weight loss in overweight and obese adults with asthma has shown to improve 
asthma control and decrease daily symptoms, even though they may not reduce 
eosinophilic airway inflammation216. There are scarce data on overweight or 
obese children216.  
Pulmonary rehabilitation improves exercise capacity and disease specific and 
generic questionnaire scores in the long term in asthmatic adults217. 
2.6.3. Education 
Educating asthmatic patients and their families is an important part of the 
management of these patients, as it reduces the risk of suffering acute 
exacerbations, it increases quality of life and decreases health care costs218,219. It 
is therefore an indispensable part of a comprehensive asthma care37,220-222. The 
main objective is to provide the patient with the necessary knowledge and skills 
to improve his/her self-management and adherence to treatment. This may 
improve asthma control and the patient’s self-sufficiency. 
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Knowledge and skills  
From a practical point of view, education in asthma should consider both the 
knowledge transmission and the acquisition of necessary skills223. The patient’s 
needs, previous knowledge, beliefs, age, asthma severity and the degree of 
involvement necessary for an adequate self-management should all be 
considered when considering the information given145. Educational interventions 
should include: self-management (by symptoms and PEF monitoring), written 
asthma action plans, and regular review of the level of asthma control and 
treatment by the health care worker224. Interventions that do not include an 
asthma action plan are less effective224,225, and those which only include 
information actions have been shown to be ineffective222,224,225. 
As for the development of skills, the asthmatic patient should receive inhaler 
technique training for the specific device he/she may be using226-231; should be 
taught how to recognize and manage an exacerbation promptly; and how to avoid 
triggers232. 
Asthma action plan:  
The written asthma action plan (WAP) is a set of written instructions 
individualized for each patient, according to the severity and level of control of 
their asthma and the treatment prescribed. The main objective of this action plan 
is early recognition of an acute worsening of their asthma and a quick initiation 
of actions to enable a rapid remission. The level of control may be assessed by the 
frequency and severity of symptoms or the measurement of daily PEF, depending 
on patient and doctor preferences233-235. A meta-analysis of randomized 
controlled trials to assess the efficacy of symptom-based vs peak-flow-based 
WAPs in the paediatric population, concluded that those using symptom-based 
WAPs had lower risk of exacerbations requiring acute care visits236. Therefore, 
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symptom-based WAPs should be preferably used when treating asthmatic 
children, over peak-flow based WAPs. 
The action plan should comprehend two main parts: the usual patient’s 
treatment during the stable phase of asthma and the actions that should be 
followed in case a worsening occurs237-239. It should be revised during each 
medical visit, as well as during ED visits or hospital admissions. 
In adults, providing asthmatic patients WAPs can reduce hospital admissions, 
acute care visits, missed days of work and night awakenings by one third225. This, 
together with its simplicity and low cost, is the reason why WAPs are now 
universally recommended for all asthmatic patients as part of their regular 
management. 
Treatment adherence:  
The patient’s adherence to the medication prescribed is a critical factor to attain 
and maintain an adequate level of control of the disease. It is estimated that 
treatment adherence in asthma is below 50%240,241. Poor adherence has been 
associated with morbidity and mortality, as well as a greater use of health care 
services242,243. 
There are three main types of non-adherent patients: the erratic (forgets to take 
the medications), the intentional (does not want to take the medication), and the 
involuntary (who is unaware of the disease or its treatment)244,245. 
It is vital to assess the patient’s adherence to treatment, using additional methods 
than only clinical history which tends to overestimate adherence. These may 
include the use of the pharmacies’ electronic records of the medication 
withdrawn or standardized questionnaires completed by the patient37, such as 
the Medication Adherence Report Scale for Asthma (MARS-A)246. 
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The educational programme should always consider assessing the adherence to 
treatment and promote appropriate corrective measure in case of poor 
adherence, adapted to the type of non-adherent patient. 
2.7.1. Introduction 
Latin America extends from Argentina to Mexico, comprising 20 different 
countries with highly varied geographical and climatic contexts. Its 600 million 
inhabitants are also a mixture of Amerindian, African or European descendants 
and their primary languages are Spanish and Portuguese. Poverty and inequality 
are, however, present throughout the region where approximately 25% of the 
population live in poverty (less than 2 USD per day)247-249. 
2.7.2. Asthma prevalence 
 
 
 
 
 
 
 
 
Source: Forno  et al., Thorax 2015250. 
2.7 Latin American perspective of asthma 
Table 2.10 Current wheeze and asthma in 
children ages 13–14 years and asthma 
mortality in Latin American countries 
Figure 2.14 Prevalence of childhood asthma 
in Latin America. Prevalence in the 
Dominican Republic is based on adult 
asthma. 
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Some Latin American countries were among those with the highest asthma rates 
worldwide, as was the case of Costa Rica (25.5%), Peru (22.8%) or Brazil 
(21.3%) for current wheeze in 13-14-year olds, and again Costa Rica (34.8%), 
Brazil (22.9%) or Panama (23.1%) for 6-7-year olds in the ISAAC III studies2. 
Even though the majority of the participating centres had >15% prevalence of 
current asthma symptoms and lifetime asthma, there were great variations both 
between and within countries. Current wheeze ranged between 8.7% in Mexico 
and 30.8% in El Salvador, and lifetime asthma diagnosis ranged between 6.9% in 
Mexico and 33.1% in Peru250. Similarly, lifetime asthma diagnosis in Brazil varied 
from 7.3% in Nova Iguaçu to 21.2% in Porto Alegre. These variations appeared 
regardless of their cultural or ethnic background and the level of socioeconomic 
development250. 
Table 2.11 Prevalence of recent wheeze (within the previous 12 months) among 
school children participating in the ISAAC studies in Latin America 
 
 
 
 
 
 
 
 
 
 
Source: Cooper et al, Allergy, 200925 
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When considering the regional variations on asthma symptoms prevalence in 
Latin America, no differences were observed between coastal and inland centres, 
as well as between tropical and non-tropical centres251. There seemed to be an 
inverse correlation between altitude and lifetime asthma and current wheeze, 
though the correlation disappeared once the 8 centres situated at an altitude 
>2000m were excluded from the model251. When studying socioeconomic status 
indicators, such as gross national income (GNI) or percentage of population living 
under the poverty line, no correlation was found with asthma symptoms251. 
Finally, when considering the latitude of the participating centre, only current 
wheeze showed an association (greater prevalence in Southern latitude 
centres)251, while there were no differences in lifetime asthma. 
Over the years following ISAAC Phase III, other countries from Latin America 
undertook population-based cross-sectional studies using similar methodology 
and questionnaires to investigate asthma prevalence in 6-7 and 13-14-year olds. 
Table 2.12 includes the results of some of these published studies. As with the 
ISAAC studies, the prevalence of asthma symptoms was highly heterogeneous 
between countries and studies. 
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Table 2.12: Latin American studies of asthma symptoms prevalence undertaken 
after ISAAC study. 
Study Location Year Size Age Asthma Symptom Prevalence 
Cooper 
200333 
Ecuador 
(Esmer. & 
Pichincha) 
1998
- 
2001 
4443 5-18 
y 
Current wheeze 2.1% 
Lifetime asthma dx 10.3% 
De 
Farias 
2010252  
Brazil 
(Amazon) 
2007 1072 6-7 y Current wheeze 21.4% 
Lifetime asthma dx 5.8% 
999 13-
14 y 
Current wheeze 12.4% 
Lifetime asthma dx 6.1% 
Del Rio-
Navarro 
2006253 
Mexico 
(Mexico city) 
2002
-
2003 
3211 6-7 y Current wheeze 6.8% 
Lifetime asthma dx 4.5% 
> 4 attacks last 12m 0.8% 
3899 13-
14 y 
Current wheeze 9.9% 
Lifetime asthma dx 8.0% 
> 4 attacks last 12m 2.5% 
Dennis 
2012254 
Colombia (6 
large cities) 
2009
-10 
5878 5-17 
years 
Current wheeze 30.5% 
Lifetime asthma dx 8.6% 
Garcia 
2008255 
Colombia 
(Bogotá) 
2002 3256 6-7 y Current wheeze 10.4% 
Lifetime asthma dx 5.6% 
3829 13-
14 y 
Current wheeze 8.6% 
Lifetime asthma dx 9.7% 
Kausel 
2013256 
Chile (Los 
Ríos) 
2002 
+ 
2009 
3105 13-
14 y 
Current wheeze 16.0% (urban) 
Asthma ever 15.8% (urban) 
159 13-
14 y 
Current wheeze 16% (s-urban) 
Asthma ever 28%(s-urban) 
100 13-
14 y 
Current wheeze 6% (rural) 
Asthma ever 20% (rural) 
Moncayo 
2010257 
Ecuador 
(Esmeraldas) 
2005
-7 
3858 6-16 
years 
Current wheeze 10.5%  
Penny 
2001258 
Peru (Lima) 1997 808 8-10 
years 
Current wheeze 9.5% 
Lifetime asthma dx 20.7% 
Robinso
n# 
201186 
Peru (Lima 
and Tumbes) 
2009
-
2010 
725 13-
15 y 
Current wheeze 10.1% (urban) 
Lifetime asthma dx 13.0% (urban) 
716 13-
15 y 
Current wheeze 2.8% (rural) 
Lifetime asthma dx 2.2% (rural) 
Rodrigu
es Valle 
2014259 
Brazil (Rio d 
Janeiro) 
 3216 6-7 y Current wheeze 20.9% 
Lifetime asthma dx 7.3% 
Severe asthma* 8.8% 
Roncada 
2016260 
Brazil (Porto 
Alegre) 
 2500 8-16 
years 
Current wheeze 28.6% 
Asthma** 20.4% 
Schei 
200431 
Guatemala 
(W. Highlands) 
1998 1058 
homes 
4-6 
years 
Current wheeze 3.3% 
Lifetime asthma dx 2.6% 
Soto 
2014261 
Bolivia 
(Oropeza) 
2011 2340 9-15 
years 
Current wheeze (WQ) 16.4% urban 
21.7% rural 
Current wheeze 
(Video) 
7.3% urban 
3.9% rural 
*: ≥4 wheezing episodes, >1 night disturbance or speech limitations due to wheezing; **: Answered 
Yes to all 4 questions: asthma symptoms last 12 months, rescue treatment last 12 months, 
physician asthma diagnosis ever in life, asthma symptoms ever in life; #: Cross-sectional household 
survey, not ISAAC methodology. 
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The reasons why urbanisation may increase asthma prevalence are still being 
studied, though some contributing factors have been proposed, such as changes 
in diet and lifestyle, exposure to higher levels of environmental irritants (indoor 
and outdoor air pollution, household allergens and tobacco smoke), decreased 
parasitic infections  and increased viral infections in early life, greater antibiotic 
use and vaccine coverage, increased stress and smaller families262-268. To better 
understand the effect of urbanisation on asthma prevalence, Rodriguez et al87 
undertook an ecological study in 59 communities in transition from 
rural/traditional to urban/modern way of life, in Esmeraldas, Ecuador. They 
found a current wheeze prevalence ranging from 0 to 31.4% with an overall 
10.1%, in 7-15-year-old children87 (same population as Moncayo et al257 in Table 
2.12). The global summary urbanisation index was associated with current 
wheeze, and the variables indicating a higher socioeconomic status and a more 
urban lifestyle were shown to be more relevant compared to those related to 
urban infrastructure87.  
One other interesting finding that emerged from the ISAAC studies when 
comparing asthma rates in Phase I and III, was that the prevalence in Latin 
America is rising in contrast with the stabilization experienced in other high 
prevalent countries such as the UK or New Zealand2. Current wheeze increased in 
Latin America an overall 0.32% per year in 13-14-year olds and 0.07% in 6-7-
year olds; severe asthma (>4 attacks per year) increased 0.02% and 0.09% per 
year respectively; and lifetime asthma 0.25% and – 0.15% per year, respectively2.  
However, the results from the video questionnaire in 13-14-year olds, were 
slightly different, with an overall 0.04% decrease in current wheeze prevalence 
in Latin America2. As discussed previously, the discrepancies between findings 
obtained through the video and the written questionnaire were one of the 
limitations of the ISAAC studies. Of note was the increase described in Costa Rica 
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with already a high asthma prevalence in Phase I, as well as other low and 
intermediate prevalence countries (Argentina, Panama, Mexico, Chile and 
Paraguay), raising the concern that asthma rates in Latin America may continue 
to rise over the coming years (Table 2.11). On the other hand, the apparent 
decline in a high asthma rate country (Peru) may also indicate the possibility that 
asthma rates in high prevalent countries in Latin America may be reaching a 
plateau as described in the UK or Australia2.  
2.7.3. Asthma control 
The high rates of asthma symptoms in some Latin American countries are only 
one of the reasons that explain the significant burden of asthma in this region. 
One other factor is high morbidity consequent to inadequate management of the 
disease25. To study the quality of asthma control and treatment in Latin America 
through the patient’s experience, Neffen et al.24 undertook the Asthma Insights 
and Reality in Latin America (AIRLA) in 2003 in 11 countries. Children and adults 
with asthma diagnosis were identified by systematic household surveys in urban 
areas in each country. As seen in Table 2.13, they assessed the proportion of 
asthmatic children and adults that met the GINA criteria for adequate control. 
Nearly 70% of 808 children had used emergency care during the previous 12 
months (twice as much as reported in a similar study in Europe269), 57% 
reported asthma symptoms in the past month, 68% referred daily activities 
limitation due to asthma and only 2.4% fulfilled all GINA criteria for optimal 
asthma control24. On the other hand, there was a poor recognition of asthma 
severity, and even though 21% of the participants (children and adults) had 
severe asthma according to the GINA guidelines, only 6% of them perceived their 
disease as severe. Similarly, 44.7% of those with severe persistent asthma 
described their asthma as well or completely controlled24.  
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Table 2.13 The Global Initiative for Asthma (GINA) recommendations and results of 
the Asthma Insights and Reality in Latin America (AIRLA) survey in 11 Latin 
American countries in 2003 
 
 
 
 
 
 
 
 
 
 
Source: Neffen et al., Rev Panam Salud Publica, 200524.  
 
A new survey was undertaken in 2011 in Argentina, Brazil, Mexico, Puerto Rico 
and Venezuela: The Latin America Asthma Insight and Management (LA AIM)270. 
The aim of this survey was to explore the realities of living with asthma, to 
identify the disconnect between expectations in asthma management and the 
patient experience, and to identify unmet needs in asthma management270. They 
identified 2168 patients with asthma aged older than 12, of which only 7% had 
well-controlled asthma, 57% partially controlled asthma and 36% uncontrolled 
asthma271, as defined by GINA criteria37. For those aged between 12-17 years old 
asthma control was better, with a distribution of 23%, 16% and 15%, 
respectively271. The proportion of well-controlled asthma ranged from 3% in 
Venezuela to 9.3% in Brazil271. Patients with uncontrolled asthma had a higher 
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medication (relievers, oral corticosteroids and preventers) and health care 
(emergency room visits and hospitalizations) use271, than patients with well-
controlled asthma. 
Several other smaller studies have described a similar picture in diverse Latin 
American countries. In Peru, of those children reporting current wheeze, 28.6% 
and 45.5% (urban and rural residency, respectively) reported an emergency 
department (ED) visit during the previous year86. Similarly, in a population 
survey in the 6 largest cities of Colombia, 38% of 6507 asthmatic adults and 
children had visited the ED or had been hospitalized during the previous year272. 
We obtained comparable results from a case-control study in Esmeraldas, 
Ecuador, with 86% of the children treated for a bronchodilator responsive 
wheeze at the ED reporting having been treated for a similar episode during the 
previous year34. Even though the population, setting and outcome of these 
studies differed, the findings were very similar, suggesting that asthma control in 
Latin America is very poor, resulting in an excessive use of emergency care and 
hospitalisations for acute exacerbations273. 
In Salvador, Brazil, Antunes et al.274  studied the hospitalization rates for asthma 
over the period 1998-2009. Although asthma accounted for 18% of all 
respiratory diseases hospitalizations, they also experienced the largest decline in 
this period (88%), with a mean annual drop of 1.2 per 10 000 inhabitants, and 
this drop was greater between 2003-2006274. There are scarce data on 
hospitalization trends for asthma in Latin America, and even though this study is 
highly relevant, it is important to acknowledge some of its limitations, such as the 
use of secondary data (Hospital Information System and Brazilian Institute of 
Geography and Statistics) which may lead to under-reporting and lack 
representation of private hospitals or the possibility of incorrect or altered 
diagnosis (to maximise repayment for hospitalisation).  
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2.7.4. Asthma mortality 
Asthma mortality in Latin America is higher than that reported in other 
regions29,275. Neffen et al.275 studied asthma mortality rates in 11 Latin American 
countries in the 1980s, showing a high asthma mortality rate in most of them. 
The lowest rates were found in Colombia (1.35 per 100 000) and Paraguay (0.8 
per 100 000) and the highest in Uruguay and Mexico (5.36 per 100 000)275.  
Since then, several studies from Brazil revealed a rising trend of asthma 
mortality, up to a peak of 1.5 deaths per 1000 during the 1990s276, followed by a 
decline after the mid 1990s277,278. The same was described in Puerto Rico, with a 
mean asthma mortality rate of 4.77 per 100 000 and a decrease after 1999 (3.01 
per 100 000)279. These asthma mortality rates were 1.77 to 4 times greater than 
that in the US. A study from Uruguay, presented a progressive decline in asthma 
mortality rates over the period 1984-1998 (mean 5.10 per 100 000) with a more 
pronounced decrease in 1995-98280. This decreasing trend was inversely 
correlated with sales of inhaled corticosteroids280. An analogous inverse 
correlation between inhaled corticosteroid sales and asthma mortality trends 
was also described in Argentina, where crude asthma mortality rates decreased 
from 3.38 (per 100 000) between 1980 to 89 to 2.58 in the following decade281. 
Still, this decline was also positively correlated with the decrease in theophylline 
sales281.  
Even though asthma mortality rates varied greatly between countries, it is clear 
that they are declining throughout the region. Nevertheless, when analysing 
asthma mortality trends in different regions of Brazil, De Souza-Machado et al.282 
showed that this decline was mainly seen in the most affluent regions, while it 
had increased in the less affluent regions, highlighting the effects of inequality on 
health. One of the reasons for this, as explained below, is that asthma, a complex 
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chronic disease, is mostly being managed as if it were an acute illness rather than 
a chronic disease. 
There is scarce data on asthma mortality in children in Latin America. A study 
undertaken in Brazil, showed that there were 9051 deaths due to asthma in 
patients under 19 years old, and that 69% of these occurred before the age of 
5283. As described in adult studies, mortality rate also decreased during the study 
period, from 0.89 per 100 000 children in 1980 to 0.30 in 2007283 (Figure 2.15). 
This decline was more accentuated in the 1-4 year old group283, as seen in Figure 
2.15. However, Lotufo et al.278 showed that, even though there was a decreased in 
asthma mortality rate in Brazil between 2001- 2010 in the 15-24 and 24-34 year-
old groups, this decrease was not observed among the 5-14 year olds. 
 
Figure 2.15: Asthma mortality in children under 19 years old in Brazil, 1980-2007 
 
Source: Prietsch et 
al., J Pediatr, 
2012283. 
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2.7.5. Asthma risk factors 
Figure 2.16: Conceptual framework for environmental and host factors affecting 
the development of atopic and nonatopic asthma in Latin America. 
 
 
 
 
 
 
 
 
The figure illustrates how different environmental exposures and genetic susceptibilities 
may lead to the development of bronchial hyper-reactivity and asthma symptoms that are 
associated with or not associated with atopy. The effects of intestinal infections (such as 
helminths), crowding, and older siblings may modify the development of asthma through 
effects on the development of allergic inflammation, while other distinct (environmental 
irritants and respiratory tract infections) or similar (crowding) exposures may affect the 
development of asthma through distinct biological mechanisms and genetic factors. Many 
social and environmental factors may be involved in determining asthma severity. Risk (+) 
and protective (-) effects are shown. Arrows pointing at arrows represent interactions. 
Urban residence would be expected to increase both atopic and nonatopic asthma through 
effects on important environmental exposures (e.g. decreasing helminth infection 
prevalence, increasing exposure to pollutants, urban diet and physical inactivity, increased 
allergen exposure, etc.). 
Source: Cooper et al., Allergy, 200925. 
The observation of asthma rates being higher in large Latin American cities 
where overcrowding, dirt and infections are frequent, has led researchers to 
study whether risk factors for asthma in Latin America are different to those in 
Europe or North America, and do not conform to the ‘Hygiene Hypothesis’ 
described in the first section of this chapter. One of the reasons for these 
observed discrepancies may be due to the predominance of non-atopic asthma as 
discussed above, with alternative physiological pathway sand causal 
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mechanisms, and therefore different risk factors (Figure 2.16)25. In this sense, 
urban lifestyle and environments characterized by overcrowding, intestinal and 
respiratory infections, indoor and outdoor pollution, smoking, among many 
factors and frequently observed in Latin American cities, may be more conducive 
to the development of a non-atopic rather than atopic asthma phenotype. 
However, when reviewing the associations between poor hygiene and infections 
and asthma risk, current evidence is not sufficient to allow us to derive a 
conclusion as to whether poor hygiene exposures and early life infections affect 
the risk of developing childhood asthma in Latin America284. This was the 
conclusion of a systematic review we undertook, where we found that selective 
reporting of statistically significant results was common to many studies (except 
for the 6 cohort studies included in the review), exposure variables measured 
varied greatly between studies, and most of studies showed no associations with 
asthma or wheeze. The exception was early life acute respiratory infections, 
which showed reasonably consistent positive associations with wheeze/asthma 
across studies284. Nevertheless, as mentioned above, most of the studies did not 
stratify their results by atopic and non-atopic asthma hampering an analysis of 
the specific risk factors for each phenotype. Barreto et al.285 highlighted the 
importance of selecting appropriate comparison groups for asthma studies to 
avoid bias (Figure 2.17). In this sense, they investigated separately risk factors 
for asthma among atopic and non-atopic children, concluding that factors related 
to poverty, dirt and contact with other young children (day care attendance) 
were associated with a higher risk of non-atopic wheeze alone285. Overall, large 
prospective cohort studies with standardised outcomes are needed in Latin 
America to clarify the role of poor hygiene exposures and early life infections on 
the development of childhood wheeze or asthma. Such studies should help guide 
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policy makers on decisions of potential strategies to reduce the high asthma 
burden in Latin America. 
Figure 2.17: Conceptual framework for development of asthma/wheezing, with and 
without atopy, and choice of appropriate comparison groups. 
 
 
 
 
 
 
 
 
Source: Barreto et al., Respiratory Research, 2010285. 
Other than poor hygiene and infections, risk factors that have been associated 
with asthma in Latin America include overweight, psychosocial factors and diet. 
Being obese and overweight are now major public health problems in Latin 
America286, and have been associated with non-atopic asthma287. A study from 
Salvador, Brazil, reported that wheezing and asthma were more common among 
overweight children (4-12 years old) (prevalence ratio: 1.34; 95%CI 1.07-
1.67)288.  
When studying intrafamilial violence, Barreto et al.289 (2015) found that 
maltreatment non-violent discipline (adjusted OR: 1.95; 95% CI: 1.19-3.20) and 
non-violent discipline (adjusted OR: 1.95; 95% CI: 1.17-3.25) were associated 
with non-atopic asthma but not with atopic asthma in Brazil. For the most severe 
form of intrafamilial violence (maltreatment violent discipline), this association 
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disappeared after adjustment for confounders289. On the other hand, minor 
maternal psychiatric or mental disorders were associated with both atopic and 
non-atopic asthma in 4-12-year-old children99,100. Similarly, behavioural 
problems in children and community violence were also shown to be associated 
with asthma risk in Brazil97,98. Contextual violence (both from the community and 
family) as well as minor psychological or behavioural disorders may be 
frequently found in poor and highly stressed neighbourhoods that tend to grow 
at the peripheries of Latin American cities. 
As for the role of diet, a Mediterranean diet has been described to reduce asthma 
risk in Mexico and Peru290-292. In addition, fish consumption was found to have a 
protective effect against asthma in Brazil293. Fish fried in palm oil (a frequent way 
of consuming fish in Latin America) is rich in selenium, zinc and vitamin A, all of 
which may protect against asthma given their antioxidant effects294. Gomes de 
Luna et al.295 also showed that consumption of biscuits and fried snacks ≥3 times 
per week, was associated with asthma in adolescents in Brazil, while fruits ≥3 
times per week were found to be protective. All these factors have been 
associated previously with asthma outside Latin America as already 
discussed81,82. 
Other highly relevant risk factors, such as atopy and urbanisation have already 
been discussed in the previous sections. 
2.7.6. Asthma phenotypes in Latin America 
As presented previously in this thesis, asthma may be classified into very 
different phenotypes according to several characteristics (time of onset, 
associated symptoms or comorbidities, complementary tests results, etc.). We are 
now going to focus on the most widely used phenotype classification of atopic 
and non-atopic asthma. According to several studies, non-topic asthma is the 
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predominant presentation in Latin America. This was the case in Penny et al.258 
study in a low-income urban area in Peru, were there was no association 
between atopy (measured by Skin Prick Test, or SPT) and recent asthma, and 
only 28.6% of children with recent asthma and 24.3% with lifetime asthma were 
atopic. In another low-income urban population in Chile, the proportion of atopy 
(measured by SPT) among children with and without current wheeze was similar 
(44.2% vs 42.3%, respectively)296. Likewise, only 21% of the 9-13 year-old-
children with current wheeze in the small town of Uruguaiana (Brazil) were 
atopic (measured by SPT)297. Furthermore, 26.2% of Cuban schoolchildren with 
current wheeze were SPT positive and 38.2% were specific IgE positive298. 
Finally, the Phase II ISAAC study, revealed that only 11% of asthma was 
attributable to atopy in Latin American participating centres30. None of the 
previously mentioned studies reported the population attributable fractions 
(PAFs) of asthma due to atopy. 
However, there are also contradictory findings. In Peru, 77% of urban asthmatic 
children were atopic and 55.9% of the rural, when using SPT as a measure of 
atopy86. A study from urban Colombia found a 60% atopy among asthmatics and 
40% among non-asthmatics using allergen specific IgE254. In Esmeraldas, 
Ecuador, 68% of the children treated at the ED for bronchodilator-responsive 
wheeze were atopic when measured by SPT and 82% when measured by allergen 
specific IgE34. These discrepancies may be due to the prevalence of atopy among 
the general population in each location, the method used to diagnose atopy (SPT 
vs allergen specific IgE), as well as the severity of the disease. The differences in 
the degree of urbanisation and climate may also explain some of the variation 
observed, though for both low and high proportions of atopy among the 
asthmatics, there were studies carried out in similar Latin American urban 
settings. The study by Ardura-Garcia et al34 in Esmeraldas, Ecuador, included 
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children recruited at the ED for acute asthma, a sample of asthmatic children 
with a higher severity profile than those obtained from school or home-based 
surveys when enquiring about current wheeze. All in all, even in the populations 
where asthma is predominantly non-atopic, atopy is still one of the most 
important risk factors for those with persistent or severe asthma299.  
Urban or rural residency may also play a role in the differences observed in the 
proportions of atopy among Latin American asthmatics. Endara et al.300 analysed 
the fraction of wheeze attributable to atopy in urban vs rural residency, obtaining 
similar results both using SPT (23.5% vs 10.1%, respectively) or allergen specific 
IgE for house dust mite (26.5% vs 10.5%, respectively). Atopy was therefore 
more strongly associated with current wheeze in urban than rural populations 
(adjOR: 5.19; 95% CI: 3.37-8.00 vs. adjOR: 1.81; 95% CI: 1.09-2.99)300.  
2.7.7. Asthma management and costs 
Asthma is inadequately managed in many Latin American centres. Many factors 
may be responsible for this situation (Table 2.14) and the result is that in 
numerous Latin American countries, asthma is managed as an acute disease301.  
Table 2.14: Barriers to reduce asthma morbidity and mortality in Latin America 
Feature 
High asthma prevalence  
Lack of specialist doctors  
Poor asthma diagnosis and management 
Basic asthma drugs not available or affordable 
Limited availability of lung function tests  
Lack of regular follow-up of asthmatic patients 
Insufficient use and poor accessibility to long-term  
      medications for asthma control 
Low adherence to long-term medications for asthma control 
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Data from the AIRLA study24 revealed that only 38% of the children included in 
the study had ever had a lung function test, and 49% had a written asthma action 
plan. In addition, just 6% of the children and adults interviewed were using 
inhaled corticosteroids, with no increasing trend with increasing severity24. In 
addition, 57.1% of the participants had required an unscheduled health care 
attendance and 45.1% had visited the ED department for acute asthma during 
the previous year10. These proportions were even higher among children10 
(Figure 2.18). Similarly, we found that only 20% of the children treated at the ED 
for acute asthma in Esmeraldas, Ecuador were being followed-up regularly for 
their asthma, none had received inhaled corticosteroids, and 86% had had a 
previous ED visit for acute asthma during the preceding year34. This lack of long-
term follow-up and baseline medication is likely playing a vital role in the poor 
asthma control in Latin America, and it is an issue that affects patients, families 
and health care providers. 
 
Figure 2.18: Unscheduled health care resource use in children under 16 years old. 
 
 
 
 
 
 
 
Source: Neffen et al., J Investig Allergol Clin Immunol, 201010. 
Chapter 2 | Literature review 
74 
 
The AIRLA study also evaluated the costs associated with the use of unscheduled 
health care resources in Latin America. According to this study from 10 Latin 
American countries, 74.6% of annual costs for childhood asthma-related health 
care was due to unscheduled health care use, ranging from 45.6% in Ecuador to 
90.4% in Venezuela10. Together with these direct health costs, there are other 
indirect costs which should also be considered, such as those related to the 
school and work days lost due to acute asthma exacerbations. This clearly reflects 
the importance of poor asthma control on the economic burden to families and 
health systems produced by this disease. 
Asthma is an important economic burden for the patients and their families. 
Stirbulov et al.302 estimated that the annual direct costs per patient with severe 
asthma incurred by families varied between USD 764 and USD 929 in Brazil. 
Another analysis of the economic impact of severe asthma in low-income families 
in Salvador, Brazil revealed that up to 47% of family members had lost their job 
due to asthma, and that the costs derived from asthma management consumed 
29% of family income303. It is easily understandable that low-income families will 
abandon long-term treatments such as inhaled corticosteroids if forced to choose 
between basic necessities.  
However, there are examples of public health intervention programmes in Latin 
America for severe asthmatic patients that have proven to be cost-effective in 
reducing direct and indirect costs for families and public health systems, as well 
as improving asthmatic patients’ and their families’ quality of life. This is the case 
of The Programme for control of asthma and Allergic Rhinitis in Bahia (Brazil) 
(ProAR), a state-funded project aimed at acquiring control of severe asthma by 
providing free medication and care for severe asthmatics of low income in the 
city of Salvador304. ProAR reduced the hospital admissions rate for asthma in the 
city of Salvador by 74% (with an inverse correlation with inhaled corticosteroid 
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prescriptions), improved the asthma control scores by 50% and the quality of life 
by 74%304. This decreased consequently the costs to the public health system by 
387 USD per patient/year and the families by 789 USD per patient/year, thus 
increasing annual income of families by 18%304. The ascertainment of the 
feasibility and cost-effectiveness of such public health asthma programmes is of 
extreme importance to design similar interventions in other Latin American 
countries, supported by the Ministries of Health. 
2.8.1. Geographical Location 
Ecuador is situated in South America, surrounded by Peru and Colombia and the 
Pacific Ocean. It comprises 4 very differentiated areas: coast, Andean, Amazonian 
and Galapagos Islands. Each has a different climate, culture and population 
characteristics. 
 
Figure 2.19: Political Map of 
Ecuador (Source: Perry-
Castañeda Library Map 
Collection. University of Texas 
Libraries. 2011305.  
http://www.lib.utexas.edu/maps/
americas/txu-pclmaps-oclc-
785902207-ecuador_pol-
2011.jpg)  
2.8. Ecuador
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2.8.2. Population 
In 2010306, the total population in Ecuador was 14.5 million inhabitants. The 
distribution according to self-determined ethnicity was as follows: 72% mestizo, 
7% Afro-Ecuadorian, 7% indigenous, 6% white and 8% other. The median age 
was 28.4 years. 
2.8.3. Poverty 
The proportion of people living under poverty line has decreased from 36.7% in 
2008 to 22.9% in 2016 (less than 84.68 USD/month), with 8.7% living under 
extreme poverty (less than 47.72 USD/month) in 2016307. The GINI index, a 
standard economic measure of income inequality, (0 represents perfect equality 
and 1 represents total inequality) was 0.466 in Ecuador for the year 2016307. 
2.8.4. Employment 
As for the employment rate, 68.9% of the population of working age (11.7 
million) were economically active, of which 95.6% were employed (including 
self-employed) in March 2017308. The national unemployment rate in 2017 was 
4.4% (5.5% for men and 3.6% for women)308. However, only 47.3% of the 
considered ‘employed’, have an adequate or full employment, the rest are 
considered underemployed (20.9%), not fully employed (20.5%) or in an unpaid 
employment (5.4%)308. There is also a very high proportion of informal 
employment (45.6% in 2017), that is, employed in small unregistered 
businesses308. The mean monthly income for the employed population was 325 
USD in 2017 (355 USD for men and 277 USD for women)308. 
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2.8.5. Access to clean water and sanitation 
Around 70% of Ecuadorians have access to a source of safe water (piped, water 
well, spring or bottled water), 79% of those living in an urban setting and 51% of 
those in a rural setting309. Up to 86% of people have access to basic sanitation 
(sewerage, septic tank or latrine) for the household exclusive use, in Ecuador 
(89% urban, 80% rural)309. Finally, 86% of Ecuadorians have access to a hand-
washing station (water and soap) inside the household (90% urban, 75% 
rural)309. 
2.8.6. Health system 
Organizational levels 
The health system in Ecuador is organised at three different levels. 
a. First level: 
- Health sub-centre: Operational unit that performs basic health 
promotion, prevention and rehabilitation activities, including emergency delivery 
care for normal labour and dental care. On certain occasions, it promotes basic 
environmental sanitation and communal activities. It is formed by a basic team 
of: doctor, dentist, nurse and auxiliary nurse. It is normally situated in the parish 
centre. 
- Health Centre: Operational unit that offers integrated, comprehensive 
health promotion, prevention and rehabilitation activities and dental care. It 
offers auxiliary diagnosis services such as clinical laboratory and imaging studies 
(optional) and promotes environmental sanitation and communal activities. 
Some centres have observation beds for normal delivery and rehydration, and 
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others fulfil health control functions. It is normally situated in the province 
capital and main town of the municipality. 
Health centres are now divided into three categories: A, B and C. 
  A: For a population of 2000 – 10 000 inhabitants.  
     B: For a population of 10 000 – 50 000 inhabitants. It offers auxiliary 
diagnosis services such as clinical laboratory, basic imaging studies, 
optional audiometry and pharmacy. Attends referrals and counter-
referrals. 
 C: It offers also basic specialties (gynaecology and paediatrics), dental 
care, psychology, nursing, short stay delivery and emergency care, as 
well as auxiliary diagnosis services such as clinical laboratory, basic 
imaging studies, optional audiometry and pharmacy. Attends referrals 
and counter-referrals. The emergency department of these health 
centres operates 24 hours a day. 
- Basic hospital: Offers outpatient care, emergency care and short stay 
hospitalization in: general medicines, gynaecology and obstetrics, paediatrics and 
emergency surgery. It is part of the first level services for patients’ referral and 
counter-referral system and is normally situated in the main town of the 
municipality. 
b. Second level:  
- General hospital: Offers outpatient and inpatient care for the main four 
medical specialties as well as other subspecialties. It resolves the referrals 
received from less complex units and counter-refers them if necessary. It 
undertakes training and research. It corresponds to the second level of sanitary 
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services and is normally situated in the province capital and of the municipalities 
with a larger population. 
c. Third level: 
- Specialised hospital: Operational unit that offers specialised outpatient 
care, reference and inpatient care for a specific specialty or subspecialty, or that 
serves a specific age group. It serves both local and national population through 
the referral and counter-referral system and it may act as an acute or chronic 
care unit. It corresponds to the third level of sanitary services; it undertakes 
training and research and is normally situated in cities considered highly 
developed and with the greatest population density. 
Distribution 
Of the 742 establishments with hospitalization in Ecuador in 2014, 25% belonged 
to the public system, most of them being basic hospitals (52%)310. The vast 
majority of the private sector establishments were general clinics (91%). 
Figure 2.20: Number of Health Establishments with Hospitalization, divided by 
sector and establishment class. Ecuador, Year 2014. 
 
 
 
 
 
 
 
Source: INEC 2014310 
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The distribution of health care professionals throughout the country was unequal 
in the year 2014310, as reflected in Figure 2.21. The highest ratio of doctors per 10 
000 inhabitants was found in the provinces of Galapagos (33.68) and Napo 
(30.20), and the lowest in Los Ríos (13.61) and Esmeraldas (13.04)310. 
Figure 2.21: Ratio of doctors per 10 000 inhabitants in Ecuador years 2005 and 
2014, divided by provinces. 
 
 
 
Source: INEC 2014310 
Health care access 
Health care access in Ecuador is universal, that is, everyone has the right to have 
access to health care (management and treatment). However, health care is 
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Institute (Instituto Ecuatoriano del Seguro Social, IESS), which are used by all 
those who are regularly employed or who pay social security/national insurance 
voluntarily. Together with this, the Police, the Armed Forces and the Navy, have 
their own hospitals for their employees. 
Patients treated at any of these hospitals or health centres mentioned above do 
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included in the List of Essential Medicines of Ecuador, based on the WHO 
recommendations311. 
Private health centres and hospitals are also available to any person who wishes 
to pay for the services and treatment provided. 
2.8.7. Asthma in Ecuador 
Asthma prevalence and mortality 
There are scarce data regarding asthma prevalence in Ecuador. In the last GINA 
burden report, 16% of the Ecuadorian population had self-reported current 
asthma symptoms29, while 0.8% prevalence of recent wheezing amongst children 
aged 8-12 years old was found in a rural setting in the ISAAC phase II study30.  A 
studies undertaken in rural schools, from the provinces of Pichincha 
(mountainous area) and Esmeraldas (coastal area), found a prevalence of current 
wheeze of 2.1% and of lifetime asthma of 10.3%33 (Table 2.12). On the other 
hand, children attending rural schools in Afro-Ecuadorian communities in 
Esmeraldas alone, had a 10.5% prevalence of current wheeze257.As described in 
other Latin American countries 31,32, asthma cases in Ecuador may be 
concentrated in growing and overpopulated cities such as the city of Esmeraldas, 
while rural populations may have  a much lower prevalence33.  
To our knowledge there is no published data on asthma mortality from Ecuador. 
According to the WHO, in 2012, 4% of total deaths in Ecuador (81 000) were 
attributable to chronic respiratory conditions. 
Asthma management 
Asthmatic patients (both adults and children) may be treated at the public 
hospitals or the IESS hospitals, depending or whether they (or the child’s 
parents) pay social security quotas or not. Second level hospitals may be found in 
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every province capital, and these may or may not have a respiratory specialist, 
depending on the demand and the hospital’s health priorities. Third level 
hospitals are only found in the largest cities of Ecuador (Quito and Guayaquil), 
where there are both adult and paediatric pulmonologists and allergologists 
available. Therefore, asthmatic patients are mainly treated by general doctors or 
paediatricians (either at a hospital or primary care). In cases when asthma is not 
easily managed, then they are referred to specialist in Quito or Guayaquil. 
Patients may also be treated at private hospitals or with private specialists who 
visit province capitals once or twice a month.  
As for asthma medicines, acute bronchodilators (salbutamol and ipratropium 
bromide), systemic corticosteroids (oral prednisone, intramuscular or 
intravenous dexamethasone or hydrocortisone) and inhaled corticosteroids 
(budesonide) are part of the list of basic medicines from the Ministry of Health312 
and should therefore be available for free at the public hospitals. The IESS 
hospitals have their own list of available medicines (also for free for the IESS 
patients) and cover the same asthma medications. Even though these drugs 
should be available for free, this is not always the case, for different reasons. 
First, each hospital decides which medications to order from the basic medicines 
list, based on doctor’s demands. In the province of Esmeraldas, for example, 
inhaled corticosteroids (ICS) were not available at the public hospital, as they had 
not been demanded by the treating doctors. Second, the bureaucratic procedure 
to order medicines may delay the arrival of certain drugs. This was also the case 
with the ICS during the study period. I was invited to be part of the 
Pharmaceutical Committee at the public hospital of Esmeraldas during the study 
period, in order to ask for the inclusion of ICS in the hospital’s pharmacy. This 
was approved, but as budesonide (the ICS described in the list of basic 
medicines) was out of stock in the country, the procedure to order another ICS 
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(fluticasone), which was not in the list, was very slow and time consuming. As a 
result, ICS were still not available at the public hospital by the end of the study 
period). Third, on occasions specific medications run out of stock at the hospital’s 
pharmacy due to an unexpected overuse or to an inadequate stock control or 
inaccurate estimate. 
The public health system in Ecuador has a list of basic medicines that should be 
available for free at the public hospitals. This list includes acute bronchodilators 
(salbutamol and ipratropium bromide), systemic corticosteroids (oral 
prednisone, intramuscular or intravenous dexamethasone or hydrocortisone) 
and inhaled corticosteroids (budesonide)312. However, at the moment there were 
no inhaled corticosteroids available at the health centres, nor at the public 
hospital (HDTC), only at the social security hospital (IESS hospital), and there 
were no combined ICS with long acting beta-agonists or leukotriene receptor 
antagonists (LTRA) (montelukast) available for free. 
Oral salbutamol (both tablets and syrup) were freely available and widely used at 
the initiation of the study. However, they were no longer included in the 2014 list 
of basic medicines312 and were therefore no longer available at public and IESS 
hospitals in Ecuador. This led to a shift in the prescription of salbutamol during 
the study period, from oral to inhaled. Nevertheless, oral salbutamol is still 
available at pharmacies all over the country and is easily bought over-the-
counter. 
2.8.8. Risk factors for acute asthma in the city of Esmeraldas, Ecuador: a 
case-control study 
In October-December 2012 we undertook a case-control study in the city of 
Esmeraldas, Ecuador34. We aimed to collect some pilot data on the characteristics 
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of 5-15 year old children treated at the city’s public hospital for an acute episode 
of bronchodilator-responsive wheeze with difficulty breathing. These were 
defined as cases, while controls were age- and sex-matched children attending 
the emergency department for a reason other than asthma.  
The children’s parents completed a filed-tested questionnaire based on the ISAAC 
questionnaire. We collected blood (haematocrit, total white cell and differential 
count, ant total and specific IgE), stool (intestinal parasites detection) and 
nasopharyngeal swabs (PCR for respiratory viral infections). Lung function (pre 
and post-bronchodilator spirometry) and inflammation (fraction of exhaled nitric 
oxide (FeNO)) were also measured.  
We recruited 60 cases and 119 controls. The most relevant findings were that 
82% of children with an acute asthma attack had a positive allergen specific IgE 
for any aeroallergen (vs 43% of controls), all of them being positive to house dust 
mite. The population fraction of asthma attributable to mit IgE was 64%. History 
of bronchiolitis in early childhood, atopy (any positive sIgE), and higher parental 
education level were all independent risk factors for acute asthma when 
compared with non-asthmatic controls. Thirty-six percent of the 59 cases and 8% 
of the 103 controls with a nasopharyngeal swab sample were positive for rhino 
virus infection.  
As for asthma management, 77% of the 60 cases had been previously diagnosed 
with asthma by a doctor, 20% had had a regular asthma control appointment 
during the previous year, and 86% had suffered an acute asthma exacerbation 
requiring emergency care during this same period. Only 5 children had been 
taking long-term controller treatment during the previous year, being 
montelukast (none had taken ICS). On the other hand, 91% had used oral 
bronchodilators (salbutamol) during asthma exacerbations (Figure 2.22). 
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Figure 2.22: Treatment received during the previous 12 months by children with 
acute bronchospasm.  
 
 
 
 
 
 
 
ICS, inhaled corticosteroids; IV, intravenous. Source: Ardura-Garcia et al, Pediatric 
Allergy and Immunology, 201534. 
 
To conclude, this study showed that children treated for acute asthma symptoms 
at an ED in coastal Ecuador were mainly atopic, underdiagnosed and 
inadequately managed. 
 
2.9.1. General definition 
An acute asthma attack or acute exacerbation, is an acute or subacute worsening 
of respiratory symptoms and lung function. They are identified as episodes 
outside the patient’s usual status and daily variations, that require an increase in 
treatment (mainly anti-inflammatory treatment, as they do not improve on 
increased bronchodilators alone) and an unscheduled health-care visit. These 
2.9 Acute asthma attacks 
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events may vary in severity, as well as in speed of onset (from minutes to 2 
weeks) and time to resolution (5 days to 2 weeks)47,313. Several different terms 
are also used throughout the literature, for example, ‘asthma attack’ is usually 
used to refer to severe asthma exacerbations8. 
Asthma exacerbations are very common9. These acute events are especially 
relevant among children in whom they are extremely frequent, often following a 
viral respiratory tract infection11,12. 
2.9.2. Severity 
Severe asthma exacerbation  
The American Thoracic Society (ATS) and European Respiratory Society (ERS) 
published a joint statement in 2009 on asthma control and exacerbations, where 
they included the following definitions for severe exacerbations8: 
“Events that require urgent action on the part of the patient and physician to 
prevent a serious outcome, such as hospitalization or death from asthma. 
The definition of a severe asthma exacerbation for clinical trials should include at 
least one of the following: 
- Use of systemic corticosteroids (tablets, suspension, or injection), or an 
increase from a stable maintenance dose, for at least 3 days. For consistency, 
courses of corticosteroids separated by 1 week or more should be treated as 
separate severe exacerbations. 
- A hospitalization or ER visit because of asthma, requiring systemic 
corticosteroids.”8 
Moderate asthma exacerbation  
This same document also included a definition for moderate exacerbations: 
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“Events that are troublesome to the patient, and that prompt a need for a change 
in treatment, but that are not severe. These events are clinically identified by 
being outside the patient’s usual range of day-to-day asthma variation. 
A moderate asthma exacerbation is an event that, when recognized, should result 
in a temporary change in treatment, in an effort to prevent the exacerbation from 
becoming severe. 
The definition of a moderate asthma exacerbation should include one or more of 
the following: deterioration in symptoms, deterioration in lung function, and 
increased rescue bronchodilator use. These features should last for 2 days or 
more, but not be severe enough to warrant systemic corticosteroid use and/or 
hospitalization. ER visits for asthma (e.g., for routine sick care), not requiring 
systemic corticosteroids, may be classified as moderate exacerbations. 
The magnitude of change in these outcomes will differ depending on the 
population studied and each individual patient’s baseline variation.”8  
Mild asthma exacerbations: 
According to the referred ATS/ERS joint statement, there is no clear definition of 
what a mild asthma exacerbation is, as it is extremely difficult to differentiate 
from a person’s daily asthma symptoms variation, that is, a transient and short-
lasting loss of asthma control. 
2.9.3. Pathophysiology 
The decreased expiratory airflow evidenced during an asthma attack is caused by 
mucus hypersecretion, airway wall inflammation and bronchial smooth muscle 
contraction (Figure 2.23). This produces luminal obstruction and airwall oedema, 
that narrow the luminal space available for adequate airflow314,315. 
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These series of events occur as a response to a trigger (see below), though the 
specific immunologic mechanism underlying this process varies between 
patients, depending on their asthma phenotype and endotype, as described 
previously315. 
Figure 2.23: Mechanisms of asthma exacerbations 
 
 
 
 
 
 
 
  
Source: Graham et al, Curr Med Res Opin, 2015315. 
 
When analysing peak expiratory flow (PEF) variability, Reddel et al.316 observed a 
linear decrease during the duration of the asthma attack (few days) followed by a 
similar linear improvement. However, PEF variability during these same days 
was quite low, comparable to that found during stable asthma periods (7.7% vs 
5.4%). This contrasted with the great PEF variability observed during poor 
asthma control periods in these same patients (21%)316. Additionally, 
bronchodilator response was barely inexistent during asthma attacks (1% mean 
differences improvement of pre vs post-bronchodilator PEF) compared to the 
mean 28% increase in PEF after bronchodilator use during poor asthma control 
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periods316. These findings suggest a different physiological phenomenon 
underlying loss of asthma control and asthma attacks317. 
2.9.4. Triggers 
A wide range of factors have been described to trigger acute asthma attacks. 
These include allergens (both indoor and outdoor), smoking, air pollutants 
(indoor and outdoor), occupational exposures, foods and drinks (additives), 
exercise, drugs (e.g. non-steroidal anti-inflammatory drugs), viral and bacterial 
infections, hormones (menstruation and pregnancy) and emotional stress314. 
An asthmatic person may be affected by one or more of these triggers, and 
associations between them have been also described. This is the case of allergen 
sensitization and viral respiratory infections. Around 80% of adult and childhood 
asthma exacerbations may be secondary to viral respiratory infections, with 
human rhinovirus being the most common virus associated with asthma 
attacks318-320. However, several studies have shown how allergen-sensitized 
children and adults are more prone to suffering an asthma attack during a viral 
respiratory infection, especially if caused by human rhinovirus320,321. This 
association is stronger as the allergen-specific IgE titre increases321. Similarly, an 
exposure to high-levels of allergens (such as mite) may increase the risk of 
asthma attacks322. 
2.9.5. Short and long-term consequences of asthma attacks 
The relevance of acute asthma attacks, is not only due to their high frequency, but 
to the serious short and long-term consequences they may cause. 
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Clinical consequences 
a. Hospitalization and mortality: Severe asthma attacks may lead to 
hospitalization and even death if not treated promptly and adequately314. For 
example, half a million people were hospitalized for an acute asthma 
exacerbation in 2004323 and 3651 died in 2014, in the US324. 
b. Loss of lung function: A decline in lung function may appear secondary 
to airway remodelling caused by the activation of diverse inflammatory pathways 
during acute asthma exacerbations, leading to airway narrowing314. As part of the 
inhaled Steroid Treatment As Regular Therapy in early asthma (START) study, a 
randomized controlled study analysing the effect of early intervention with low-
dose inhaled budesonide on severe asthma-related events, which included 7165 
patients between 5-66 years old, an association between severe asthma 
exacerbations and a more rapid decline in lung function was found16. In a 
separate retrospective cohort study of 93 non-smoking asthmatics with 
moderate-to-severe disease, those who had suffered a severe exacerbation in the 
previous year had accelerated loss of lung function, with a 30.2ml greater annual 
decline in FEV1 compared to those who did not experience any exacerbations325. 
This association was independent of airflow obstruction at baseline325, an 
important finding that suggests asthmatics with chronic airflow obstruction 
(reduced FEV1) have a greater risk of asthma exacerbations, and that this 
reduced FEV1 may be caused by specific types of lung inflammation or other 
factors such as smoking, which would act as effect modifiers by increasing the 
risk of asthma exacerbations and reducing lung function at the same time314. 
Strunk et al.14 analysed how children with mild to moderate persistent asthma 
have a decreased lung growth when compared to healthy children, despite 
treatment with budesonide or nedocromil. However, to our knowledge there is 
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still a lack of data concerning the study of the effect of asthma attacks on lung 
growth and lung function on the long-term, in children. 
c. Stress and anxiety: Active asthma (asthma attacks or asthma-like 
breathing problems in the previous 12 months) was associated with panic 
disorder and/or panic attacks in a cohort study of 591 young adults326. Multiple 
other studies have shown an increased rate of anxiety and depression in 
asthmatic patients327,328. Additionally, extreme anxiety regarding asthma 
symptoms may negatively affect the patient’s response to an asthma attack329. 
d. Quality of life: Suffering an exacerbation in the previous year reduces 
quality of life measures330. This may be caused by the stress and anxiety 
mentioned above, as well as by the clinical symptoms and economic burden that 
asthmatic patients suffer because of acute exacerbations. 
Economic consequences 
Asthma attacks may incur in both direct (inpatient care, emergency visits, 
physician visits, nursing services, diagnostic tests and education) and indirect 
costs (school and work days lost, traveling and waiting time). Even though there 
is some discrepancy between studies, some publications have shown that 
indirect costs associated to asthma may be as high or even higher than direct 
costs331. 
a. Health care costs: According to Rodrigo, Rodrigo and Hall332, developed 
countries spend about 1-2% of total health-care expenditure on asthma. A total of 
$6 billion are spent on asthma each year in the US333. Acute asthma exacerbations 
account for a large proportion of health care costs associated to asthma, due to 
unscheduled outpatient appointments, emergency care visits or hospitalizations. 
In the US, patients that have been admitted to emergency care or hospitalization 
for an acute asthma exacerbation account for more than 80% of total direct costs 
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for asthma, even if they represent only 20% of the total asthmatic population332. 
Similarly, 73.2% of annual health care asthma-related costs was due to 
unscheduled health care in a study including 10 Latin American countries, though 
in this case, 57.1% of the patients required unscheduled health care resource 
use10. These unscheduled health care visit costs may take away resources from 
other clinical priorities, such as chronic asthma management.  
b. Missed school and work days: Data from the US revealed that adult 
asthma patients spent 1.4 times more days off work annually than non-asthmatic 
adults and they are also more likely to have activity or work limitations334. School 
and work performance may also be adversely affected by asthma attacks, even if 
these are not severe enough for them to stop their daily activities335. 
2.9.6. Prevention of acute asthma attacks 
Asthma attacks are generally preventable, either by avoiding previously 
identified triggers (acute respiratory infections, aeroallergen exposure, etc.) or 
by appropriate preventive treatment.  
Triggers and environmental factors avoidance 
Removing triggers and environmental risk factors completely is not always 
feasible unless severe restrictions are imposed on patients. However, minimizing 
the exposure should be attempted when possible315. Figure 2.24 includes some 
examples of who to minimize asthma exacerbation risk by avoiding 
environmental factors and triggers. 
Through asthma education, patients should be given advice on how to stop 
smoking and lose weight when indicated37,336. An initial correct diagnosis of 
asthma and associated co-morbidities (allergic rhinitis and gastroesophageal 
reflux) is also essential to attain adequate control37,336. 
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Figure 2.24: Strategies to reduce exposure to environmental triggers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Graham et al, Curr Med Res Opin, 2015315. 
Preventive treatment 
Although exacerbations may occur despite the use of inhaled corticosteroids 
(ICS) 15, they have been shown to be the single most effective treatment for 
reducing asthma exacerbations in adults when taken regularly337.  ICS reduce the 
number of overall exacerbations by 40% when compared to other anti-
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inflammatory treatments such as leukotriene receptor antagonist7, or by 55% 
when compared to placebo or short-acting beta2 agonists337, as well as attenuate 
the decline in lung function associated with acute exacerbations16. 
Certain add-on medications may decrease the risk of exacerbation even further 
than ICS alone. Long-acting beta2 agonist (LABA) reduced the rate of 
exacerbations by 26% when added to ICS, compared to ICS monotherapy337. 
Montelukast (a leukotriene receptor antagonist) can reduce the risk of asthma 
exacerbations in around one third of the patients when combined to fluticasone 
(ICS), compared to the combination of fluticasone and salmeterol (LABA)338. In 
addition, omalizumab (humanized monoclonal antibody to IgE) may also reduce 
asthma exacerbations by 26% when combined with high-dose ICS and LABA, 
compared to high-dose ICS and LABA alone, in patients with severe allergic 
asthma, reduced lung function and clinically significant exacerbations339. A 
Cochrane meta-analysis concluded that omalizumab may reduce asthma 
exacerbations by 45% and hospitalizations by 84%, as an adjunct to ICS in 
patients with moderate to severe asthma340. Omalizumab, however is a very 
expensive medication that needs to be administered subcutaneously and is only 
effective in allergic asthma patients. 
Nevertheless, when considering the use of a certain medication, side-effects, cost 
and patient preferences should be all considered to assess the benefit-harm 
balance. Inhaled corticosteroids have demonstrable systemic effects, especially 
affecting the hypothalamo-pituitary-adrenal axis. They produce a reduced 
growth velocity and slight reduction in final adult height (a 1cm decrement)160 
and have been associated with decreased bone mineral density and increased 
risk of fratures161, cataracts162, oropharyngeal candidiasis163, skin thinning and 
bruising164, and a higher risk of pneumonia341. These side effects are related to 
dose and type of ICS (higher risk with fluticasone)342. Montelukast has also been 
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associated with headaches, pharyngitis, abdominal pain, dyspepsia, cough, 
arthralgia, pulmonary eosinophilia, hypersensitivity reactions, gastrointestinal 
disturbances, respiratory infections, seizures, raised liver enzymes and 
neuropsychiatric adverse effects343-345. On the other hand, it is important to bear 
in mind patient’s preferences. For instance, an asthmatic patient may prefer 
suffering an acute asthma attack a year (even if it means going to the ED) than 
taking daily medication for years. This would inevitably lead to a lack of 
adherence to preventive medication. Finally, the cost of baseline treatment (used 
daily) should also be considered, for an effective use of the resources: Is it cost-
effective to treat every asthmatic child that suffered an acute asthma attack with 
a preventive medication? Which of these children should then be treated? All 
these questions need to be answered before deciding upon initiating an 
asthmatic child on preventive treatment (Figure 2.25). 
Figure 2.25: The balance of benefits and harms that need to be considered before 
initiating an asthmatic child on preventive treatment. 
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Education and self-management 
There are several other important factors that may affect asthma exacerbation 
risk and that may be attained through adequate patient information and self-
management. Improving inhaler technique and increasing medication adherence 
are early steps to be taken when asthma control is not optimal37. As mentioned 
previously, providing the patient with a written asthma action plan that he/she 
may follow to modify their treatment accordingly when suffering an acute 
worsening of the respiratory symptoms may reduce hospital admissions for 
acute asthma by 40% and emergency care attendances by 20%225. 
On the other hand, increasing the community’s awareness of asthma may reduce 
asthma mortality as it reduces the risk of patients ignoring their symptoms or not 
being prepared for them346. This is the case of the Stop Asthma Deaths campaign 
by Asthma UK346. 
The relationship between health care providers and patients has been changing 
over the years in high income countries, shifting from a paternalistic position 
where the doctor makes all the decisions concerning the patient’s health and 
treatment, to one where the patient is included in the process of discussing and 
selecting the most appropriate treatment. This later is commonly referred to as a 
shared decision making (SDM) process in which the patient plays an important 
and active role, expressing his preferences and opinion after being informed of 
the evidence available by the health care provider 347. Evidence-informed patient 
choice "involves providing people with research-based information about the 
effectiveness of health care options and promoting their involvement in decisions 
about their treatment"348.  
2.10. Communicating risk 
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For patients to be able to make informed choices, evidence needs to be presented 
in a way which is easy for them to understand. This should include risk 
communication, which is the base of the uncertainty that is present in everyday 
general practice349. Different tools have been developed to help patients consider 
the best choice for them by presenting the information in a structured fashion 
and using lay language. These tools, or ‘decision aids’ have been shown to 
improve patient’s understanding and increase their participation, decrease the 
proportion of hesitant patients, as well as decrease the disagreement and 
increase the concord between patient and provider350. However, decision-aids 
are not commonly used in clinical practice, particularly in lower income settings.  
A study consisting of focus group discussions to address the use of an informative 
webpage for patients with chronic back pain, showed that patients acknowledged 
the accessibility of the easy to understand, research-based information, though 
they did not rely entirely on the source of the information351. The credibility 
depended more on the previous patients’ beliefs or attitudes towards research 
than on the presentation of the information, especially if they considered this 
information could be biased if derived from the government or a pharmaceutical 
company351. Finally, they expressed a difficulty in applying the research-based 
information to them, particularly when addressing medical uncertainty, as they 
found that a population-level statistic was not relevant for them at an individual 
level351. This study reflects the problems encountered when transferring medical 
evidence to patients, specifically risk and uncertainty in chronic diseases with 
multiple treatment alternatives, where one choice does not preclude the rest. 
Even though this setting may seem very different to that affecting asthmatic 
children in Ecuador, patients’ beliefs and attitudes towards research in relation 
to chronic diseases could show similarities across the globe. In a setting where 
patients and caregivers are offered less information regarding there disease and 
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where patients may have a lower health literacy, it may prove even more difficult 
to transfer medical evidence to patients. 
Several studies have explored risk communication for conditions with a high 
level of concordance between the patient and the provider, such as cancer or 
genetic conditions 352. However, there is a relative lack of evidence regarding 
health behaviours including those involving long-term daily medication to 
prevent future risks353. The RISAP study, aimed to investigate the effect of shared 
decision making and risk communication tools in a long-term condition such as 
hypercholesterolemia and future cardiovascular risk353. The general practitioners 
participating in this study, identified two types of medical uncertainty: the 
epistemological uncertainty (related to the evidence-based medicine) and the 
situational uncertainty (related to the patient-provider relationship)353. They 
described optimal risk communication tools as those with simple access and 
handling, easy to understand and obvious colouring, as well as with straight 
forward explanations of the risk and available options353. 
Asthma is an example of a chronic disease requiring long-term treatments to 
prevent future risks. There is scarce evidence around risk communication in 
asthma, and even less concerning provider-caregiver-child communication, given 
asthma is more prevalent in the paediatric population. Children present a greater 
challenge, as medical interaction is normally dominated by the provider and the 
caregiver, and therefore they seldom speak during visits354. They have difficulties 
communicating and reporting their symptoms and questions, even more the 
greater the asthma severity is355,356. Even when provided specific educational 
interventions to improve communication skills, they still need prompting to 
disclose symptoms to the provider357. This may hamper the patient-provider 
communication and the shared decision-making process. For example, Gilette et 
al.358 described that providers rarely discussed asthma drug risk with children.  
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Another adversity faced when communicating risk to asthmatic children in our 
specific setting, is the disparities that have been found in asthma outcomes and 
care concerning minority populations. The differences in socioeconomic status, 
educational level, environmental exposures and access to care, only partially 
explain the greater asthma morbidity observed in certain minority groups, such 
as African-Americans in the United States359. Therefore, another important factor 
to consider may be the disparate quality of care these minorities receive359. The 
reasons behind this disparity in the quality of care are numerous, including a 
poor patient-provider communication359. Bicksey et al.360 found in a study of 12 
families, that white parents of asthmatic children were more conscious of asthma 
triggers in their home environment compared to African American parents, while 
there were no differences by education or income level. Additionally, African-
American parents admitted not having received any information concerning 
asthma triggers by their providers, while white parents had received such 
information360. Thus, health care disparities in the doctor-patient communication 
are not only due to the differences in health literacy or beliefs on the patient’s 
side, language barriers and lack of self-efficacy, but also to the stereotyping and 
expectations of health outcomes from the doctor’s side, an inadvertent racial bias 
in decision making and deficient appreciation of ethnic and cultural disease 
experience359. Consequently, minority asthmatic patients receive less information 
from their providers.   
A cross-sectional survey to caregivers of asthmatic children in Mexico361 revealed 
how they frequently change of health care providers (5 or more doctors seen in 
72% of the children included in the study), due mainly to a lack of improvement, 
high costs and long delays. This frequent relay of health care provider may well 
be a consequence as well as a cause of a deficient patient-provider relationship. 
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More than half of the families surveyed were little or not satisfied with the care 
their asthmatic children were receiving361. 
There is no published data of communicating asthma risk to children in Ecuador, 
though many of the raised points could be easily applied. However, in Ecuador, 
doctor-patient communication has not yet evolved into a shared decision making 
relationship, but rather it is the doctor who tells the patient what to do and 
information offered is scarce. The disparities that have been described in asthma 
care in minority populations may well be experienced in Ecuador as a whole, and 
even more in areas of lower income and with a predominance of ethnic 
minorities (Afro-Ecuadorian or Indigenous).  
All in all, it is vital to explore the best way to inform asthmatic children and their 
carers of their future risk of suffering acute asthma exacerbations, as only 
through this knowledge will they understand the importance of having an 
adequate follow-up and adhering to baseline long-term treatment when 
indicated. To the best of our knowledge there is no published study analysing the 
communication of future risk of acute asthma exacerbations to children, nor in a 
setting with low health-care literacy. Together with this, it is also crucial to 
understand the barriers to health care access and treatment, as the final aim of an 
adequate asthma management is to minimise future risk in every patient, either 
through lifestyle modifications, appropriate self-management of exacerbations or 
long-term medications if needed. Mixed-methods, that is, combining quantitative 
with qualitative data is the only way we may obtain a complete picture of a highly 
complex aim, such as an improving the management of asthmatic children with 
frequent acute asthma attacks, reducing their future risk (both of asthma attacks 
and side-effects of medications), and decreasing asthma health-care costs. 
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2.11.1. Asthma acute attacks significance 
Initiatives to improve asthma control highlight the need for: qualitative data to 
better understand and address asthma; the creation of associations between 
patients and providers (such as asthma clubs); improving their participation 
through the recognition of perceived barriers and facilitators; increasing their 
self-efficacy asthma care skills362.  Understanding how asthma is perceived by 
caregivers and health care workers, how they deal with asthma and its 
recurrence, and exploring their needs and expectations is a challenge for health 
researchers both in high and low-income countries.  
In general terms, for Latin-American populations residing in the United States, 
paediatric asthma is perceived as a burden, not only for the child, but for the 
caregivers and family. Latino caregivers of asthmatic children in Connecticut, US, 
reported being concerned about asthma, especially about asthma attacks, which 
they perceived as inevitable363. They felt powerless and were afraid of not being 
well prepared in case their child suffered an acute asthma attack, because of their 
lack of knowledge 363. They discussed feeling vulnerable, deflated and confused, 
mainly because of limited English which made them struggle with 
communication and understanding363.  
Chen et al.364 described how persistent asthma in children caused a negative 
impact on the health and daily life of caregivers in Taiwan, as it brought along 
feelings of chaos and instability, such as worry, fear, frustration, helplessness and 
physical distress. Likewise, Mansour et al.365 undertook a qualitative study in 
Cincinnati, US, with low-income caregivers of asthmatic children who voiced 
2.11 Qualitative data on acute asthma attacks significance and 
barriers and facilitators to health care access 
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concerns about the constraints that their child’s asthma made on them, and how 
their quality of life was affected.  
A study from Detroit, US, described how caregivers often forget about their own 
health and chronic diseases366, and in order to fight these stressors, caregivers of 
asthmatic children need to develop different coping strategies such as 
meditation, prayer, time management or self-awareness of emotional 
reactions366. 
Caregivers perceive asthma as unpredictable and causing fear365,366. Even though 
some caregivers talked about being afraid of the next exacerbation and felt 
overwhelmed, others experienced denial, anger and rejection, or even 
resignation364,367.  
Together with these, caregivers discussed how the burden of the child’s asthma 
care also caused a disorientation of daily activities and economic constraints. 
This could also lead to family disagreements or mistrust on certain family 
members who take care of their asthmatic children364,366,368. On the other hand, 
social support is also discussed as something important that relieves caregivers 
from the burden of taking care of their child’s asthma, though the degree of social 
support they may count on is highly variable365,366. 
There is scarce data on caregivers’ perception of their children’s asthma from 
Latin America, though these may not vary significantly from other settings. A 
Mexican cross-sectional study including 300 caregivers of asthmatic children 
(different degree of severity) reported that 77% of the caregivers agreed that 
their child’s asthma affected their family life in a variety of ways (emotional, 
functional, social and labour wise)369. Similarly, a Colombian analysed family 
functionality (capacity to confront stressful situations and perform basic tasks 
such as communication or problem-solving) among caregivers of asthmatic 
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children aged 7-12 years370. Family dysfunctionality was more frequently 
observed among families of children with uncontrolled asthma when compared 
to those with controlled asthma370.   
As was the case in non-Latin American qualitative studies previously described, 
Colombian caregivers of asthmatic children perceive asthma attacks as 
potentially fatal episodes that could mean the death of their child371. They also 
reported how asthma affects the quality of life of their children, by limiting their 
daily activities371. Similarly, In Peru, mothers of children hospitalized for asthma 
described feeling confused, uncertain, nervous, desperate, angry and scared at 
the possibility of their child dying372. These mothers reported feeling guilty, as 
they are responsible for taking care of the child372. During these moments of 
uncertainty, mothers relied on their faith in God and that gave them strength to 
bear such a stressful event372. Finally, as described above, caregivers of asthmatic 
children in Brazil also highlighted the importance of social support (family, 
friends) to share the burden of the care373. Taking care of asthmatic children may 
cause social isolation and lack of self-care for the caregivers, given the excessive 
time they need to dedicate to their sick child373. 
There are also some published papers of the children’s perception of asthma and 
experiences. Several Brazilian qualitative studies undertaken with children with 
asthma, showed how asthmatic children are also worried about missing school 
days and decreased opportunity to learn, due to their asthma attacks, even more 
than their parents are374,375. As described previously, missed school days and 
work-days for caregivers are an important consequence of asthma attacks. Other 
effects on their daily life that children mentioned in these studies were daily 
activity and play restrictions, and conflicting interactions with other 
children374,375. The level of activity limitations depended on the asthma severity, 
from living a normal life between asthma attacks, to having their daily activities 
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and routines greatly affected most of the time375. These limitations and make 
them feel sad, and isolated. The fear of transmitting asthma to their peers and of 
showing their limitations in front of others increased even further this 
isolation375. They also reported night-time symptoms as those more trouble or 
worrisome for them375. 
Several qualitative studies have been undertaken among asthmatic adolescents, 
though mainly in non Latin-American countries376. Adolescents, as did children, 
described having activity limitations, feeling different from their peers, the 
importance of social support (family, teachers, friends, etc.) for an adequate self-
management and the difficulties faced to access/use treatment during school 
time376. Social stigma for use of inhalers in public is a concern associated to 
asthma that has also been reported by adolescents377.  
These qualitative studies explored the caregivers’ or asthmatic children’s 
understanding of the disease process of paediatric asthma, though they did not 
specifically study the significance of children’s acute asthma attacks for them. 
There is even less published information on the significance of paediatric acute 
asthma from the health care workers point of view. 
2.11.2. Barriers for Health and Home Care Access 
Multiple qualitative studies have described the perceived barriers to health care 
access for different diseases. Hirmas et al378 published a qualitative systematic 
review of barriers and facilitators to health care access, including 19 studies 
undertaken in people who had contacted health care systems (mainly) and health 
care workers, between 2000-2010. The 230 barriers found were classified 
according to Tanahashi’s model379 into 4 categories: acceptability (87), 
accessibility (67), contact (51) and availability (25)378 (Figure 2.26). This 
classification proved to be very useful, as there was great heterogeneity in the 
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barriers identified and the classification systems used. Figure 2.26 shows the 
main barriers identified, organised into subcategories with the percentage 
number for each subcategories and category. Only 4 of the included studies 
identified barriers perceived by health care workers, which corresponded mainly 
to availability and contact categories378. Even though this systematic review 
included studies analysing barriers to general health care access, they could well 
be applied to asthma health care. These studies were carried out mainly in the US 
and Canada, though it included also 5 studies from Latin American countries, and 
one from Zambia. 
Figure 2.26: Barriers to health care access 
 
 
 
 
 
 
 
 
 
 
The percentages illustrated by the bars and the numbers along them represent the proportion of the 
number of barriers identified for that subcategory (e.g. social stigma) in relation to the number of 
barriers in that category (e.g. acceptability). The percentage in brackets along each category 
represents the proportion of the number of barriers identified in that category in relation to the total 
number of barriers. 
 Source: Modified from Hirmas et al., Rev Panam Salud Publica, 2013378. 
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Acceptability 
For the acceptability domain, that includes social, cultural, or religious factors, 
beliefs, cultural norms and values that may influence the health services 
perception and its use, German caregivers of asthmatic children expressed 
mistrust in generic prescribed asthma drugs367. Similarly, caregivers of children 
discharged from the emergency department (ED) following an acute asthma 
attack in the US, reported feeling concerned about the health care worker’s 
judgement380.  
Health beliefs led caregivers to modify the asthma management prescribed in the 
US365, as they prefer non-medical alternatives to drugs368. They also mistrusted 
the physician’s interests (more worried about costs than the patient)365 or feared 
hospitals366. Another acceptability barrier, described by caregivers, is a cultural 
difference with health care workers in that they do not treat their asthmatic child 
in the ‘holistic’ manner, they preferred365,367. 
Belief in natural or ancestral remedies, or alternative medicines, is frequently 
described in Latin American populations. Caregivers of asthmatic children from 
Colombia described having used natural remedies to treat their child’s asthma381. 
They follow their family’s advice to choose the adequate natural remedy381. Some 
caregivers reported preferring natural remedies371, a belief that may be 
influenced by the cosmovision of the indigenous peoples and their traditional 
knowledge of natural resources. However, they are frequently taken as a 
complement of traditional medicines381.  
In addition, caregivers from Peru and Colombia reported several myths 
concerning inhaled drugs for asthma, such as that they damage the heart and 
lungs, cause dependency and behavioural problems, affect growth, the nervous 
                                                                          Chapter 2 | Literature review 
107 
 
and osteomuscular system, cause overweight and obesity, affect the child’s 
intellectual abilities and cause asthma371,382. 
Accessibility 
Accessibility barriers include physical and geographic location of the health 
service in relation to the population served, as well as administrative 
requirements. Cost of drugs and the inconvenience of their use (inhalers), waiting 
times and waiting lists, difficulties obtaining time off-work, as well as 
transportation issues have also been mentioned by caregivers of asthmatic 
children as accessibility barriers to asthma health care365-368,383. These barriers 
were also reported in Latin-American studies361,372. 
On the other hand, the cost of making lifestyle adjustments such as replacing a 
carpet or buying an air conditioner were also barriers for an adequate asthma 
care at home365. These adjustments, or similar ones adapted to the different 
climates would be even more inaccessible for deprived families, especially when 
living in low-resource settings.  
In a qualitative study of focus group discussions with general practitioners, the 
cost of the drugs and the patient’s access to drugs and medical care was also 
reported as a barrier to adherence to medication384. 
Contact 
Characteristics and quality of the health care service and treatment continuity, 
including doctor-patient relationship are classified as contact barriers. One of the 
contact barriers to asthma health care that is frequently described in qualitative 
studies with caregivers is the mistrust in medications, due to either their side-
effects, or the fear of developing dependency, addiction or 
tolerance364,365,367,368,383. These beliefs have also been mentioned in the 
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acceptability section, and it affects not only inhaled corticosteroids, but 
salbutamol inhalers too371,382. 
In a qualitative study that included both adult asthmatic patients and caregivers 
of asthmatic children, participants reported not taking their medication as they 
believed their disease was not serious and that they should only be taken in 
response to symptoms368. Colombian caregivers also reported interrupting their 
child’s asthma inhalers once the symptoms had improved371. 
Dissatisfaction with communication with health care workers is also commonly 
brought up. Caregivers feel misunderstood, ignored and helpless and report that 
health care workers act in a judgemental or discriminating manner and distrust 
caregivers, and that there is no real shared decision-making process nor patient-
centred approach365-368. Language barrier is an important component of a 
deficient patient-physician communication, as was described by some 
caregivers363,368 who also reported the use of medical terminology which they 
could not fully understand380. General low quality or inadequate care and burden 
of care for the caregiver associated with the management of the asthmatic child, 
were also reported364,367. 
Availability 
Lack of available health care services and programmes for the population served 
are defined as availability barriers. Some availability barriers such as scarce 
office hours and protected time with the health care provider, or limited health 
care resources were also reported by caregivers361,367,368,380. Likewise, general 
practitioners (GPs) in the UK also stated that they needed more time to spend 
with the patient, but that they were often time-pressured384. Additionally, they 
reported a lack of access to spirometry to offer a correct diagnosis384. There is a 
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lack of comparable studies undertaken in health care providers in Latin America 
with which to compare these findings. 
Caregivers in different studies discussed the lack of information that they 
received from health care workers on asthma medications, home care and 
recommended physical activity, leading to a lack of knowledge concerning their 
child’s asthma management365,367,368,380. They also reported discordant or 
contradictory indications from different health care workers 367,368,371,380. 
Besides, GPs in the UK also thought that they needed a continuing medical 
education, though they lacked time and access to it 384. The cost and time needed 
to provide patient education on asthma was again reported as a barrier by GPs384. 
The written asthma action plan, which is recommended to be offered to every 
asthmatic patient in asthma management guidelines, was not valued by either 
patients or health care workers, who reported several barriers to its 
implementation such as lack of time to provide and explain, not being available, 
not having storage space for them, the need to update them regularly and the 
existence of different formats 385. 
2.11.3. Facilitators for health and home care access 
The qualitative systematic review also identified 35 facilitators to health care 
access, though they did not follow the same classification378. Some of these were: 
social support, value assigned to health care to reduce risks and complications, 
adaptation of health care services to the patient’s needs and management 
programmes, patient-physician communication and quality of their relationship, 
diagnosis acceptance, available reminder systems for treatment adherence, and 
trust in medication prescribed378. Some of the previously mentioned qualitative 
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studies also described facilitators reported by caregivers, which we will classify 
into the same 4 categories.  
Acceptability 
Colombian caregivers of asthmatic children also appreciated and believed in 
traditional medicine, even if taking natural remedies as a complement371. 
Accessibility 
As for the accessibility category, caregivers reported that the existence of a public 
health system or drug plan that enabled them buy cheaper or free medicines, was 
a facilitator for adherence to long-term treatment368. The existence of new, more 
efficient drugs was also discussed by caregivers as a facilitator to increase 
adherence to their child’s asthma medication368. Finally, caregivers expressed 
feeling reassured when they had access to health care professionals and 
prescription renewal368. 
A Brazilian qualitative study evaluated the effect of a specific asthma programme 
(National Plan for Asthma Control) from the caregivers’ perspective386. This 
programme included, among other measure, access to free drugs to treat mild 
and moderate asthma. Caregivers expressed relieve at receiving free treatment 
for their asthmatic child, as they did not count with the necessary money to pay 
for it always386. They reported how their children’s asthma had improved after 
being enrolled in the programme and how they were now less worried386.  
Contact 
In the contact category, some caregivers reported using the asthma medication 
prescribed for their children (both acute medications and preventive long-term 
treatment), understanding asthma as a chronic condition, finding asthma 
medications easy to use, perceiving their child’s asthma as well-managed and 
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feeling satisfied with the medication which they perceived had beneficial 
effects367,368.  
They discussed how being proactive (to obtain information on asthma 
management) and establishing routines for taking the medication helped adhere 
to long-term baseline treatment368. Likewise, some caregivers were fond of Peak 
Expiratory Flow (PEF) measurements and used them for own estimation and 
reassurance367. They also reported finding rehabilitation positive and helpful367. 
Another contact facilitator caregivers brought up was having a good relationship 
with the health care worker, trusting him/her, being followed-up by the same 
professional in a structured way and receiving a patient-centred approach in 
which the caregiver and health care worker agreed together on the management 
plan and treatment367,368. Trusting the health care worker is also part of the 
acceptability category, for which we found no other published facilitators.  
Mothers of children admitted to hospital for acute asthma in Peru, reported 
having a good relationship with the healthcare workers, for whom they felt 
grateful372. They highlighted the nurses’ role, who did not only take care of the 
medical aspect of the treatment, but also treated affectively372. 
Availability 
As for the availability category, caregivers in different studies expressed the 
desire to improve their asthma knowledge and receive further asthma 
education363,380, though they differed on the preferred way to receive this 
information: video363, verbal teaching and communication380 or oral information 
direct from the treating doctor367.  
Sufficient explanation about asthma and its management, good inter-professional 
communication and adapting the information provided to the patient, improved 
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reported adherence to the health care worker’s indications368. Some caregivers 
reported feeling comfortable with their asthma knowledge and how they manage 
their child’s asthma and his/her medications365,368. They also discussed how they 
found the written asthma action plans useful, motivational, and reassuring as 
well as helpful to mitigate the language barrier363,365,368. Likewise, they reported 
how self-management could be useful in anticipation of triggers368. 
Social support and agreement between the asthmatic child caregivers was seen 
as an availability facilitator to health and home asthma care access by 
caregivers366,368. Some caregivers reported that the availability of a written 
asthma action plan could act as a motivational instrument for other family 
members to use363. Others discussed how receiving a clear and precise diagnosis, 
together with a formal assessment of their child’s asthma severity could also act 
as an availability facilitator368. 
Other 
Another facilitator caregivers brought up, which is difficult to classify in any of 
the 4 categories, was the use of coping strategies to reduce the stress produced 
by taking care of their asthmatic child366. These coping strategies included 
prayer, laughter, meditation, time management, social support and conscious 
self-awareness of emotional reactions366. Religious faith was mentioned in some 
Latin American studies, as a mechanism that enabled them to cope with stressful 
situations371,386. 
Possible facilitators or opportunities described by general practitioners were: 
improving patient education and self-management, including the use of written 
asthma action plans; establishing continuing medical education , especially for 
the use of new drugs, managing severe asthma, diagnosis, use  of spirometry and 
stages and complications of treatment; prioritising patient’s access to asthma 
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medications and medical care; reviewing patients regularly; offering the patient 
an accurate diagnosis; increasing the available time per patient; improving care 
at the community level by increasing public awareness384. 
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3. Predictors of risk of re-attendance to 
emergency care and hospital readmission due to 
asthma attacks in children: a systematic review 
and meta-analysis. 
 
Asthma attacks are common 9 and are associated with high healthcare costs 10 as 
well as missed school and workdays. They cause anxiety 13 and carry a risk of 
death and long-term effects such as loss of lung function11,14. These acute events 
are especially relevant for children among whom there is the greatest potential 
for reduction in disability. Attacks often follow a viral respiratory tract 
infection11,12 but secondary care attendance is generally preventable. Attacks may 
occur despite the use of inhaled corticosteroids 7,15, though it is neither affordable 
nor safe to provide all children with more aggressive treatment, particularly in 
low-middle income countries. It is therefore important to be able to identify 
patients at greatest risk of further attacks and hospital admission to better 
prioritize limited resources and provide additional education and support or 
adjustments to treatment where most needed.  
Currently, it is not possible to predict which children amongst those treated for 
an acute asthma attack, are at a greater risk of suffering repeated attacks. The 
development of a tool to enable clinicians to identify such children could be 
useful to optimise treatment strategies and address modifiable risk factors. This 
is especially relevant when treating patients with discordant manifestations of 
asthma such as few daily symptoms but evidence of active eosinophilic 
inflammation in the airways and therefore a high risk of exacerbations, and vice 
3.1. Introduction 
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versa23, and when healthcare resources are stretched. Individualising therapy has 
the potential to reduce the patient’s risk of adverse outcomes from their disease 
and from medications.  
Several factors have been associated with a higher risk of attack amongst 
asthmatic children387 such as past attacks and low FEV1. However, findings from 
large database or cohort studies do not necessarily reflect the population seen in 
the emergency department (ED) or hospital ward. They therefore may not be 
informative for the common clinical scenario of reviewing a child in the ED or 
ward and deciding who needs changes in treatment or specialist referral.  
3.2.1. Research question 
What are the risk factors for repeated asthma exacerbations that require 
emergency care re-attendance or hospital readmission among children? 
3.2.2. Objectives 
1. To describe and critically appraise study designs and methods that 
have been used to analyse factors associated with subsequent asthma 
exacerbations that require emergency care amongst children. 
2. To identify factors related to a future risk of re-attendance to 
emergency care due to asthma exacerbations. 
3. To quantify the influence of factors associated with a future risk of re-
attendance to an emergency room due to asthma exacerbations. 
 
3.2 Study objectives
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3.3.1. Data sources and search strategy 
We conducted systematic searches of bibliographic databases as described in the 
Annex A. All databases were searched with no date or language of publication 
restriction. Searches were carried out by a Cochrane Information Specialist up to 
9th January 2017. Duplicate references were removed using reference 
management software (EndNote X7). The reference list of each selected 
publication was hand-searched for relevant studies. 
3.3.2 Study selection 
Studies with the following criteria were included: (1) prospective observational 
design (cohort and case-cohort) analysing factors related to asthma clinical 
history, previous treatment, lung function, biomarkers or readily measured 
environmental exposures; or controlled trials that involve a lifestyle or social 
(not educational or pharmaceutical) interventions; (2) asthmatic children aged 
between 5 to 15 years old recruited from the ED or ward, treated for an acute 
asthma exacerbation, included as participants; (3) emergency re-attendance or 
hospital readmission due to an asthma attack listed as outcomes. 
The list of abstract and titles was reviewed to exclude publications that were 
clearly not contributory on this basis and duplicate titles. Full text articles of 
selected papers were obtained via University library and inter-library loan and 
reviewed for eligibility, excluding those not fulfilling inclusion criteria.  
3.3.3. Data extraction 
Data were extracted by three independent authors using a standard data 
extraction form. Possible disagreements were resolved by discussion. RevMan 5 
3.3. Methods
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and Endnote X7 software were used to assist in the collection and management of 
data from abstracts and papers. 
3.3.4. Quality and risk of bias assessment 
Studies’ accuracy and risk of bias was assessed using the criteria of the Cochrane 
Handbook for Systematic Reviews of Interventions. Observational studies’ quality 
was also assessed using the Newcastle-Ottawa Quality Assessment Scale388, with a 
score of 7 or more defined as of high methodological quality. 
3.3.5. Analysis 
Data from comparable studies were combined in quantitative analyses. We 
pooled data using a random effect model in RevMan5, creating pooled estimates 
of effects for Hazard and Odds Ratios separately. Reports that presented the 
results using mean values, with no other data, were not included in the meta-
analyses. We used the generic inverse variance as the analysis method for some 
of the pooled estimate of effects, as some studies only reported Odds or Hazard 
Ratios. We assessed the degree of statistical variation in study outcomes using 
the I2 statistic389. 
A total of 3259 records were identified and screened for eligibility with one 
additional paper obtained through reference list screening (Figure 3.1). Forty-
three papers fulfilled our inclusion criteria after full-text screening, accounting 
for 36 studies. 
 
 
3.4. Results 
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Figure 3.1: Flow diagram of included and excluded studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.1. Studies’ characteristics and definitions (Table 3.1) 
Design, participants and setting:  
Twenty-three studies were retrospective analyses of health-care databases. 
There were 5 prospective cohorts, 3 randomised-controlled trials (RCT), and 4 
with other prospective designs. Most studies were carried out in North America 
(21 in USA and 3 in Canada). Participants were recruited among inpatients 
admitted for acute asthma in most of the studies (27). 
Outcome  
The study outcome was ED re-attendance in 4 reports, ED or hospital 
readmission in 6, hospital readmission alone in 21 studies and a further 5 studies 
analysed data for both outcomes separately. 
3259 records identified through 
database searching and screened 
for suitability 
3132 records excluded on 
basis of title and abstract  
(587 reviews) 
128 full-text 
articles assessed 
for eligibility 
43 full-text articles 
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36 studies 
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Predictors  
The risk factors or predictors studied varied amongst studies, including: socio-
demographic characteristics such as age, gender, sex and socioeconomic status (SES, 
including household/neighbourhood income, private vs. public insurance and working 
rank); and asthma characteristics (severity, treatment, previous admissions). 
3.4.2. Risk of bias 
The number of reports with low, unclear or high risk of bias was 22, 7 and 7 
respectively. Those with an unclear risk of bias lacked information on relevant aspects 
of the methods, mainly sample selection, or did not state clearly the number or factors 
studied to assess reporting bias. The details of the risk of bias assessments are shown 
in Table 3.2. 
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Table 3.2: Statistical Methods and Risk of Bias 
Study 
Design 
Study 
 
Analysis 
Method 
Adjust-
ment* 
Multiple 
testing 
Risk of 
Bias 
Source risk of bias N-O 
Score 
RCT Gorelick 
2006390 
Analysis per 
risk factor NA Few Low -  
Kercsmar 
2006433 
Analysis per 
risk factor NA Few High 
Performance and 
detection (blinding)  
Madge 
1997434 Cox regression NA Few Unclear 
Performance and 
detection  
Cohort Bloomberg 
2003393 Cox regression Adequate NA Low -  
Brittan 
2017394 Log regression Unclear NA Low - 7 
Camargo 
2007435 
Cox and log 
regression Partial NA Unclear Reporting 7 
Chabra 
1998436 Log regression Adequate NA Low - 7 
Chen E. 
2003397 Log regression Adequate 
Statistical 
correction Unclear Response 7-8 
Chen Y. 
2003398 Cox regression Partial Few Low - 7-8 
Cincinnati I 
cohort399-402 
Log and Cox 
regression Adequate NA/Few Low - 8-9 
GCARS403-407 Log and Cox 
regression Adequate NA/Few Low - 9 
Giarola 
2014408 
Analysis per 
risk factor NA Few Low - 7 
Gurkan409 Log regression Unclear NA Unclear Reporting 6 
Kenyon 
2014411 Log regression Adequate NA Low - 8 
Kenyon 
2015410 
Log and Cox 
regression Unclear Few Low - 7 
Kocevar412 Cox regression Adequate Few Low - 7 
Lasmar 
2006413 
Log regression 
+ survival Adequate NA High Selection 8-9 
Li 2012414 Cox regression Adequate NA Unclear Selection 9 
Liu 2009415 Cox regression Adequate NA Low - 9 
Minkovitz 
1999416 
Analysis per 
risk factor NA NA High Reporting 7 
Mitchel 
1994417 Cox regression Adequate NA High Reporting 9 
Morse 
2011437 GLE Adequate 
Statistical 
correction Low - 7 
Rasmusssen 
2002438 Log regression NA NA Unclear 
Reporting and follow-
up 7 
Rod-Mart 
2014419 
Poisson 
regression Adequate NA High Selection 7 
Rusworth 
1995421 Log regression Partial NA Low Reporting 7 
Smiley422 Cox regression Adequate Few Low - 9 
Sporik 
1993439 
Analysis per 
risk factor NA Few Low - 7 
Taylor 
1999424 
Analysis per 
risk factor NA Few Low - 7 
Tolomeo 
2009440 Log regression Adequate NA High Selection and reporting 8 
Wallace426 None NA NA Low - 6-7 
Wu 2016427 Multivar. 
Poisson 
regression 
Partial Few Low - 7 
Zipkin428 Log regression Adequate NA Low - 8 
Other Bergert 
2014429 
Analysis per 
risk factor NA 
Few 
analysis Low - 6-7 
Davis 
2011441 Cox regression Adequate NA 
High + 
unclear 
Selection (high), follow-
up and response 7 
Fassl442 Log regression Adequate NA Low - 9 
Vicendese 
2015432 Log regression Adequate NA Unclear Selection 7 
*: Adjustment for: age, sex, ethnicity and sociodemographic status. GCARS: Greater Cincinnati Asthma Rik 
Study; NA: Not addressed, N-O: Newcastle Ottawa Score; GLE: Generalized Liner Equations 
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3.4.3. Predictors 
Factors related to the person:  
Age: The effect of age on the future risk of ED or hospital readmission was 
examined in 16 studies (Table 3.3). There was a marked variation in the age group 
classification and statistical methods used for the comparisons, precluding a meta-
analysis of this factor. As shown, in general, studies were consistent in reporting that 
younger children had a higher risk of ED or hospital readmission. 
Table 3.3: Association between age and risk of ED or hospital readmissions 
Study 
Design 
Study Exposure Outcome Associ
ation 
Measure C.I. 95% P value 
Cohort Brittan 
2017394 2-4 years 
Hospital 
readmission N (%) 92 (35.3)  
0.05 
No hosp 
readmission 
N (%) 3519 (39)  
5-11 years 
Hospital 
readmission 
N (%) 119 (45.6)  
No hosp 
readmission 
N (%) 4306 (48)  
12-18 years 
Hospital 
readmission 
N (%) 48 (18.5)  
No hosp 
readmission 
N (%) 1204 (13)  
Camar 
2007435 Older age 
ED/Hosp 
readmission HR 0.98 0.95-0.99 0.032 
Chabra 
1998436 6-12 years vs 1-6y 
Multiple hosp 
admissions OR 0.91 0.75-1.09  
Chen Y 
2003398 Males (vs 15-
19 
years) 
<1 
Hospital 
readmission HR 
2.36 2.15-2,59  
1-4 1.54 1.41-1.61  
5-9 1.08 0.98-1.19  
10-14 1.05 0.95-1.17  
Female
s (vs 
15-19 
years) 
<1 1.54 1.42-1.66  
1-4 1.15 1.08-1.22  
5-9 0.87 0.80-0.93  
10-14 1.15 1.06-1.24  
Cincinn. 
I401 Age (years, continuous) 
Hospital 
readmission AHR 0.99  NS 
Gurk 
2000409 
Age ≤5 years  
(vs 5-15 y) 
Multiple 
hosp admis OR 5.12 
2.02-
12.95 0.02 
Kenyon 
2014411 
Age (vs. 
2-4 
years) 
5-11 y 
Hospital 
readm 30d 
AOR 
1.0 0.9-1.2  
Hospital 
readm 1 y 1.0 0.9-1.0  
12-18 y 
Hospital 
readm 30d 2.0 1-7-2.5  
Hospital 
readm 1 y 1.1 1.1-1.2  
Kenyon 
2015410 2-4 years 
H. readmis*  N (%) 681 (44)  
0.001 
No hosp 
readmiss* 
N (%) 12410 
(41)  
5-11 years 
H. readmis*  N (%) 613 (39)  
No hosp 
readmiss* 
N (%) 13116 
(44)  
12-18 years 
H. readmis*  N (%) 273 (17)  
No hosp 
readmiss* 
N (%) 4565 (15)  
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Li 
2012414 
Age (vs. 
2-5 
years) 
6-9 y 
ED re-visits HR 
0.83 0.78-0.89  
10-13 y 0.76 0.71-0.82  
14-17 y 0.80 0.74-0.87  
Age (vs. 
2-5 
years) 
6-9 y 
Hospital 
admission HR 
0.56 0.46-0.67  
10-13 y 0.51 0.41-0.65  
14-17 y 0.42 0.32-0.57  
Liu 
2009415 
Age (vs 
0-4 y) 
5-10 y Hospital 
readmission HR 
0.58 0.64-2.03  
11-18 y 0.57 0.40-0.81  
Mitch. 
1994417 Age <5 y (vs. 5-14 y) 
Hospital 
readmission AOR 1.71 1.41-2.08  
Rod-Ma 
2014419 Age (continuous) 
Hospital 
readmission IRR 1.08 0.39-3.03 0.87 
Smiley 
2016422 
Age  
(vs 12-
17) 
2-4 y 
ED re-visit AHR 
1.69 1.48-1.93 < 
0.001 5-11 y 1.24 1.10-1.39 
Wallace 
2004426 
Female 
(vs 10-
14 y) 
W 
1-4 y 
Hospital 
readmission 
within 180 
days of index 
admission 
RR 
1.1   
5-9 y 0.8   
B 
1-4 y 0.6   
5-9 y 0.7   
H 
1-4 y 0.8   
5-9 y 1.0   
Male (vs 
10-14 y) 
W 
1-4 y 0.9   
5-9 y 0.7   
B 
1-4 y 0.8   
5-9 y 0.8   
H 
1-4 y 1.0   
5-9 y 1.0   
Zipkin 
2016428 
Age (vs 
13-17 
years) 
2-5 years 
Hospital 
readmission 
AOR 
0.45 0.25-0.80 0.007 
ED re-
utilization 2.23 1.32-3.79 0.003 
6-12 years 
Hospital 
readmission 0.41 0.22-0.75 0.004 
ED re-
utilization 1.29 0.75-2.21 0.36 
Other Vicende
se 
2016432 2-6 years 
 ≥2 Hospital 
admissions 
N (%) 17 (77)  
0.73 1 hospital 
admission 
N (%) 16 (73)  
7-14 years 
 ≥2 Hospital 
admissions 
N (%) 5 (23)  
0.73 1 hospital 
admission 
N (%) 6 (27)  
 
 
 
 
 
 
 
 
*: in 15-90 days time. Abbreviations: ED: Emergency Department; HR: Hazard Ratio; AHR: 
Adjusted Hazard Ratio, OR: Odds Ratio; AOR: Adjusted Odds Ratio; IRR: Incidence Rate Ratio; SD: 
Standard Deviation; NS: Non statistically significant; W: White ethnicity; B: Black ethnicity; H: 
Hispanic ethnicity. 
 
Sex: Six reports analysed sex as a risk factor for ED and 17 for hospital 
readmission, though some of them stratified its effect by age. There was a decreased 
odds of hospital readmission among boys compared to girls (OR 0.91, 95%CI: 0.86-
0.97) in the pooled analysis of data from 17 studies (Figure 3.2C), but no difference in 
the pooled analysis of other 2 studies reporting hazard ratios (Figure 3.2D). There was 
no difference in ED re-attendance by sex in the studies reporting either odds or hazard 
ratios (Figure 3.2A and 3.2B). 
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Figure 3.2: Forest plots for the association of sex with emergency department re-
attendance and hospital readmission for acute asthma in children using a random effects 
model.  
 
 
Ethnicity: The effect of ethnicity on ED or hospital readmission was included in 
18 reports, using different classifications. The most frequent was the comparison 
between black or African-American and white or other origins, and the risk of 
readmission for asthma. The results of 7 of these comparisons were pooled together 
A: Odds Ratio ED Re-attendance 
B: Hazard Ratios ED Re-attendance 
D: Hazard Ratios Hospital Readmission 
C: Odds Ratios Hospital Readmission 
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A: Hazard Ratios ED Re-attendance 
B: Odds Ratio Hospital Readmission 
C: Hazard Ratios Hospital Readmission 
obtaining a positive association between black ethnicity and the odds of hospital 
readmission for acute asthma (OR: 1.42, 95% CI: 1.11-1.81) (Figure 3.3B). This model 
had a considerable heterogeneity (I2= 95%), mainly due to the Liu 2009 study. Four 
other studies reporting Hazard Ratios for hospital readmission showed no association 
between black ethnicity and hospital readmission (Figure 3.3C). There was also an 
increased risk of ED re-attendance among African-American compared to white 
children (HR: 1.60, 95% CI: 1.29-1.98) in the pooled analysis of 3 studies reporting 
Hazard Ratios (Figure 3.3A). One paper studying hospital readmission was excluded 
from the meta-analysis as results were stratified by age and sex 426.   
Figure 3.3: Forest plots for the associations of ethnicity (black vs other) with emergency 
department re-attendance and hospital readmission for acute asthma in children using a 
random effects model.  
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Socioeconomic status (SES):  21 reports examined SES as a predictor for ED or 
hospital readmission for asthma. The specific predictor used differed, with public 
insurance (vs. private or other) or low household income being the most frequent 
markers adopted for low SES. A meta-analysis of data from 4 studies showed increased 
odds of ED re-attendance for acute asthma in children of low SES (OR: 1.23; 1.17-1.30) 
(Figure 3.4A), consistent with the pooled analysis of  3 other studies reporting HR (HR: 
1.40, 95% CI: 1.08-1.82) (Figure 3.4B). Another 9 studies reporting odds ratios and 5 
studies reporting Hazard ratios were used to analyse the effect of low SES on hospital 
readmission for acute asthma, producing a pooled OR: 1.25 (95% CI: 1.07-1.47) (Figure 
3.4C) and a pooled HR: 1.20 (95% CI: 1.07-1.35) (Figure 3.4D).  
Figure 3.4: Forest plots for the associations of socioeconomic status (SES) with emergency 
department re-attendance and hospital readmission for acute asthma in children using a 
random effects model.  
 
 
 
 
 
 
 
 
 
 
 
 
A: Odds Ratios ED Re-attendance 
B: Hazard Ratios ED Re-attendance 
C: Odds Ratios Hospital Readmission 
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Comorbidities: Seven reports analysed the risk of hospital readmission among 
children with other concomitant allergic diseases, including allergic conjunctivitis, 
allergic rhinitis or eczema. The pooled OR of six of these studies showed an increased 
risk of hospital readmission for asthma for children with concomitant allergic diseases 
(OR: 1.90, 95% CI: 1.43-2.52) (Figure 3.5). The heterogeneity of the model was 
moderate (I2= 44%).  
Figure 3.5: Forest plot for the associations of concomitant allergic diseases (allergic 
rhinitis /rhinoconjunctivitis or eczema) with hospital readmission for acute asthma in 
children using a random effects model (odds ratios).  
 
 
 
 
Factors related to asthma characteristics: 
Previous ED or hospital admission: Eight reports included data on the risk of ED 
or hospital readmission according to a history of previous hospital or ED admissions, 
either in the previous 12-24 months (the most common) or ever in life. The 3 reports 
studying ED re-attendance odds ratios (OR: 5.81, 95% CI: 1.32-25.67) and the 2 reports 
studying hazard ratios (HR: 1.88, 95% CI: 1.58-2.24), showed an increased risk among 
children with a history of previous ED or hospital admissions for acute asthma (Figure 
3.6A and 3.6B). The same occurred with the 8 studies reporting odds ratio and the 3 
studies reporting hazard ratios for hospital readmission (Figures 3.6C and 3.6D). The 
D: Hazard Ratios Hospital Readmission 
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substantial heterogeneity of the odds ratio models (I2= 95 and 99%) were due mainly 
to the Taylor 1999 424 study, though when removed from the model the association was 
still significant (results not shown).  
Figure 3.6: Forest plots for the associations of previous ED or hospital admissions for 
acute asthma with emergency department re-attendance and hospital readmission for 
acute asthma in children using a random effects model. 
 
 
 
 
 
 
 
 
 
 
 
 
Asthma severity and controller treatment: Ten studies assessed the association 
between asthma severity, control or controller treatment received with the risk of ED 
or hospital readmission (Table 3.4). The type of predictor and definition of severity 
varied greatly between studies, precluding a meta-analysis. The findings related to 
severity as defined by treatment were inconsistent, though past events were associated 
with increased future risk.  
A: Odds Ratios ED Re-attendance 
B: Hazard Ratios ED Re-attendance 
D: Hazard Ratios Hospital Readmission 
C: Odds Ratios Hospital Readmission 
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Table 3.4: Association between asthma severity, control and baseline treatment and risk 
of ED or hospital readmissions 
Study 
Design 
Study Exposure Outcome Associ
ation 
Measure C.I. 95% P value 
Cohort Camargo 
2007435 
Pre-index OCS use ED/Hosp 
readmission HR 
1.10 1.07-1.14 <0.001 Pre-index SABA use 1.04 1.02-1.05 
Cincinna
ti cohort 
Severity (ICS use in the 
past) 
Hospital 
readmission AHR
** 1.49 1.03-2.15  
Severity (ICS use in the 
past)401 
Hospital 
readmission AHR
 0.81  NS 
GCARS403
-407 Severity (vs 
mild 
intermit.) 
Severe 
persistent 
Hospital 
readmission HR 1.83 1.07-3.14  
Moderate 
persistent 
Hospital 
readmission HR 1.70 1.18-2.46  
Mild 
persistent 
Hospital 
readmission HR 1.12 0.80-1.56  
Use of 
controllers 
Yes 
Hosp readmis N(%) 57 (23) 
 <0.001 
No hosp readm N(%) 192 (77) 
No 
Hosp readmis N(%) 45 (12) 
No hosp readm N(%) 324 (88) 
Gurkan 
2000409 Using ICS 
Multiple 
hospital admis OR 0.37 0.16-0.86 0.03 
Kenyon 
2015410 ≥1 controller fill 
Hosp 
readmission N(%) 
1013 
(65)  <0.001 
No hosp readm N(%) 14488 (48)  
Persistent asthma 
Hospital 
readmission N(%) 
1093 
(70)  <0.001 No hospital 
readmission N(%) 
15070 
(50)  
Lasmar 
2006413 
Moderate persistent  vs. 
mild intermittent 
Single vs 
multiple hosp 
admissions 
AOR 6.23 2.82-13.76 <0.001 
No. attacks >4/month OR 2.19 1.03-4.71 0.03 
Minkovit
z 1999416 ICS as usual medication 
SHA N(%) 4 (5)  0.03 MHA 6 (17) 
Prescribed routine 
asthma medications 
SHA N(%) 65 (77)  0.07 MHA 32 (91)  
Rasmuss
en 
2002438 
FEV1 % predicted  
at 9 y 
SHA 
Mean 
±SD 
94 ± 13  
0.04 
MHA 86 ± 11  
FVC % predicted at  9 y 
SHA 99 ± 10  
0.93 
MHA 99 ± 12  
FEV1/VC at age 9 y (%) 
SHA 84 ± 6  
0.03 
MHA 78 ± 7  
AHR at age 9 y 
SHA 
N(%) 
51  
0.03 
MHA 82  
Smiley 
2016422 
Controller 
medic. (vs 
LTRA) 
None 
ED re-visit AHR 
0.90 0.73-1.10  
ICS 1.10 0.94-1.28  
ICS/LABA 1.20 1.02-1.41  
ICS+LTRA 1.19 0.94-1.49  
ICS/LABA 
+LTRA 1.43 1.16-1.75  
AMR ≥0.5 vs <0.5 ED re-visit AHR 0.68 0.58-0.81  
Zipkin 
2016428 Discharged with ICS 
Hospital 
readmission OR 0.67 0.44-1.02  
Ed utilization OR 0.92 0.70-1.20  
*Asthma control scale: 0-2 (higher score=worse control); #: Parents perceiving asthma as more severe. 
**: Adjusted for: age, ethnicity, insurance, maternal education and income; 
OCS: Oral corticosteroids; SABA: short-acting β-adrenergic agonist; ICS: inhaled corticosteroids; ED: Emergency 
Department; PEFR: Peak Expiratory Flow Rate; FEV1:  Forced Expiratory Volume in the first second; FVC: Forced Vital 
Capacity; AHR: Airway hyperresponsiveness; HR: Hazard Ratio; AHR: Adjusted Hazard Ratio; SHA: Single Hospital 
Admission; MHA: Multiple hospital admission; OR: Odds Ratio; AOR: Adjusted Odds Ratio; SD: Standard Deviation; AMR: 
Asthma Medication Ratio 
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Factors related to potential follow-up 
Asthma follow-up: Ten papers examined aspects of follow-up after the index ED 
or hospital admission (Table 3.5).  
 
Table 3.5: Association between asthma follow-up and management after index admission 
or ED visit for asthma and risk of ED or hospital readmissions 
Study 
Design 
Study Exposure Outcome Assoc
iation 
Meas
ure 
C.I. 95% P 
value 
RCT Gorelick 
2006390 
Usual Care 
ED re-visit (self-
reported) 
% 38.4  
0.90 
Intensive primary care 
linkage % 39.2  
Case management 
programme % 35.8  
Cohort Brittan 
2017394 Post-discharge outpatient visit 
Hospital 
readmission 
(15-90 d) 
OR 1.00  NS 
Cincinnat
i 
cohort402 Med. home access vs. 
adequate 
Almost 
always 
adequate 
Hospital 
readmission AHR
 1.11 0.77-1.60  
Sometime/ 
often/neve
r adequate 
Hospital 
readmission AHR 1.56 1.06-2.32  
Li 
2012414 
Follow-up visits  
(vs no) 
ED re-visit 
AHR 
0.98 0.93-1.03  
Hospital readm 1.06 0.92-1.23  
Number  
FU visits  
(vs 0) 
1 
ED re-visit 
AHR 
0.99 0.94-1.05  
Hospital readm 1.05 0.89-1.23  
2 
ED re-visit 
AHR 
0.91 0.82-1.01  
Hospital readm 1.12 0.94-1.56  
≥3 
ED re-visit 
AHR 
1.07 0.91-1.26  
Hospital readm 0.78 0.48-1.29  
Type of 
physicia
n for FU 
(vs 
none) 
General 
ED re-visit 
AHR 
0.98 0.93-1.04  
Hospital readm 1.05 0.91-1.22  
Specialist 
ED re-visit 
AHR 
1.01 0.83-1.23  
Hospital readm 1.41 0.88-2.26  
General + 
special. 
ED re-visit 
AHR 
0.93 0.71-1.21  
Hospital readm 0.86 0.38-1.93  
Minkovit
z 1999416 
Post-
discharg
e visit  
Paediatrician 
Single hosp 
adm N(%) 
77 
(92)  0.28 Mult hosp. 
admission 
34 
(97) 
Allergy 
Single hosp 
adm N(%) 
10 
(12)  0.40 Mult hosp. 
admission 
6 
(18) 
Pulmonary 
Single hosp 
adm N(%) 
10 
(12)  0.002 Mult hosp. 
admission 
13 
(37) 
Morse 
2011437 
CAC-3 compliance  
(5% improvement) 
ED re-
visit 
30d 
OR 
0.97 0.90-1.04 0.36 
90d 0.96 0.77-1.18 0.68 
Hospital 
readmi 
30d 0.99 0.96-1.02 0.53 
90d 1.01 0-90-1.12 0.90 
Multip hosp. 
admission 82   
Smiley 
2016422 
Follow-up appointment 
(vs no) ED re-visit AHR 0.86 0.76-0.93 0.002 
Zipkin 
2016428 HMPC compliance 
(partial/full vs none) 
Hospital 
readmission OR 0.63 0.41.0.95 0.028 
Ed re-utilization OR 0.73 0.56-0.96 0.022 
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Other Bergert 
2014429 
Post-CAC Implementation 
vs Pre-CAC 
ED re-
visit 
0-
30d 
OR 
N/A N/A  
31-
90 d 1.60 0.44-5.81  
91-
180 
d 
0.57 0.20-1.67  
Hosp 
readm. 
0-
30 d 0.29 0.05-1.73  
31-
90 d 0.87 0.21-3.50  
91-
180 
d 
0.29 0.11-0.78  
Fassl 
2012442 
Post-CAC Implementation 
vs Pre-CAC 
Hospital 
readmission AOR 0.67 0.50-0.91 0.01 
Abbreviations: RCT: Randomized Clinical Trial; HR: Hazard Ratio; AHR: Adjusted Hazard Ratio, OR: Odds 
Ratio; AOR: Adjusted Odds Ratio; ED: Emergency Department; FU: follow-up; CAC: Children’s’ Asthma Care; 
HMPC: Home Management Plan Care (part of the CAC); N/A: not applicable; d: days. 
 
Three studies explored the effect of the Children’s Asthma Care (CAC) measures set 
implementation, which comprises providing reliever medication and systemic 
corticosteroids for children admitted to hospital for asthma, and discharging them with 
a home management plan. They showed no effect on ED re-attendance after the initial 
admission for asthma and two of them demonstrated a reduced risk of hospital re-
admission after the implementation of the CAC measures. One further study showed a 
decreased risk of both hospital readmission and ED re-utilization for acute asthma after 
Home Management Plan Care implementation (part of CAC)428. 
Five studies analysed the effect of different follow-up visit characteristics and ED or 
hospital readmission for asthma with disparate outcomes. Three reports studied the 
effect of receiving an asthma action plan at discharge on the risk of ED or hospital 
readmission. Two of them were combined (Figure 3.7) showing no association.  
Figure 3.7: Forest plots for the associations of being offered an asthma action plan at 
discharge with emergency department re-attendance or hospital readmission for acute 
asthma in children using a random effects model (odds ratios).  
 
  
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Other factors: 
Exposure to tobacco smoke (ETS): Five studies included data on ETS, producing 
a pooled odds ratio of 1.60 (95% CI: 0.94-2.72) for hospital readmission for acute 
asthma for those exposed to tobacco smoke (Figure 3.8). One other paper 401 measuring 
Hazard ratio, showed no association between ETS and hospital readmission risk for 
asthma (AHR: 0.83, 95% CI: not published, p value:  not significant).  
 
Figure 3.8: Forest plots for the associations of second-hand tobacco smoke exposure 
(ETS) with hospital readmission for acute asthma in children using a random effects 
model (odds ratios).  
 
 
 
 
 
Other factors included: family history of asthma or allergic diseases, parental level of 
education, personal history (previous immunizations, early life feeding methods), 
caregiver’s situation (psychological stress, beliefs, knowledge, marital status or 
concerns), asthma triggers, exposure to allergens or pollution and home characteristics, 
adherence to asthma treatment, characteristics of index asthma admission, and home 
remediation interventions of water infiltration. The outcomes and specific exposures 
used were highly heterogeneous between studies meaning no robust consensus 
conclusions could be drawn. 
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Asthma is a very common reason for emergency attendance. Clinicians are therefore 
often faced with decisions on whether to increase treatment and who to refer for a 
specialist opinion. This systematic review and meta-analysis has identified a history of 
previous ED or hospital admissions to be the major risk factor for emergency care and 
hospital readmissions for acute asthma in children. Further, our results indicate that 
children of African-American ethnicity (compared to white or other ethnicity), low 
socioeconomic status (as measured by having public insurance or low family income), 
with concomitant allergic diseases (allergic rhinitis/rhinoconjunctivitis or eczema) and 
being younger than 5 years of age, are at a greater risk of subsequent emergency care 
visits or hospital readmissions for acute asthma.  
This systematic review answers a relevant question with public health implications for 
future asthma management that has been developed in accordance with best practice 
and using an extensive search with no time or language publication restrictions to 
ensure the inclusion of potentially suitable studies. The data collected had a moderate 
to low strength of evidence. Risk of bias was assessed and presented for each included 
study separately. We were also able to undertake a quantitative analysis of the most 
relevant predictors, increasing the relevance of our findings. 
Most of observational studies included were retrospective cohorts using hospital or 
insurance databases with a large number of patients (more than 10 000 participants in 
6 studies). However, unclear and high risk of bias were common because of inadequate 
sampling and reporting of only significant results in more than 50% of the 
observational studies. The RCT’s included in the review had some important risk of 
biases which precluded increasing the strength of evidence of the review.   
 
3.5. Discussion
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Despite a wide literature search with no language restriction, all selected papers were 
published in English and the clear majority were developed in Anglophone countries, 
mainly in the US. This likely reflects the fact that asthma has been an important public 
health problem in these countries for a long period29 but limits the generalizability of 
the findings to other relevant regions such as Latin America were asthma has emerged 
as an important public health issue2. Decisions on who should be the focus of treatment 
are crucial in such settings where resources are likely to be very limited. Another 
important factor is the inclusion of children younger than 2 years old in several studies, 
an age at which it is difficult to ascertain an asthma diagnosis443. The outcomes used in 
the studies are also a possible source of bias, as there is no consensus on when a child 
should be admitted to the ED or hospital for acute asthma. However, this is the current 
definition used by the ATS for a severe asthma attack8. 
Children younger than 5 years old were at a higher risk of ED or hospital readmission 
for acute asthma when compared to different age groups in more than half of the 
studies that explored age as a predictor of future risk. Preschool children suffer a larger 
number of acute asthma attacks driven mostly by respiratory viruses320,444. It is also 
difficult to diagnose asthma in this age group 443, potentially leading to inadequate 
management. Lintzenich et al.445 showed that children 1-6 years old hospitalized for 
asthma were less likely to receive ICS baseline treatment and asthma education than 
older children. 
Children from families with lower SES had a higher risk of ED or hospital 
readmission446. Lower SES has previously been shown to be associated with more 
frequent ED visits and hospital admissions for other diseases447. It may reflect poorer 
long-term management due to inadequate access to primary and specialist care, and 
that caregivers may be less able to adequately manage a long-term condition thus 
relying more on ED attendance. Flores et al.448 showed that among ethnic minority 
Chapter 3 | Systematic review 
136 
 
children with asthma in urban settings, poorer children were less likely to have an 
asthma specialist than wealthier children. 
Children of African-American origin living in Anglophone countries were at higher risk 
of re-attendance for asthma. It is likely there is some residual effect of SES as not all 
reports provided an adjusted odds ratio that could be used in the analysis. This 
confounding was shown by Beck et al.404 who reported that up to 80% of the 
readmission disparity between African-American and white asthmatic children could 
be explained by other associated factors, such as access to care or disease management. 
Nevertheless, non-white ethnicity has also been described as a predictor of 
hospitalisation or ED visits in adults with severe or difficult-to-treat asthma449.  On the 
other hand, when selecting child’s characteristics which best predict future ED or 
hospital use for acute asthma, black ethnicity should be considered, irrespective of 
whether it is a confounder or causal factor.  
Allergic rhinitis and asthma often coexist and have been described to be two symptoms 
of the same disease450. This may explain why children with co-existing allergic diseases 
(allergic rhinitis/rhinoconjunctivitis and eczema) had a greater risk of hospital 
readmission for asthma. Treatment for allergic rhinitis, such as nasal corticosteroids 
and antihistamines has been, associated with a decreased risk of emergency care use 
for acute asthma attacks451.  
Asthmatic children with a history of a previous ED or hospital admission for acute 
asthma had between 2 to 5.8 times more risk of ED re-attendance and 2.5 to 3 times 
more risk of a hospital readmission. This was therefore the clearest factor related to 
asthma that was associated with future risk. Similarly, other studies have identified 
several variables related to previous healthcare utilization for acute asthma that are 
associated with future risk of severe asthma attacks452,453.  
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Table 3.6: Identified risk factors for subsequent severe asthma attacks requiring 
emergency care re-attendance or hospital readmission. 
Identified Risk Factors for Subsequent Severe Asthma Attacks 
Requiring Emergency Care re-attendance* Requiring Hospital Readmission* 
-  Younger age (no summary measure) - Younger age (no summary measure) 
- African-American ethnicity (HR) - African-American ethnicity (OR) 
- Low socioeconomic status (OR, HR) - Low socioeconomic status (OR, HR) 
- Previous ED or hospital admission for 
asthma (OR, HR) 
- Previous ED or hospital admission for 
asthma (OR, HR) 
- Female sex (OR) 
- Concomitant allergic diseases (OR) 
OR: Odds ratio; HR: Hazard ratio. 
*: In parenthesis are the summary measures that showed an association 
 
In conclusion, we have identified individual-level and factors related to asthma severity 
that are associated with a greater risk of future asthma attacks requiring emergency 
care or hospital readmission. This description of the current evidence base and its 
limitations could help inform future prospective studies that robustly assess the 
magnitude and interaction of such risk factors.  In future, being able to identify children 
at risk of future asthma attacks requiring emergency care will guide specific 
interventions such as educational sessions, management of comorbidities, and 
personalised treatment adjustments. This approach has the potential to reduce the 
chance of long-term complications such as loss of lung function, psychological 
morbidity, and death. 
 
3.6. Conclusion and key findings 
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4. Predictors for emergency care re-attendance for 
acute asthma in Ecuadorian children: a prospective 
cohort study 
 
Severe asthma attacks requiring emergency care, hospital admission or systemic 
corticosteroids8 are a common source of preventable morbidity in children. As 
discussed in Chapter 2, asthma attacks are associated with loss of lung function14,16, 
anxiety in patients and their families326, as well as elevated healthcare and family 
costs10, and missed school and workdays. Asthma attacks remain common despite 
international guidelines and a range of effective treatments9. They are a major problem 
in Latin America, given the high prevalence of asthma2, the relative lack of available or 
affordable essential drugs26,27 and the inadequate capacity to provide long-term asthma 
management28. As a result, children with asthma are treated mainly in emergency 
health service settings, and have a poor control of their disease24,34.  
Many asthma attacks are preventable, either by avoiding previously identified triggers 
or by appropriate preventive treatment. For example, use of long-term inhaled 
corticosteroids (ICS) reduces the number of asthma attacks in children by 
approximately 40%7 and can attenuate the decline in lung function associated with 
acute exacerbations16. However, asthma medicines can be associated with significant 
side-effects and costs as shown in Chapter 2. It is not appropriate or feasible to offer 
treatment and specialist follow-up care for every person with asthma, especially in 
overburdened health care systems. Thus, it is important to be able to identify patients 
at risk of further attacks and hospital admission to target resources such as additional 
education and support or augmentation of treatment. Given the absence of asthma 
4.1 Introduction
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clinics and specialist follow-up in many Latin American cities, the emergency 
department is a key opportunity to identify children at the highest risk of recurrent 
attacks. 
Previous emergency department (ED) attendance for asthma exacerbations414,435,440,454, 
younger age414,422,435, black ethnicity399,422 and low socioeconomic status400,422,428 have 
been associated with a higher risk of subsequent asthma exacerbations requiring 
emergency care in children. However, such studies have been almost exclusively 
conducted in North America, and have not considered the potential additional 
information provided by biomarkers commonly available in higher income countries. 
This Chapter presents the findings from a prospective cohort study to analyse clinical 
factors and biomarkers associated with recurrent severe asthma attacks in children 
presenting with bronchodilator-responsive wheeze to a regional emergency 
department in Esmeraldas, Ecuador.  
The objectives of the study were to: 
- Describe the characteristics of children attending emergency care with 
bronchodilator-responsive wheeze. 
- Estimate the proportion of children attending emergency care with 
bronchodilator-responsive wheeze who recur with a subsequent severe asthma 
exacerbation requiring emergency care in the following 6 months. 
- Determine the factors associated with emergency care re-attendance for later 
asthmatic exacerbations among Ecuadorian children. 
 - Use this cohort of children to design an instrument to provide an assessment 
of the risk of future asthma exacerbations requiring emergency care re-attendance, and 
thus assist with decision-making regarding lifestyle modifications, medication use, and 
tertiary referral. 
4.2 Objectives
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4.3.1. Study setting 
The research project took place in the city of Esmeraldas, the provincial capital of the 
north-eastern province of Esmeraldas, one of the poorest regions in Ecuador. 
Esmeraldas province has a population of 534.000 inhabitants, with 44% considered 
Afro-Ecuadorians and 45% mestizos306. The province is divided into 7 cantons, as 
represented in Figure 4.1. 
 
 
 
 
 
Figure 4.1: Geographic location of 
Esmeraldas province and 
subdivision in cantons.  
Source: De David C. S. – Own 
work, CC BY-SA 3.0,  
https://commons.wikimedia.org/
w/index.php?curid=16949148455 
 
 
 
4.3. Methods
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In the province of Esmeraldas, there were a total of 26 hospitals, 11 public and 15 
private, in 2014310. Of the public institutions, 8 belonged to the Ministry of Public 
Health (1 of them situated in the city) and 1 to the Social Security Institute (IESS), 
situated in the city of Esmeraldas. There were a further 158 health units without 
hospitalizations facilities in the province in 2014, of which 152 were public310. Of the 
total 864 294 consultations documented during 2014 in Esmeraldas province, 7.5% 
were for children 5-9 year old and 6% for 10-14 years old. As reported in the Chapter 2, 
Esmeraldas province had the lowest ratio of doctors per 10 000 inhabitants in 2014 
(13.04). In addition, the distribution of health care workers throughout the province is 
highly heterogeneous, with nearly 70% of doctors present in the urban areas310. 
The city of Esmeraldas is situated in the Esmeraldas ‘canton’ and has a population of 
over 150 000 inhabitants, of which nearly 50 000 are under 15 years old and 55% are 
considered Afro-Ecuadorians. The urban population comprises mainly communities in 
the district of Esmeraldas city, which is the provincial capital and home to the country’s 
largest refinery, a thermoelectric power plant and a wood-processing plant. 
4.3.2. Recruitment and study centres 
The city’s public hospital, Delfina Torres de Concha Hospital (HDTC), belongs to the 
Ministry of Public Health, offers free attention and treatment at the point of care and is 
the only second-level Hospital in Esmeraldas province, receiving patients from 
throughout the province. The IESS (Instituto Ecuatoriano de Seguro Social, social 
security institute) hospital offers free treatment to people who contribute to national 
insurance (social security). Health centres offer universal free attention and treatment. 
Patients were recruited from these two hospitals, as well as from the two largest health 
centres in the city which had an emergency consultation room. Esmeraldas opened a 
specialised health centre (Type C) with a 24-hour emergency department in February 
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2015. Patients were recruited from this site for the study from February 15th, 2015. 
Figure 4.2 represents the location of these centres. 
Figure 4.2: Map of Esmeraldas city with the location of study and recruitment 
centres 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DTCH: Delfina Torres de Concha Hospital; IESS: Instituto Ecuatoriano del Seguro Social 
(Social Security Institute of Ecuador). 
 
Study Centre 
DTCH 
Health Centre No. 2 
IESS Hospital
Health Centre No. 1 
Health Centre Type C 
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Children were recruited and initially evaluated at the hospital’s or health centres’ 
emergency department. A basic laboratory and office was set-up close to the DTCH to 
process samples, perform pulmonary function tests, follow-up consultations, data 
entry, and study-coordination. 
4.3.3. Study population: 
All children aged between 5 to 15 years treated at the DTCH or IESS Hospital 
emergency department, or health centres, for an acute episode of bronchodilator-
responsive wheezing over an 18-month period were invited to participate. We set the 
age limit between 5 and 15 years old, as older patients are no longer treated as 
paediatric patients. Children younger than 5 years old may sometimes present mild 
wheezing episodes secondary to viral respiratory infections that disappear around the 
ages of 5-10 years old. As many of the children that were included in the study did not 
have a previous doctor’s asthma diagnosis, we excluded children younger than 5 years 
old to avoid including those with isolated viral wheeze. We also excluded children with 
other chronic diseases as their asthma characteristics may differ from other asthmatic 
patients. 
Inclusion criteria: 
 - Age 5-15 years old. 
 - Treated at the DTCH or IESS Hospital emergency department, or health 
centres for an acute attack of bronchospasm: respiratory distress, coughing and 
wheezing, together with a clinical improvement after administration of nebulised β2 
agonists (e.g. salbutamol). 
 - Parents or guardians willing to participate in the study and to sign the 
informed consent form. 
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Exclusion criteria: 
 - Parents or guardians unwilling to participate in the study or to sign the 
informed consent form. 
 - Children with other chronic respiratory (cystic fibrosis, pulmonary 
hypertension, etc.), cardiac (congenital heart disease) or neurological (which may 
impair them from answering questionnaires, carrying out lung function measurements 
or accepting having samples taken) diseases. 
 - Parents/guardians and children who cannot commit to a minimum follow-up 
of 6 months.    
4.3.4. Study design: prospective cohort study 
We chose a cohort study design as such studies have the potential to provide strong 
scientific evidence, given the existence of a temporal framework to assess causality. 
This was a prospective study following up a cohort of children who present at the 
emergency department (ED) with an acute asthma attack. Exposures (risk factors) 
were assessed at the time of inclusion in the study and were followed-up to observe 
whether they had another acute asthma attack requiring emergency care or not, and in 
what time-frame. A cohort study design enabled analysis of the ‘time to the next 
exacerbation’ which is more clinically relevant as an outcome when compared to 
exacerbation ‘yes’ vs. ‘no’: e.g. a child having an asthma attack every 6 weeks may need 
more or a different intervention when compared with one who has an exacerbation 
every 6 months. Time to event analysis uses continuous data and therefore has greater 
statistical power than a binary outcome; it can also permit the inclusion of multiple 
attendances for one child. 
 
 
Chapter 4 | Prospective cohort study 
 
145 
 
Recruitment
(Day 0)
•Eligibility criteria
•Informed 
consent
•Blood sample
•Nasal wash
• Study 
questionnaire
• C-ACT
• NAKQ
Visit 1 
(Day 15)
•PFTs
•FeNO
•Results blood 
sample
•PAQLQ
•Stool sample
Phone follow-up
(Bi-monthly)
•Exacerbation 
questionnaire
Day 0
•Recruitment
Day 15
•Visit 1
Day 60              
(2 months)
•Follow-up call
Day 120          (4 
months)
•Follow-up call
Day 180          (6 
months)
•Follow-up call
Figure 4.3: Study plan and procedures 
 
 
      
 
 
 
 
 
 
 
 
 
4.3.5. Study plan 
Children were recruited during their visit to the emergency department. A description 
of the objectives of the study and the evaluations to be done were explained to the 
child’s parent/s or guardian. The study procedures were described to the child at the 
time of informed consent and assent forms, in a simple language.  If agreeing to 
participate, an informed written consent form was read out to the parent/guardian to 
be signed by them, as well as an assent form to be signed by children over 7 years. At 
the time of presentation, the treating doctor informed the caregiver of the existence of 
the study and if interested they left their contact number to be called on the following 
day by a member of the study team. 
PFTs: Pulmonary function tests; FeNO: Fraction of Exhaled Nitric Oxide; C-ACT: Childhood Asthma 
Control Test; PAQLQ: Pediatric Asthma Quality of life Questionnaire; NAKQ: Newcastle Asthma 
Knowledge Questionnaire. 
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After agreeing to participate, study procedures were undertaken (see section below), 
including study questionnaires and a blood and nasal wash sample. They were also 
given a container to collect a stool sample. 
Children and their caregivers were then asked to come back to the study clinic in 15 
days’ time, to allow for the acute asthma symptoms to disappear. In case the participant 
was still under medication that could alter the results of some of the procedures (such 
as corticosteroids), this visit took place another 7 days (21 days after recruitment). 
They received the full blood count results and a summary of findings from the other 
tests during this visit, and we carried out the following procedures: Fraction of Exhaled 
Nitric Oxide (FeNO) measurement, pre and post-bronchodilator spirometry and 
remaining study questionnaires. 
Participants were recruited during an 18-month period to assure including asthmatic 
children who suffer exacerbations during different periods of the year (e.g. rainy and 
dry seasons) and to obtain the estimated sample size. Each participant was followed up 
for a minimum of 6 months from the time of recruitment with bimonthly telephone 
calls to enquire about asthma exacerbations (number, severity, duration and treatment 
received). They were also asked to contact the study team present at the study office 
(in person or by telephone) at each emergency care re-attendance due to an asthma 
exacerbation during the follow-up period. Hospital and health centres’ records were 
checked twice a week to record any unscheduled visit for asthma exacerbation not 
already notified. To achieve the longest follow-up possible for each patient, those 
wishing to continue being followed-up in the study were contacted with bimonthly 
telephone calls to enquire about asthma exacerbations until the end of the study. 
Future asthma management was discussed with each patient and their caregivers, 
according to the patient’s asthma characteristics, their knowledge, and number and 
severity of asthma exacerbations suffered during the follow-up period. Participants’ 
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asthma severity was classified by the Principal Investigator (a Paediatrician), using the 
Ecuadorian Asthma Consensus 2011456. They were offered available beta-agonists 
and/or inhaled corticosteroids for future exacerbations, in accordance with these 
guidelines that follow GINA recommendations5. Only medications available through the 
Ministry of Public Health were used in accordance with Ecuadorian law. The Principal 
Investigator also provided recommendations for future exacerbations and written 
asthma action plans. 
4.3.6 Study procedures 
The study procedures included collection of data by questionnaire (to design the study 
instrument) and data collected using objective clinical measurements to identify 
potential biomarkers, as well as to allow us to determine the phenotype of asthma in 
our study population and the populations to which our study findings were most 
relevant. 
 - Weight and height: Children were weighed using an electronic scale and 
height measured. Body Mass Index (BMI) was then estimated. 
- Questionnaire: A questionnaire in Spanish modified from the ISAAC Phase II 
study457 extensively field-tested33,458 and previously used in Esmeraldas city by the 
same study team34, was administered to the child’s caregiver. It included the core 
asthma symptom questions of ISAAC and others regarding socio-demographic 
information, household characteristics and other environmental exposures, potential 
risk factors, severity of asthma and asthma triggers, and previous management and 
treatment for asthma.  
- Newcastle Asthma Knowledge Questionnaire (NAKQ)459: To assess previous 
asthma knowledge, we used the NAKQ, a 31 item test (25 true/false items and six open 
ended questions) that provided a comprehensive assessment of: general facts about 
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asthma, triggers, symptoms, and asthma treatment and management. It has been 
extensively used in multiple studies, as well as translated to Spanish and validated in 
Spanish-speaking countries460. 
 
 
 
 
 
 
 
Figure 4.4: Study nurse undertaking study questionnaire with participant and his 
caregiver, at the study centre. 
 
- Childhood Asthma Control Test (C-ACT)4: validated instrument included in 
the current Diagnosis and Management of Asthma Expert Panel Report 3 (EPR-3)6 to 
assess asthma control in children 4 to 11 years old. A score of less than 20 from a total 
of 27 (obtained from 7 different questions) indicates poor asthma control. The Asthma 
Control Test (ACT)3 (adult version) was used for children over 12 years old. 
 - Blood sample: 5ml of blood were obtained by venipuncture from the child 
into a Vacutainer tube containing EDTA as anticoagulant. A white cell and differential 
count for eosinophil counts was done manually at the research study clinical laboratory 
and plasma aliquoted and stored at -20C. 
- Nasal wash: was done to determine the proportion of granulocytes 
(eosinophil vs. neutrophils). It was used as a surrogate of sputum cytology for 
determining airway inﬂammation461. This was done using a modification of a 
methodology designed by Dr Peter Heymann at the University of Virginia that allows 
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the collection of small volume samples to reduce dilutional effects462. With the child 
sitting straight on a high chair and breath holding, we instilled 2ml of phosphate 
buffered saline (PBS) at ambient temperature into one of the nostrils, using an 
intranasal mucosal atomization device, MAD NasalTM (Teleflex, USA) Wolfe Tory 
Medical, Inc., Salt Lake City, UT), after which the child blew his nose into a glass funnel 
and collection tube. The same process was repeated with the second nostril and the 
funnel was then washed with an extra 2ml of PBS into the collection tube, obtaining a 
total of 4-8ml.  
Figure 4.5: Study lab technician obtaining a nasal 
wash sample from a participant, at the study centre. 
 
 
Four 500µl aliquots were frozen for later 
respiratory virus analysis. Two slides were 
prepared for each sample using a cytospin to 
estimate the proportion of eosinophils present 
in the nasal wash. 
 
 
- Stool samples: children were asked to collect a stool sample following 
recruitment. If found positive for intestinal parasites, caregivers were informed at the 
following visit and offered appropriate treatment.  
 - Pediatric Asthma Quality of Life Questionnaire (PAQLQ)463: Disease-
specific questionnaire available in both interviewer and self-administered formats, 
designed for children aged 7 to 17 years of age. The PAQLQ has 23 questions in 3 
domains (symptoms, activity limitation and emotional function). The activity domain 
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contains 3 ‘patient-specific’ questions. Children are asked to think about how they have 
been during the previous week and to respond to each of the 32 questions on a 7-point 
scale (7 = not bothered at all - 1 = extremely bothered). The overall PAQLQ score is the 
mean of all 23 responses and the individual domain scores are the means of the items 
in those domains.  
 - Lung function: Standard spirometry was carried out to measure FEV1 (Forced 
Expiratory Volume in the first second) and FVC (Forced Vital Capacity), before and after 
administering a β2 agonist to identify reversibility, using a portable Microloop 
spirometer (Micro Direct, UK). We followed the ERS and ATS criteria for a correct 
spirometry131 (Miller 2005). The centile spirometry values predicted for age and height 
were estimated using Global Lung Initiative standards464, using ‘Afro-American’ 
standards for Afro-ecuadorians, ‘Other’ for mestizos and ‘White’ for white, as reported 
in the parental questionnaire. An increase of FEV>12% was taken to be a positive 
bronchodilator reversibility test. FEV post-bronchodilator improvement was calculated 
by the formula: (Post FEV - Pre FEV / Pre FEV) x 100.  
 
Figure 4.6: Study nurse 
supervising spirometry at 
the study centre. 
 
 
 
 
- Fraction of Exhaled Nitric Oxide (FeNO) was measured using NObreath 
device (Bedfont Scientific, UK), at a fixed flow of 50ml/sec. Three measurements were 
taken to choose the best performed one or the mean of those with the highest quality. 
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Figure 4.7: Principal 
investigator supervising 
FeNO measurements, at the 
study centre. 
 
 
4.3.7. Laboratory procedures 
Stool examinations 
Single stool samples were analysed for geohelminth eggs and larvae by direct wet 
mount. They were then taken to the FEPIS (Fundación Ecuatoriana para Educación en 
Salud) laboratory in Quinindé, Esmeraldas, to do formol-ethyl acetate concentration 
analysis465.  
PCR for respiratory viral infections 
Nasal wash aliquots were transported to the FEPIS laboratory situated at the 
Universidad Internacional de Ecuador (UIDE) in Quito, Ecuador, and stored at -80°C. 
Commercial kits (Qiagen) were used to extract RNA. Specific RNA for rhinovirus, 
respiratory syncytial virus (RSV), human metapneumovirus (HMPV) and parainfluenza 
viruses (PIV) 1–4 was converted to cDNA and amplified by reverse transcriptase real-
time Polymerase Chain Reaction (PCR) (AgPath-IDTM One-Step RT-PCR kit, Invitrogen) 
using primer/probe combinations (Budge 2014) on a 7500 Fast machine (Applied 
Biosystems). A positive test was defined as Ct values ≤38.  
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IgE measurements 
Plasma was shipped to Professor Tom Platts-Mills, Asthma and Allergy Center of the 
University of Virginia, Charlottesville, Virginia, USA, for measurement of total and 
specific IgE for D. pteronyssinus, P. americana, and Ascaris using the CAP system 
(Pharmacia Diagnostics). A positive assay for sIgE was defined as >0.70 kU/l. A sample 
of 33 plasma samples were shipped and analysed. 
4.3.8. Study outcomes 
Primary outcome: 
 - Time to an acute asthma exacerbation requiring emergency department 
attendance or systemic corticosteroid prescription during the 6 months following first 
attendance.  
Secondary outcomes: 
 - Acute asthma exacerbation requiring emergency department attendance 
during the 6 months following first attendance. 
- Acute asthma exacerbation requiring hospital admission during the 6 months 
following first emergency department attendance.  
4.3.9 Definitions 
a.  Pets at home: Children were considered to have pets at home when the response to 
the question: ‘Which of the following pets do you keep inside your childʹs home?’, was 
either: ‘Dog, cat or other furry pets’.  
b. Humid household: Was defined as a positive response to the question: ‘Does your 
child’s home have damp spots on the walls or ceiling?’  
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b. Urban setting: A child was considered to live in an urban setting when the response 
to the question: ‘How would you describe the surroundings of your child’s home?’, was: 
‘Urban with no parks or gardens.’ 
c. Intense traffic near the house: A child was considered to have intense traffic near the 
house, when the response to the question: ‘How intense is the traffic in the street where 
the child’s home is located?’, was: ‘Very frequent.’        
d. Exposure to tobacco smoke: Was defined as a positive response to the question:  Does 
anybody, at present, smoke inside your child’s home?  
e. Severe attack in the last 12 months: was defined as a positive response to the 
question: ‘In the last 12 months, has wheezing ever been severe enough to limit your 
child’s speech to only one or two words at a time between breaths?’ 
f. Severe asthma attack: During the follow-up, a severe asthma attack was recorded as 
that needing emergency care attendance or systemic corticosteroid prescription. This is 
the definition included in the ATS/ERS 2009 statement8.  
4.3.10. Sample size calculations 
We estimated that we would be able to recruit 350 children and expected to have a 
50% emergency care re-attendance during the follow-up period, based on previous 
experience in this setting. This would represent around 50% of the total number of 
children treated for an acute asthma exacerbation at the HDTC emergency department 
in a year.  
A cohort of 250-350 children would provide 80% power to detect factors that reduce 
the proportion of children re-attending the emergency room within 1 year from 50% to 
31.4%% (hazard ratio of ≥1.46), and 90% power to detect factors that reduce the 
proportion of children re-attending emergency room within 1 year from 50% to 33.9% 
(hazard ratio of ≥1.37), using log-rank tests and actuarial statistical methods. 
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4.3.11. Statistical analysis  
All statistical analysis was done using STATA 13.1, with confidence interval of 95%, and 
a level of significance of p≤ 0.05, to describe statistically significant results.  
The primary outcome was an acute asthma exacerbation requiring emergency care, 
occurring between 2 weeks and 6 months after the index exacerbation. For children 
with more than one exacerbation during the study period, only the first exacerbation 
was taken into account. T-tests were used to examine continuous risk factors 
univariably. In the case of non-normal data, Mann-Whitney U-tests were undertaken. 
Categorical variables were compared using Fisher’s exact test. Correlation between 
FeNO values and blood eosinophilia, as well as between the asthma control, asthma 
knowledge and quality of life tests, were estimated using simple linear regression. 
Multivariable logistic regression was used to evaluate the effects of multiple risk factors 
for emergency care re-attendance for acute asthma exacerbations. A time-to-event 
analysis was also performed, via a multivariable Cox proportional hazard model. 
Collett’s method466 of variable selection was used with a p-value threshold of 0.2, and 
confounding and interactions between variables were also assessed. The parsimonious 
logistic and Cox models were selected based on the explained variation (R2). The 
proportional hazards assumption required by the Cox model was tested via the 
inclusion of time-dependent variables.  
The predictive ability of the models was evaluated by estimating the area under the 
Receiver Operating Characteristics curve (ROC)467, with 0.5 indicating a model with no 
discriminating power and 1.0 a perfectly discriminating model468. Internal validity was 
then assessed by bootstrapping techniques, using 200 random bootstrap samples with 
replacement, to evaluate potential upward bias (overfitting). Optimism in regression 
coefficients due to overfitting was estimated by measuring the difference between the 
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model’s c-statistic (apparent c-statistic) and the c-statistic computed by nonparametric 
bootstrap resampling (internal bootstrap validation c-statistic)469.  
To investigate the effect of missing values for variables with greater than 5% of missing 
data we performed a sensitivity analysis using the “ice”470 procedure for multiple 
imputation in Stata 13.1.  The “mim” procedure in Stata471 was then used to average the 
estimates of results across the 20 imputed data sets created, according to Rubin's 
rules472. The imputation models included all variables selected, the outcome of interest, 
and the Nelson Aalen estimator of the cumulative baseline hazard473.  
4.3.12. Data management, curation and storage  
Information was collected directly from the child’s parent or guardian by the study 
team, including only the participant’s unique study number assigned at time of 
recruitment on the completed questionnaires.  Consent forms, list of children’s names 
with their study number and other identifiable data (contact details with detailed map 
of home location) were stored in a locked filling cabinet in the study clinic, with access 
limited to the site study team. They were then transferred to the FEPIS research unit in 
Quinindé where they are being stored in a dedicated secure facility.  
Laboratory samples were labelled with the participant’s unique identifier number at 
the collection or extraction point. Plasma was stored at -20°C in a secure facility at the 
FEPIS research unit in Quinindé with 24/7-back-up power from a dedicated generator. 
All the information collected from the questionnaires and the different exam results 
were entered into a computer database, using double data entry. Data were entered 
daily, and any inconsistencies or missing information was checked with the 
participant’s parents or guardians by phone or during the follow-up visit. The 
participant’s study number was the only identifier included in this database. The study 
number accorded to each child was kept on a separate Excel File by the principal 
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investigator. The principal investigator’s files were kept in a password protected 
computer, and backed-up in a password protected USB storage device and secure web-
based files. All data collected, stored and shared complied with Good Clinical Practice 
(GCP) standards. 
Access to the study database was password protected and limited to the principal 
investigator and PhD supervisors. Anonymised study databases were exported to 
SPSS/STATA to be analysed by the principal investigator with support from study 
supervisors and study statistician. 
4.3.13. Ethical considerations 
Studies with children 
Children are always a vulnerable group, as it is their parents or guardians who decide 
what is best for them and they can also be easily manipulated. Our research included 
only children for the cohort study, as it is in this age group that we wished to study risk 
factors. A study of these characteristics in children is most urgently needed as they are 
the group least likely to receive preventive therapy, most likely to attend as an 
emergency, and are most vulnerable to loss of lung function (so they do not reach peak 
lung growth and have a longer duration of decline thereafter)14.  
The Declaration of Helsinki states that research should only be undertaken in 
vulnerable groups if “the research is responsive to the health needs or priorities of this 
group and the research cannot be carried out in a non-vulnerable group. In addition, 
this group should stand to benefit from the knowledge, practices or interventions that 
result from the research.”474. This was the case of this study, which aimed to benefit the 
paediatric population with asthma in this setting. Asthmatic adult patients may not be 
used for this purpose, as their disease characteristics may differ greatly from those of 
children. 
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Even though it was the children’s parents or guardians who signed the informed 
consent form, no child was forced to participate against their will, and those older than 
7 years old, signed an informed assent form.  
Studies in low and middle-income settings 
It is indispensable for low resource settings to undertake research related to healthcare 
which addresses their burden of disease. However, they cannot always count on the 
necessary resources to do so, and for that reason, it is fundamental that externally-
sponsored research that wishes to improve the health of the people living in these 
settings, is encouraged.  Nevertheless, research in low and middle-resource settings 
poses many ethical challenges.  
First, the research interest need to follow local priorities for research475. I designed my 
PhD project with the guidance of my supervisors, after I had been working in this 
setting for a year in the local public hospital and had understood the needs of asthmatic 
children and deficiencies in asthma care in this specific setting. As described in Chapter 
2, asthma in Latin America is a public health problem and a research priority, and only 
through research undertaken in Latin American countries is that we may address this 
problem. 
Second, we must prevent harm and exploitation of research participants475. Our study 
protocol was carefully designed and reviewed by two different Research Ethics 
Committees (local and the sponsor’s), to assure that participants were not harmed or 
exploited in any way. It is vital that research undertaken in low-resource settings that is 
externally-sponsored, be independently reviewed in the sponsor’s country as well as in 
the country where it will take place475. 
Third, according to the Council for International Organizations of Medical Sciences 
(CIOMS), the compensation offered to research participants, “should not be so large as 
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to persuade them to take undue risks or volunteer against their better judgment”476. In 
our study, participants were offered a small payment to cover travel costs when 
necessary, as well as guaranteed access to adequate management and treatment for the 
child’s asthma, something which was not always available outside the study centre. 
Both incentives for individuals to participate were considered appropriate and did not 
constitute coercion for participation477. 
Fourth, a complete understanding of the informed consent may always be difficult to 
assure in a low-resource setting where health literacy may be limited477. Bearing this in 
mind, the informed consent form for our study contained detailed but simple and easy 
to understand information concerning the study objectives and procedures. We had 
used a very similar form in a previous study in this same setting34, with a positive 
response from the research participants as to the level of understanding of the 
information transmitted. Similarly, children were given a simplified informed assent 
form using more elementary vocabulary, that was read out to them. 
 Finally, cultural differences should be always considered when undertaking research 
in a different country with a different culture, concept of illness and disease, doctor-
patient relationship, traditional medicine and beliefs475. As mentioned already, I had 
lived and work in this same setting for over a year before undertaking the study. I tried 
to acknowledge all these cultural differences when designing the study to assure the 
success of the project and the respect of the research participants. 
Offering additional research-supported services    
The major ethical issue involved in this research is that the majority of the asthmatic 
children recruited for the study with an episode of acute asthma were not taking any 
baseline treatment such as inhaled corticosteroids (ICS), which are the most effective 
controller therapy, and are the recommended treatment for asthma for children of all 
ages37. The standard of care offered to research participants in a low-resource setting is 
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still under debate, as some believe they should be offered the same health care they 
would receive if treated in the sponsoring country to avoid exploitation478. Others 
allege that providing a universal standard (the best available treatment) would prevent 
sponsors from undertaking research in low-resource settings475, as well as act as a 
coercion for research participants.  
There is still controversy between guidelines on which children need to be started on 
ICS, given the different classifications of asthma severity and control. The 2017 GINA 
guidelines state that one severe exacerbation in the last year is enough to classify the 
child’s asthma as persistent or not well controlled and should be therefore started on 
ICS37. On the other hand, the Expert Panel Report 3 Guidelines for the Diagnosis and 
Management of Asthma6, include specific guidelines for management of children 5-11 
years old who are not currently taking long-term control medication. They classify 
asthma as intermittent if they fulfil the impairment component and have 1 or no 
exacerbations per year (defined as those needing a short course of oral 
corticosteroids). In this case they only recommend short-acting beta-agonists as 
needed for symptoms6.  
Locally, the Ecuadorian Guidelines146 include a specific section for childhood asthma, 
for which they follow the Spanish Asthma Guide (Guía Española de Manejo de Asma, 
GEMA 2009479 guidelines (Spanish guide for Asthma Management). They classify 
asthma as occasionally episodic (5 or fewer episodes per year), frequently episodic (6-8 
episodes per year), moderate persistent (1 episode per month) and severe persistent 
asthma (see definitions in Chapter 2). According to this, patients with occasionally 
episodic asthma do not need to be on daily ICS.  
If we were to follow these national recommendations, we would only start children on 
ICS if we recorded 6-8 episodes of acute asthma during the study period. On the other 
hand, following Ecuadorian law, as we were working with the city’s public hospital 
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patients, we were only able to offer the drugs available through the Ministry of Public 
Health. This is the approach we decided to implement for the study, to assure an 
adequate asthma management on one side, and so not to disrupt the usual management 
these children should be receiving in our absence and be able to explore the risk of re-
attendance for acute asthma before any changes in management were implemented. 
However, even following the national guidelines and offering only the treatments 
available through the Ministry of Public Health (inhaled corticosteroids), the children 
were receiving a better asthma care than that normally offered at the hospitals and 
health centres from which they were recruited. At these centres, most doctors do not 
prescribe any baseline treatment for asthma34 and patients are not regularly followed-
up for their asthma, let alone educated on self-management and prevention. Therefore, 
during the cohort study, some patients varied their usual asthma care, as they received 
education sessions on asthma and written asthma action plans, together with their 
reliever and baseline treatment inhalers. Nevertheless, as the education and treatment 
offered was the same for all participants, the analysed predictors of re-attendance for 
acute asthma should not have been greatly biased. 
4.3.14. Ethical approval 
Every effort was made to safeguard the participants’ confidentiality throughout the 
study. Stored laboratory samples were identified by the study number and date of 
collection. The study protocol was approved by the Bioethics Committees of the 
Liverpool School of Tropical Medicine Research Committee (Research Protocol 
14.021RS2) and the Pontificia Universidad Catolica del Ecuador (PUCE). The latter has 
federal-wide assurance from the US department of Health and Human Services.  
 
Chapter 4 | Prospective cohort study 
 
161 
 
4.4.1 Cohort characteristics 
A total of 283 children were recruited over 18 months. After the first three months, the 
study recruitment location was extended to another hospital in the city managed by the 
government’s national insurance (Instituto Ecuatoriano del Seguro Social (IESS) 
Hospital), and to three health centres with emergency services. 
The number of potentially eligible participants could not be ascertained given the lack 
of an electronic record of children attended at the public hospital (HDTC) and the 
health centres. We did not record either the exact recruitment location of each 
participant, as some of them were seen at more than one location during the index 
asthma attack. 
Figure 4.8: Number of participants recruited and completing 6 months follow-up. 
 
Thirteen children (4.6%) were lost to follow-up after the initial recruitment visit, and 
264 (93.3%) completed 6 months follow-up. Of these, 121 (45.8%) suffered a 
subsequent asthma exacerbation requiring emergency care during the first 6 months 
(Figure 4.8 and 4.9). The median follow-up time was 407.5 days (IQR: 265-541 days, 
Total cohort:
283
264 (93.3%) 
6 months FU
121 (45.8%)
Readmitted first 6m
6 (2.1%) 
<6 months FU 
13 (4.6%) 
LTFU
4.4 Results
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range 44-697 days) and the median time to a subsequent asthma exacerbation was 91 
days (IQR:  39-178 days). 
Figure 4.9: Kaplan-Meier curve of the cases of subsequent severe asthma attacks over 
time (requiring emergency care re-attendance or systemic corticosteroid prescription). 
 
 
  
 
 
 
 
 
Sociodemographic, personal and family history 
The sociodemographic, personal and family history for the whole cohort are shown in 
Table 4.1. The median age was 8 years old (range: 5-15), 59% were male and more 
than half (54%) self-reported as Afro-Ecuadorians. The median total years the mother 
and father had studied was 24 (range: 0-36), which is equivalent to finishing secondary 
education. Two thirds of the children lived in an urban setting and one third reported 
intense traffic near the house. The median household monthly income was 400 USD 
(range: 0-12000), slightly over the national minimum wage. Less than 20% reported 
being exposed to tobacco smoke, half of the houses had humid stains and 43% had pets 
at home.  
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Table 4.1: Socio-demographic characteristics, personal and family history of the 
whole cohort and divided by readmission status at 6-month follow-up. 
 
 
Total Cohort Readmission by 6 months 
Yes No P 
Age (median, IQR) 8 (6-11) 7 (5-10) 9 (7-11) <0.001 
Sex male (%) 58.7 60.3 59.2 0.900 
Ethnicity  
(%) 
Afro-Ecuadorian 53.8 52.1 54.7 0.963 
Mestizo 42.9 44.6 41.7 
White 1.5 1.7 1.4 
Other 1.9 1.7 2.2 
BMI (median, IQR) 16.6  
(15.1-19.4) 
16.4  
(15.0-19.2) 
16.9  
(15.1-19.7) 
0.265 
Siblings (%) 89.6 88.4 90.9 0.547 
No. of years mother and father 
studied (median, IQR) 
24 (18-28) 24 (18-28) 24 (19-29) 0.304 
Early life respiratory illness  (%) 48.7 58.5 40.1 0.013 
Allergic rhinitis ever  (%) 72..0 74.4 70.0 0.490 
Allergic rhinitis diagnosis (%) 20.5 20.0 21.0 0.878 
Eczema ever  (%) 13.0 14.1 12.1 0.713 
Eczema diagnosis (%) 4.2 6.6 2.1 0.119 
Paternal/maternal asthma (%) 46.3 52.7 40.6 0.175 
Paternal/maternal 
asthma/rhinitis/eczema (%) 
68.4 69.9 66.4 0.788 
Pets at home  (%) 42.9 44.6 41.8 0.708 
ETS  (%) 18.3 16.5 20.6 0.474 
Humid household  (%) 46.6 41.3 51.1 0.137 
Urban setting  (%) 65.7 59.5 69.5 0.094 
Intense traffic near house  (%) 30.1 29.8 30.3 1.000 
Monthly household income 
(USD) (median, IQR) 
400 (255-
700) 
400 (260-
700) 
350 (250-
700) 
0.981 
ETS: Exposure Tobacco Smoke; IQR: Interquartile range; USD: US Dollars; BMI: Body Mass Index. 
 
As for the children’s personal history, half of the cohort had a history of an early life 
respiratory illness associated with wheezing and difficulty breathing (bronchiolitis), 
and 72% and 13% reported symptoms of allergic rhinitis and eczema ever in life, 
respectively. Forty six percent of the children had a family history of asthma (either 
father or mother) and 68% had a family history of allergic disease (eczema, asthma or 
allergic rhinitis). Less than 7% of the children were recruited during their first ever 
episode of acute bronchospasm and less than 15% of the total 283 did not suffer any 
wheezing episodes during the previous year (Table 4.2). Thirty-six percent did not have 
a previous doctor’s asthma diagnosis and 2% were receiving long-term treatment with 
inhaled corticosteroids.  
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Table 4.2: Asthma characteristics and history of the whole cohort and divided by 
readmission status at 6-month follow-up. 
 
 
Total 
Cohort 
Readmission by 6 months 
Yes No P 
Wheezing ever (%) 93.5 97.5 90.1 0.021 
Wheezing last 12m (%) 86.5 93.3 80.7 0.003 
No. attacks last 12m (median, IQR) 3 (2-6) 5 (2-6) 3 (1-5) <0.001 
Days since last attack (median, IQR) 60  
(30-120) 
60  
(30-120) 
60  
(30-150) 
0.120 
Wheezing at night 
last 12m (%) 
Never 18.8 15.8 21.3 0.424 
<1 night per week 1.2 1.7 0.7 
≥1 night per week 13.8 16.7 11.4 
Only during acute 
attacks 
66.3 65.8 66.7 
Severe attack last 12m (%) 36.0 44.2 29.8 0.014 
Wheezing with 
exercise (%) 
No 35.8 29.9 40.9 0.188 
Yes 40.2 44.4 36.5 
Only during acute 
attacks 
24.0 25.6 22.6 
Asthma diagnosis (%) 64.2 76.5 53.9 <0.001 
Number of triggers 4 (2-6) 4 (3-6) 4 (2-5) 0.117 
Food as trigger (%) 36.9 46.2 28.9 0.006 
Doctor visit for 
acute asthma last 
12m (%) 
None 15.3 8.3 21.3 <0.001 
1-3 49.4 45.8 52.5 
4-12 27.2 31.7 23.4 
>12 8.1 14.2 2.8 
Doctor visit for 
asthma control 
last 12m (%) 
None 68.2 65.0 71.1 0.592 
1-3 24.0 25.8 22.5 
4-12 7.4 8.3 6.5 
>12 0.4 0.8 0 
ICS treatment (%) 2.0 0.9 3.0 0.374 
Emergency visits last 12m for asthma (%) 76.0 78.5 73.8 0.388 
No. ER visits last 12m for asthma (median, 
IQR) 
2 (1-4) 3 (1-6) 2 (0-3) 0.006 
No. IV/IM CS courses last 12m for asthma 
(median, IQR) 
0 (0-1) 1 (0-3) 0 (0-1) <0.001 
Ever admitted for asthma (%) 25.2 33.9 17.7 0.004 
Admitted to hospital for asthma last 12m (%) 7.6 11.6 4.2 0.034 
Ever admitted to ICU for asthma (%) 10.0 13.3 7.1 0.102 
IQR: Interquartile range; m:months; ER: emergency room; ICU: Intensive Care Unit. 
 
The median number of acute asthma attacks during the previous 12 months was three 
(range 0-24) and the median time since the last attack was two months (range 0-365 
days). Markers for asthma severity in the last 12 months were reported as follows: 
wheezing ≥1 night per week 14%, wheezing with exercise 40%, and severe attack 36%. 
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Eighty-five percent of the children had visited a doctor at least once (35% more than 
four times) for acute asthma and 32% for a control visit (8% more than four times) 
during the previous 12 months. Three quarters of the cohort had visited the emergency 
department for an acute attack during the previous year, with a median number of 2 
visits (range: 0-30) and 0 courses (range: 0-12) of intramuscular or intravenous 
corticosteroids courses in the last year. As for history of hospital admissions for 
asthma, 25% and 10% had been ever admitted to hospital and ICU, respectively, and 
7.5% had been admitted to hospital in the previous 12 months.  
Allergy and inflammatory markers 
Table 4.3 includes the results from the allergy and inflammatory markers, as well as the 
lung function tests. The median percentage of blood eosinophils was 5.0% (range: 0-
18%), the total count 372 cells/ml (range: 0-2368) and the median nasal eosinophils 
was 11% (range: 0-100%). One third of the children had blood eosinophilia (defined as 
5% or higher), while 72% of them had nasal eosinophilia (defined as 5% or higher). 
The median FeNO was 33 ppb (range: 0-300) at a flow rate of 50ml/s (which is defined 
as high for children). There was no correlation between the proportion of nasal 
eosinophils and the FeNO measurements (r=0.038, p=0.880), nor between the 
proportion of blood eosinophils and FeNO (r=-0.11, p=0.907), using simple linear 
regression. 
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Table 4.3: Allergy and inflammation markers, and lung function parameters of the whole 
cohort and divided by readmission status at 6-month follow-up. 
  
  
Total Cohort Readmission by 6 months 
Yes No P  
Haemoglobin (mean, SD) 13.0 (0.86) 12.9 (0.87) 13.1 (0.84) 0.032 
Blood eosinophils (median, IQR) 372 (185-729) 306 (147-
653) 
449 (227-
790) 
0.061 
Blood eosinophils (%) (median, 
IQR) 
5.0 (2.0-8.0) 4.0 (2.0-7.0) 5.0 (3.0-8.5) 0.071 
Blood eosinophilia  (%) 33.0 28.1 37.1 0.148 
Nasal eosinophils (%) (median, 
IQR) 
11.0 (4.5-22) 9.5 (4.5-26) 13.3 (4.3-
22) 
0.595 
Nasal eosinophilia  (%) 72.1 72.7 71.6 1.000 
FeNO measurements (ppm) 
(median, IQR) 
33 (3-79) 31 (1-72) 40 (12-99) 0.095 
Pre FEV1 (% of predicted) 
(median, IQR) 
97 (86-107) 94 (84-106) 98 (88-108) 0.112 
Pre FEV1 Z-score (median, IQR) -0.24  
(-1.09-0.51) 
-0.46  
(-1.26-0.44) 
-0.18 (-0.92-
0.70) 
0.100 
Pre FEV1/FVC (median, IQR) 91 (85-97) 92 (87-98) 91 (84-97) 0.613 
Pre FEV1/FVC Z-score (median, 
IQR) 
0.24  
(-0.61-1.15) 
0.27 (-0.57-
1.07) 
0.23 (-0.72-
1.15) 
0.658 
Post FEV1 (% of predicted) 
(median, IQR) 
105 (93-115) 104 (93-
114) 
106 (93-
115) 
0.650 
Post FEV1 Z-score (median, IQR) 0.35  
(-0.53-1.16) 
0.33 (-0.58-
1.06) 
0.43 (-0.51-
1.25) 
0.526 
FEV1 improvement (%) (median, 
IQR) 
6.3 (1.7-13.7) 6.4 (1.9-
14.6) 
5.7 (1.3-
12.7) 
0.286 
SD: Standard deviation; IQR: Interquartile range; FeNO: Fraction of Exhaled Nitric Oxide; FEV1: 
Forced Expiratory Volume 1st second; FVC: Forced Vital Capacity. 
 
Total and allergen specific IgE were only measured for a subsample of 33 participants, 
given unexpected problems in transporting the samples from Ecuador to the US 
(Ecuadorian law changed during the study period). The median total IgE was 982 kU/l. 
Five of the 33 samples were negative for mite IgE (D. pteronyssinus and B. tropicalis 
IgE <0.70 kUA/l), which indicated that 85% of the children in the subsample were 
atopic to mite.  
Respiratory viruses 
The first 25 samples were tested for rhinovirus, respiratory syncytial virus (RSV), 
parainfluenza virus 1 and 3 (PIV 1 and PIV 3), human metapneumovirus (HMPV) and 
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adenovirus Hco2 HKU1, Hco3 N63. None of them were positive for adenovirus, PIV1 
and PIV3, and only one of them was positive for HMPV. Given the very low prevalence 
of the PIV 1 and 3, HMPV and adenovirus, the rest of the available samples were tested 
for rhinovirus and RSV, alone. Of the total 243 samples, 84 (34.6%) were positive for 
rhinovirus and 11 (4.5%) were positive for RSV. 
Intestinal helminths 
Of the 147 stool samples obtained, 2 were positive for Ascaris lumbricoides and 1 for 
Trichuris trichiura. There were no other intestinal helminths in the analysed samples. 
Lung function 
The children had a median pre-bronchodilator FEV1 value of 78% (range: 48-122%) of 
predicted for age and size, a FEV1/FVC median ratio of 91% (range: 65-166%), and a 
post-bronchodilator FEV1 value of 86% (range: 53-138%) of predicted. 
109 (40%) of the 270 children that underwent spirometry had a positive response to 
bronchodilator (FEV1 predicted improvement >12%). 
Asthma control, asthma knowledge and quality of life 
The results of other tests included in the preliminary child’s study are shown in Table 
4.4. Sixteen percent of the participating children had uncontrolled asthma according to 
the ACT and C-ACT scores. The median score for the Asthma Control Test was 16 
(range: 10-24) for the adult version (ACT) (considered uncontrolled asthma if below 
20) and 16 (Standard Deviation, SD: 3.75) the mean C-ACT (childhood version). Specific 
knowledge of asthma was low, with a median score in the Newcastle Asthma 
Knowledge Questionnaire (NAKQ) of 18 out of 31 (range: 9-27). The median score for 
the PAQLQ (Pediatric Asthma Quality of Life Questionnaire) completed by 222 children 
was 3.5 (IQR: 3.0-4.0), of a 1-7 scale, the lower score representing a poorer QoL. The 
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median scores for each PAQLQ domain were: symptoms 3.5 (IQR: 2.8-4.1); activity 3.4 
(IQR: 2.6-4.0); emotional 3.7 (IQR: 3.1-4.5). 
Table 4.4. Results for the Asthma Control Tests (ACT and C-ACT), Newcastle Asthma 
Knowledge Questionnaire and the Pediatric Quality of Life Questionnaire of the whole 
cohort and divided by readmission status at 6-month follow-up. 
  
  
Total 
Cohort 
Readmission at 6 months 
Yes No P  
C-ACT score (mean, SD) 16.03 (3.75) 15.4 (4.05) 16.5 (3.41) 0.077 
ACT score (median, IQR) 16.0 (13-18) 16 (14-18) 15.5 (13-18) 0.936 
NAKQ score (median, IQR) 18.0 (16-20) 17 (15-20) 18 (16-21) 0.041 
PAQLQ  total score (median, IQR) 3.5 (3.0-4.0) 3.5 (2.9-
4.0) 
3.5 (3.0-4.2) 0.275 
PAQLQ symptom score (median, 
IQR) 
3.5 (2.8-4.1) 3.6 (2.8-
4.0) 
3.5 (2.8-4.2) 0.479 
PAQLQ activity score (median, 
IQR) 
3.4 (2.6-4.0) 3.4 (2.6-
4.0) 
3.4 (2.6-4.2) 0.525 
PAQLQ emotional score (median, 
IQR) 
3.7 (3.1-4.5) 3.5 (3.0-
4.2) 
3.9 (3.2-4.6) 0.030 
SD: Standard deviation; IQR: Interquartile range; C-ACT: Childhood Asthma Control Test; ACT: 
Asthma Control Test; NAKQ: Newcastle Asthma Knowledge Questionnaire; PAQLQ: Pediatric 
Asthma Quality of Life Questionnaire. 
 
We studied the correlation between asthma knowledge, asthma control and asthma 
related quality of life using simple linear regression. There was no correlation between 
asthma knowledge and asthma control or quality of life. Asthma control as measured by 
ACT (taken by children older than 12 years old) was positively correlated with quality 
of life as measured by the PAQLQ total score (r= 0.297, p=0.041). 
4.4.2. Risk factors for emergency care re-attendance 
Re-attendance by six months 
Tables 4.1-4.4 show the results of the socio-demographic, personal and family history, 
asthma characteristics, the allergy and inflammatory markers divided by readmission 
status after the first 6 months of follow-up following the initial emergency care 
attendance for acute asthma. In univariable analyses, risk factors for recurrence were:  
younger age, early life severe respiratory illness, food triggers, previous asthma 
Chapter 4 | Prospective cohort study 
 
169 
 
diagnosis, number and severity of previous attendances for asthma and lower 
haemoglobin levels.  
a. Allergy and inflammatory markers and lung function: There were no 
differences in the blood and nasal eosinophilia or FeNO measurements between those 
that were readmitted during the first 6 months and those that were not (Table 4.3 and 
Figure 4.10). The same was true of the different lung function parameters (Table 4.3 
Figure 4.11). 
Figure 4.10: Allergy and Inflammatory Markers Box Plots. P values represent the 
differences between the medians and the distribution of the data of those readmitted vs 
those not readmitted as measured by Mann-Whitney U-test. 
 
 
  
FeNO: Fraction of Exhaled Nitric Oxide 
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Figure 4.11: Lung Function Parameters Box Plots. P values represent the differences 
between the medians and the distribution of the data of those readmitted vs those not 
readmitted as measured by Mann-Whitney U-test. 
 
FEV1: Forced Expiratory Volume 1st second; FVC: Forced Vital Capacity  
b. Asthma control, asthma knowledge and quality of life: The parents of children 
who were readmitted at 6 months for acute asthma, showed less specific asthma 
knowledge (NAKQ score). There were no differences in the level of asthma control 
(ACT and C-ACT scores). A high NAKQ (OR: 0.91, 95% CI: 0.85-0.98) and PAQLQ 
emotional domain (OR: 0.72, 95% CI: 0.55-0.94) score were associated with a lower 
risk of subsequent asthma attacks requiring emergency care. We found no significant 
association between PAQLQ total score, symptoms or activity domain, and future risk.   
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Figure 4.12: Asthma control tests, asthma knowledge (NAKQ) and quality of life (PAQLQ) 
Box Plots. P values represent the differences between the medians and the distribution of 
the data of those readmitted vs those not readmitted as measured by Mann-Whitney U-
test. 
 
 
 
 
 
 
 
 
C-ACT: Childhood Asthma Control Test; ACT: Asthma Control Test; NAKQ: Newcastle Asthma 
Knowledge Questionnaire; PAQLQ: Pediatric Asthma Quality of Life Questionnaire. 
 
c. Respiratory viruses: The proportion of children with a positive sample for 
rhinovirus and RSV did not differ between those that suffered a subsequent severe 
asthma attack and those that did not during the first 6 months follow-up (Table 4.5).  
Table 4.5. Results for the respiratory viruses analysed by PCR from the nasal wash 
samples, of the whole cohort and divided by readmission status at 6 month follow-up. 
  
  
Total Cohort (229) Readmission by 6 months 
Yes No P  
RSV (number, %) 10 (4.4) 5 (4.9) 5 (4.0) 0.757 
Rhinovirus (num, %) 79 (34.5) 39 (37.9) 40 (31.8) 0.402 
RSV: Respiratory Syncytial Virus. 
 
Multivariable analysis 
In the final multivariable logistic regression model, younger age, an existing asthma 
diagnosis, food triggers, number of intravenous or intramuscular corticosteroid courses 
Not Readmitted   Readmitted 
 
p=0.529 p=0.146 p=0.041 p=0.275 
ACT Score  C-ACT Score  NAKQ Score  PAQLQ Score  
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for acute asthma in the previous 12 months, and previous eczema diagnosis, were 
associated with a higher risk of subsequent asthma exacerbations requiring emergency 
care in the 6 months following the index ED attendance (Table 4.6). The area under 
curve (AUC) of the model was 0.73 (c-statistic) and the model explained 13% of the 
variation. After internal validation (bootstrapping), the AUC reduced to 0.72 and the R2 
to 14%, indicating little overfitting of the regression coefficients. This was estimated by 
measuring the difference between the model’s c-statistic (apparent c-statistic) and the 
c-statistic computed by nonparametric bootstrap resampling (internal bootstrap 
validation c-statistic)469.  
Table 4.6. Multivariable logistic regression for the risk of ER re-attendance for acute 
childhood asthma during 6 months follow-up. 
 
Crude 
OR 
95% CI P value Adjusted 
OR* 
95% CI P 
value 
Age 0.87 0.79-0.95 0.001 0.87 0.79-0.96 0.006 
Existing asthma 
diagnosis 
2.78 1.62-4.76 <0.001 2.17 1.19-3.94 0.011 
No. IV/IM  CS courses 
last 12m for asthma 
1.36 1.15-1.61 <0.001 1.28 1.08-1.53 0.006 
Food as trigger 2.11 1.25-3.55 0.005 1.99 1.11-3.55 0.020 
Eczema diagnosis 3.26 0.84-12.6 0.086 4.22 1.02-17.54 0.048 
*: Adjusted Odds Ratios were adjusted for all other variables in the model. OR: odds ratio, CI: 
confidence interval; IV: intravenous; IM: intramuscular; CS: corticosteroids. P values to 3 
decimal places. 
Cox regression analysis 
Table 4.7 shows the final Cox regression model. Children of a younger age, with an 
existing asthma diagnosis, a greater number of intravenous or intramuscular 
corticosteroid courses for acute asthma in the previous 12 months, and not living in an 
urban setting showed a higher rate of recurrent acute asthma exacerbations requiring 
emergency care over time. The AUC of the model was 0.65 (c-statistic) and overfitting 
of the model was estimated as <1% after bootstrapping. This was estimated using the 
same method as for the logistic regression model (see above). The proportional 
hazards assumption was valid for all included variables. 
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Table 4.7. Multivariate Cox regression model for the risk of ER re-attendance for acute 
childhood asthma. 
 
Crude 
HR 
95% CI P 
value 
Adjusted 
HR* 
95% CI P 
value 
Age 0.92 0.87-0.97 0.002 0.93 0.88-0.98 0.009 
Existing asthma diagnosis 1.78 1.26-2.53 0.001 1.66 1.15-2.39 0.007 
No. IV/IM  CS courses 
last 12m for asthma 
1.17 1.10-1.24 <0.001 1.13 1.06-1.20 <0.001 
Urban residence 0.65 0.47-0.89 0.007 0.69 0.50-0.95 0.023 
*: Adjusted Hazard Ratios were adjusted for all other variables in the model. HR: hazard 
ratio, CI: confidence interval; IV: intravenous; IM: intramuscular; CS: corticosteroids. 
 
4.4.3. Post-hoc analysis 
Differences urban vs rural 
As living in a rural environment was found to be a risk factor for emergency care re-
attendance for acute asthma, we aimed to undertake a post-hoc analysis to explore any 
possible differences between the children living in rural or sub-urban, compared to 
those living in urban environments. The only differences observed are shown in Table 
4.8. 
Table 4.8. Results for the exposures that differed between the children residing in an 
urban vs. rural area.  
 Urban (176) Rural (92) P value 
Humid household 90 (51.4%) 35 (38.0%) 0.040 
Days since last attack 75 (30-135) 44 (30-90) 0.0031 
FeNO 29 (1-73) 43 (14-97 0.0316 
NAKQ 19 (16-21) 17 (16-21) 0.0270 
 
It was more common to have evidence of humidity in the household for children living 
in an urban environment than those from a rural one. This factor was not associated 
with the risk of future acute asthma attacks requiring emergency care. Additionally, the 
time elapsed between the acute asthma attack and the current one at which children 
were recruited was shorter for rural than urban children (Table 4.8). As before, this 
was not identified initially as a predictor for emergency care re-attendance for acute 
Chapter 4 | Prospective cohort study 
174 
 
asthma, though it may be an indicator that the population of rural children attended at 
the city’s ER suffer more frequent attacks than those coming from the urban area and 
may be therefore at a greater risk of suffering subsequent attacks. Rural children also 
had a higher median FeNO value, which indicates a greater lung eosinophilic 
inflammation, and their caregivers obtained a lower score on the asthma knowledge 
questionnaire (NAKQ). This latter factor was initially identified as a predictor for future 
severe acute asthma attacks, though the association disappeared when adjusted for 
other related factors in the multivariable analysis. 
Sensitivity analysis 
To investigate the effect of missing values for variables with greater than 5% of data 
missing we performed a sensitivity analysis using multiple imputation. There were no 
differences in the final logistic regression and Cox regression multivariable models 
obtained when using the multiple imputation dataset compared to the original dataset 
(data not shown).  
There were two relevant and important findings in this cohort study: i) we 
characterised a cohort of asthmatic children with acute asthma recruited from an 
emergency care room in a low-resource setting in tropical Latin America; and ii) we 
identified independent predictors for emergency care re-attendance for severe asthma 
attacks among children treated at an emergency room in Ecuador.  
Many of the children treated at an emergency room for an episode of acute 
bronchodilator-responsive wheezing were previously underdiagnosed, inadequately 
managed and had received no formal asthma education, as reflected by the low asthma 
knowledge of the caregivers, the poor asthma control and the deficient baseline 
treatment. This cohort of children appears representative of a Latin American urban 
4.5. Summary of findings
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population, of low socioeconomic status, with atopy (family history, concomitant 
allergic rhinitis, nasal eosinophilia and positive allergen specific IgE to mite) and 
frequent severe asthma exacerbations. 
Forty six percent of the children suffered a subsequent severe asthma requiring 
emergency care during the first 6 months after the index attack. From the identified 
predictors for emergency care re-attendance for severe asthma attacks, previous 
severe asthma exacerbations was the most reliable predictor of future risk: each acute 
corticosteroid course received during the previous year for acute asthma increased the 
odds of a subsequent attack requiring emergency care by a factor of 1.28. Other factors 
relating to the risk of attack and the time to the next attack were similar, though not the 
same, and included: younger age, an existing asthma and/or eczema diagnosis, food 
triggers for asthma attacks and rural residency. In this unselected cohort, none of the 
biomarkers or lung function parameters, were useful for predicting future risk of 
severe attacks. These predictors could be combined into a user-friendly risk 
assessment tool to be used at the emergency room by the treating doctor of the child 
with an acute asthma attack. Even though such risk assessment tool has not yet been 
formally developed and validated, here is a representation of how it might look: 
 
Table 4.9 Initial model of the risk assessment tool 
 LOW RISK AVERAGE HIGH RISK 
Age: 5-6 years old 
Answered Yes 
to ≤ 1 
question 
Answered Yes 
to 2 questions 
Answered 
Yes to ≥ 3 
questions  
Previous asthma diagnosis 
Received at least one IV/IM  
corticosteroid course during previous 
12m for asthma 
Lives in a rural setting 
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According to this classification, 68% of the children from this cohort classified as high 
risk suffered a subsequent asthma attack requiring emergency care in the following 6 
months, compared to the 28% classified as low risk. 
This study included a relevant number of children treated for acute bronchospasm at 
the ED in Esmeraldas and attained a high follow-up rate and an accurate record of 
subsequent asthma attacks by keeping continuous contact with the study participants. 
The comprehensive questionnaire and laboratory tests together with the lung function 
and FeNO measurements were designed to explore a broad range of potential risk 
factors that could be associated with the risk of subsequent severe asthma attacks, 
including those normally available or measured in high income country paediatric 
practice, though not routinely used in Latin America. Furthermore, the study 
represented real-life asthma attending emergency rooms, by including all the 
bronchodilator-responsive wheeze, irrespective of their previous asthma diagnosis or 
their lung function parameters. 
However, the study has several limitations. First, the fact that this cohort of asthmatic 
children were actively followed-up, educated and offered a written asthma action plan, 
may have modified their asthma knowledge, treatment adherence and self-efficacy in 
treating asthma attacks. However, all the children were treated alike and in accordance 
with local and international guidelines, so the predictors we identified likely represent 
the reality of the setting.  
Second, the study population has certain specific characteristics (race, socioeconomic 
status, asthma knowledge, etc.), which may differ from other Latin American settings, 
given its large geographical area and population diversity. Nonetheless, Latin American 
cities, where asthma is more prevalent, share common characteristics such as 
4.6. Strengths and limitations of the study 
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overcrowding, air pollution and greater exposures to dirt (e.g. an unhygienic 
environment) in low-resource areas. 
Third, we were only able to recruit an estimated 60% of all bronchodilator-responsive 
wheeze episodes treated at the ED during the study period. However, this is only an 
estimation, as we did not record the potential number of eligible participants for two 
reasons. First, during the first months in the public hospital (HDTC) and during the 
whole study in the health centres, there was no electronic records of patients seen at 
the ED and the paper record system was very incomplete and unreliable, therefore we 
did not know the total number of patients seen with an acute asthma exacerbation. 
Second, the initial diagnosis recorded in the paper records was not ascertained in those 
patients who were not contacted or who did not come the study clinic to participate in 
the study. We could therefore not be sure whether the patients were eligible or not.  
In addition, we do not have data to assess differences between those included and 
those not included in our analysis, other than the age of the child, his/her caregivers 
name and address available at the hospital’s record. Reasons for not being recruited 
were: i) did not wish to leave a contact number with the study team to call them; ii) not 
having a contact number (mobile phone or land line); iii) providing incorrect contact 
details; iv) not wishing to participate when contacted later by the study team; and v) 
not being available for an appointment during office hours, or missing the scheduled 
appointment on at least 3 occasions (after which we did not arrange another 
appointment unless the participant’s caregiver demanded it). Non-participation may 
have introduced some form of selection bias in the final study sample. For example, not 
having a contact number is a proxy for low socioeconomic status and such children 
could have been underrepresented in our sample. However, they were given an 
information sheet at the emergency department and told they could visit the study 
office the next day without a scheduled appointment. 
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Fourth, we did not have the opportunity within the restricted time of the study to 
increase the sample size further or validate a possible risk-assessment tool such as that 
shown above in a different setting. We managed to increase patient recruitment 
initially, by including further health centres and hospitals in Esmeraldas, increasing the 
number of children recruited to attain the minimum sample size. We then made 
arrangements to augment the sample by inclusion of health centres in two other cities, 
Guayaquil and Santo Domingo, but were unable because of bureaucratic impediments. 
Although a prediction model has not been validated, the predictors identified could be 
used to guide the decision-making process at the ED when treating a child with an 
acute asthma exacerbation. 
Finally, we did not classify the severity of the asthma attacks, other than they were 
being treated at the ED. Although perception of severity may vary depending on the 
treating doctor or triage nurse, as well as the acute asthma management skills and 
knowledge of the caregivers, a severe asthma attack has been defined at the ATS/ERS 
joint statement8 as an attack requiring systemic corticosteroids (and for at least 3 days 
if oral). The prescription of systemic corticosteroids was not used to define asthma 
attacks in our study for several reasons including a lack of national guidelines for the 
management of acute asthma exacerbations, a very variable approach to asthma 
management between different doctors, and low prescription rates of oral 
corticosteroids. Additionally, we were aiming to assess a real-life situation to obtain 
predictors to allow us to design a risk-assessment tool to be applied at the ED for any 
child treated for a bronchodilator-responsive wheeze. 
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4.7.1. Baseline cohort characteristics 
Most children with a severe asthma exacerbation participating in this study were not 
adequately managed: few (2%) were taking inhaled corticosteroids as controller 
treatment and only 32% were being regularly followed-up for their asthma. Only 64% 
of the children had had a doctor diagnosis of asthma, while 76% had visited the 
emergency department for a severe bronchodilator-responsive wheezing episode 
during the previous year. This reflects the inadequate management of asthmatic 
children in many Latin American settings where asthma is treated as an acute disease 
during acute exacerbations in emergency rooms with no follow-up or long-term 
treatment offered (estimated at <6% of asthmatic patients in certain Latin American 
regions)24.  
 A high proportion (85%) of children with acute asthma in our study who were tested, 
displayed atopic sensitization to mite (D. pteronyssinus and B. tropicalis IgE >0.70 
kUA/l). As discussed in Chapter 2, the predominance of atopic or non-atopic asthma in 
Latin American countries is still under debate due to contradictory study findings. In a 
clinic-based study in Quito, Ecuador, 67% of adults and children with allergic 
respiratory diseases (asthma and/or rhinoconjunctivitis) had a positive skin reaction 
to at least 1 mite species480, while in a population-based survey in Esmeraldas, a third 
of schoolchildren with current wheeze living in either rural or urban settings had a 
positive SPT for any allergen or a specific IgE to dust mites300. We measured mite-
specific IgE measurement on a sample of this cohort (33 participants) and showed that 
85%  had mite atopy, a similar finding to our previous case-control study of 120 
children with acute asthma from  the same setting34. It would, therefore, be reasonable 
to assume that the majority (~85%) of the cohort would have had mite atopy. Such a 
predominance of atopic asthma contrasts with the findings of the ISAAC phase II study 
4.7. Findings related to other studies
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which showed variable rates of atopy (measured by SPT) between non-affluent and 
affluent settings, varying predominance of non-atopic wheeze (with atopy measured by 
SPT) in non-affluent settings from 4.7% in Ghana to 86% in Hong-Kong and from 21% 
to 25% in the participating Latin American countries30. These disparities may be 
explained by differences in study populations: our study was clinic-based and recruited 
acute asthmatics while the ISAAC study was a population survey of school children 
irrespective of asthma symptoms, where they used ‘current wheeze’ as the outcome 
definition. More severe disease has been associated with a greater prevalence of atopy, 
eosinophilia and concomitant allergies297.  
Lung function of the children included in our cohort was similar to that found in 
asthmatic children in other Latin American countries. For example, in a cohort of 6-7 
year olds in Pelotas, Brazil, the mean FEV1 (% of predicted), FVC (% of predicted) and 
FEV1/FVC ratio were 100%, 108% and 105% respectively481. Of these, children with 
current asthma had lower lung function volumes (-6.5% for FEV1, -0.3% for FVC and -
6.4% for FVC/FEV1 ratio) as did those children with more than 4 episodes of wheezing 
episodes in the last year (-5.4% for FEV1, -4.3% for FVC and -10% for FVC/FEV1 
ratio)481. Median lung function (of predicted for age and size) of the children included 
in our study (78% FEV1, FVC and 91% FEV1/FVC) are comparable to the Pelotas 
cohort481.  
Forty percent of the children who underwent spirometry, had a positive response to 
bronchodilator (FEV1 %predicted increase >12%), as described by international 
guidelines37. This was the only objective measure we could use to identify children with 
a definite asthma diagnosis, so we could argue that only 40% of our study sample had a 
definite asthma diagnosis according to guidelines. However, and even lower proportion 
of positive BDR has been previously described among controller naïve asthmatic 
children (19%)482. This may well be due to an overdiagnosis, though some of our 
patients did show improved clinical symptoms and/or lung function during trial 
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inhaled or oral corticosteroids and bronchodilators. According to international 
guidelines37, these patients may still be diagnosed with asthma. We were not able to 
record in our study a clinical or lung function improvement after the use of asthma 
treatment, as spirometry was only undertaken at the study initiation and not during the 
follow-up. 
Asthma control, as measured by the Childhood Asthma Control Test (C-ACT) and the 
Asthma Control Test (ACT) for children 12 or older, was low in our study sample. This 
was expected, as the test was taken at the moment of an asthma exacerbation. In the 
bivariate analysis, there was no difference in the initial level of asthma control between 
the  children who suffered a subsequent asthma exacerbation requiring emergency 
care over the following 6 months and those who did not and neither C-ACT nor ACT 
scores were associated with future severe exacerbations in multivariate analysis, as 
children with well-controlled asthma may still be at risk of suffering acute asthma 
exacerbations7.  
 The caregivers’ asthma knowledge of the children who participated in the study, as 
measured by the NAKQ score was relatively low, with a median score of 18 out of the 
31, when a score under 21 is considered inadequate asthma knowledge. Other studies 
measuring asthmatics parents’ or caregivers’ asthma knowledge using this same 
questionnaire obtained median scores between 16 and 20483-486, all under the 21-point 
cut-off score for adequate knowledge. These studies were undertaken in different 
countries (Spain, Australia, Brazil), and on different study populations (children 
admitted to hospital or ICU for a severe asthma attack or being followed-up by a 
pulmonologist) and still showed a similar degree of parental asthma knowledge. This 
was not a surprising finding in our study, given the lack of asthma education 
programmes and adequate follow-up, though we expected it to be lower compared to 
other more resource-rich settings. This is therefore a reflection of the general 
disinformation and lack of knowledge concerning asthma that caregivers of affected 
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children have worldwide, as their score was very similar to that obtained from parents 
of non-asthmatic children in Brazil (median score 17.2)485 or from school teachers in 
Spain (median score 15.7)487. 
We assessed the children’s quality of life as referred to their asthma disease using the 
Pediatric Asthma Quality of Life Questionnaire, divided into 3 domains: activity, 
symptoms and emotions, all evaluated using a Linkert scale from 1 to 7. The results 
were very similar between the three domains (median scores of 3.4, 3.5 and 3.7 
respectively) lying in the middle of the scale. It is difficult to interpret these scores in an 
isolated manner, as this questionnaire was developed to evaluate the variations in a 
child’s asthma quality of life, for example after the implementation of an intervention, 
rather than to evaluate a specific score at one point in time463. For example, Yilmaz et 
al.488 reported a 2-point increase in the total PAQLQ total score (from 4.5 to 6.5 median 
scores) and the different domains, 4 months after the initiation of regular follow-up for 
recently diagnosed children who were started on controller medications. Similarly, 4-
12-year olds with asthma PAQLQ median scores improved 6 months after the 
implementation of a small group educational intervention (from 5.9 to 6.5)489. In both 
these studies, the initial quality of life of the participating asthmatic children was 
higher than in our study. Once more, this difference may have been due to the timing of 
the questionnaire (in our study the children had just suffered a severe asthma 
exacerbation whilst in the other studies children were recruited from a consulting 
room), as well as for the more severe asthma profile of the children included in our 
study, as PAQLQ scores have been shown to be correlated with asthma control463,490. 
However, in our study only the asthma control measured in children 12 or older using 
the ACT was positively correlated with the PAQLQ total score, but not the C-ACT score 
(used for children under 12 years old). This may be due to the C-ACT not being 
completed only by the children, but by also caregivers who have a different perspective 
of the child’s diseases severity491. 
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4.7.2. Emergency care re-attendance for severe asthma exacerbation predictors 
Forty six percent of the 264 children who completed the 6-month follow-up suffered a 
subsequent severe asthma attack that required emergency room treatment during the 
first 6 months after the index attack. This was the proportion we had expected, based 
on the results obtained from our previous case-control study in this same setting, 
where 53% of children with acute asthma had suffered at least 4 episodes of acute 
wheezing during the previous year34. In similar studies from US and Canada, ED re-
attendance for acute asthma attacks rates varied from 15% to 39% 12 months after the 
index ED admission or between 11% and 30% after the first 3 months of follow-
up399,414,422,427,428,435,437,440. These proportions of re-attendance were all lower than the 
one we registered, even after extending the follow-up time to 12 months compared to 
our 6-month follow-up. Our study sample had therefore a greater number of severe 
exacerbations probably due to poor asthma control and inadequate management, as 
the proportion of children receiving baseline treatment in the North American studies 
mentioned, was much higher than in our study399,414,422,427,428,435,437,440. 
A history of severe asthma attacks during the previous year has been found to be the 
most strongly associated factor with severe future attacks in this and several other 
studies414,424,435,440. This may be measured as previous ED attendances, number of 
systemic corticosteroid courses or unscheduled contacts for acute asthma. All these 
factors were associated with future risk in our study, though, due to the characteristics 
of this setting (low oral corticosteroid prescription and variable degree of severity of 
asthma attacks attended at the ED), the number of intramuscular or intravenous 
corticosteroid courses resulted to be the predictor included in the final model.  
Younger children in this study were found to have a greater risk of suffering 
subsequent asthma attacks requiring emergency care, as was the case in similar studies 
carried out in high income countries414,422,435. Further, younger children are also at risk 
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of hospital readmission for acute asthma414,415,428. This is especially true for children 
younger than 5 years old398,409,414, who were not included in our study in order to 
exclude pre-school wheezers in whom asthma may not be an appropriate diagnosis. 
Younger children are more exposed to viral upper respiratory infections, such as 
rhinovirus, which have been found to be important triggers for asthma attacks11,12.  
Atopic asthma may be present as part of the ‘atopic path’, which includes eczema, 
allergic rhinoconjunctivitis and atopy. Previous studies410,412,432 have shown that 
children with concomitant allergic diseases may have a higher risk of future severe 
asthma attacks, as was the case in our study with children with an existing eczema 
diagnosis. Even though the proportion of children with an eczema diagnosis was low, 
they had a 4 times greater odds of suffering subsequent asthma attacks requiring 
emergency care. Eczema was also associated with poor asthma control (one 
hospitalization for asthma or high frequency of symptoms in the last year) among 
children in urban Brazil492. Individuals with allergic asthma appear particularly 
susceptible to exacerbations from viruses, and other studies have shown that 
suppression of allergic mediators reduces virally-mediated attacks493. Further studies 
are necessary to better understand the nature of this association.  
Similarly, there was a greater risk of repeated severe asthma attacks among children 
who described having some kind of food as a trigger for their attacks. These included 
both children with food allergies and those who identified food colorants or cold foods 
and drinks as triggers. It is a difficult factor to interpret due to its variable perception, 
although food allergies are definitely a risk factor for severe asthma attacks, especially 
in a population where these children and their families are not adequately diagnosed, 
followed-up and informed. 
Children living in an urban area had a lower risk of subsequent severe asthma attacks 
than those from a rural area, a finding which has not been described previously. The 
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hospitals and health care centres included in our study were situated in urban 
Esmeraldas, therefore the distance to the ED may have biased the severity of asthmatic 
children treated for an asthma attack depending on their residency, towards a more 
severe asthma in those living in a rural setting. On the other hand, there are many other 
factors that vary depending on the place a child lives, such as education and 
socioeconomic factors, which have been associated with the risk of severe asthma 
attacks400,422,428. However, these factors were considered when designing the final 
multivariable model. 
Interestingly, two highly relevant characteristics that have been previously identified 
as risk factors for repeated asthma attacks did not appear to predict future risk in our 
study: low socioeconomic status400,422,428 and African-American ethnicity399,422. The 
population in which we worked in Esmeraldas is predominantly from a low SES 
(median monthly household income 400 USD, range: 0-12 000 USD) and Afro-
Ecuadorian (58% of the total cohort), resulting in a relatively homogeneous cohort, 
perhaps reducing power to identify such factors as predictors. Monthly household 
income was sometimes difficult to estimate due to the frequency of informal 
employment with highly variable incomes. We therefore also included the number of 
years the parents had studied as a measure of SES, which was also not associated with 
future asthma attack risk. Recently, black ethnicity was found to act as a confounder for 
risk of subsequent severe asthma attacks when careful adjustment was made with 
other socioeconomic factors which may be associated with ethnicity403. This may be the 
reason why we did not identify Afro-Ecuadorian ethnicity as a predictor in our study. 
Further studies in similar low and middle-income settings appear necessary to clarify 
the role of SES and ethnicity in severe asthma attack risk beyond high income 
countries. 
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Poor asthma control, inadequate management and frequent severe asthma 
exacerbations are all very serious issues that need urgent attention. This cohort study 
was designed as an attempt to improve this situation by identifying asthmatic children 
at high risk of frequent severe exacerbations from those already attending an 
emergency room for acute asthma in a low resource setting. This should aid health care 
workers in the decision-making process of initiating baseline treatment and/or 
referring to specialist care where available. The next natural step would be to design a 
validation study for the risk assessment tool both in the same setting where it was 
elaborated, as well as in other national and international settings, to be able to 
implement the risk-assessment tool into daily practice. Two different aspects would 
need to be evaluated. First, risk factors or a prediction model would need replicating. 
Second, the questions themselves would need validating and refining to make sure 
people would use and understand them, as well as the algorithm or flowchart that 
would indicate health care workers who to apply the risk model too and what to do 
with the results. Only then we would be able to assess its efficiency and cost-
effectiveness. 
However, there are many other steps in asthma management that still need to be 
further studied to improve asthma outcomes. Understanding the patient’s, caregivers’ 
and health care workers perspectives on acute asthma and its management is essential, 
as they are the main actors involved. This was addressed through a qualitative study 
presented in the following chapter, together with the caregiver’s and health care 
workers’ understanding of the barriers and facilitators to health care and home care 
access for asthma, as well as their opinion regarding the risk-assessment tool. 
Novel interventions to improve all steps that lead to an adequate asthma management 
are a research priority, as it is still an unsolved long-time problem occurring 
4.8. Implications for future studies
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worldwide. These include: the proportion of asthmatic children with access to basic 
asthma medicines (both relievers and controller medications), the number of children 
prescribed baseline long-term treatment, and finally, adherence to treatment. Reasons 
for low adherence and effectiveness of interventions may differ between high and low 
resource settings. Studies addressing these issues should be undertaken in both types 
of settings. 
To conclude, around half of the children treated at a public ED for a bronchodilator-
responsive wheeze in a tropical city in Ecuador, suffered a subsequent exacerbation 
requiring emergency care over the following six months. Those who had suffered 
severe exacerbations during the previous year had a higher risk of a new asthma attack, 
as is the case in a range of settings in high-income countries. A combination of a few 
predictors in a questionnaire could be used as an effective and simple risk-assessment 
tool in EDs to identify asthmatic children at a higher risk of recurrent severe asthma 
attacks. Biomarkers appeared to be less useful in this context. A simple risk assessment 
tool for emergency consultations based on data such as this may prove extremely 
useful to target resources towards those most in need of continuing support and 
treatment. Further studies are now necessary to confirm these predictors as relevant in 
other settings, both within and outside Latin America. 
 
 
4.9. Conclusions
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5. Acute asthma significance, barriers and facilitators 
to health care access for asthmatic children, and 
opinions regarding the use of a recurrent asthma 
attack risk assessment tool, from health care 
workers’ and caregivers’ perspective: a qualitative 
study 
The prospective cohort study described in the previous Chapter analysed potential 
predictors for emergency care re-attendance for acute asthma, with the future aim of 
combining them to design a risk assessment tool to be implemented in emergency 
departments. This tool would aid decision-making concerning treatment and follow-up 
of children treated for an acute asthma attack.  
Even though further studies are necessary to refine and validate this tool before it is 
implemented, it is also vital to understand what is the significance of a childhood acute 
asthma attack, both for the caregivers and the health care workers, as well as what are 
their perceptions of the current barriers and facilitators for adequate asthma care.  
Similarly, it is important to hear their opinions regarding the use of a recurrent asthma 
attack risk-assessment tool and whether understanding the future risk of a subsequent 
asthma attack would modify in any way their attitude and management of the 
asthmatic child. Making a context sensitive risk assessment tool may ensure its utility. 
With this background, we designed a qualitative study to better understand the 
significance of acute asthma attacks and recurrent asthma attacks, the barriers and 
facilitators for health and home care access, generated from the social construction of 
5.1. Introduction 
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health care workers and caregivers of asthmatic children, as well as their opinions 
regarding the use of a recurrent asthma attack risk assessment tool. 
5.2.1. Research questions 
- What is the significance of acute asthma attacks and recurrent asthma attacks, 
generated from the social construction of health care workers and caregivers of 
asthmatic children? 
-What are the barriers and opportunities to diminish the gaps in health care 
access and home care, in asthmatic children? 
-What are the opinions regarding the use of a recurrent asthma attack risk 
assessment tool? 
5.2.2. Objectives  
General objective 
Our aim was to describe the significance of acute asthma attacks and their recurrence, 
the barriers and facilitators for health and home care access, generated from the social 
construction of health care workers and caregivers of asthmatic children, as well as 
their opinion regarding the use of a recurrent asthma attack risk assessment tool. 
Specific objectives  
1. To explore the meanings of acute asthma attacks and their recurrence, in 
children from the caregivers’ and health care workers’ perspective, in Esmeraldas, 
Ecuador. 
2. To describe the barriers that limit health care access and home care and 
opportunities, in children with recurrent asthma exacerbations, from the caregivers’ 
5.2. Research question and objectives
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and health care workers’ perspective, in Esmeraldas, Ecuador, following Tanahashi’s 
model.  
3. To describe behaviours and beliefs towards the use of a recurrent asthma 
attack risk assessment tool in asthmatic children with recurrent asthma attacks, from 
the caregivers’ and health care workers’ perspective, in Esmeraldas, Ecuador. 
5.3.1. Study design 
This was an interpretative qualitative study, based on phenomenological approach, to 
identify and interpret discourses (health care workers and caregivers) on individual 
experiences in asthma care expressed through language, and conducted at the end of a 
cohort study on asthmatic children in the city of Esmeraldas.  
The phenomenological focus assumes that there are one or more essential experiences 
that represent key meanings, and that these are shared. These experiences on a 
phenomenon are related, analysed and compared, to identify the essence of the event 
studied and to show how the important meanings are constructed from the direct 
experiences494,495. The researcher must become detached of his/her own experiences to 
avoid the thought that he/she understands better what it is for a person to experience 
the phenomenon studied. He or she must keep a reflexive and critical attitude, 
dialoguing with him/herself and practice active listening496.  
This strategy enables quick access both to health care workers and caregivers, based on 
the idea that the characteristics of a qualitative study with a phenomenological 
approach is crucial to understand and address the symbolic construction of asthma and 
recurrent asthma attacks.  
5.3. Methods
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5.3.2. Study setting  
The study took place in Esmeraldas city, Esmeraldas, Ecuador. The details of this 
setting have already been described in Chapter 4. For the qualitative component, we 
considered doctors and respiratory therapists, as well as caregivers of asthmatic 
children.  
There are two different kinds of doctors treating asthmatic children in Esmeraldas: 
specialists (paediatricians in this case) and general doctors in training (named 
residents in this setting). The latter are less experienced, are usually younger and are 
either training in a specific medical speciality or applying for a training programme 
outside Esmeraldas. There are no specialty training programmes in Esmeraldas now.  
It is important to understand the role of Respiratory Therapists to understand our 
choice of study sample. Asthmatic patients in this population are diagnosed, treated 
and managed exclusively by doctors in this setting. Respiratory Therapists act as a 
bridge between the asthmatic patient and the doctor, by applying the medication 
and/or respiratory therapy prescribed by the doctor, and have therefore a close contact 
with the asthmatic patients and their families.  
On the other hand, caregivers of asthmatic children are normally their mothers or 
fathers, though on occasion they may also be other family members such as 
grandparents. Caregivers are responsible for the child’s care at home during the asthma 
attack, of taking him/her to be seen at the health care service, to deliver the prescribed 
medicines and on many occasions of buying these, as there is a lack of asthma drugs in 
the public health system. Sociodemographic characteristics of asthmatic children 
caregivers in Esmeraldas, have been described in the Results section of the cohort 
study in Chapter 5. 
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5.3.3. Study sample 
The study population was defined by purposive criteria, using pragmatic and feasibility 
criteria. We included health care workers (both doctors and respiratory therapists) 
from the city of Esmeraldas, Ecuador, as well as the carers of asthmatic children 
(caregivers) who had previously participated in the cohort study. 
5.3.4. Heterogeneity criteria 
These were the criteria used to compare the discourses (heterogeneity criteria): 
Health care workers 
The health care workers’ profile was initially proposed according to three criteria: sex 
(men and women), work description (doctors and respiratory therapists) and level of 
training and experience (just graduated vs experienced). We included professionals 
working in the two main city’s hospitals (Hospital Delfina Torres de Concha, HDTC, and 
Instituto Ecuatoriano de Seguro Social Hospital, IESS), as well as those working in large 
and specialised health centres. Some of these health care workers also work part-time 
in private clinics in Esmeraldas. We aimed to include both highly and inexperienced 
doctors, as well as respiratory therapists. 
Caregivers 
The caregivers’ participant profile initially proposed followed three criteria of 
heterogeneity: sex (men and women), degree of kinship to asthmatic child 
(mother/father, aunt/uncle, grandparent), and socioeconomic status (low vs high 
resources).   
We collected other further information from the participants, such as age, degree of 
education, workplace, age of child with asthma, to describe the characteristics of the 
study participants, although they did not constitute part of the heterogeneity criteria. 
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5.3.5. Inclusion and exclusion criteria 
We used the following inclusion and exclusion criteria. 
Inclusion criteria 
Health care workers: 
- Involved in the treatment and/or management of asthmatic children. 
- Willing to participate. 
Caregivers: 
- Carers of children who participated in the asthma cohort study. 
- Available contact number. 
- Carers of children of any age. 
- Willing to participate. 
Exclusion criteria 
Health care workers: 
- Not involved in the treatment and/or management of asthmatic children. 
- Not willing to participate. 
Caregivers: 
- Carers of deceased children. 
- No available contact numbers. 
- Not willing to participate. 
5.3.6. Study sample recruitment 
The health care workers were invited to a presentation of the study findings of the 
previous cohort study. At the end of the presentation, they were informed of the 
existence of a qualitative study and a list was passed around the assistants for them to 
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write their name and contact number if they were interested in participating. Three 
presentations were organised at the two main hospitals and the specialised health 
centre in the city of Esmeraldas, Ecuador.  
The participant profile criteria were used to identify those to be selected for the study 
from the ones that appeared on the contact list. Given the small number of health care 
workers initially available, all of them were contacted by telephone to arrange an 
interview time and place, to the convenience of the interviewee. To increase the 
number of participants, the snowball technique was also implemented, by asking the 
health care workers that participated to inform other colleagues of the study.  
All the carers of the asthmatic children of any age who participated in the cohort study 
with updated contact numbers, were contacted by telephone and invited to assist an 
informative session to present the findings from the previous prospective cohort study. 
Two general meetings were held. At the end of these meetings, we informed the 
assistants of the existence of a new qualitative study and a list was made available for 
those interested in participating to leave their names and contact numbers.  
Purposive sampling of caregivers interested in participating was then undertaken and 
individuals were contacted and invited to participate in focus group discussions. As 
with the health care workers, snowball technique was also used, and we encouraged 
the participants of the focus group discussions to inform other possible carers of 
asthmatic children of the study we were undertaking. 
5.3.7. Methods for collecting qualitative data  
The methods for collecting qualitative data in this study were in-depth interviews (ISI) 
and focus group discussions (FGD) (Annex C: Interview Guide). The ISI were 
undertaken with the health care workers involved in the management of children with 
asthma.  
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The FGD were composed of asthmatic children’s caregivers. We tried to include fathers 
and mothers, as well as other relevant caregivers such as grandparents or 
aunts/uncles. 
5.3.8.  Participant coding 
Table 5.1 represents the coding system we used to identify the study participants, both 
for the ISI and the FGD.  
For the ISI, we used the coding for the sex of the participant (man or woman), the 
training (medical resident, paediatrician or respiratory therapist) and the number of 
the interview for that specific training level. For example, the number IT2W 
represented the interview of the second respiratory therapist, who happened to be a 
woman. 
For the FGD, participants were identified for the number of the focus group discussion 
(1-5), and the degree of kinship to the asthmatic child, which already represented the 
sex of the participant. For example, the number F3G represented a participant from the 
focus group discussion number 3, who was a grandmother. There were no grandfathers 
in our study sample. 
Table 5.1: Participant coding 
In depth interviews Focus Group Discussions 
Work description R= Resident doctor 
T= Respiratory 
therapist 
P= Paediatrician 
Degree of kinship M= Mother 
F= Father 
G= Grandmother 
Sex M= Man 
W=Woman 
  
 
5.3.9. Study procedures 
We applied ISI for health care workers and FGD for caregivers. Before the ISI and FGD, 
participants completed a short questionnaire to collect sociodemographic information 
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(age, sex, level of studies, occupation, work place, degree of kinship with asthmatic 
child, age of onset of asthmatic symptoms in child).  
In-depth semi-structured interviews (ISI) with health care workers 
We organised a total of 12 interviews: 3 paediatricians, 3 respiratory therapists and 6 
general doctors (medical residents). Given the limited number of paediatricians and 
respiratory therapists in the city of Esmeraldas, we were unable to undertake more 
interviews for these two groups of health care workers. The 6 general doctors and the 3 
respiratory therapists were considered as the less experienced health care workers.  
Most of ISIs took place in a private room at the hospital or health centre where the 
health care worker worked, together with one interview which took place at the study 
office and one other at the health care worker’s home, depending on the interviewee’s 
preference. They lasted between 35-55 minutes and refreshments were offered 
depending on the time and location of the interview. 
A topic guide was used to briefly explore the health care workers’ perspective 
regarding asthma exacerbations, as well as their perception of transmission of 
information to caregivers concerning the future risk of suffering subsequent asthma 
attacks. To explore the significance of the future risk of recurrent asthma 
exacerbations, we worked with the risk assessment tool presented below. The in-depth 
interviews were undertaken by the PI (Principal Investigator). (9 interviews) and Dr 
Natalia Romero (Universidad Internacional de Ecuador, UIDE) (3 interviews), an 
experienced qualitative researcher. Data saturation was achieved, that no more new 
themes were emerging. 
Focus group discussions (FGD) with caregivers 
We organised a total of 5 groups of 6-8 people, though the final number of participants 
was 4 in three of the groups and 5 and 3 in the other two groups. Both men and women 
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were invited equally to the discussions, though of the 20 participants who attended the 
discussions, only 2 were men.  
The discussions took place in a wide room in a private health centre very near the city’s 
public hospital (HDTC), where the study office for follow-up of the asthmatic children 
participating in the previous cohort study had been set up. The discussions lasted for 
around 1 hour and refreshments were offered at the end. The FGD were facilitated by the 
P.I (3 FGD) and Dr Natalia Romero (2 FGD), an experienced qualitative researcher. 
A topic guide was used to briefly explore the caregivers’ perspective and experience 
regarding acute asthma exacerbations, as well as their understanding of future risk of 
subsequent asthma exacerbations. To explore the significance of the future risk of 
recurrent asthma exacerbations, we worked with the risk assessment tool presented 
below. Data saturation was achieved. 
Opinion regarding the use of a recurrent asthma attack risk assessment tool 
As shown in Chapter 5, as a result of the prospective cohort study we obtained specific 
predictors of recurrent severe attack requiring emergency care using Cox regression 
analysis. These predictors could be easily combined to design a risk assessment tool. In 
the Table 4.9 an example is provided of how this risk assessment tool might look. Even 
though it has not been validated, we used this design to explore the health care 
workers’ and caregivers’ opinions regarding its hypothetical use. 
It is a tool to be used at the emergency department by health care workers who are 
treating a child for an acute asthma attack. This tool will hopefully identify children at a 
greater risk of coming back to the emergency department for acute asthma, to assist 
with decision-making regarding appropriate treatment and tertiary referral, as well as 
to inform the patient and his family so they may undergo necessary lifestyle 
modifications.  As the model has not yet been validated, all we discussed is whether the 
carers participating in the discussion could understand the information this tool is 
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trying to show and whether this information would change their attitude towards their 
children’s asthma in any way.   
Following our third objective, we included in the ISI and FGD a moment to capture the 
HCWs and CGs perceptions concerning the use of this risk assessment tool, from a 
global perspective. We did not pretend to acquire such an insight into the participants 
point of view as to see it with their own eyes, but to gain the participants’ perspective, 
understand their mental categories, their interpretations, their perceptions and the 
motives behind their comments concerning the use of the proposed risk assessment 
tool.  
Recording and transcriptions 
The audio from the ISI and FGD were digitally recorded, prior participant’s consent and 
transcribed verbatim by expert transcriptors. The transcriptions were compared with 
the recordings for accuracy, and any errors in transcription were corrected. 
5.3.10. Ethics and informed consent 
The study was approved by the Ethics Committees of the Liverpool School of Tropical 
Medicine (Research Protocol 17001) and the Universidad Internacional de Ecuador 
(International University of Ecuador) (UIDE). Once the carer or health care worker had 
been contacted, the interviewer introduced herself and explained briefly why they had 
been contacted. A description of the objectives of the study and the evaluations to be 
done were then explained. If agreeing to participate, an informed written consent form 
was handed out to the participant to be signed by them. The informed consent form 
included a summary of the importance of the study, its objectives, the procedures and 
when they will be carried out, the risks and benefits of participating in the study, and 
the options and rights they had as participants. They were able to ask as many 
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questions as needed to completely understand all the points included in the informed 
consent forms.  
5.3.11. Emerging design 
The design of the study was subject to an emerging design, enabling an iterative 
development of a thematic framework to explore experiences of, and barriers and 
facilitators to, asthma management in general and future risk of asthma attack 
understanding in particular. Following development of the initial thematic framework, 
the data were reanalysed to assess appropriateness of the fit, to allow modification and 
to highlight deviant cases. To construct the emerging design, we included verbatim 
notes, field notes, a diary, the researcher's reflective notes made during the research, 
and the transcribed recordings of the first 4 ISIs and the first FGD.  
We evaluated: a) the heterogeneity criteria, b) procedures, c) the a priori categories 
and sub-categories, and d) the use of the topic guide.  
Heterogeneity criteria:  
Among the criteria used for the health care workers, we modified the classification by 
including two groups: one for the more experienced HCWs, and another for the 
younger, inexperienced HCWs. We excluded the initial criteria of sex (male and female) 
and work description (doctors and respiratory therapists) based on the analysis of the 
first ISI. There were no more respiratory therapists and Paediatricians in the city of 
Esmeraldas that treat asthmatic children, apart from those contacted, therefore it 
would not have been possible to reach data saturation for the criteria of sex and work 
description.  
Among the caregivers, we did not consider an equitable presence of participants by sex, 
degree of kinship to asthmatic child, or socioeconomic status, as there was no 
variability of these conditions among the cohort study participants.  
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Procedures  
To reduce the bias that my presence may have introduced in the opinions obtained by 
the caregivers, the last two FGD were undertaken by Dr Natalia Romero, who the 
participants had not met previously. I had had a very close contact with the caregivers 
participating in the FGD, as they were all part of the previous cohort study, and this 
may have conditioned or influenced the caregivers. 
A priori categories and sub-categories  
Table 5.2 shows the categories and subcategories initially planned. 
Table 5.2: Initial thematic framework before study was started 
Categories Subcategories 
Acute asthma attack perception - Meanings 
- Behaviours 
Gaps in health and home care - Barriers 
- Opportunities 
Perceptions of the use of a recurrent 
asthma attack risk assessment tool 
- Perceived susceptibility 
- Perceived severity 
- Perceived benefits 
- Perceived barriers 
- Cues to action 
- Self-efficacy 
 
At this point, we used an inductive analysis that enabled us to re-define once more the 
thematic framework to include the emerging categories and subcategories. We 
discarded the use of the Health Belief Model to subcategorise the perceptions of the use 
of a recurrent asthma risk assessment tool for a simpler ‘benefits’ and ‘barriers’, as the 
data did not suit this sub-categorisation. Similarly, we classified divided barriers and 
opportunities to asthma health and home care in two separate groups, and we 
subcategorised each of them using Tanahasi’s379 classification of measurements of 
health care coverage. These 4 categories were implemented in a qualitative systematic 
review analysing barriers and facilitators to health care access378, and include:  
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 - Acceptability: social, cultural, or religious factors, beliefs, cultural norms and 
values that may influence the health services perception and its use. 
 - Accessibility: physical and geographic location of the health service in relation 
to the population served, as well as administrative requirements. 
 - Contact: Characteristics and quality of the health care service, treatment 
continuity, including doctor-patient relationship. 
 - Availability: Available health care services and programmes for the population 
served. 
The emerging design process was supervised and guided by an experienced qualitative 
researcher (Dr Natalia Romero) to refine the chosen approach to determine the 
categories and subcategories, which are described in Table 5.3. 
Table 5.3: Final thematic framework following emerging design 
Category Subcategory 
Acute asthma significance  
Asthma health and home care access barriers Acceptability 
Accessibility 
Contact 
Availability 
Asthma health and home care access facilitators Acceptability 
Accessibility 
Contact 
Availability 
Emergency care Re-attendance risk assessment tool Benefits 
Barriers 
 
Topic guide 
We noted that the responses that we were obtaining from the ISI were on some 
occasions very short (yes/no answer or no details, descriptions or feelings) and very 
technical. We therefore modified the topic guide accordingly to obtain the perceptions 
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of the health care workers and facilitate the development of skills, vision, and integrity 
of the researcher team. 
5.3.12. Analysis strategy 
We analysed the data using the analysis strategy suggested by Pope et al.497. The 
analysis took place sequentially, starting with the first ISI and FGD, and continuing with 
the following transcriptions, in a systematic and rigorous manner. Once all the data 
were obtained, all the ISI and FGD transcriptions were read in detail (to familiarize 
ourselves with the collected data) and then were analysed inductively, using content 
analysis guided by the categories and subcategories, considered as key issues, concepts 
and themes by which the data could be examined and referenced. Qualitative software 
for analysis (QDA Miner) was used as an aid to organise the data.  
Each interview was individually coded (by the PI) by organizing the text into codes 
(sub-categories) and group codes (categories), using an open coding process. Each data 
segment could be indexed against one or more code or category. We therefore 
undertook a thematic analysis approach to describe and analyse the data obtained. Dr 
Natalia Romero read some of the ISI and FGD, and met with the writer on several 
occasions to discuss and agree upon the coding system and the thematic framework, to 
triangulate the analysis.  
The final thematic framework included the different contextual, social, psychological 
and behavioural aspects that may influence the significance of acute asthma 
exacerbations in children and adolescents from the health care workers’ and 
caregivers’ perspective. 
Once the data were analysed and organised, they were summarised under the key 
categories and sub-categories and related the data to the objectives of the study, using 
quotes from the participants to illustrate the findings discussed. 
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5.3.13. Quality control and credibility 
The PI was trained in qualitative interview techniques and focus group discussion. She 
is a Paediatrician who has been working during the last 3 years with asthmatic children 
and their families in Esmeraldas, Ecuador.  She was directly supervised by Dr Natalia 
Romero Sandoval, an experienced qualitative researcher in Ecuador 
The ISIs and FGDs took place in a comfortable and private setting, to ensure an 
interactive and reliable atmosphere. 
There were frequent meetings with the study group during the interviews and analysis, 
to agree upon the coding used and the categorization. Data saturation was reached, as 
now more themes emerged during the last interviews. Triangulation was assured by 
the participation of experts and the review of published literature. 
5.4.1 Participants characteristics 
Health care workers (ISI) 
A total of 12 health care workers participated in the in-depth, semi-structured interviews 
(ISI), 3 of them experienced paediatricians (more than 10 years of clinical experience) 
and the younger, less experienced (8 years or less of experience) respiratory therapists 
(three) and medical residents (or general doctors, 6 of them). Most participants were 
currently working at the city’s public hospital (HDTC), except for 3 from the social 
security hospital (IESS) and one from a rural, specialised health centre. The less-
experienced health care workers were between 26 to 35 years old, while the more 
experienced ones were over 40. There was a mixture of female and male, as well as of 
Afro-Ecuadorian and Mestizo workers. The characteristics of health care workers 
participating in the in-depth, semi-structured interviews are shown in Table 5.4. 
5.4 Results
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Table 5.4: Characteristics of health care workers participating in the in-depth, semi-
structured interviews (ISI) 
Participant 
Code 
Gender Age Ethnicity Formal 
education 
Place of work Years 
experience 
IR1 F 30 Af GD HDTC 3 
IR2 F 31 Af GD HC (rural) 5 
IR3 M 34 M GD HDTC 6 
IR4 M 32 M GD HDTC <1 
IR5 F 28 Af GD HDTC <1 
IR6 F 26 M GD HDTC 1 
IT1 M 35 Af RT HDTC 8 
IT2 F 35 Af RT HDTC 8 
IT3 F 32 M RT IESS Hospital 6 
IP1 F 40 Af Paediatrician IESS Hospital 12 (6 as a 
Paediatrician) 
IP2 M 64 M Paediatrician IESS Hospital 27 
IP3 M 62 M Paediatrician HDTC 26 
F: female; M: male; Af: Afro-Ecuadorian; M: Mestizo; GD: general doctor; RT: respiratory therapist; 
HDTC: Delfina Torres de Concha Hospital; HC: Health Centre; IESS: Instituto Ecuatoriano del Seguro 
Social (Ecuadorian Social Security Institute). 
 
Caregivers (FGD) 
Twenty caregivers participated in the 5 focus group discussions (FGD). All of them were 
mothers of asthmatic children, except for two grandmothers and two fathers, with an age 
between 25 and 63 years old. Only four of them were mestizos (the rest were Afro-
Ecuadorian) and 13 worked in their homes. Four of them had received only primary 
education, 8 some level of secondary education, and the following 8 had attended the 
university. The age of the asthmatic child they cared for was between 7 and 12 years old. 
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Table 5.5: Characteristics of caregivers participating in the focus group discussions 
Partici-
pant 
Code 
Gen-
der 
Age Ethni-
city 
Asth-
ma*  
Years** 
Formal 
Education 
Job Relation 
asthmatic 
child 
Age 
asthmatic 
child# 
FG1-1 F 32 Af Y 6 House Mother 12/9 
FG 1-2 F 25 Af N 12 House Mother 7 
FG1-3 F 35 Af N 12 Nursery Mother 9 
FG1-4 F 35 Af Y 6 House Mother 12 
FG2-1 F 45 Af N 6 House Mother 8 
FG2-2 M 43 Af N 11 Own 
business 
Father 8 
FG2-3 F 43 Me N 6 House Mother 7 
FG2-4 M 50 Me N 16 Secreta-
ry 
Father 9 
FG3-1 F 63 Af N 15 Retired 
(auxiliar
y nurse) 
Grandmot
her 
7 
FG3-2 F 37 Me N 16 Mana-
ger 
Mother 7 
FG3-3 F 31 Af Y 14 House Mother 8 
FG4-1 F 60 Af Y 9 House Grandmot
her 
12 
FG4-2 F 32 Af Y 12 House Mother 7 
FG4-3 F 61 Af N 9 House Grandmot
her 
12/10 
FG4-4 F 47 Af N 15 House Mother 14 
FG4-5 F 48 Af Y 16 School 
teacher 
Mother 12 
FG5-1 F 30 Me Y 16 House Mother 10 
FG5-2 F 45 Af N 12 House Mother 11 
FG5-3 F 42 Af N 16 Nurse Mother 11 
FG5-4 F 33 Af N 12 House Mother 11 
*: If the participant had suffered asthma him/herself; **: total number of years the participant had 
studied (6= primary school; 12= secondary school; >12= university); #: When two different ages 
appear, there are two different asthmatic children. F: female; M: male; Af: Afro-Ecuadorian; Me: 
Mestizo; Y: Yes; N: No;  
5.4.2. Acute asthma significance 
Health care workers  
Health care workers expressed that for them, acute asthma attacks represent a scenario 
in which they clearly experience their relationship with life, illness and death, and put 
into practice their professional disciplining.  
“You are responsible for what could happen with that child in the future. Let´s say 
that, if he doesn´t recover from the attack, […] then the attack could become more 
Chapter 5 | Qualitative study 
206 
 
severe. Then, one feels such commitment […] I mean, the life of the patient depends 
on me.” [IR5] 
“It is a severe disease, it is a disease that can cause your death, and there are some 
attacks that are pretty strong.” [IR2] 
The more experienced health care workers reported not feeling fear when dealing with 
a child with an acute asthma attack nor mistrust towards the medications used to treat 
these cases. They expressed a sense of superiority and confidence in themselves when 
contacting an asthmatic child, as well as feeling the responsibility of being adequately 
prepared to manage them. 
“My experience, ours, tells me that if I see a child who is tremendously distressed I 
don´t make a big deal, I mean I don´t get scared. I mean come on, nothing at all; I 
mean I know I will reverse the attack. Easily.” [IP3] 
“I think it is a controllable disease. Yes, of course, it is a controllable disease. I am 
not afraid of inhaled corticosteroids.” [IP1] 
“We must be very – very well prepared to provide care to any child. […] So, when 
someone shows up, I mean, you must assume that situation as a great responsibility. 
The mum does not want to let go of the child, but they do give it to you. So, one must 
be tremendously ready to solve those cases.” [IP2] 
However, another experienced health care worker discussed feeling worried about 
other associated complications or consequences of asthma in children, such as loss of 
school days and obesity. 
“School dropout, they miss a lot of school-days, they miss class, that child […] if they 
don’t go to school, they fail to learn.” [IP1] 
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“I also see often that they have a tendency to obesity, I mean, I am concerned about 
the curve rising and rising” [IP1] 
On the other hand, young health care workers reported feeling fear and despair when 
treating a child with an acute asthma attack, as well as concern and caution when using 
medications for asthma. On some occasions, they also felt helpless towards the 
caregivers’ questions regarding their child’s asthma. When informing about an asthma 
diagnosis, young health care workers felt sorry for the patient and their family. 
“That he requires mechanical ventilation, so… it is my greatest fear, that the child 
comes here in acidosis, I don´t know, and he… and he goes to mechanical ventilation 
at once. Then it, it is the… the greatest fear. When he comes… a child comes with a 
severe attack and I can´t reverse it.” [IT2] 
“Going there and feeling a little bit – a bit of despair, I mean, seeing the mother 
feeling helpless and upset; sometimes the medicine doesn´t work immediately. Then, 
one feels discomfort […] Many times it does cause despair.” [IR5] 
“And that shouldn´t be given in an excessive amount because it provokes a com… 
more complications. The Salbutamol. Then it causes tachycardia and… and 
sometimes even the respiratory distress increases.” [IR3] 
“As a doctor, you want to have the answer for everything, and always reassure the 
parent. But there are cases in which the doctors – and not only for asthma – we 
don’t know what to say to them. It’s infuriating, even for oneself.” [IR6] 
“Giving a child, an asthma diagnosis is not something that makes me glad, because 
it is a chronic disease, and many times with an extended course.” [IR6] 
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Health care workers explained that, in general, they have the necessary skills and 
knowledge to act quickly when facing a child suffering asthma and that their job is to 
administer medications.  
“Well, thanks – thanks to the gained experience and, now, to the safety and 
handling of medicines, to be able to reverse the attack, we are a little more 
prepared and not so scared as we were some time ago when I was starting, it was 
catastrophic.” [IP2] 
“We end up getting used to it. So, asthma attack –ok– medication, oxygen and try to 
calm her down, because the mum arrives in a desperate state and all that, so we say 
to them –please calm down–. And then we’re done.” [IT3] 
They believe they should keep a cool head to control the situation and act effectively. 
“Though the doctor should keep a cool head, shouldn´t he? […] To act well. […] I 
mean, cold in the sense – at the moment of acting, not cold to the family or patients. 
I mean, cold at the moment when it’s necessary, I don´t know, to do one more 
procedure – intubation – it is, for procedures, isn´t it? But not in the other sense, I 
mean he must be warmer with – with the families.” [IP2] 
Besides, experienced health care workers discussed feeling concerned regarding the 
inadequate management of asthmatic children that some young and non-specialised 
doctors offered. Young health care workers did not comment on similar or 
contradicting perceptions. 
“I do feel worried or restless about the inadequate handling that sometimes 
resident doctors have during asthma attacks in the emergency department” [IP1] 
Health care workers commented on the importance of informing and educating the 
child’s caregivers when treating him/her for an acute asthma attack. They frequently 
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used terms such as ‘raising awareness’ or ‘scaring’, when referring to educating families 
about asthma, as seen in the representative extract. They described the caregivers as 
being scared and not knowing anything about what is happening to the child and the 
management needed, so the health care worker should act as a guide for them.  
“We tell them: “Next time, your child may arrive in a worse state, and he is not 
going to arrive walking, he will arrive with a tube in his mouth.” […] At least, in that 
way, they will become a little afraid.” [IR3] 
“But you are the one who has to come to talk to him. You are the one who must tell 
him/her that he must buy this, apply this, use this. He/she doesn´t know [the 
caregiver]. He/she has no idea when he/she gets there, he/she is afraid. So, that is 
the issue, it´s a responsibility to guide him/her.” [IP3] 
Another experienced health care worker indicated that what is really important is to 
establish a good patient-doctor relationship to be able to convey the information to the 
caregivers. 
“In general, there has to be a good interrelation with both [father and mother]… 
you have to be very charismatic.” [IP3] 
Finally, some health care workers expressed feeling satisfied, fulfilled and relieved 
when the child improves after being treated for an acute asthma attack. 
“I mean, a child who arrives with respiratory insufficiency and who, with medicine, 
inhalers, the use of spacers, it´s really satisfying to see how they react. They recover 
immediately.” [IP2] 
“I feel fine, I feel relieved [seeing that the patient responds to the treatment of an 
asthma attack].” [IR5] 
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Caregivers: 
 Caregivers described feeling fear, despair and anxiety towards their child’s acute 
asthma attacks.  They expressed how asthma affects not only the child, but also the 
caregivers and the family.  
“Gosh, it is worrying, because one thinks that one can die that very moment.” 
[FG4M] 
“It is such a horrible thing… you feel that you choke, you can’t breathe, and, at 
times, it seems that you are going to die.” [FG1M] 
“So yes, as parents we feel grief. We feel lost and sometimes do stupid things 
because we want to help our children, right? And, of course, it is a disease that does 
affect us, parents, very much, and I don´t know, I mean, seeing our children 
suffering at that moment.” [FG3M] 
They believe that the disease is unpredictable, that it will be present during a long 
period of time and that it may bring some associated complications, as well as death.     
“[…] that sickness, in the long term, becomes chronic and it is like death 
approaching. You don´t get to know when you choked. And, if you don’t have anyone 
to look after you, you may die. Because if it starts during adolescence… ok, it affects 
the child, in the adolescence it stops, but when you are a grown up, it comes back 
again.” [FG1M] 
“[…] we have to be careful because it develops, and it brings complications later.” 
[FG2F] 
A mother who had suffered asthma herself, expressed a divergent opinion, reporting 
that she took her child’s acute asthma attacks calmly.  
“Take it easy, I have also suffered from that disease.” [FG4M] 
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According to the caregivers, acute asthma attacks are situations when they feel forced 
to take immediate action, and for which they usually contact the formal health care 
system.  
“[…] once she even fainted, we had to rush to the hospital in the middle of the night. 
[…]. You must run to the hospital or clinic. But run.” [FG2F] 
“[…] he has already gotten to the extreme where he couldn’t breathe, there is a lot 
of effort in - the muscle of the chest, of the abdomen, it already started to hurt 
him/her and that moment, let´s run to the hospital […]” [FG3M] 
“She got sick and I took her to the emergency room at the hospital and she received 
treatment, she got oxygen because she couldn´t breathe and all that, she even got 
an injection.” [FG5M] 
They expect that their child will be given a fast and appropriate treatment that will get 
him/her better. 
“[…] we are pretty sure that taking him there will make him get better, because she 
is the doctor for that.” [FG4G] 
“[…] that´s why I went to the doctor, so he can give him the medicine, so the kid can 
get better.” [FG4M] 
However, some caregivers feel fear, deception, frustration and defeat when taking their 
child to be treated for an acute asthma attack to the hospital or health care centre.  
“I had another granddaughter who had asthma and she got horribly bad, and my 
husband said: ‘No, you aren´t going to take her there, she will get traumatized 
because she will get an injection’, that when taking – taking her to the hospital she 
was going to get an intravenous fluid and she was going to die there.” [FG4G] 
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“It´s only that Salbutamol is a medicine that you have to be careful about. Exactly 
what must be given is exactly what the doctor gives, because if you administer too 
much Salbutamol, forget that, he can even die! It is very dangerous.” [FG3G] 
 “But Salbutamol, that bromide, it doesn´t even tickle him. Because I go to the clinic, 
they nebulize him, I get back home, and three hours later he is again [with 
respiratory distress]. And as a mother, you worry.” [FG5M] 
Some caregivers described how they prefer treating their own child at home when 
suffering an acute asthma attack. 
“No, I do it at home. I don´t take her to the hospital. I don´t take her. I have my own 
supplies, the same that I have right here, I have at the hospital.” [FG2M] 
Caregivers also brought up how their child’s asthma limits the life of the child and the 
whole family, as they are afraid that certain activities or foods may trigger an acute 
asthma attack. Similarly, they reported how the children miss school days during the 
acute asthma attacks. 
“He/she couldn´t go the beach, he/she couldn´t have ice cream” [FG4M] 
“Many times, I haven’t sent her to school, because she woke up very sick because of 
that [asthma].” [FG5M] 
Some caregivers discussed the lack of knowledge concerning their child’s asthma and 
how to treat their acute asthma attacks. 
“Because I really – I mean, I have always heard about asthma, asthma, but I really 
don´t know what it is, no.” [FG4M] 
“Because many times, eh, at the beginning I didn´t – didn´t have medicines at home. 
No, I didn´t know who – eh, then that´s why I went to the doctor, so they can give 
him the medicine, so the child can get better.” [FG4M] 
Chapter 5 | Qualitative study 
 
213 
 
“I don´t know about my little girl either because she looks fine to me. Sometimes she 
gets a cold. Sometimes she goes to the doctor but no… I don´t know much about 
asthma. [FG2F] 
On occasions, caregivers felt guilty for their child’s acute asthma attack, as if it were 
their sole responsibility. 
“It did happen to me once because I went out with him and – I mean – it was cold, 
and I got home at night. And he had – he had a little cold, not much. And the night 
came and – and when we arrive, it seems that the cold, because we were travelling, 
it seemed to hurt him and that – that made him agitated. So yes, I really felt guilty 
at that moment because I said if I had taken him home at a different hour, or – or if 
I had gone there earlier.” [FG4M] 
5.4.3. Barriers to Asthma Health Care and Home Care Access 
We classified the reported barriers into 4 categories, based on Tanahashi’s model379 
(see Methods section).    
Acceptability 
a. Health Care Workers 
The caregiver’s educational and socioeconomic level was described as a perceived 
barrier by health care workers, together with carelessness and neglect towards the 
disease. 
“First, the educational level of the parents […] I think it is crucial. Um, illiterate 
mothers or fathers can sometimes have the intention, but they don´t carry it out in a 
correct way. Second, the socio-economic level they belong to. It has too much to do 
too. I think that mainly they both – they are the barriers to do it [follow the doctor´s 
instructions].” [IR6] 
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“Then I try to talk and explain them everything. Then […] it seems that there are 
caregivers […] who don´t listen to us. Then, they get […] the medical consultation, 
they talk to a specialist, then things are explained to them, then eh, parents start to 
have […] a good management with their children. But there are others who 
sometimes, eh, the same culture is a barrier, …the indifference, and they come 
again, and they recur with an attack again.” [IR4] 
A second relevant barrier for health care workers, in the context of cultural factors, was 
the use of traditional or natural remedies for their child’s asthma, and the reliance on 
friends’ or neighbours' advice by the caregivers. 
“But here they are used to visit – this – let´s use the right words – a witchdoctor or a 
healer around the corner. It is very common.” [IP2] 
“You tell the patient that he/she has to take that medicine for some time, don´t you? 
And that he/she must return before finishing. He/she doesn´t, the neighbour tells 
him that the sap of a tree cures asthma and they change and take that, and after 2-
3 months you see that… 4 months, 5 months, that they have another asthma 
exacerbation.” [IT1] 
Similarly, health care workers believed that caregivers were told (by non-health care 
workers) of certain false side effects of the medication prescribed for the child’s 
asthma. 
“[…] I was told that if I gave it to him, I mean the Salbutamol, they become addicted 
or they start with heart problems […]” [IT2] 
Health care workers also brought up the issue of caregivers’ poor adherence to their 
child’s long-term medication. 
Chapter 5 | Qualitative study 
 
215 
 
“Here the idiosyncrasy makes people live from… from aromatic teas, from a certain 
plant´s tea, from the tea of… the preparation of … the witchdoctor who massages 
children. Then, a person here can´t adhere to medication.” [IR3] 
Another barrier some health care workers reported was that caregivers only take 
asthmatic children to be treated once they are severely ill. Consequently, asthmatic 
children were treated solely at the emergency department during acute asthma 
exacerbations. 
“In the area where we live there are many parents whose child starts with a 
common cold, and only when the child situation becomes complicated, that’s when 
they go to the doctor.” [IR2] 
Young doctors referred that on some occasions they felt rejected as general doctors (vs. 
specialists), by the caregivers, and this created a barrier between them, hampering 
understanding and confidence. 
“Sometimes parents […] create a barrier between the doctor and the – and the 
parent – the patient´s parent, and that barrier prevents them from understanding 
the information correctly […] they refuse to be assisted by a general doctor, they 
prefer to get the treatment from a specialist immediately.” [IR6] 
There were no other differences in the social and cultural factors, as well as in the 
norms, beliefs and values between young and experienced health care workers, related 
to acceptability barriers to health and home care access for asthmatic children. 
b. Caregivers 
Caregivers admitted using a variety of natural remedies and following other people’s 
advice in respect to asthma medication, as part of their beliefs in alternative medicine 
and how much value they give to it, and justified in the search for a solution for their 
child’s asthma, which they do not find in doctors and biological medicine.  
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“And do you know how it stopped [my child´s asthma]? Cockroach tea” [FG2M] 
The use of natural remedies, however, did not always interfere with the adherence to 
acute asthma medication (like relievers), though it may have done so with baseline 
long-term treatment (such as inhaled corticosteroids).  
“Because a woman told me…not to let my girl use the inhaler too often, because 
eventually it will end up hurting her lungs.” [FG1M] 
Some caregivers were reluctant to expose their children to a large amount of 
medication or for a long period of time and preferred more ‘natural’ remedies. 
“The norm would be for a person, regardless being sick or not, he/she is not going to 
spend his/her whole life taking medication. Because our body is not going to be 
under medication all the time; this medication has effects on certain parts of our 
organism and our defences. For us, growth, intelligence, a lot of medication, or how 
we call it here, too many drugs, because it makes them become fool.” [FG1M] 
Some caregivers expressed fear towards the hospital care and mistrust of the doctors 
and medications prescribed or given for free at the hospital. This led them to seek 
advice outside the health care services, not to attend at all, or to buy over-the-counter 
medicines. 
“[…] that when taking him to the hospital, he would get an intravenous treatment 
and that he would die there.” [FG4M] 
“But one had to buy them, because those medicines that they prescribed him did 
nothing to him. Instead, the medicine that I used to buy over the counter, eased his 
discomfort.” [FG5M] 
 “I don´t trust all doctors […]. In fact, I go there, or I come here, because he has 
social security cover, he, I don´t like to take him to IESS [social security hospital]. 
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And, I have him in the [public] hospital, I lie to get in […] I don´t trust the IESS.” 
[FG3M] 
Accessibility 
a. Health Care Workers 
A common complaint among the health care workers was the lack of a specialist doctor 
to follow-up asthmatic children in the City of Esmeraldas. The process of referring a 
patient to be followed up by a specialist, was described as slow and complicated. They 
had to be sent to one of the larger cities that are 8-9 hours away (Quito or Guayaquil), 
with long waiting lists and associated costs (both for the caregivers and the health 
system). 
“Sometimes one wants, or the patient is already diagnosed, and you need them to be 
evaluated by specialists, paediatricians or allergists. The – the time that, eh, is used 
or needed to generate that referral and for the patient to be treated is also a delay.” 
[IR6] 
“but our [Esmeraldas’s public hospital] level is second level, then I shouldn´t have to 
start, of course that I can replicate and to refer to a third level, but this issue is a bit 
more complicated, I can help you get an appointment with the allergist and all. It 
isn´t that easy.” [IP3] 
“Here in the city we don´t have a specialist in – in – in respiratory diseases, and in – 
and in asthma and – it is a little far.” [IR5] 
Health care workers discussed the economic difficulties some of the caregivers 
encountered to buy the medicines that were not freely available through the hospital, 
to access the health centre or hospital, or to transfer the child to be seen and followed-
up by a specialist in another city. 
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“And if the families are low-income and they can´t obtain the medication, it is like 
they are tying our hands, us, the professionals.” [IR6] 
“It could be that – that they don´t have the economic resources. I mean, one thinks 
of some things – difficulty to get to the health centre, eh, the access depending on 
where you come from.” [IP2] 
“[…] then that patient must go to another third level, I don´t know if he has the 
economic capacity to get there.” [IP3] 
Similarly, health care workers blamed the economic situation that forced both parents 
to work outside the house and leave the child under the care of a third person who may 
not be as thorough in the management of the child’s asthma. 
“No parent wants a child to suffer like that, but unfortunately due to the economic 
situation they have to go out [to work] and to leave them with people who they 
don´t know.” [IT1] 
In addition to this, an experienced doctor raised her concern about caregivers only 
being given days off work when their child was acutely ill, and not when they had to 
attend necessary follow-up visits. 
“They don´t give them authorization to be absent [from work] to have a medical 
check-up, just if the child is sick they get permission.” [IP1] 
On the health workers side, some felt that in the private practices, doctors are more 
worried about obtaining economic benefits than in improving the asthmatic child’s 
quality of life. In this sense, they reported that some private health care workers do not 
want to prevent the child’s future asthma attacks to receive more visits.  
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“Unfortunately, here we are very commercial, so the doctor: ‘Ah! The more attacks 
he has, the more he comes for a medical consultation’. But that is not… I mean, that 
is not the objective that the health staff should have.” [IT2] 
Some young doctors commented on the long working hours and the little time they 
could dedicate to each patient, which, in their opinion, reduced the quality of the 
service provided and the amount of information and explanations they could offer the 
caregivers concerning their child’s asthma. 
“There is a large demand from patients, and because we provide care to all of them, 
and we try to generate quantity, numbers, we don´t generate good quality care.” 
[IR6]  
“Doctors who work exhaustingly for many hours and who don´t have, eh, enough 
time to rest adequately, obviously, they won´t generate correct work. So, I think that 
it is another – another cause why some doctors can simply say: ‘Take this 
medication and leave’. Right? For fatigue, physical exhaustion.” [IR6] 
Another barrier some young doctors reported was that they were told by the 
caregivers that, on some occasions, they were denied access to the emergency 
department or they were referred to the health centre when they attended with their 
child for an acute asthma attack. This may cause the caregivers to lose their trust in the 
health services provided and stop attending when their child is suffering an acute 
asthma attack. 
“Most of my patients say that. In fact, they really say that – I mean, they say: ‘They 
didn´t – didn´t want to see me’.” [IR5] 
Finally, some health care workers expressed the impression that the health authorities, 
at least at the provincial level, did not give the necessary relevance to the problem of 
asthma. This resulted in a lack of specific preventive and follow-up programmes.  
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“It is a serious public health problem [asthma], as well as an indefinite number of 
pathologies that exist, but in our province, it is no… it is not being taken with the 
importance that it deserves.” [IT1] 
b. Caregivers 
The participant caregivers reported several barriers when accessing the health care 
services for their asthmatic child. First, they mentioned the difficulties faced when 
trying to arrange an appointment, second the service hours available, and third the 
waiting hours before their child is seen for an acute asthma attack. Because of these 
downsides, some of the caregivers had a negative opinion of the quality and 
accessibility of the health services provided.   
“To get an appointment sometimes you get an answer, sometimes you don´t and it is 
a chaos. One goes there, but they tell you: ‘Wait for your turn’. Then you stop giving 
him/her the medication.” [FG1M] 
“You get to the hospital at 10 at night and they don´t… don´t open the door. They 
send you to the medical dispensary, the health sub-centre to get an appointment 
again” [FG2F] 
“You get to the clinic at 6 in the morning and they see you at 12. It is the same at the 
hospital.” [FG2F] 
“If you go to the health sub-centre, you have to wait and wait and wait.” [FG1M] 
As the health care workers had reported, caregivers described the economic hardships 
experienced when having to buy prescribed drugs not available at the hospital, to go to 
a private specialist, or the struggle to find transport to get to the hospital at certain 
times of the day. 
Chapter 5 | Qualitative study 
 
221 
 
“They prescribe him/her a medicine and sometimes there is, in one way or another, 
there are times… when there is no money to get it.” [FG1M] 
“This moment he only has… I bought the blue one [salbutamol inhaler] for him. 
Because I didn´t have money for the other. I was broke.” [FG1M] 
“I took him but in [name of the clinic] the medical appointment was very expensive. 
One got there and waited, all the medicines the doctor prescribed were expensive at 
that moment, but I bought them the same.” [FG5M] 
“Anything that is unexpected, and it affects you at night. And there isn´t money to 
take a cab, it´s a problem:” [FG2F] 
Some caregivers reported logistic difficulties, especially when having their child 
admitted to hospital or referred to a specialist in another city. 
“Once she was about 4 or 5 days at the hospital. I was working, my wife was with 
the little child at home. I…left from my work, I prepared the food, I got back to 
attend home. So, it was a problem.” [FG2F] 
“After that I was sent to Quito, and I was going there constantly, I went to Quito for 
one year, for a year I was going up and going down, every month with him.” [FG5M] 
Time off work was sometimes complicated to obtain, as explained by some caregivers. 
They felt that employers do not understand the importance of the situation or the time 
needed when their child was going through an acute asthma attack. This is even more a 
problem when dealing with a chronic and recurrent disease such as asthma. 
“Sometimes at work they don´t –don´t understand, at work they don´t understand 
that you have a sick relative and if you don´t get a medical certificate, they think it 
is a lie.” [FG4M] 
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“And sometimes they called me from work, and I said: ‘I am going to the hospital’. I 
used to work 24 hours at that time. It was not possible to leave, I had no one to 
cover for me, no. So, it’s a problem. Um…It´s like I tell you, it has you thinking 
about…3 parts: work, home and hospital. Where should I run to first? And 
sometimes you ignore something. I remember one day I said: ‘If you want to, fire 
me’. Because I am not going to lose my daughter over work. I can get a job 
tomorrow or the day after tomorrow.” [FG2F] 
Caregivers also felt that asthma was not taken seriously enough by health authorities in 
their country and even more in their city. 
“In the first place, something is missing, as you said, in the first place they need to 
take it [asthma] more seriously here, in our country, over all. Here in our city, in 
Esmeraldas city.” [FG1M] 
Contact 
a. Health care workers 
Health care workers complained that caregivers did not follow the indications given 
and did not adhere to the entire treatment. They thought this occurred because of 
caregivers not being aware of the importance of their child’s asthma and not taking it 
seriously.  
“No, they are not very aware of the disease. I don´t think they realize it – from what 
I have seen, no they don´t.” [IP2] 
“They don´t care too much about environmental measures, to eliminate the source 
of mites.” [IP1] 
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“They stop the treatment, because as they know it always happens, a treatment is 
always applied to them, then they say: ‘No, I, I am already healed’, and they simply 
leave.” [IT3] 
“Sometimes, I explain it to parents and I give it written to them, and they don´t give 
the child the medicine as it is written.” [IR1] 
As for the doctor-patient relationship, some health care workers expressed that on 
some occasions, the caregivers did not even listen or pay attention to what they were 
told, while on other occasions they did not seem to fully understand the indications or 
explanations given. This would also explain the lack of adherence to treatment and 
lifestyle indications. 
“There are caregivers who don´t listen to us.” [IR4] 
“Sometimes I feel that they don´t understand me. Sometimes I feel that – that they 
don´t understand what I tell them, no – they don´t, although I like to be very clear.” 
[IR6] 
Another reason why health workers thought that caregivers did not adequately treat 
their asthmatic children or alter their lifestyles to reduce the child’s risk of future 
asthma attacks, was complete ignorance or lack of knowledge concerning their child’s 
asthma management. This was therefore a consequence of them not being informed of 
their asthmatic child’s treatment and necessary care at home. Health care workers also 
reported that, even if the main caregiver of the child knew about the child’s treatment 
and care, they did not share this with the rest of the cohabitants in the house, who may 
take care of the child at some point. 
“[…] from the caregivers’ part there is total lack of knowledge too, eh…real lack of 
knowledge of the management, of the life style that patients must have, in this case 
the caregiver ignores all this.” [IT2] 
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“They don´t inform at home. For example, the mother can know his/her trigger, let’s 
see, she is, I drinking soda, eh… the colorants, right? But maybe his/her cousins, 
uncles, siblings, even his/her father, ignore it.” [IT3] 
Some health care workers discussed the fact that caregivers only take the asthmatic 
child to be seen and treated during the acute asthma attacks, but not for the follow-up 
visits. They blamed it on the caregivers’ customs and culture, as they think are not used 
to visiting a doctor when not feeling ill. They even felt that caregivers wait too much 
before taking the child to the emergency department with an acute asthma attack, until 
they are severely ill. The following phrases show the health care workers’ perception of 
how they believe that the child’s asthma care is their responsibility, and when they are 
not able to establish a continuous and close relationship with the child’s caregivers, 
they take them for being responsible for the child’s poor asthma control.  
“The cultural aspect, thinking that it is only when the patient is ill that he has to go 
to the doctor.” [IP1] 
“There are many parents who, when the attacks are over they don´t go to follow-up 
consultations.” [IR2] 
“In the area where we are there are many parents who see their child to have a 
light flu but only when the child gets worse, that moment they take him to the 
doctor.” [IR2] 
Another barrier to offer a high-quality health care service reported by some young 
doctors, was the fact that there is sometimes a lack of organization and cooperation 
among the health care workers’ team, especially at the emergency department.  
“Sometimes, we are supposed to be a team, aren´t we? And there they are, and there 
are people who don´t do things quickly, who don´t hurry up. And then the patient 
gets more complicated.” [IR5] 
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There were no other differences in the social and cultural factors, as well as in the 
norms, beliefs and values between young and experienced health care workers, related 
to contact barriers to health and home care access for asthmatic children. 
b. Caregivers 
Most of caregivers described having been ill-treated or even abused by health care 
workers, on some occasions, when attending the emergency department or health 
centre with their child for an acute asthma attack. Caregivers expressed that a 
perceived poor doctor-patient relationship may result in the children or the caregiver 
not wanting to attend that particular health service again. 
“And after that she said no, they didn´t want to give him the medicine. Then, I had to 
tell them that: ‘I am not a nurse, but here where I am standing, I can hear my son 
[the wheezing], look at his abdomen’. So, she had to call another nurse to observe 
him, and the other nurse said that he needed attention.” [FG3M] 
“Once I got there with – with my child with an attack and a nurse put a 
thermometer, I was there with the child, and she sat down, I swear that she took a 
nail polish, and she started to paint her nails.” [FG1M] 
“My child almost didn´t want to come, because he says that the other doctor is 
different. […] He said that the doctor is kind of angry.” [FG1M] 
Another barrier that some caregivers discussed was that their children were not 
followed-up by the same health care worker, but that it changed at every visit. This may 
hamper an adequate doctor-patient relationship, as well as the child’s management, as 
their treatment may be interrupted. 
“If you are not seen by the same doctor, one sees you then another.” [FG1M]. 
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Some caregivers reported being afraid of the side effects of the medications their 
children were prescribed for their asthma. On the other hand, other caregivers 
commented that on some occasions they did not give their children the complete 
treatment as recommended by the health care worker. They explained that once the 
child was feeling better, they would stop the treatment.  
“I heard that when you take Salbutamol, your heart beats a little faster.” [FG3M] 
“One took her to the doctor and she had some medicine and then we knew that on 
the fourth day she was better so I didn´t finish all the medication.” [FG2M] 
“When I see him better, I don´t give him anything more. I stop worrying. […] There is 
medicine left.” [FG2M] 
Together with these fear and mistrust, caregivers seemed not to be aware of the effect 
and duration of the effect of certain medications used for their child’s asthma. For 
example, they did not know that after 3-4 hours, the effect of salbutamol (an acute 
bronchodilator) wore out and another dose should be administered.  
“But that Salbutamol, that bromide, it doesn´t even tickle him. Because I go to the 
clinic, they put a nebulizer on him, I get back home and after three hours he is sick 
again.” [FG5M]  
Availability 
a. Health care workers 
Both young and experienced health care workers commented on the lack of diagnostic 
tools, such as spirometry, human resources and drugs for treating asthmatic children at 
the hospital or health centre. They felt this precluded them offering an adequate 
management for these children. 
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“And not really – we don´t have all the medicines, an appropriate stock of medicines 
in hospitals.” [IP2] 
“There aren´t even enough human resources. It has happened to me sometimes that 
just one doctor oversees all the emergency area, and he doesn´t attend just one 
patient, but there are some patients who are less severe.” [IR6] 
“[I am used to diagnosing children with asthma] Clinically only. I don´t have, any 
methods, spirometry, nothing like that.” [IP1]  
This was especially noted at the health centre, were health care workers reported there 
were no drugs or professionals to take care of the follow-up of asthmatic children. The 
reason why this happens is because of how health care is organised by the Ministry of 
Health, as health centres (primary level) do not have access to drugs for ‘specialised’ 
diseases, such as asthma. 
“It is a big problem too because in the health centre, for example, in the first level 
unit there isn´t any treatment for asthma, for the long term.” [IR4] 
Similarly, some health workers explained that because their hospital was only a 
‘second’ level hospital, they could not have access to certain diagnostic tools. 
“I can´t carry out immunology tests here, if there is deficiency of IgA or, the 
deficiency of alfa – 1 – antitrypsin, either of these things, I couldn´t do it. Then I 
have to think about the third level.” [IP3] 
Another barrier that health care workers reported was the lack of follow-up and 
educational programmes for asthmatic children. They mentioned that this kind of 
programme exists for other chronic diseases (hypertension or diabetes) or for 
pregnant women, which even include home visits. Young doctors who only work shifts 
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at the emergency department (ED) expressed the difficulty of following-up a child they 
may have treated at the ED for an acute asthma attack. 
“There are TAPS [physician assistants], who are technicians that help, they visit 
people at home, they follow-up the patient. But overall in pathologies, it is like… 
more about morbidity, about diabetic and hypertensive patients, but following-up 
patients with asthma, no.” [IR2] 
“That´s what we are lacking, education programmes for asthmatic patients.” [IT2] 
“I would like to see them [asthmatic patients] again, but here unfortunately we 
have work in shifts, I don´t get to see them.” [IR3] 
Experienced doctors complained about the lack of training programmes for the general 
doctors that work at the emergency department and health centres treating and 
managing children. They referred that young doctors sometimes treated acute asthma 
attacks inadequately and that they thought they felt unsure given their lack of specific 
knowledge concerning paediatrics in general and paediatric asthma in particular. Even 
worse, experienced doctors reported that some young doctors base their practice on 
their own experience, instead of clinical guidelines or scientific recommendations. 
“When the general doctor sees a child closely, he is already scared.” [IP3] 
“The norm that residents in training need to come here to learn Paediatrics hasn´t 
been set up. To become a clinical paediatrician. They think that with the experience 
of repeating things gives them the reliability to do it, they say: ‘I have repeated it’. It 
is not science; you can repeat things wrongly.” [IP3] 
Other health care workers reported that, on occasions, asthmatic children and their 
caregivers receive incomplete or even misleading information regarding their child’s 
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management. As an example, they described how some health care workers impose 
unnecessary limitations to the child’s life, such as, those referred to sports activities. 
“Some doctors can simply say: have this medication and leave.” [IR6] 
“Then we have […], lack of knowledge about the management, and wrong 
information, I think, given to the patient´s caregivers.” [IT2] 
“ ’You can´t eat, […] strawberry. You can´t play, you can do nothing.’ So, it becomes 
a strong taboo, and they [health care workers] scare the caregivers so much […], 
that they have created such carelessness and fear towards the asthmatic patient.” 
[IT2] 
Some young doctors also brought up the mistrust they felt when using certain drugs to 
treat asthmatic children, given their side effects. These fears were sometimes based on 
certain beliefs that did not coincide with guidelines recommendations. 
“The corticosteroids, for me, all of them the inhaled as well as the injections, oral, all 
of them have their faults since… they leave sediments, deposits and…in the long 
term you will see negative results, let´s say, in other organs.” [IT2] 
“Salbutamol has its risks; besides we have to know how to use it, how to explain […]. 
Patients who aren´t asthmatic, have received this medication and they end up badly 
– to the extreme that, they even, […] have a tachycardia and they end up dying.” 
[IR4] 
b. Caregivers 
Caregivers discussed the unclear and insufficiently detailed information they received 
from the health care workers concerning their child’s asthma management and home 
care. They believed this information was sometimes incorrect. In addition to this they 
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reported receiving contradicting information or criteria from different health care 
workers. 
“Yes, it is very rare for a doctor to explain, more detailed.” [FG2F] 
“No, in general here doctors only tell you that it is an allergy. ‘No stuffed toys’. But 
here we realized that it is not only that.” [FG2F] 
“But they never told him or explained to him: ‘This medicine is good for this or for 
that’. But they gave it to him and they told him: ‘Take this medicine’, nothing else.” 
[FG4M] 
As the health care workers did, caregivers also commented on the lack of medicines 
and medical supplies at the hospital and health centres to treat their child’s asthma. 
“But we took the control of the medicine ourselves, because they [at the public 
hospital] didn’t have anything. They didn´t even have disposable masks [to 
nebulize].” [FG2] 
Caregivers explained that their children were diagnosed with asthma without having 
had any specific tests or samples taken. This led them to mistrusting the diagnosis. 
“You go there, and the doctor tells you: ‘The child has this’. But never before he was 
checked up, he didn´t have any tests done, to say that this [asthma] is what the child 
really has.” [FG4G] 
Some caregivers expressed that, on some occasions, the health care workers had told 
them that they did not have the necessary training to manage their child’s asthma and 
that they should take them somewhere else. 
“He told me: ‘Definitely your child needs another type of medicine and another kind 
of doctor who can attend him, take him to another place’.” [FG5M] 
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Other caregivers reported that they were not aware of any other treatment available 
for their child’s asthma, except for the relievers (bronchodilators, such as salbutamol).  
“I only knew about Salbutamol, and no more.” [FG3M] 
Finally, female caregivers discussed how the burden of the asthmatic child’s care falls 
on the women in the house (mothers and grandmothers), with an absence or a low 
participation from the father. 
“They [fathers] aren´t awaken at night, I say, well, there aren´t many cases. But in 
most of them, mothers are the ones who stay awake, and we don´t sleep when the 
child is sick. But the father sleeps, and then he asks: ‘How is he?’, ‘He is ill’, ‘Ah, OK’. 
And he leaves and falls asleep, right? I say: ‘How can he be sleeping when he sees his 
child like that?’” [FG3M] 
5.4.4. Facilitators to health care and home care access 
Both caregivers and health care workers discussed facilitators to health and home care 
access for asthmatic children. We have also included in this section ideas they 
expressed of how health and home care could be improved to reduce barriers to access. 
Acceptability 
a. Health care workers: 
Both young and experienced health care workers believed that certain taboos and 
myths about asthma could be easily eliminated through specific community asthma 
education programmes. They reported that caregivers have a sufficient cultural and 
educational level as to understand what health care workers explain to them about 
their child’s asthma. 
“Education programs and health programs that teach what asthma is and that can 
remove all the taboos that we have about asthma.” [IT2] 
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 “One explains them, because mothers or caregivers don´t have such a low cultural 
level as to not understand.” [IT3] 
Some experienced health care workers explained that certain caregivers do follow the 
indications given and attend their regular follow-up appointments. They even offered 
caregivers their personal mobile number in case they need some guidance or help. 
“Some of them do. Some come, even… and I give my cell number to those asthmatic 
patients. Some of them call me: ‘Doctor, my medicine is finished, help me with an 
appointment’.” [IP1] 
Some young health care workers expressed feelings of affection towards the asthmatic 
children and their caregivers, and were willing to help them in whatever way they 
could. 
“Sometimes one as I have just told you, one tries to be neutral, as a doctor I try to be 
neutral so not to create feelings. But sometimes, you get to feel some affection 
towards them [asthmatic children].” [IR6] 
“They already know that they can support us and that we are ready to help them.” 
[IR4] 
Young health care workers discussed the difference they observed in the degree of 
implication in the care of the asthmatic child among the fathers in the urban compared 
to the rural area. In the city, on some occasions, both parents are present at the 
emergency department and they both show the same level of interest towards their 
child’s disease, according to young health care workers. 
“Yes, there are changes [in the urban setting compared to rural setting]. Both of 
them are usually here. So far in – in a month that I am here, both of them come, the 
father and the mother. And they both say: ‘Do you know what´s going on?’ The 
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mother leaves and the father comes:’ I want to know what´s wrong with my baby’.” 
[IR5] 
b. Caregivers: 
Some caregivers explained that they do follow the doctor’s indications and give their 
asthmatic children the medicine such as it was prescribed. This is especially so, if they 
believe it is going to make them get better.  
“Because if the doctor tells me: ‘Give it to him for seven days and it has to finish all 
of it [the medication]’. I do.” [FG2M] 
 “’[…]Take the medicine, you will feel fine with this. If you don´t take it, you won´t 
feel good’. Sometimes I de-stress and he de-stresses, because if he doesn´t take the 
medicine all the time, then he won´t be fine. And, if there is a medicine that will have 
an effect on him, I mean, using it for 1, 2, 3, 4 days and the attack won´t affect him 
until after 6 months, or 4 months, then, I would feel good.” [FG1M] 
“Then, yes, I would be interested if there were a treatment like that, that can change 
it, eh, I don´t know, the frequent attacks, I would do it. Whatever the cost.” [FG3M] 
Another facilitator some caregivers expressed is that they trust the medications 
prescribed and the doctors’ criteria, given they have undertaken scientific studies to 
develop such drugs. Some, even trust them more than traditional or natural remedies, 
which were shown to be of no use in some cases.  
“If they know that it is a medication that they first must research, many people, 
many doctors, and that is why they prescribe it for asthma. And that´s why, as she 
says, many people say that at in the long term it hurts him… and why can it hurt 
him… what is the reason why it can hurt the lungs, will it be too much air or what?” 
[FG1M] 
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“My daughter is 23 years old, the oldest of my children. My daughter did suffer from 
this disease [asthma], and we only gave her home remedies. But now…this… those 
remedies have no effect on my boy. It does nothing.” [FG2M] 
However, some caregivers also suggested a more holistic approach to asthma care from 
the health care workers, to include other recommendations or therapies apart from the 
use of drugs, as some of them do not believe it is good for the body to take medications 
for a long time. 
“It could be another… another methodology, not always taking medicine.” [FG1M] 
Finally, some caregivers commented on the possibility of making older children and 
adolescents responsible of their own asthma care, as they are old enough to understand 
the implications and the importance of an adequate follow-up, management and 
prevention. 
“A ten-year old child, he can be aware. For instance, my daughter – she knows. Then 
when she tells me: ‘Oh, mom, I want a little [of something that may trigger her 
asthma]’. I say to her: ‘You decide if you take it, because you can take a little now, 
but your body will be affected’. Then she, when I say that to her, she doesn´t take it.” 
[FG5M] 
Accessibility 
a. Health care workers: 
Another facilitator health care workers reported was the availability of necessary drugs 
and equipment at the hospital, for free.  
“I mean we have a type of bronchodilators. But in the private clinic they need to buy 
those in private drugstores. But, here in the hospital, we are well-equipped. We have 
bronchodilators.” [IP3] 
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 “At least, we have in the hospital all the necessary supplies to attend the patient.” 
[IR4] 
“No, because here, we give all the medication to them. We give them what the 
doctor prescribes. At least, for respiratory diseases, we provide them with all the 
medication. It is never missing. Supplies, materials, disposable masks and other 
things too. So, it’s not about missing medicines or supplies.” [IT3] 
On the other hand, experienced health care workers working in the private practice, 
commented that they try to help caregivers that may not have the economic resources 
to buy prescribed medication, by maybe inviting him or her to visit the hospital where 
he may be offered the drug for free. 
“I don´t let him be without the medicines. I mean, if people tell me that they don´t 
have any money to buy it, I tell him that I will wait for him in the hospital 
tomorrow. I help that patient. I give everything to him, I give the pills to him. I give 
it to all the patients.” [IP3] 
Similarly, other experienced health care workers discussed that certain caregivers can 
buy the medication that may not be available at the hospital without problems, and that 
some way or other they end up obtaining the prescribed drugs. 
“They can buy the medicine perfectly, what…the only thing we don´t have here is 
what I have just told you, the Montelukast, they buy it without problem.” [IP1] 
“In general, they do get it. It takes one day, maybe, but they get it.” [IP3] 
Both experienced and young health care workers expressed several ideas of ways to 
improve asthmatic children’s asthma, such as organising periodic home visits or a 
specific team to take care of these children, what they call an ‘Asthma Club’.  Some 
health care workers believe this is the responsibility of the Ministry of Health or the 
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local health authorities, who should implement specific public health programmes for 
asthma. 
“Having coverage, a better health coverage, and the existence of health promoters 
who get to the houses and who are constantly educating them.” [IP2] 
“We could improve if we could visit mothers, be in touch with them by phone, I 
mean, creating an…an Asthma Club. An institution which is kind of an Asthma Club. 
Like that, we could follow-up that baby, visit his house, see the conditions, and have 
a complete dedicated team.” [IP1] 
“That could be solved with a public health programme, right? To have the patients 
identified and carry out home visits.” [IT1] 
b. Caregivers: 
Caregivers commented that in general they found no difficulties in obtaining days off 
school for their asthmatic child. 
“We give you the time-off you want.” [FG4M] 
As for health care workers, some caregivers also believed that health care for asthmatic 
children could be improved by organising specific areas in the hospital for their 
management. 
“Here at the hospital there should be an area for that system only [asthma].” 
[FG1M] 
Contact 
a. Health care workers: 
Some health care workers felt that communicating with asthmatic children’s caregivers 
was not difficult, especially if they had a higher educational level, and that by using 
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repetition, most of caregivers would easily understand the information they were 
trying to convey to them. On occasions, they reported meeting caregivers who were 
very cooperative, understanding the indications given and following them. 
“It´s an advantage to work here, because the type of patient that comes here is not 
always the public patient. Here we have many mothers who have a higher level of 
education, isn´t it? I mean, they ended high school, or they are professionals. Then, 
that facilitates the message getting across.” [IP1] 
“I liked it because the mother was very cooperative, in this case.  She understood 
me, I explained to her what we had to do, what we were going to do with him. […] 
She understood because she started to give the medication to him properly.” [IR6] 
Other health care workers described how they use different methods such as drawings 
or games to help children and their families understand asthma. They also commented 
that being honest and direct was sometimes useful to engage caregivers in the 
management of their child’s asthma. 
“Mainly, I would have to search the way to help these children. Telling them, 
teaching them, by motivational speeches, games. Maybe, with my hands, taking 
their little hands, showing them, organizing workshops, motivating them to do all 
that we have explained and doing it with interest.” [IR6] 
“[…] you have to explain it all, drawing IgE, the hypersensitivity. It is the fastest way 
[…] In general, if one guides and tells them what the topic is about, they will get to 
know it.” [IP3] 
“I mean, making the parents aware, telling them the truth, being honest: ‘These are 
the conditions, and this is what may happen if you don´t do this’, and this kind of 
stuff.” [IR5] 
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Some young health care workers felt motivated and happy when caregivers turned up 
to inform them that their child was getting better thanks to their indications. 
“So, when a child or a mother tells me: ‘Doctor, he is much better with your 
indications, with the specialist´s indications, he is fine.’ One feels happy. I mean, it is 
motivating.” [IR6] 
The same happened when the health care workers in a department worked together as 
a team, cooperating and giving feedback to improve asthma management. 
“What makes me feel good? Well. That I and all my co-workers talk in the same 
way, that we understand each other with the same diagnosis, that if we fail we 
correct each other, that there is always a good feedback in the cases of patients. 
That is what induces a state of well-being.” [IR6] 
b. Caregivers: 
Some caregivers reported having received an adequate care when taking their child to 
be treated for an acute asthma attack to the hospital. They describe specific moments 
when they were nicely treated, explaining that even if the child does not improve as 
much as they expected, they still felt satisfied with the care received if they treated 
them promptly and with respect. 
“The times that I’ve been to the hospital I´ve received good attention.” [FG4G] 
“He was attended, he received first aid, but, no, he didn’t get better, but he was 
taken care of. I mean, I leave happy.” [FG4M] 
“In general – in all the places where I have taken my son to get nebulized or receive 
attention, they have always – always treated him very well.” [FG5M] 
Caregivers also expressed gratitude for the guidance received from some health care 
workers. 
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“We have to feel good for it, thankful because we have received advice, they have 
helped us in that aspect, to have that responsibility, that aid, what they have offered 
us. Because they have given us advice for a reason, haven´t they? It is for us to know 
how to cherish that. We have to learn from what the doctor offers us.” [FG4G] 
Similarly, they discussed how some health care workers recognise the emergency of 
acute asthma attacks and try to treat them quickly. 
“Once, I got there and my child was – was very distressed with the fever. And the 
nurse said: ‘Sit down and wait – wait for your turn’. […] And – and then a doctor 
showed up […], and he – he made me get in immediately.” [FG4M] 
Another facilitator that caregivers brought up is that certain health care workers do 
follow up their asthmatic children more closely. 
“In December, I had an appointment with my son. Instead, the doctor this time did 
tell me to get an appointment because he told me that my son needs to be followed-
up month by month.” [FG1M] 
Finally, some caregivers commented on the effect the specific asthma programme (the 
cohort study during which they were followed up by phone every two months) had on 
them and the home care of their asthmatic children, by reminding them the importance 
of the disease and its prevention. On the other hand, a father also expressed how 
participating in the focus group discussion had made him realise the relevance of his 
daughter’s asthma and how he now felt he should be more involved in the management 
of her asthma. 
“[…] From here, from the asthma centre [asthma study centre] they always call me 
at home. And when they call me I feel so grateful, and I remember, and I start 
cleaning, […] So, it is like they are telling me: ‘Clean, clean.” [FG4M] 
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“But, sometimes I receive phone calls telling me that she is in the hospital, that the 
girl has a headache or something else. Then, well, at least what I do is to provide 
money for the doctor, buy the prescribed medicine. But, it is important that I came 
[to the focus group discussion] to ascertain all these things well.” [FG2F] 
Availability 
a. Health care workers: 
Health care workers did not report any facilitator for increasing availability of health 
and home care access for asthmatic children. However, they expressed many different 
opinions and ideas of how this could be improved. For instance, they gave great 
importance to the increasing asthma knowledge of caregivers and the general 
population using media or specific education campaigns in schools, for example. 
“Improving the knowledge of the ones who suffer from the disease, right? And not 
only the affected should be educated but also all the general population.” [IP2] 
 “Keep educating the family, educating at school, creating education programmes 
there… there at school, educating.” [IT2] 
“It would be a matter of prevention, of communication, I don´t know, with speeches 
for people who are proactive in this management. To use the media, I don´t know, 
radio, television.” [IP2] 
Once more, the concept of organising a ‘Club of Asthma’ to improve asthma knowledge 
and management at home. Some health care workers also highlighted the importance 
of broadening this education and training to the extended family and friends who may 
be in charge of the asthmatic child at some point. 
“They should do the same, shouldn´t they? A mothers’ club, for asthmatic people, 
mothers whose children have asthma.” [IP2] 
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“I don´t know if it could be with greater, I mean, organizing something like a more 
aggressive campaign for the families, of education, explaining them.” [IT2] 
“I think that teaching all the [extended] family and the closest friends. I believe that 
way we can avoid, [asthma] attacks.” [IT3] 
Experienced health care workers also discussed how to improve asthma knowledge 
and management among young doctors, by specific lectures and daily training. 
“I do really think that the topic should be managed. It can be. A lecture, prepared 
for the residents [general doctors], about this topic. It is the only way, if not they 
[general doctors] will continue. […] It must be on a daily basis, daily. To learn and to 
train them […].” [IP3] 
Some young health care workers felt motivated to study more about asthma and 
allergies, following the end of the cohort and qualitative study on asthma at the 
hospital, for which they had collaborated. 
“It is motivating for me that you are, doing this. Thank God, in the long term, well, I 
also continue with my studies, studying this [asthma] in more depth. I like it very 
much – Allergology - I’m interested in it, a lot.” [IR6] 
b. Caregivers: 
Caregivers also discussed how an enhanced asthma knowledge would improve their 
child’s management and care. Some caregivers felt empowered to treat their child 
during an acute asthma attack.  
“The thing is, if I know what the cause is, I would be more careful, making him not 
to – not to be in contact with what hurts him, trying to keep him away. But if I don´t 
know, how am I supposed to know what I should protect him from? Because I really 
don´t know what it is.” [FG4M] 
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“If he gets sick in the middle of the night, or if he doesn´t have the pills here, we soon 
give him one, two or three puffs [salbutamol inhaler]. We would do it, so the child 
could – could get better – be fine the next day. It ends quickly - doing that 
[salbutamol inhaler].” [FG4G] 
Some caregivers believed their asthma knowledge and skills could be improved with 
education sessions or lectures. 
“It could be possible that we can do something. That´s why I say… with lectures, 
attending good seminars. [FG1M] 
5.4.5. Use of recurrent asthma attack risk assessment tool 
Benefits 
a. Health care workers 
Health care workers discussed the usefulness of the risk assessment tool and described 
it as being simple, easy to use, clear, ideal, excellent, practical and didactic. They 
expressed it would be very helpful and important.  
“It would really be of great help. A clear, simple and understandable tool.” [IR6] 
“So, they are very valid tools and if they are implemented, they are of good help.” 
[IP2] 
“It is something very didactic, very practical and very simple and it is a very 
important tool.” [IT1] 
Both experienced and young health care workers described how it would improve their 
daily practice, by helping them identify the children at a higher risk of suffering a 
subsequent asthma attack. They reported how this would facilitate the decision-making 
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process regarding treatment, necessary follow-up and level of health care needed 
(primary vs tertiary). 
“It would be useful to know which of them will be coming back, and which won´t […] 
To know who requires more attention and who doesn’t.” [IR1] 
 “To know when to follow-up a patient at a first level [health centre], or when he 
needs to be treated at a more advanced level of care […] it would be good to follow-
up those of low-risk at a primary level of health care, while the high-risk patients 
need a […] They come to emergency room with these attacks constantly, they go 
directly to the specialist.” [IR4] 
“We would identify them. We would call them. We would have a more direct control 
over high-risk and low-risk patients.” [IT1] 
“It would also help us a lot to know when to start using or not the corticosteroids 
and all that stuff.” [IR2] 
“We would communicate to the mother that [her child] has a higher risk of 
triggering another attack in the future. Then, the medical check-ups for that child 
will be stricter, or the follow-up, or the treatment or the – physical examination […] 
First, the treatment, I mean, I would have to see what kind of inhaler to use, how 
frequent it will be used […]. I would see for how long, I would schedule the 
appointments much better.” [IP1] 
Some health care workers even thought it might reduce the number of severe acute 
asthma attacks, the number of deaths due to asthma and it would increase the 
adherence to asthma treatments and life-style modifications. 
“Then yes, with this tool and explaining it to the professional appropriately, and 
then applying it correctly on the population, I think we would find or we would have 
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fewer cases of children who have asthmatic attacks that could be the cause of some 
types of serious and acute illnesses that could even lead to death.”[IP2] 
“Yes, yes, yes. In fact, it would. [It would help fathers and mothers to become aware 
of the importance of the treatment]. Of course [it improves the treatment 
compliance].” [IP1] 
“I do think that it would change [the parents´ attitude a little if they could see 
something as visual as this tool].” [IT1] 
Another benefit health care workers discussed was how it would enable the 
transmission of information to caregivers, concerning the child’s asthma, especially 
their future risk of severe acute asthma attacks. They commented on how they would 
change the amount and type of information they would offer caregivers, depending on 
the predicted future risk. 
“The tools which are used are great instruments for the doctor, for sure. And if they 
are understandable or correctly and simply explained to the doctor, obviously much 
clearer for the patient, so the doctor may convey that information to the patient, it 
would be much better.” [IR6]  
“Yes, it [the tool] is easy to use. I would say: ‘Madam, it´s important that you come 
back after a certain time and to manage this amount and frequency of medication 
because that child has a high-risk or medium-risk to have it again…or let´s not do 
much because he has a low-risk of experiencing an attack so frequently.’ It does 
work for me.” [IP1] 
“It would be more specific [the advice given to patients], wouldn´t they? I won´t give 
the same - treatment to the ones who are in the high risk zone as to the ones who 
have recently started, right? Well, it does change the attitude.” [IP2] 
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Experienced health care workers also brought up that the risk assessment tool would 
be especially useful for young health care workers, trainees and students, to decide 
upon specific treatment and follow-up needs. 
“It is a very important aid for one and for […] the residents [general doctors], the 
interns. To be able to give these tools to them so they can assess and try to cure the 
patient.” [IP2] 
“And also for the resident [general doctor], they would know which patient they 
need to refer to me that moment and which not.” [IP1] 
Finally, some health care workers had specific ideas of how the risk assessment tool 
could be implemented in the health care system, for example at the emergency 
department, to initiate a whole management team including social workers to assure 
that high risk children are given the necessary information, treatment and follow-up. 
“It would be very useful for emergencies: admitting the child to hospitalization, 
making sure that parents understand that he is a high-risk patient, that the social 
worker has to be in touch with this patient, right? Finding out who is the most 
responsible of the family members: his extended family, his father or his mother; 
knowing which is their nearest health centre.” [IT1] 
b. Caregivers 
As the health care workers did, caregivers felt the risk assessment tool was easy to 
understand, simple, good and important. They commented on the familiarity of the 
traffic-light colours (green-yellow-red) and how visual the tool was. 
“Because you can see it there, like the traffic lights. Because red is danger and 
everything. It is fine for me like that, because one is able to understand like that, 
because you know what the dangers are, and that’s how the colours are.” [FG1M] 
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“I find it simple. If you have made it so, then some of your experience is integrated 
here. So, I find it easy to understand for lay language. It quickly found out that I am 
here [pointing at one of the risk areas in the tool].” [FG2F] 
“Red means high-risk, yellow is medium-risk and green is low-risk, almost nothing.” 
[FG3M] 
Some caregivers discussed how the risk assessment tool helped them understand their 
child’s future risk and how this would affect their degree of concern and worry 
regarding their child’s asthma. They reported how they would be more prepared for 
the next acute asthma attacks.  
“For me, it´s fine too. Because with it, one knows what he has and what he hasn’t; 
and the risk you are taking.” [FG1M]  
“If you tell me that he/she is in the green zone [of the tool], then it means that…I 
shouldn´t worry that… that much, right? Because I know that it would take some 
more time [for the asthma attack to recur] […], right? And if he/she is in the yellow, 
I must be a little more [worried], but not much. But if he/she is in the red, it means 
that I must be there with that person because I don´t even know if at what moment 
he/she stay there [die], and not come back.” [FG1M] 
“I think it would even be a good method for me because I would know the truth, 
because a doctor can say: ’Your child is in this stage and he/she has this risk or 
he/she doesn´t’, then I am facing a disease with a risk and I know it for sure, if not – 
the doctor sends us the medicine, we take care of him, but we don´t know what the 
risk is and how the illness may progress.” [FG5M] 
“We have to be more careful. We know that in 4-5 months the [asthma] attacks will 
return, then we already have to be aware of what will happen.” [FG2F] 
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“[…] Because if he/she is in red I have to pay attention […]. In yellow, a little. In 
green, well, when it is green then, the concern is less. […] He is out of danger. But if 
it is red or yellow we must be a little careful, but if it is green, then the danger exists 
but it is lower.” [FG3M] 
As a consequence, some caregivers explained that being more worried due to their 
child’s high risk of recurrence, would mean they would increase their adherence to 
doctor’s indications and treatment prescriptions, would be more vigilant of the child’s 
home care, and would take extra care of the high-risk child. 
“For me, yes, it would [change my life style a little or the use of the medicine 
prescribed to them]. Because I wouldn´t see my child daily, or every day. I would 
also say: ‘Take the medicine because you will feel fine with this. If you don´t take it, 
you won´t feel good’. Sometimes I de-stress and he de-stresses, because if he doesn´t 
have the medicine all the time, then he won´t be fine. And, if there is a medicine that 
will have an effect on him, I mean, using it for 1, 2, 3, 4 days and the attack won´t 
affect him until after 6 months, or 4 months, then, I would feel good.” [FG1M] 
 “I would. I would take control every day and I would follow-up my son to see how 
he is doing.” [FG2M] 
“If I would see that, for instance, he/she is in yellow. Then, I want him/her to be 
lower, right? […] So, yes, I would be interested if there was a treatment like that, so 
it could change him [the level of risk in the tool], the frequency of the attacks, I 
would do it, whatever the cost.” [FG3M]  
Finally, some caregivers discussed how they would rely on the risk assessment tool, as 
it comes from a research study. They commented on how this instrument was 
developed to help them (caregivers of asthmatic children) and how they believed it was 
an example of a medical advance. 
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“In any of the three stages, we must follow the methods, because it is supposed that 
thanks to this research which is being done and which is being done through the 
university and all that stuff, well, it means that it is to improve… so our children can 
get better and we can also get some well-being for ourselves, as parents.” [FG1M] 
“Through this, you help us.” [FG1M] 
“I find it to be very good and a medical advance, as medicine is progressing little by 
little, and gaining more knowledge.” [FG4G] 
Barriers 
a. Health care workers 
Some health care workers believed that all the patients seen at the emergency 
department would be classified as high-risk patients according to the risk assessment 
tool, making no difference between them. 
“Here everybody would be high-risk patients because here everybody has been 
under treatment using corticosteroids, most of the patients are from the rural 
area.” [IR1] 
“Because here everybody is high-risk patients. Most of them. Most of them if you 
realize. Because they get here when they have been under many treatments and 
since they can´t reverse the mild attacks… they can´t and they realize it and then, 
they come here.” [IT1] 
Other health care workers commented that there were some important or relevant 
questions missing from the risk assessment tool, or they did not completely understand 
how the tool should be used or the information it offered. 
“I think that we have to include more questions.” [IR1] 
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“At first glance we could add […] the time since his/her last attack. We could add 
something there.” [IT2] 
“It could say: ‘Living in a rural or urban area’. I would add: ‘or urban.’ And about 
the ones who use inhalers, I would expand it. I would.” [IP1] 
Another barrier some health care workers brought up regarding the implementation of 
the risk assessment tool in their daily practice, was that it would not change their 
management of the asthmatic child nor the caregivers’ attitude, regardless of the risk 
group the child was assigned to. 
“As for the treatment, no…my attitude would be the same because if I neglect these, 
the low-risk ones, they will end up on the other side. So, I would continue in the 
same way. All of them would be kept in the level they are, avoiding them to pass to 
another.” [IT1] 
“I wouldn´t change my attitude [when informing the patients].” [IR3] 
“If they are recurrent patients, well, they know they already know about their 
disease and we tell them: ‘It will last for a certain time, until…or that they will 
always have factors that trigger the attacks’, I mean, I don’t think that telling them: 
‘You are in a group, or not’… I don´t consider that they will go, or they will get more 
motivated to continue with the treatment.” [IT3] 
Finally, some young health care workers highlighted the importance of the risk 
assessment tool being adequately explained to the health care workers that will be 
using it, before it is implemented. 
“Obviously with the right instruction and training. […]Some tools get here, we have 
a demonstration, but we don´t get an explanation or it is not understandable for the 
doctor or the doctor might not be here – it’s difficult to understand for the doctor 
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the assessment of such tools. Then, if the doctor cannot understand the evaluation, 
how can he/she explain this to a caregiver?” [IR6] 
b. Caregivers 
Some caregivers reported that they would not change their attitude towards their 
child’s care regardless of the level of future risk they were informed of, according to the 
risk assessment tool. Other had even doubts of the effectiveness of the risk assessment 
tool. 
“I would continue in the same way. Let´s suppose that he/she is here and when I 
don´t give him/her the medicine, he/she gets here [to a higher risk] due to my 
carelessness. So, I continue in the same way.” [FG1M] 
“I don´t know if it will work.” [FG2F] 
Another barrier that some caregivers brought up concerning the risk assessment tool 
was that once some time has passed by, and their child is asymptomatic, then they 
would stop worrying and taking the medication. The same would happen in the case of 
caregivers who have some experience with the disease, because of other siblings or 
themselves suffering asthma and surviving it. 
“It is about a year, and I don´t…I told you…it is almost a year that he she doesn’t 
have… [asthma attacks]. Imagine I have the inhaler they gave me, and it’s not been 
used. I’ve got two inhalers, and both are brand-new. Then, no, there’s no reason to 
stop [taking care of him/her].” [FG2F] 
This qualitative study offers novel and relevant findings by including the opinions and 
experiences of both HCWs and CGs of asthmatic children, concerning acute asthma 
significance, and asthma health and home care access.  
5.5. Main findings
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The main finding related to acute asthma significance is how CGs and HCWs experience 
this event from their perspective, and how this could also be observed between 
experienced and less experienced HCWs.  
HCWs focus on improving the child’s situation during the acute attack and feel 
responsible for them, a moment that young, inexperienced professionals may endure 
with fear and uncertainty, while more experienced workers are confident on their skills 
and knowledge.  
For the CGs, acute asthma attacks are troublesome and urgent events that they live 
with fear, desperation and resignation in some cases. They affect the family’s economy, 
organisation and activities. Both CGs and HCWs feel responsible for the child and are 
aware of the possibility of the attack resulting in his/her death. 
HCWs and CGs identified multiple barriers to health care access for asthmatic children, 
and a few related to home care. The barriers are summarised in Table 5.6, divided into 
the 4 categories of Tanahashi’s model379. Some of them were shared by both HCWs and 
CGs, with contradicting opinions on others.  
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Table 5.6: Barriers to health and home care access for asthmatic children according to 
HCW and CG. 
Category Health care workers (HCWs) Caregivers (CGs) 
Ac
ce
pt
ab
ili
ty
 - Use of natural remedies and other people’s 
advice by CGs 
- Poor adherence to medication and 
indications  
- Education and SES CGs 
-Rejection by CGs (Y) 
- Natural remedies and other people’s advice  
- Reluctant to expose children to long-term 
medications  
- Fear and mistrust towards doctors and 
hospitals 
- Seek advice outside health service 
Ac
ce
ss
ib
ili
ty
 - Cost of medicines, transport and specialist 
consultations. 
- CGs not given days off-work for follow-up 
appointments. 
- Lack of specialists and slow and 
complicated referral system. 
- Child cared by a third person 
- Health authorities not interested in asthma, 
not taken seriously. 
- CGs not given access to emergency 
department (ED) when child with acute 
asthma attack. (Y) 
- Economic hardship (drugs, transport) 
- Difficult to obtain days off-work 
- Logistic difficulties (hospitalizations) 
- Difficulties in obtaining appointments. 
- Limited office hours and long waiting times. 
Co
nt
ac
t - No adherence to treatment and indications, 
CGs not aware of importance of asthma. 
- CGs do not listen or pay attention. 
- Lack of knowledge in CGs (not informed 
adequately) 
- CGs take childsren when severely ill. 
- Private HCW looking for profit (no 
prevention strategies) 
- No sense of team work at ED (Y) 
- Afraid of asthma drugs side-effects. 
- Stop treatment if no symptoms. 
- Ill-treated and abused by HCWs. 
- Not aware of effects and duration of the effect 
of asthma drugs. 
 
Av
ai
la
bi
lit
y - Lack of diagnostic tools, human resources 
and drugs. 
- HC have no access to asthma controller 
medicines 
- Lack of follow-up and asthma education 
programmes. 
- Long working hours, short time per patient. 
(Y) 
- Misleading and incomplete information to 
CG (Y) 
- Mistrust in asthma drugs based on beliefs 
(Y) 
- Lack of training for GDs (E) 
- Inadequate management by GDs (E) 
- Lack of medicines and medical supplies 
(nebulizing masks). 
- Not aware of asthma controller drugs. 
- No diagnostic tests for asthma. 
- Unclear, insufficient and incorrect 
information from HCW 
- Contradicting information and criteria 
- GDs do not have necessary training to 
manage asthma. 
- Burden of care on women 
HCWs: Health care workers; CGs: Caregivers; SES: socioeconomic status; Y: young, 
inexperienced HCWs; E: Experienced HCWs; ED: Emergency Department; HC: Health centre; GD: 
general doctor. 
 
Chapter 5 | Qualitative study 
 
253 
 
Table 5.7: Facilitators to health and home care access for asthmatic children according to 
HCW and CG. 
Category Health care workers Caregivers 
Ac
ce
pt
ab
ili
ty
 - CGs that do follow indications, treatment 
and control appointments. 
- CGs have sufficient cultural and educational 
level to understand explanations. 
- Taboos and myths easily eliminated with 
asthma education. 
- HCW offer private mobile number for CGs 
to call when needed. 
- Affection towards children and CGs 
- Greater implication of fathers in the city. 
- Follow HCWs indications and treatment. 
- Trust HCWs and drugs prescribed (over 
natural remedies). 
- Possibility of making older children 
responsible of their asthma management. 
* Prefer a more holistic approach. 
Ac
ce
ss
ib
ili
ty
 - Free drugs and equipment available. 
- HCW help low-resource families in private 
practice. 
- Families that can buy prescribed medicines. 
* Periodic home visits, ‘Asthma Club’, public 
health asthma programmes. 
- Easy to get days off from school for children. 
* Organization of a specialised area for asthma 
in the hospital /HC. 
 
Co
nt
ac
t - Easy to communicate with CGs. 
- Cooperative CGs, follow instructions. 
- Use of alternative methods to convey 
information (pictures, etc.). 
- Being honest and direct with CG 
- Some HCW are motivated and happy when 
children improve or there is a feeling of team 
work. (Y) 
- Adequate care by HCW, kind and quick. 
- Feel gratitude for guidance offered. 
- Close follow-up by certain HCWs. 
- Importance of specific asthma programmes 
that increase awareness. 
Av
ai
la
bi
lit
y - Feel motivated to study asthma further. (Y) 
* Increase asthma knowledge for CGs and 
general population. 
* Organise an ‘Asthma Club’ for patients and 
families. 
* Education for extended family. 
*Improve GD’s knowledge. (E) 
- Feel empowered to manage their child’s 
asthma (self-efficiency). 
- Enhanced knowledge improves child’s 
management. 
* Education sessions or programmes for 
patients and CG to improve asthma knowledge. 
 
HCWs: Health care workers; CGs: Caregivers; SES: socioeconomic status; Y: young, 
inexperienced HCWs; E: Experienced HCWs; ED: Emergency Department; HC: Health centre. 
* Ideas or suggestions to improve health and home care access for asthmatic children. 
 
A small number of facilitators for health and home care access for asthmatic children 
were reported by either HCWs or CGs, represented in Table 5.7. On the other hand, 
several ideas and proposals of how to overcome the discussed barriers were brought 
up. These proposals included both changes in the way they (HCWs and CGs) behaved in 
front of an asthmatic child or how they managed their asthma attacks, as well as how 
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other people or institutions could modify the health services’ structure and 
organization. 
Finally, when shown a preliminary design of a risk-assessment tool for recurring severe 
asthma attacks, HCWs and CGs felt quite positive about its usefulness in improving 
asthma management, transmission of information to CGs, and adherence to indications 
and treatment. They could understand the information it provided and found it simple 
and easy to use. However, some HCWs and CGs felt reluctant towards the tool, and 
expressed their doubts about the use of the tool resulting in a change in CGs’ or HCWs’ 
behaviours and attitudes towards asthmatic children. 
The main strength of this study is the inclusion of both HCWs and CGs of asthmatic 
children, at the same time and addressing the same topic, to be able to contrast their 
opinions, beliefs and experiences. Similarly, the involvement of both specialist doctors, 
respiratory therapists and young general doctors added value and richness to the data 
obtained, facilitating once more the analysis of the difference between experienced and 
inexperienced HCWs. We were also able to obtain a wide picture of the childhood 
asthma experience by exploring the significance of acute asthma on one side, and the 
perceived barriers and facilitators to health and home care access. This enabled us to 
reflect the importance of the disease for the patient’s CGs and HCWs, as well as 
perceptions of why asthma management is not as adequate as it should be, and 
opportunities to overcome these barriers. Finally, by discussing the use of a 
hypothetical risk assessment tool of recurring severe asthma attacks, we could describe 
whether this tool could act as a facilitator to improve asthma management from the 
CGs’ and HCWs’ point of view.  
5.6. Strengths and limitations
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In qualitative research, authors should first explain their own background and context 
before presenting the study findings, as these may be influenced by the researcher’s 
subjectivity. I am a paediatrician who has been working in the setting where the study 
was undertaken for over two years, having a close working relationship with some of 
the HCWs that we interviewed. I also conducted the previous cohort study from which 
the CGs were recruited, therefore they had all already met me before and some had had 
a close contact with me concerning their child’s asthma, as I had been following them 
up for between 6 months to over a year.  
The cohort study enabled nearly 300 children to access asthma-specific follow-up and 
treatment, which otherwise was not available in the city of Esmeraldas, therefore some 
of CGs and some HCWs had previously expressed their gratitude to the study team in 
general and to me in particular.  
Bearing in mind that I conducted 9 of the 12 in-depth interviews and 3 of the 5 FGD, my 
presence may have influenced the answers obtained from both the HCWs and the CGs. 
However, most of the HCWs I interviewed, I had not worked with before. As for the CGs, 
I focused the discussion towards the use health care services outside the study centre, 
for which they could speak freely as they knew I had no connection with any of the 
hospitals or health centres they referred to.  
I also had several preconceived ideas and assumptions of the underlying barriers and 
facilitators concerning asthma management in Esmeraldas, given my clinical 
experience in this setting. Nevertheless, during the analysis of the data, Dr. Natalia 
Romero’s guidance, precluded me from introducing my preconceptions when 
interpreting the data. 
This study presented some other limitations. First, men (fathers) were 
underrepresented in the CGs’ FGD, as only 2 out of 20 participants were male. The same 
happened with other degrees of kinship apart of mothers, as there were only 2 
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grandmothers and no grandfather or aunts/uncles. This was due to the mothers and 
grandmothers being the ones who are normally in charge of the child’s asthma care, 
and they are therefore the ones who attended the invitation to the FGD, even if this was 
directed specifically to the father. However, we could at least recollect the opinions and 
experiences of two fathers, and on the other hand, it reflects the real situation as the 
women in the house are the ones responsible for the asthmatic child’s care in most of 
the households in this setting.  
There was a small number of experienced HCWs (3 out of the 12 interviews), though 
they were all the available specialists (paediatricians in this case) that treated 
asthmatic children in the city of Esmeraldas. However, we did seem to reach data 
saturation in the opinions and experiences expressed by this subgroup of HCWs. 
Second, it was undertaken in a setting, the city of Esmeraldas, with a specific socio-
cultural environment that may differ significantly from other settings, such as rural 
population or a city in a high-resource country. On the other hand, it may have some 
characteristics in common with other similar settings in Latin American countries, 
where qualitative studies have not been undertaken addressing this topic in both CGs 
of asthmatic children and HCWs. Many Latin American countries share a similar 
cultural background (indigenous and Spanish/Portuguese) as well as socioeconomic 
context. 
Third, when studying barriers and facilitators to health care access, it is important to 
include people that, having suffered the same condition, did not access health care 
services, as they may have encountered different barriers than those that finally 
accessed health care. This was not the case in our study, given that all the participant 
CGs had been previously recruited from an emergency room for the cohort study. Even 
though this is the ideal procedure to include a sample as heterogeneous as possible, it 
was not feasible in our setting, as there is no available record of asthmatic children in 
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the city and we did not have the resources, nor the time to conduct a previous 
populational survey to search for CGs of asthmatic children that had not accessed any 
health care service. However, it is also true that this thesis is focused around severe 
asthma attacks, that by definition are those that require an unscheduled appointment 
with a doctor (or emergency room) and the prescription of systemic corticosteroids.  
Fourth, due to time constraints, we were unable to share our findings and 
interpretations with the study participants, an important step to add credibility to our 
findings. Nonetheless, we did contrast our findings with first participants and my own 
previous experience and knowledge as a Paediatrician living and working in this same 
setting with asthmatic children, and having a very close contact with both CGs and 
HCWs, often having discussed with them similar issues as those addressed in the 
current study. These observations and discussions were registered in the field diary 
that was completed during the study. We were also able to triangulate our findings with 
those from the cohort study, where we collected data on use of health care services for 
asthma during the previous year and treatment prescribed, and finally with the 
literature reviewed. 
5.7.1. Asthma acute attacks significance 
HCWs perceive severe paediatric asthma attacks as urgent events that need to be 
overcome, and that it is their responsibility to do so by applying the necessary 
treatments. To do so successfully, they need to keep a cool head and avoid feelings to 
distract them from their objective: to improve the child’s health during that acute 
episode. This situation is lived with fear and uncertainty by the young, inexperienced 
HCWs, as they are afraid the child might suffer severe complications or even death.  
5.7. Findings in relation to other studies
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On the other hand, the more experienced, specialised doctors feel confident that the 
child will improve as a result of their knowledge and skills. This contrasts with the 
asthma management reality in Latin America, with a high asthma morbidity24,25 and 
mortality275 when compared to other regions. However, it is the young and 
inexperienced HCWs that need to manage the children with severe asthma attacks at 
the ED, while the specialised doctors only treat them once they have been stabilised 
and are admitted to hospital or seen for follow-up at the consultation room. 
Nevertheless, the more experienced doctors expressed worry for other associated 
consequences of acute asthma attacks in children, such as lost school days and obesity, 
secondary to exercise avoidance.  
Only once the child had improved did HCWs concentrate on information transmission 
and education of CGs on asthma, which they considered highly relevant to avoid future 
severe exacerbations. In this sense, they regarded the CGs as the sole responsible for an 
inadequate management of the child’s asthma in case of a recurrent asthma attack. 
Similarly, HCWs from primary and secondary care in the UK also reported the CGs 
being responsible for the child’s acute exacerbation following a withdrawal of 
controller therapy after symptom improvement, and that this was due to the 
caregiver’s lack of understanding of asthma treatment498.  
To increase the CGs’ awareness, the HCWs in our study reported the use of strategies to 
improve the physician-patient relationship, as well as frightening or even intimidating 
CGs by exaggerating or lying about their child’s future risk. Patient and caregiver 
education was also highlighted as essential by HCWs participating in a qualitative study 
on interventions to increase physical activity in asthmatic children499. 
Severe asthma exacerbations in children are experienced by CGs with anxiety, fear, 
helplessness and despair, affecting not only the child, but the whole family. The disease 
is part of their lives, limiting their activities and commanding the family’s organization. 
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They perceive these attacks as unpredictable and asthma as a chronic disease which 
may improve, but not disappear completely. The inevitability of the attacks, the burden 
on the families and the feelings of fear and frustration have been mentioned in other 
similar qualitative studies with CGs of asthmatic children undertaken in very different 
high-resource settings363-366,500,501, as well as in other Latin American countries 
reflecting the universality of these findings371-373. 
In contrast, feelings of rejection, denial and anger that were also brought up in these 
other qualitative studies364,367,372, were not expressed by the CGs from Esmeraldas. 
Interestingly, CGs in our study also felt guilty of their child’s asthma attack on 
occasions, as if it occurred because of their inadequate care towards the child. This 
feeling of guilt was also reported by Peruvian mothers of asthmatic children admitted 
to hospital372. In addition to these, CGs may also feel blamed by other family members 
who think the asthma is caused by a lack of care, as described by South-Asian mothers 
living in the UK500. 
During the acute asthma attacks, CGs relied on the health care services, for which they 
seek a fast and effective solution, as they are afraid of complications or even death. 
However, during the encounter with the HCWs, they often feel frustration, deception 
and defeat, as they do not receive the treatment or the results they expected. CGs of 
asthmatic children in other studies expressed annoyance and anger towards HCWs, a 
feeling that they did not meet their expectations and that they were not taken 
seriously500,501. 
These experiences of frustration may also appear when not being believed by the 
child’s teacher or the staff in nursery or school501. CGs in our study also felt fear and 
mistrust towards the doctors or the medications prescribed, due to the side effects or 
their beliefs. Even though some CGs prefer treating their child’s asthma attack at home, 
it was often expressed that they lacked the necessary knowledge to do so.  
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As we will discuss later, this is a recurrent barrier reported by CGs of asthmatic 
children499,500. In this sense, CGs were afraid of not being able to identify when their 
child was suffering an acute asthma attack, either because the child was trying to hide 
his/her symptoms or because these are difficult to recognize. This issue has been 
already been mentioned by CGs in other studies, in relation to distinguishing the 
symptoms of asthma in comparison to those of breathlessness due to physical 
activity498. 
It was interesting to note that neither HCWs nor CGs barely mentioned the asthmatic 
children involved, as if they were not part of the significance of acute asthma for them. 
Several studies have reflected how asthmatic children play a passive role when 
accessing health care services, with their parents or CGs being the ones voicing their 
concerns and describing their symptoms, and the HCW discussing asthma drug risk 
with them rather than with the children354-356,358,498. 
5.7.2. Health and home care access barriers for asthmatic children 
When analysing the barriers to health and home care access for asthmatic children 
identified by HCWs and CGs, we realise the similarity with those included in the 
Systematic Review of barriers and facilitators to health care access, for any disease378. 
Participants in our study reported barriers for all the 4 subcategories.  
Acceptability 
There were several coincidences and overlap in the barriers expressed by HCWs and 
CGs, while there were also differences between them, as well as between more and less 
experienced HCWs. For example, both CGs and HCWs discussed that CGs’ beliefs, their 
mistrust in hospitals and doctors, together with the advice they received from non-
medical people, led them to use natural remedies over prescribed drugs. The myths 
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regarding side effects of asthma drugs, such as that it may damage the hurt or cause 
addiction were very similar to those reported by caregivers in Peru and Colombia371,382. 
This is a common acceptability barrier in asthma, as well as other chronic diseases, 
causing poor adherence to asthma medications365-368,380,500. The CGs’ scepticism towards 
doctors and hospitals was also perceived by young, non-specialised HCWs who 
reported feeling rejected by CGs.  
On the other hand, HCWs believed that the CGs’ beliefs and trust in medical 
establishment, depended on their level of education and socioeconomic status. In this 
sense, it is important to note that the level of education (median of having studied high 
school) and socioeconomic status (median monthly household income of 400 USD) of 
CGs in this setting, together with the strong African influence in their culture with a 
frequent use of natural remedies and ‘traditional medicine’, are relevant characteristics 
that may affect acceptability of health care services and that may not be present in 
other similar settings. 
Accessibility 
The cost, logistic impediments, administrative complications and difficulties in 
obtaining days off-work made it challenging for CGs of asthmatic children to access 
asthma medications and medical appointments, even more when referred to medical 
specialists. These accessibility barriers were discussed by both HCWs and CGs and 
appeared frequently in the revised literature361,365-368,372,383,384. 
The lack of specialised HCWs who may adequately manage asthmatic children in the 
city of Esmeraldas resulted in a problematic situation for many asthmatic families, not 
only for the slow, bureaucratic process of the referral system, but for the necessity of 
travelling to a city that was 7-9 hours away just for an appointment, with its associated 
costs and days off-work and off-school needed. For some families, this was not a 
feasible solution to follow-up their asthmatic child, with an appointment every 2-3 
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months in a distant city. The lack of a specialised doctor was one of the reasons 
Mexicans reported for changing the hospital where they treated their asthmatic 
child361. 
Lack of specialist doctors for asthmatic children was also reported by HCWs in 
secondary care in the UK498, therefore it may not only be a problem affecting low-
resource settings. HCWs in Esmeraldas, claimed that some of these accessibility 
barriers were caused by the lack of interest in asthma of the health authorities, who did 
not take the disease seriously enough. It is worrisome that some inexperienced HCWs 
reported having been told by the CGs that they were denied access to the ED when 
arriving with their child suffering an acute asthma attack, though CGs themselves only 
mentioned that they were made to wait for a long time before being seen by a doctor. 
This may be a consequence of not having a professionally trained triage nurse at any of 
the emergency rooms in Esmeraldas, who may classify the emergency of the patient to 
be treated according to their severity. Long waiting times were also reported by 
Colombian and Mexican caregivers361,371. 
Contact 
As contact barriers, HCWs reported lack of interest of the CGs of asthmatic children in 
what HCWs had to say, poor adherence to medication and indications, taking the 
children to be seen by a HCW only when he/she was severely ill, and how they thought 
this happened because of the lack of awareness CGs had about asthma and its 
consequences. Brazilian CGs reported taking the child to the emergency department 
when he/she is very ill, as before that, they try to treat him/her at home373. This could 
also be secondary to the lack of knowledge that CGs have, according to HCWs in our 
study, due to not being informed correctly.  
Poor CGs asthma knowledge was documented in our previous cohort study and was 
also mentioned by both CGs and HCWs in qualitative studies from high-resource 
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settings498-500. On the other hand, CGs admitted stopping their child’s treatment once 
the acute symptoms had disappeared, as well as being afraid of the side effects of the 
asthma medications prescribed, and some were unclear about the effects and duration 
of the effects of the different asthma drugs (both relievers and controllers).  
Adhering to asthma medications only during the acute exacerbations, not being aware 
of the seriousness of the disease, and fear to side-effects, addiction or tolerance to 
drugs are common contact barriers that threaten adherence to medications, and have 
been previously reported in in high364,365,367,368,383,500,502 and low income countries371,382. 
These could all be consequences of inadequate or incomplete information on asthma, as 
HCWs had claimed in our study. 
Special attention should be brought to the provider-patient relationship, as it is the key 
to most of the contact barriers identified. While the HCWs in our setting felt ignored by 
the CGs, the CGs on their side reported having been ill-treated by HCWs in different 
circumstances, especially when attending due to an acute asthma attack. Lack of a 
shared-decision process, discrimination, mistrust, and apportioning blame on the CGs 
are all aspects of the provider-patient contact that have been previously reported by 
asthmatic children’s CGs to hamper the establishment of a good and trustful 
relationship365-368, and these were all mentioned by the CGs in our study.  
As highlighted before, none of the HCWs and CGs participating in our study mentioned 
the asthmatic children when discussing communication issues, therefore excluding 
them completely from the patient-provider relationship. On the contrary, HCWs from 
the UK believed that including the child in this process was essential498. 
Interestingly, some HCWs discussed that in private practice, doctors were more 
worried about obtaining economic profit than about the patient’s wellbeing, avoiding 
establishing preventive strategies or prescribing preventive treatment, as this would 
cause the children to stop attending the clinic for acute asthma episodes.  
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We did not include any HCWs who worked only in private clinics, as all the doctors in 
Esmeraldas work in the public sector and some in both public and private. None of the 
CGs mentioned this barrier that may clearly affect the quality of the health service 
received, and we found no referral to it in the revised literature either, though there 
were remarks about the general low quality or inadequate care received364,367. 
Availability 
The most reported availability barriers by both HCWs and CGs were the lack of asthma 
drugs, medical supplies, human resources and diagnostic tools, something commonly 
acknowledged in other qualitative studies361,384. The fact of the CGs receiving unclear, 
insufficient, incorrect and sometimes contradicting information and criteria depending 
on the HCW, made them feel unprepared and insecure to manage their child’s asthma 
and not being knowledgeable about the existence, for example, of asthma controller 
drugs.  
Scarce (and contradicting) information and education for CGs and patients, and them 
not having a clear understanding of the effects and indications of the asthma drugs, is 
one of the availability barriers identified by Hirmas et al.378 in the Systematic Review, 
together with other qualitative studies on asthma365,367,368,371,380,498,500. This situation 
was worsened by the uncertainty the CGs felt towards their child’s asthma diagnosis, as 
they had not been offered any kind of specific diagnostic test for asthma.  
This same issue was discussed by South Asian families of asthmatic children residing in 
UK, who reported that a lack of clear diagnosis led to a poor adherence to asthma 
medications500, together with CGs in Sweden who complained about delayed 
diagnosis501. We did not find any reference diagnosis uncertainty as a barrier to health 
care access in the qualitative studies undertaken in Latin America361,371-373,382. The fact 
that HCWs and CGs did not talk about written asthma action plans (WAPs) was a 
reflection of the complete absence of these in Esmeraldas, an even worse situation than 
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that described in other qualitative studies where HCWs reported barriers to 
implementing them (time, space, updating)384,385 and CGs reported not receiving them, 
not using them, or the WAP not being updated500. Similarly, caregivers from other Latin 
American studies did not mention asthma action plans361,371-373,382. 
Both CGs and experienced HCWs reported that general doctors did not have the 
necessary training to manage asthmatic children adequately, as an availability barrier. 
This lack of specific asthma knowledge was described in a Mexican study undertaken 
with general practitioners (GPs) and doctors with a leadership role (managers)503. 
Barriers described by the GPs to access continuing education and advance training 
were the lack of support from the hospital managers and the long distance to training 
centres, while managers believed the problem was the GPs’ lack of motivation and 
interest503. This inadequate asthma knowledge could be ascertained by the mistrust or 
even fear, that some young and inexperienced HCWs in our study expressed towards 
certain asthma drugs (mainly salbutamol), which was based more on beliefs or 
personal experience than on clinical guidelines.  
General practitioners from the UK reported requiring more time and resources to 
receive extra training on asthma384 and CGs wished to be referred to an ‘asthma 
specialist’361,500,501, as did the CGs in our study. It was interesting that only 
inexperienced HCWs in our study brought up the issue of long working hours and high 
demand, with short times available per patient, as availability barriers that hampered 
an adequate patient and CG asthma education. This barrier was also reported by GPs 
and health professionals in secondary care in the UK, a group of HCWs that, similar to 
young doctors working in the emergency department, are frequently time-pressured 
irrespective of the setting384,498.  
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5.7.3. Health and home care access facilitators for asthmatic children 
Acceptability 
An acceptability facilitator that contrasted with what was discussed as barriers to 
health care access for asthmatic children, was that both HCWs and CGs reported that 
some CGs did follow the indications and treatment prescribed by HCWs. This was 
possible because of the trust some CGs had in HCWs and the asthma drugs prescribed, 
and the involvement of the older children in the management of their own asthma.  
Trust in the medication prescribed was one of the facilitators identified in the 
systematic review by Hirmas et al.378. Some caregivers (both from high income and low 
income countries) of asthmatic children also described using the drugs as prescribed 
by HCWs, as they feared their child could worsen if they did not371,500. 
HCWs believed that the CGs in Esmeraldas had the sufficient cultural and educational 
level to be able to understand the information provided and manage their child’s 
asthma adequately, and that existing beliefs and myths could be easily eliminated with 
asthma education sessions. Some of the HCWs interviewed felt affection towards the 
asthmatic children and their family, and even offered their private mobile numbers for 
them to call whenever they needed., showing that they cared for these children. 
Accessibility 
As for the accessibility facilitators, HCWs claimed that all necessary drugs and 
equipment are available at the health care services where they work. The public health 
system in Ecuador has a list of basic medicines that should be available for free at the 
public hospitals. This list includes acute bronchodilators (salbutamol and ipratropium 
bromide), systemic corticosteroids (oral prednisone, intramuscular or intravenous 
dexamethasone or hydrocortisone) and inhaled corticosteroids (budesonide)312. 
However, at the moment there were no inhaled corticosteroids available at the health 
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centres, nor at the public hospital (HDTC), only at the social security hospital (IESS 
hospital), and there were no combined ICS with long acting beta-agonists or 
leukotriene receptor antagonists (LTRA) (montelukast) available for free.  
On the other hand, HCWs claimed that families are normally able to buy the medicines 
needed (if not available for free) and that they tried to help low-resource families who 
could not afford them, in different ways. Reinforcing patient’s access to asthma drugs 
and health care services was one of the facilitators mentioned by general practitioners 
in the UK384.  
The only accessibility facilitator that CGs mentioned in our study was that it was easy 
for the children to obtain days off-school during their asthma attacks and for control 
appointments. Both HCWs and CGs believed that the establishment of a specialised area 
for asthmatic patients, an ‘Asthma Club’, home visits or public health asthma 
programmes would facilitate the accessibility of asthmatic children to health care, 
improving their asthma management. Access to free asthma drugs and to health care 
professionals through an asthma control programme were described as facilitators to 
improve asthma control in children in Brazil386. 
Contact 
In the contact category of facilitators, some of the HCWs found it easy to communicate 
with CGs of asthmatic children, who could be very cooperative on occasions and follow 
the indications given. To make sure CGs did understand the information given on 
asthma, several HCWs in our study reported using alternative methods such as 
drawings, and they expressed that being honest and direct helped in the transmission 
of information to CGs. CGs of asthmatic children in other settings perceived their child’s 
asthma as well-managed and were satisfied with the care received, the drugs 
prescribed or the review appointments367,368,500.  
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Similarly, CGs of asthmatic children in Sweden held in high regard the asthma nurses 
that worked at the outpatient clinics, who they considered knowledgeable, competent 
and able to manage their children’s asthma treatment501. Mothers of children 
hospitalized for asthma in Peru also spoke well of the nurses, both for their medical and 
humane quality372. In this sense, some of the participant CGs in our study reported 
having been treated kindly and adequately by HCWs when attending with their child 
suffering an asthma attack and they expressed gratitude for the guidance and close 
follow-up offered by certain HCWs.  
Building a good patient-provider relationship is essential to improve asthma 
management, and being followed by the same professional who may establish a 
patient-centred approach with a shared decision-making process and who includes the 
child in these conversations, is vital for this367,368,498. However, none of the participants 
in our study discussed the decision-making process, as it is common in this setting to 
apply a more paternalistic, controlling and directed approach by the HCWs who do not 
rely on the CGs’ knowledge and criteria. Additionally, when follow-up by one same 
provider is not possible, special care should be taken at standardisation of prescribed 
treatment and indications given to asthmatic patients, as differing recommendations 
make patients lose faith in the doctors and in there being a clear and consistent plan of 
action, as was mentioned in this study. 
This is an issue that should be discussed and worked with the HCWs, as shared decision 
making has proved to reduce the number of severe asthma exacerbations in children504. 
The improvement of a child’s condition and a sense of team work were two situations 
that made some HCWs in our study feel motivated and happy, a facilitator to improve 
patient-provider relationship and asthma management quality. 
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Availability 
Finally, several availability facilitators were mentioned. CGs in our setting felt 
empowered to manage their child’s asthma and believed that increasing their 
knowledge on asthma would further improve their self-efficacy. To address this, both 
HCWs and CGs exposed several proposals to enhance asthma knowledge for CGs, 
extended family and general population, a proposal also shared by general 
practitioners from the UK384. The desire to increase their asthma knowledge was 
frequently described by CGs of asthmatic children in other qualitative studies363,367,380, 
though some also felt confident in their current asthma knowledge and management 
skills, understood asthma and its medications, and trusted their children in alerting 
them of exacerbation symptoms365,367,368,498.  
Experienced doctors in our study also proposed improving general doctors’ asthma 
knowledge and management, while some young and inexperienced HCWs reported 
feeling motivated to study asthma further. Similarly, general practitioners in the UK 
were willing to attend training sessions to improve their knowledge on all aspects of 
asthma management384. They also suggested increasing the time available for each 
asthmatic child and reviewing patients regularly by the same HCW384, a facilitator that 
was not mentioned by the HCWs interviewed in this study. 
5.7.4. Emergency care re-attendance acute asthma risk assessment tool 
When presented with the risk assessment tool for emergency care re-attendance for 
acute asthma, the first reaction of both HCWs and CGs was quite positive, as they found 
the tool easy to use and understand and quite visual, due to the use of traffic-light 
colours to inform of the risk. They also emphasized the importance of such a tool both 
to facilitate the transmission of information related to future risk to asthmatic 
children’s CGs, and to facilitate the organization of the children’s need of referral to 
specialised doctors and initiation of controller asthma therapy. CGs believed it would 
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make them be more aware of the severity of their child’s disease, and therefore 
increase their adherence to the HCWs indications and prescribed medications. 
Nevertheless, some HCWs and CGs discussed that the use of the tool would not alter the 
CGs’ or HCWs’ attitude towards the child’s asthma management, something that would 
completely defy the aim of such a tool. It may well be that certain HCWs feel reluctant 
to follow guidelines (such as a risk-assessment tool) as it may challenge their position 
of knowledge and authority, a position that was expressed by the experienced HCWs in 
this study. Standardising data capture allows benchmarking between staff and units 
and between staff and gold standards, something that some HCWs may not be willing to 
do. None of the management tools, educational instruments or interventions used in 
medicine are always effective in the totality of patients and HCWs, and still may 
improve the overall outcomes of a specific disease. The same thing may happen with 
the risk assessment tool if it is implemented in the daily practice, as there will always 
be a proportion of HCWs that will not make use of it, some CGs that will not take it 
seriously, and another proportion of HCWs and CGs that will continue the same attitude 
irrespective of the risk assessment tool’s information.  
There are relatively scarce qualitative data on the use of risk assessment tools505. The 
most studied risk assessment tools are the ones analysing fall risk, and in a systematic 
review of qualitative studies analysing factors influencing implementation of fall-
prevention programmes, health care professionals from the US included in three 
different studies had reported not being reimbursed for the time required to complete 
the fall risk assessment and that time restrictions per patient were a barrier for the 
implementation of such a tool506.  
This might not be a problem with the risk assessment tool for subsequent severe 
asthma attacks, as it includes only 4 questions and may be completed in less than 5 
minutes. However, the issue of time availability should always be considered, especially 
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if the tool is to be implemented in emergency rooms where HCWs are normally 
overwhelmed and fully occupied with severely ill patients. This could be maybe 
overcome if the tool was completed by an administrator, as it does not need to be done 
by a HCW.  
Pay-for performance-programmes are designed to assess quality of care by adherence 
to protocols and clinical guidelines for specific diseases and offer economic rewards 
accordingly. Hospitals where pay-for-performance programmes have been introduced 
in the UK have shown an association with a clinically significant reduction in 
mortality507. Similar programmes could improve adherence to risk-assessment tools 
implementation in emergency rooms.   
We have identified several barriers and facilitators for health care access for asthmatic 
children as perceived by HCWs and CGs. However, as discussed in the limitations 
section of this study, all the CGs interviewed had already accessed health care services 
at some point. It would now be interesting to interview CGs of asthmatic children who 
have not accessed such health services, to explore further the perceived barriers that 
may differ in this population of asthmatic children and families. For this, we should first 
identify such families through a cross-sectional household survey. Such a study has 
already been undertaken in certain areas of the city of Esmeraldas and surrounding 
villages by our study team508. 
Similarly, male CGs were underrepresented in the present study, and even though they 
may be a minority of the usual CGs of asthmatic children in this setting, their opinions 
and experiences are still as relevant, as they may influence the attitude of the main 
female caregiver in the house. In-depth semi-structured interviews with fathers and 
5.8. Implications for future studies 
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grandfathers would add relevant data and validity to the information already collected 
and could be analysed with a gender perspective.  
An Ecuadorian study analysing the implications of the feminisation of the medical 
profession, from a gender perspective, found that female doctors who do not have a 
social and economic capital, and that have children, have fewer probabilities of 
reaching the ideal of the Ecuadorian doctor: be recognized and have money509. This 
reality poses the following question: how does feminisation of the medical profession 
affect asthmatic children’s care?  
On the other hand, older children and adolescents influence asthma management at 
home and adherence to indications and medications prescribed. Their relationship with 
the HCW may also alter adherence to appointments. In this sense, it would be desirable 
to undertake focus group discussions to address the same points that were discussed 
with HCWs and CGs, as they are also part of the process studied. 
The impressions and opinions around the risk assessment tool for severe asthma 
attacks recurrence were only based on a hypothetic situation, as it is not being 
currently used in the emergency rooms. Once the tool has been validated and 
implemented in the daily practice, it would be necessary to design a new qualitative 
study to assess the experiences of its implementation, both from the HCWs’ and the 
CGs’ point of view, and desirably from the asthmatic children’s too. 
The numerous barriers to health care access for asthmatic children identified by HCWs 
and CGs highlight the need to undertake research studies assessing interventions that 
may address these barriers. These interventions could be based on the facilitators 
reported in this study, as well as on the proposals from CGs and HCWs.  
Some of these have already been extensively studied, such as the use of written asthma 
action plans or asthma educational interventions that have shown to reduce the 
number of severe asthma exacerbations510,511. Others, such as home visits, the 
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organization of an ‘Asthma Club’ for asthmatic patients and CGs, or the use of media to 
increase the general public’s awareness on asthma are examples of interventions to be 
further studied in this setting.  
Similarly, the establishment of a specialised centre for asthmatic patients with access to 
free medication and regular follow-up has been shown to reduce adult hospitalizations 
for asthma in Salvador, Brazil304. A study of the effect on the patient’s asthma morbidity 
and quality of life, as well as the cost-effectiveness of such an intervention for asthmatic 
children in Esmeraldas would be highly relevant. 
This study has shown that asthma attacks in children are perceived and experienced 
differently by CGs, inexperienced and experienced HCWs, resulting in a distinct 
significance. Experienced HCWs perceive asthma attacks as opportunities to 
demonstrate their experience, and specific knowledge and skills mastery; it is a routine 
aspect of their professional activity; and they are annoyed by the attitude they perceive 
some caregivers to show. On the other hand, for inexperienced HCWs, asthma attacks 
mean fear and self-doubt, while they hope to act correctly, an aspect that is reflected on 
the comprehensive attitude towards the CGs’ fear and anxiety from whom they expect 
cooperation.  Both experienced and inexperienced HCWs need to keep a cool head and 
avoid feelings to distract them from their objective. HCWs and CGs perceive asthma 
attacks as urgent events that need to be overcome, and that it is their responsibility to 
do so. All of them feel responsible for the asthmatic child and are aware of the possible 
complications and risk of death of the event. 
Multiple barriers were identified by CGs and HCWs which limit asthmatic children’s 
access to an adequate health and home care. While some of these barriers refer to 
economic and health service organisational issues, others such as fear of side effects of 
5.9. Conclusion
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medication or ineffective self-management could be overcome through educational 
interventions, both for CGs and HCWs, as was mentioned when discussing facilitators to 
health care access. 
Increasing CGs’ and HCWs’ asthma knowledge as well as HCWs’ communication skills, 
to establish a patient-centred approach with a shared decision-making process could 
mean a difference in the quality of the asthma care in this setting. The use of the 
described recurrent risk assessment tool could proof useful in this process, and it 
would be largely acceptable, as reported by the participants in this study. 
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6. Summary, recommendations and conclusions 
Asthma prevalence in children worldwide is still rising, especially in certain regions of 
Latin America. Despite the development of new asthma drugs and of strategies to 
improve asthma control, such as asthma education, shared decision-making and 
promotion of self-management, severe asthma attacks continue to occur among 
asthmatic children. These attacks lead to increased direct and indirect economic costs, 
loss of lung function in patients, anxiety and panic, risk of complications and even 
death. These consequences do not only affect the asthmatic child, but the whole family 
too. For these reasons, there has been an increased interest in asthma attacks, with 
their inclusion in asthma guidelines to assess future risk in patients, and growing 
research to develop interventions and treatments that may prevent recurrent attacks. 
As an example, current randomized clinical trials for new asthma drugs are now 
assessing severe asthma attacks as one of the outcomes to be studied, together with 
daily asthma symptoms. However, there is still no clarity around predictors of 
recurrent severe asthma attacks to enable the identification of asthmatic patients at 
risk who may require medication or lifestyle alterations. 
In Latin America, asthma is a growing public health problem, not only because of the 
increasing prevalence, but also because of the high level of associated morbidity, when 
compared to other high prevalent countries such as the UK. Reasons for this include 
inadequate asthma management with limited access to specialized care and timely 
diagnosis, low prescription rates for controller medications because of cost or poor 
health care worker training, and poor adherence to long-term controller medications. 
Consequently, asthma is treated as an acute disease, through unscheduled 
appointments or emergency care visits for acute attacks and limited follow-up. This 
6.1 Summary of rationale, objectives and key findings
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combination of factors results in high health care costs, indirect costs for the patient 
and family, and low quality of life for the asthmatic patient. 
To address this problematic situation, we aimed to: 
- Identify the asthmatic children at risk of suffering subsequent severe 
asthma exacerbations requiring emergency care in the City of Esmeraldas, 
Ecuador. 
- Explore the significance and experiences of severe asthma exacerbations in 
children, as well as the perceived barriers and facilitators to health and 
home care access in asthmatic children from both caregivers’ and health 
care workers’ perspectives, in Esmeraldas. 
 
A mixed-methods research approach was adopted to answer these aims: a quantitative 
study to analyse predictors for emergency care re-attendance for acute asthma and a 
qualitative study to explore the caregivers’ and health care workers’ experiences 
regarding acute asthma attacks and its recurrence. The use of both quantitative and 
qualitative methods adds richness to the study findings, as they analyse different 
aspects of the same problem, which in isolation may not be sufficient to improve our 
understanding of the current situation of asthmatic children in this low-resource 
setting. 
The cohort study followed children who had been treated for an episode of 
bronchodilator-responsive wheeze at an emergency room and showed: i) high rates of 
re-attendance (46%) with a severe attack in the following 6 months; and ii) high rates 
of under-diagnosis (only 77% had received a previous doctor’s asthma diagnosis) and 
undertreatment (just 2% were taking inhaled corticosteroids). Several predictors were 
identified using different statistical methods, some of which had not been described 
previously. A higher risk of re-attendance with a severe attack during the next 6 
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months after the initial ER attendance was observed in: younger children (especially 
those aged 5-6 years old); those with a previous doctor’s asthma diagnosis; and those 
who had received systemic corticosteroid courses for acute asthma during the previous 
year. Other predictors were: rural residency, previous doctor’s eczema diagnosis and 
having food or drink triggers. Interestingly, none of the inflammatory markers and lung 
function parameters were useful in identifying children at future risk of severe asthma 
attacks in this setting. This is the first study to analyse predictors of severe asthma 
attack recurrence in a low-resource setting. The novelty of this study relies on the 
children being recruited from the emergency room, often the only place where 
asthmatic children are seen in settings where there is no follow-up or control of 
asthmatic patients. The predictors identified have the potential to be combined into a 
risk-assessment tool to be used in ERs to select high risk asthmatic children that 
require specialised care and long-term treatment. This may prove extremely useful in 
low-resource settings, especially as it does not require the use of expensive and 
unavailable complementary tests. 
The linked qualitative study revealed how caregivers experience severe asthma attacks 
with fear and despair, and how it affects the whole family at different levels (work, 
finance, activities, etc.). The health care worker’s perspective of severe asthma attacks 
varied in relation to their experience, as fear of death and complications disappeared in 
more experienced health care workers who felt more confident and reassured. This 
may affect the way health care workers act towards children with recurrent severe 
asthma attacks. Multiple barriers and scarce facilitators to acceptability, accessibility, 
contact and availability of health care services for asthmatic children were described by 
health care workers and caregivers. Some of them were common to both caregivers and 
health care workers, while others differed completely. Although this is the first study of 
childhood asthma of its kind undertaken among caregivers and health care workers in 
a low-resource setting in tropical America, some of the barriers and facilitators 
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identified have been described also in high-resource settings, a finding that reveals the 
multiculturality and generalizability of certain problems concerning asthma worldwide. 
Finally, there was a general positive opinion and acceptance towards the use of a risk-
assessment tool to inform caregivers and health care workers of the child’s future risk 
of subsequent severe asthma attacks. It was the opinion of some of the caregivers that 
being informed about their child’s risk of recurrence of severe asthma attacks, would 
change their attitude towards their child’s asthma management and enhance their 
adherence to asthma medications and lifestyle alterations. Given that adherence to 
long-term medications is a common barrier to adequate asthma control, an 
intervention that could improve this would proof extremely useful. 
6.2.1 Increasing asthma diagnosis in children 
Under-diagnosis of asthma is a major barrier to adequate control and management in 
Latin America and other low-resource settings 28,512. From the cohort study, we 
ascertained that one third of the children treated at an emergency room for an acute 
episode of bronchodilator responsive wheeze had not received a previous asthma 
diagnosis from a doctor. Even though not all of these children had asthma, most 
probably did, given that 76% had suffered a similar episode requiring emergency care 
during the previous 12 months. 
In the qualitative study, caregivers were concerned that their children had not taken 
any specific tests for their asthma, making them doubt the diagnosis. An uncertain 
diagnosis may reduce adherence to asthma treatment, especially to medication with 
possible side-effects such as inhaled corticosteroids (ICS), and to lifestyle 
modifications500.  This stresses the importance of obtaining an asthma diagnosis from a 
6.2 Recommendations and future directions
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doctor, and the need to avoid some frequently used terms such as ‘early asthma’ or 
‘bronchitis’ when managing children with recurrent severe wheezing episodes. 
Through the qualitative in-depth interviews, we learned that health care workers in 
this setting were reluctant to diagnose asthma in children. One of the reasons for this 
was that they do not have access to specific tests such as spirometry, allergen-specific 
IgE or skin prick tests, to diagnose reversible bronchoconstriction or atopy. Even 
though these are very useful and important tools that may aid and guide a physician in 
the diagnostic process for asthma and in treatment decisions, they are not essential to 
obtain a diagnosis. A comparison of prevalence rates of doctor diagnosis of asthma and 
asthma symptoms indicates that up to 50% of asthma cases may be missed in low 
resource settings513,514. Similarly, primary care doctors’ asthma diagnosis has been 
shown to be highly inaccurate, with 54% of under-diagnosis and 34% of over-
diagnosis515. For this reason, and given the unavailability of spirometers and 
professional training in spirometry, WHO has proposed the use of peak expiratory flow 
(PEF) meters to confirm airflow limitation, by including them in the list of essential 
tools for low-resource settings37,516. The combination of asthma symptoms together 
with PEF measurements before and after a therapeutic trial with ICS and as-needed 
short acting beta-agonists, could enable the confirmation of an asthma diagnosis prior 
to the start of long-term treatment517. This could be easily implemented in primary care 
health services in Esmeraldas, Ecuador, or at least in the Paediatric consultation rooms 
in the public and social security hospital. Nevertheless, a spirometer should still be 
available for children with a more severe asthma, who do not respond to ICS or whose 
asthma diagnosis may be in doubt. The respiratory therapists working in the public and 
social security hospitals in Esmeraldas have been trained to do lung function tests and 
could take responsibility for this procedure. 
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6.2.2 Increasing number of asthmatic children receiving baseline long-term 
treatment and follow-up 
Regular follow-up and long-term baseline treatment for asthma for those in need, are 
the next two key elements to achieve an adequate asthma control. As explained in 
Chapter 2, asthma in many Latin American settings is managed at emergency rooms 
during acute attacks and not as a chronic condition24. This was reflected in the cohort 
study, with only one third of the children visiting a doctor for a regular check-up of 
their asthma at least once during the previous year, and just eight per cent at least on 
four occasions or one appointment every three months. As a result, nearly half of the 
children participating in the study had recurrence of severe asthma exacerbations 
within the first 6 months after the initial emergency care attendance at recruitment. 
The consequences of this inadequate management may be serious for the children, 
affecting lung function14, quality of life330 and educational attainment due to missed 
school-days. 
Health care workers in Esmeraldas did report the lack of follow-up as a current barrier 
to adequate asthma care. Reported explanations were lack of asthma specialists, lack of 
training in asthma management of general doctors, excessive demand (large number of 
asthmatic children) and poor adherence of child caregivers to follow-up appointments. 
Each of these issues are equally relevant and should be dealt with using different 
strategies. 
There is currently no pulmonologist or respiratory specialist in the city of Esmeraldas 
and certainly no paediatric pulmonologist. One strategy could be to employ a 
pulmonologist in the city’s public hospital that may be feasible given the presence of 
other specialists such as a neurosurgeon, dermatologist and cardiologist. The 
contracting of a paediatric pulmonologist would have to be requested at a regional and 
central level in Ecuador and pressure from patients’ and doctors demands in the 
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context of local epidemiological data (such as that provided by the present study) 
would be important lobbying tools. Further, data are now available by disease for 
emergency and hospitals admissions through electronic records that show a high rate 
of presentations in children with respiratory diseases. Another possible need identified 
by health care workers would be to train general doctors and paediatricians in asthma 
management. The paediatricians participating in the in-depth interviews, although 
confident on their asthma knowledge and management of patients, likely require 
additional training on the importance of controller treatment for asthma384, given that 
only 2% of children were taking inhaled corticosteroids at the time of recruitment. This 
way, paediatricians in Esmeraldas would be able to follow-up and manage children 
with mild and moderate asthma or those with a good or partially controlled asthma, 
and only those children not responding to long-term maintenance therapy would 
require referral to a specialist in a tertiary centre in Quito or Guayaquil. Similarly, in 
more rural settings, general doctors could be trained to manage asthma patients with 
non-complicated and easy to treat asthma. These measures would avoid significant 
economic costs to families of asthmatic children and the healthcare system, and missed 
school and work days, associated with referrals to tertiary centres in other cities, an 
important barrier reported by both caregivers and health care workers. 
Nevertheless, for these changes to occur, asthma should be identified as a priority by 
both local and national health authorities, something that is currently not the case. 
Health care workers and caregivers interviewed reported a lack of interest in asthma 
by health authorities resulting in an absence of specific programmes, currently 
available for other chronic diseases such as diabetes or hypertension. There are no 
official national clinical practice guideline or protocols for asthma in Ecuador, 
something that would be of great help for general doctors518. In this sense, non-
communicable diseases are now the major cause of death, even in low and middle-
income countries519, and asthma is the most important chronic disease in children 
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(14% of the world’s children)1. The disability adjusted life years (DALYs) caused by 
asthma are comparable to those of hypertensive heart disease, being the 14th most 
important disorder in terms of extent and duration of disability1. These, together with 
the high asthma prevalence in Esmeraldas, Ecuador, are sufficient reasons for a 
prioritisation of asthma by health authorities. This would enable some important 
organisational changes, such as extending availability of controller medication (ICS) to 
health care centres as is the case now for medications for other chronic diseases. Lack 
of availability of asthma medications in health care centres was another barrier 
reported by health care workers in the present qualitative study. 
There is a limited number of paediatricians in the City of Esmeraldas despite the 
significant burden of asthma disease in children. General doctors working at the 
emergency rooms have neither the time nor training to start children on ICS after 
stabilization for an attack in ERs as expressed in the in-depth interviews. However, not 
all the children treated for a bronchodilator-responsive wheeze at the emergency room 
may merit the initiation of ICS. First, because presenting to the ER in this setting does 
not necessarily indicate a severe attack, given the inability of caregivers to treat even a 
mild asthma exacerbation and a lack of salbutamol inhalers and spacers at home. 
Second, because they may not suffer another asthma exacerbation in the following year, 
according to the recommendations of the Ecuadorian Respiratory Association, children 
with intermittent asthma do not need to start controller treatment146. Third, because 
controller long-term treatments have associated side-effects160-162,341 and costs (see 
Chapter 2). Identifying a group of asthmatic children at high risk of suffering 
subsequent severe asthma attacks among those presenting to the emergency room 
with a bronchodilator-responsive wheeze, would prove very useful at addressing these 
issues. This subgroup of children could be identified using a simple risk-assessment 
tool which includes the predictors analysed in the cohort study. This subgroup of high-
risk children could be then referred to a paediatrician for regular follow-up and to start 
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baseline long-term treatment with ICS. Those at low risk could also be referred to the 
paediatrician or to the general doctor at the health centre for less frequent follow-up. 
Likewise, the demand on the health care system and paediatricians would decrease and 
still, the children most in need would be receiving a regular follow-up and the 
necessary medications. As a result, the child’s quality of life would improve, and the 
direct and indirect costs caused by their asthma would decrease by reducing the 
number of severe asthma attacks requiring emergency care. This will be possible once 
the risk-assessment tool is validated in a future study. In the meantime, children with a 
history of emergency care admissions for acute asthma in the previous year should be 
managed more closely and prescribed ICS. 
The establishment of specific asthma programmes to provide follow-up and treatment 
to adults with severe asthma inside the public health system in Brazil, has been shown 
to be effective in reducing asthma hospitalizations, increasing patient’s quality of life 
and reducing costs for the health care system and families304. A pilot study of a similar 
programme in Esmeraldas, together with the use of the risk-assessment tool for severe 
asthma attack recurrence would be highly informative on the cost-effectiveness of such 
an intervention and would provide the necessary data to implement such a programme 
in the public hospital in Esmeraldas and other cities in Ecuador. 
6.2.3 Enhancing adherence to baseline long-term treatment for asthma and 
follow-up 
Increasing asthma diagnosis, regular follow-up and controller long-term treatment 
prescription would all prove useless if the asthmatic patients or their caregivers do not 
adhere to the medication prescribed. Poor adherence to medication is a constant issue 
affecting around 50% of patients520-522 especially those with chronic diseases. Similar 
adherence rates have been described for asthma - less than 50% in children523 and 30 
to 70% in adults524-526. In the cohort study, we were not able to assess adherence to 
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baseline long-term treatment, given the low initial proportion of children receiving 
controller medication and the absence of data for adherence to the medication 
prescribed during the study. However, both health care workers and caregivers 
identified poor adherence (specially to long-term treatments) as a barrier to adequate 
health care. The reasons reported for poor adherence during the qualitative study were 
multiple and included: cultural background and beliefs, lack of information regarding 
asthma medications and side-effects, preference for natural remedies, fear of side-
effects, and cost and difficulty to attend regular check-ups to obtain more medicines. 
Asthma education programmes for asthmatic patients and/or their caregivers, have 
been shown to reduce severe asthma exacerbations and hospitalizations225,510. 
Caregivers in our setting were willing to receive further information on asthma, to 
increase their knowledge and their self-management skills as they described in the 
focus group discussions (FGD). On the other hand, their asthma knowledge was 
inadequate, and similar to that of a non-asthmatic person487 as shown by findings from 
the Newcastle Asthma Knowledge Score instrument administered during the cohort 
study. Educating asthmatic patients and their families should therefore be a priority in 
this setting, and it could be part of the specific asthma programme proposed above. 
This education could be undertaken privately, during the doctor’s regular follow-up 
visits, as well as through groups sessions and through written information. We should 
highlight also the importance of completing and regularly updating a personalised 
written asthma action plan for each patient, something completely absent in this setting 
and that has been shown to be effective in reducing severe asthma attacks442. 
Improving the caregivers’ asthma knowledge would decrease their fear of side-effects 
from medications, increase their trust in the treatment and relay their cultural 
background and beliefs, increasing adherence. 
However, it is important that health care workers are well trained in asthma 
management before they inform and educate asthmatic patients and their caregivers. 
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They should not only be trained in asthmatic medications, but also in other non-
therapeutic interventions that are recommended for adequate asthma control, such as 
exercise, avoidance of exposure to tobacco smoke and other irritants, healthy 
(Mediterranean style) diet, etc37. The lives of asthmatic children should not be limited 
by their disease as recommended by some health care workers in Esmeraldas in the 
qualitative study. A more holistic approach may be the key for asthmatic patients and 
their caregivers to adhere and trust the recommendations of health care workers365,367, 
as caregivers reported in the qualitative study to prefer natural remedies, and by 
implementing other interventions apart from drugs. A good patient-provider 
relationship, and a patient-centred approach should also be attained, as they increase 
the caregivers’ trust in the health care workers and empower them to take 
responsibility of their child’s asthma improving self-management and 
adherence367,368,498. 
The use of the described severe asthma attack recurrence risk assessment tool, could 
also enhance caregivers of asthmatic children adherence to prescribed treatment, as 
reported in the qualitative study. If patients and caregivers knew their risk score, they 
could maybe help drive the change in treatment prescription and adherence by asking 
for treatment themselves to reduce their risk. Additionally, media (posters, television, 
radio, etc.) could be used to encourage asthmatic patients to get to know which is their 
own risk score. 
The application of a mixture of methods (prospective cohort and interpretative 
qualitative study) enabled the identification of strategies to improve the currently 
inadequate paediatric asthma management in a low resource setting. This thesis 
confirms the high proportion of emergency care re-attendance for acute asthma among 
children presenting to the emergency room for an asthma attack. It also shows how it is 
6.3 Conclusion
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possible to identify those children at a higher risk of suffering subsequent severe 
asthma attacks using simple questions and without the need of complementary tests. 
This could maybe aid the decision-making process regarding asthma follow-up and 
controller treatment prescription in a low resource setting, and may therefore stop the 
revolving door in which these children are found: they are treated at the emergency 
room and then go back to the same high-risk situation (no controller treatment and 
inadequate home management) that leads them back to the emergency room with a 
subsequent asthma attack. As we have seen in the qualitative study, such a tool would 
be possibly acceptable to HCWs and CGs. However, other strategies such as asthma 
education programmes for caregivers and health care workers, close and frequent 
follow-up of asthmatic children and provision of free controller treatment, should all be 
implemented in parallel to increase the effect of the risk stratification provided by the 
risk assessment tool. Further research is now needed to validate and assess the 
effectiveness of the presented risk-assessment tool to allow its implementation into 
daily practice. 
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Appendix A: Supplementary materials for systematic 
review and meta-analysis 
 
(risk OR predic* OR associat* OR probabil*) OR "Risk Factors" 
AND  
(((((asthma) AND hospital admission)) OR ((((asthma AND exacerbation)) OR ((asthma) AND 
"Disease Progression")) OR (asthmatic AND exacerbation)))) OR (asthma AND "Patient 
Readmission") 
AND  
child OR children OR childhood OR pediatr* OR paediatr* 
Supplementary Table 1: Search report Asthma exacerbation risk factors in children 
searches. January 2017  
 
 
1. Search strategy
2. Search report
Search 
No. 
Date Database searched  Hits (before duplicate 
removal) 
1 9/01/2017 Medline (Pubmed)  1835  
2 9/01/2017 Cinahl (EBSCOhost) 353 
4 9/01/2017 PsycInfo (EBSCOhost)  90 
5 9/01/2017 Embase (OVID) 2603 
6 9/01/2017 AMED (EBSCOhost) 3 
7 9/01/2017 WHO clinical trial registry platform 
(WHO ICTRP) 
8 
FINAL NUMBER OF REFERENCES IN ENDNOTE AFTER DELETING DUPLICATES = 3259 
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Appendix B:  Supplementary materials for 
prospective cohort study 
 
Informed Consent Form 
“THE CHILDHOOD ASTHMA RE-ATTENDANCE ASSESSMENT (CARA) STUDY” 
Title of Research: “Emergency care re-attendance for acute childhood asthma in a low-
resource setting: The Childhood Asthma Re-attendance Assessment (CARA) Study “ 
Date: 15 /January /2014 
Organization: “FUNDACIÓN ECUATORIANA PARA INVESTIGACIÓN EN SALUD” and 
PONTIFICIA UNIVERSIDAD CATÓLICA DEL ECUADOR. 
Name of Principal Investigator: Dr. Philip Cooper, Laboratorio de Investigaciones 
FEPIS, Calle A S/N, Barrio Fundo Limon, Nuevo Quinindé, Quinindé, Provincia de 
Esmeraldas, Ecuador. 
Co-investigators: Dra. Cristina Ardura, Dra. Maritza Vaca 
Principal Investigator contact details: Tel: 59362737158.  e-mail: 
pcooper758@puce.edu.ec 
1. Introduction 
We are inviting you and your child to participate in this research where we will study the 
characteristics of asthmatic children with acute attacks of difficulty breathing and 
wheezing requiring emergency care. The purpose of this research is to identify the 
asthmatic children with a greater risk of suffering severe acute asthma attacks.  
Your decision to have your child participate in this study is entirely voluntary. Take as 
much time as you need to take the decision and discuss it with other members of the 
family. This form includes a summary of the research, which we will analyse with you. If 
you decide to have your child to participate, you will receive a copy of this form. You may 
ask ask many questions and request as many explanations as you need to any member 
of the study team about all the different study activities and procedures.  
2. Why are we carrying out this research? 
We are carrying out this research because asthma is the most frequent chronic disease 
in children and we do not have much information regarding the risk of acute asthma 
1. Informed consent form for caregivers of participating children 
(English translation) 
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attacks in children, especially in Latin American cities like Esmeraldas. Understanding a 
child’s risk of suffering future acute asthma attacks will enable us to offer a better 
management and treatment for asthmatic children.  
3. What are the benefits of participating in this study? 
Each participant will receive an individual diagnosis and recommendation according to 
the test results (for example: treatment for intestinal parasites, referral to another 
specialist, lifestyle recommendations, etc.) Each participant will be closely followed-up 
by the study team during his/her participation in the study. If judged necessary, he/she 
will be referred to a specialist doctor.  
Asthmatic patients from Esmeraldas will benefit from this study, as it will make health 
workers aware of the importance of asthma and the large number of patients who suffer 
from this disease. This will hopefully improve asthma management and treatment. 
4. How many children will participate in the study? 
Around 350 asthmatic children between 5-15 years old will participate in this study.  
5. What are the study procedures? 
If agreeing to participate, we will carry out: 
- Three questionnaires: (a) The first one covering general questions about the child 
(personal and family history, home characteristics, etc.), the child’s asthma 
characteristics, and the previous treatment and management received. (b) A 
second one to assess the parent’s or guardian asthma knowledge. (c) A third one 
to study the child’s quality of life. 
 
- Blood sample: A small amount of blood, equal to about a teaspoon will be taken 
from your child's arm to carry out different exams, like: blood cell count and 
identifying allergy makers (total IgE and allergen specific IgE for house dust mite, 
American cockroach and Ascaris). These tests for allergy markers will be carried 
out at the University of Virginia, US, where a small sample of blood will be 
shipped to. Another small sample of this blood will be stored for future genetic 
analyses of genes associated with asthma and allergy.  
 
- Stool sample: To diagnose whether you child has intestinal parasites or not. A 
small simple will be also stored for future studies on intestinal parasites and 
bacteria.  
 
- Lung function: Your child will be asked to blow through a machine to study the 
inflammation present in his airways by measuring a substance called nitric oxide. 
He/she will also be asked to blow through another machine to measure his/her 
lung function, both before and after receiving an inhalation of a drug 
(salbutamol) to expand his/her lungs (a bronchodilator).  
 
- Nasal wash: We will finely spray in each side of the child’s nose a small amount 
(2ml) of a liquid similar to water with a nasal atomization device, while he/she 
is sitting down. We will then collect the liquid that comes back out. A small 
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sample of this liquid will be stored to study the inflammation present in his nose 
at that moment. 
 
6. How long will my participation in the study take? 
We will take the blood sample and nasal wash as soon as your child has been treated 
for his asthma attack and is stable, and you have agreed to participate in the study. You 
may bring the stool simple when it is more convenient for you. We will then set an 
appointment for a visit in two weeks’ time, to carry out the questionnaires and the lung 
tests, and give you your child’s blood and stool results. 
We will then follow-up your child for 6 months, during which we will contact you by 
telephone every 2 months, to ask about any other acute asthma attack your child might 
have had. We will also invite you to contact us (by phone or in person and the study 
office) each time your child needs emergency care for an acute asthma attack (at the 
DTCH or any other place).   
After the 6 months follow-up, we will set another appointment to repeat some of the 
questionnaires and the lung function tests. According to your child’s progress, we will 
recommend a specific treatment, follow-up and we will offer an asthma action plan for 
future acute asthma attacks. The recommended treatment will be that available at the 
DTCH in Esmeraldas through the Minsitry of Public Health.   
If you wish to, your child may continue to be followed-up after the first 6 months, until 
the end of the study (September 2015). In this case, we will continue to contact you by 
phone every 2 months. You will also be able to contact us every time your child has an 
acute asthma attack.  
7. What are the risks of participating in this study? 
A nurse or lab technician will obtain a blood sample from your child’s arm. This is a 
simple procedure that the nurse and lab technician carry out every day. Your child will 
feel some discomfort when the needle stick goes into her/his arm, there may be slight 
bruising and very rarely your child may faint.  
Your child may feel a little discomfort during the nasal wash, with nose itch and watery 
eyes.  
The lung function tests may proof a little but difficult for small children and require the 
child’s cooperation. They do not produce any discomfort. For one of the tests, we need to 
give your child an inhaled rug (salbutamol) to expand the lungs (bronchodilator), the 
same one he/she usually takes for his/her acute asthma attacks. This drug may increase 
the heart rate o cause shakiness in your child. These effects will disappear after 4-6 hours 
maximum.  
The rest are non-invasive procedures with no other associated risks. Some of the 
questions present in the questionnaire may be slightly discomforting to answer, as we may 
require details about the child’s home characteristics and how proper it is. The study team 
will explain to you that all the questions included only seek to study the child’s environmental 
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exposures, in order to better understand the risk factors of acute asthma attacks and to advise 
of possible changes they may make in their homes and lifestyles, as to minimise the child’s risk. 
8. Are my child’s samples and information given confidential? 
Your privacy is very important to us. We will keep all your information absolutely 
confidential and will only be accessed by the health workers involved in the project, and 
not by any other members of your family or neighbours. To protect your child's privacy, 
each questionnaire will be identified by a unique code. The same will happen with all the 
samples, including those sent outside Ecuador, which will not be identified with your 
child’s name, but only the code. Only the project’s researchers will know which code 
belongs to each child. The remaining samples will be kept in the FEPIS laboratory in 
Quinindé and will not be used for other purposes different to those already explained. 
Once the study results are ready, they will be published in scientific journals or presented 
at scientific meetings, without including any names or identifiable information which 
will be kept in absolute confidentiality. The data collected will be entered into a 
computer and handled only by the project’s researchers and study team. 
9. What other options do I have? 
It is very important for you to understand that your and your child’s participation in this 
study is voluntary, so you may decide not to participate. If you accept to participate, you 
may also drop out of the study whenever you wish to. The treatment your child will 
receive at this moment will not depend on your participation in the study. 
10. How much will it cost me to participate in this study? 
Participants will not have to pay for anything. The study researchers will pay for all the 
costs and materials necessary for the study.  
11. Will I be paid to participate in this study? 
Participants will not receive any payment for participating in the study. 
12. What are my rights as a study participant? 
Your participation in this study is voluntary, that is, you may decide not to participate 
and may retire at any time. There will be no negative consequences if you decide not to 
participate or if you drop out before the end of the study. You may discuss with, ask or 
request information to any of the study team members. 
13. Who should I call if I have questions or problems? 
If you have any questions regarding the project, you may contact the study doctor: Dr. 
Cristina Ardura, at the Hospital Delfina Torres de Concha Hospital emergency 
department, or by telephone: 0985021194. If you have any questions regarding the 
informed consent form, you may contact Dr. Arturo Donoso, PUCE Bioethics Committee 
Secretary, by phone: 2991-700 Ext. 1533 or by email: ajdonoso@puce.edu.ec 
14. Informed consent 
I understand the purpose of my child participating in this study, and the risks and 
benefits of doing so. I have been informed of the study procedures and I accept the 
explanations I have received. I consent voluntarily for my child to participate as a 
participant in this study. 
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Parent/guardian Surnames and 
Names______________________________________ 
Child’s Surnames and Names:_________________________________________ 
 
---------------------------------------------------------------------------------------            ------------ 
Mother’s Signature                                                                                         Date 
 
---------------------------------------------------------------------------------------             ------------ 
Father’s Signature                                                                                           Date 
 
---------------------------------------------------------------------------------------             ------------- 
Guardian´s Signature                                                                                       Date 
GUARDIAN’S RELATIONSHIP WITH CHILD:  ____________________________________ 
 
               
Name of Researcher taking the consent __________________________________ 
 
 
---------------------------------------------------------------------------------------              ------------ 
Signature of Researcher taking the consent                           Date 
 
---------------------------------------------------------------------------------------              ------------ 
Signature of a Witness (where applicable)             Date 
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Child Assent Form (7-15 years old) 
“THE CHILDHOOD ASTHMA RE-ATTENDANCE ASSESSMENT (CARA) STUDY” 
Title of Research: “Emergency care re-attendance for acute childhood asthma in a low-
resource setting: The Childhood Asthma Re-attendance Assessment (CARA) Study “ 
Date: 15 /January /2014 
Organization: “FUNDACIÓN ECUATORIANA PARA INVESTIGACIÓN EN SALUD” and 
PONTIFICIA UNIVERSIDAD CATÓLICA DEL ECUADOR. 
Name of Principal Investigator: Dr. Philip Cooper, Laboratorio de Investigaciones FEPIS, 
Calle A S/N, Barrio Fundo Limon, Nuevo Quinindé, Quinindé, Provincia de Esmeraldas, 
Ecuador. 
Co-investigators: Dr. Cristina Ardura, Dr. Maritza Vaca. 
Principal Investigator contact details: Tel: 59362737158.  e-mail: 
pcooper758@puce.edu.ec 
 
1. Introduction 
I am Dr. Cristina Ardura from the Ecuadorian Trust for Health Research (FEPIS) and my job is 
to study asthma in children.  I am going to give you information and invite you to be part of 
a research study. You can choose whether or not you want to participate. We have discussed 
this research with your parent(s)/guardian and they know that we are also asking you for 
your agreement.  
You may discuss anything in this form with your parents or friends. You can decide if you 
want to participate or not after you have talked it over. You do not have to decide now. 
There may be some words you don't understand or things that you want me to explain more 
about. Please ask me to stop at any time and I will take time to explain. 
2. Why are you doing this research and why are you asking me? 
I am doing a study to figure out why some asthmatic children suffer more frequent severe 
acute asthma attacks than others, and how to help these children better. We are asking you 
to take part in the research study because you have come to the emergency department with 
an acute asthma attack today. 
2. Child assent form (for participating children older than 12, English 
translation) 
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3. What is going to happen to me? 
For this research:  
 we will ask some questions about you and your family which may be related to 
asthma  
 we will ask you to bring a small stool sample to check if you have any parasites  
 we will take a small blood sample (equal to about a teaspoon) from your arm to study 
your defence system and if you have allergies  
 we will wash your nose with a small amount of a liquid similar to salty water and 
collect what comes out 
 we will carry out some tests to measure how well your lung is working.  
We will then follow you up during at least 6 months, calling your parents or guardians every 
2 months to ask them about any asthma attack you may have had, and we will ask you to 
come and visit us at the end of the 6 months to repeat some of the questions and the lung 
tests.  
4. Is this bad for me? Will it hurt?  
We don’t think that any big problems will happen to you as part of this study, but you might:  
 feel some discomfort while we take the blood sample,  
 feel a nose itch and watery eyes while we wash your nose, and  
 feel upset if you are not able to carry out the lung tests correctly and have to repeat 
them more than once.  
Also, for one of the lung tests we will give you a medicine to breath, the same you are given 
when you have an asthma attack. This medicine may make you feel a little bit nervous, but 
this effect will disappear after a few hours.  
5. Is there anything good that happens to me? 
During the study we will follow you up and help you and your parents learn how to treat your 
asthma attacks and how to stop them from happening so often. You can feel good about 
helping us to make things better for other children with asthma like you.  
6. Is everybody going to know about this? 
We will keep all your answers and test results private, and will not show them to other 
members of your family or friends.  Only people working on the study will see them.  
7. Can I choose not to be in the research? Can I change my mind? 
You should know that: 
 You do not have to be in this study if you do not want to.  You won’t get into any 
trouble with your parents, the doctors or you teachers if you say no. 
 You may stop being in the study at any time. 
 Your parent(s)/guardian(s) were asked if it is OK for you to be in this study.  Even if 
they say it’s OK, it is still your choice whether or not to take part.   
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8. Who can I talk to or ask questions to? 
You can ask any questions you have, now or later.  If you think of a question later, you or 
your parents can contact me at the Delfina Torres de Concha Hospital emergency 
department, at the study office or by telephone: 0985021194 
9. Certificate of Assent 
Sign this form only if you: 
 have understood what you will be doing for this study, 
 have had all your questions answered, 
 have talked to your parent(s)/legal guardian about this project, and 
 agree to take part in this research 
 
I agree to take part in the research. 
OR 
I do not wish to take part in the research and I have not signed the assent 
below.___________(initialled by child/minor) 
 
Only if child assents: 
 
 
_____________________________________________________________________ 
Your Signature                             Printed Name                                    Date 
 
______________________________________ 
Name of Parent(s) or Legal Guardian(s) 
 
_______________________________________________________________ 
Researcher explaining study 
Signature                                        Printed Name   Date  
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Appendix C: Supplementary materials for qualitative 
study 
 
1.1 In-depth interviews 
Initial Question 
What does the word ‘asthma’ mean to you? 
 
Asthma Attacks Perception 
- What dose a child’s asthma attack mean to you? 
 
- Please tell me about the last time you treated child with an asthma attack  
 
Recurrent Risk Perception 
- What does it mean to you that a child is ‘at risk’ of suffering a new asthma attack? 
 
- Please tell me about the last time you thought about the possibility of a child suffering 
a new asthma attack.  
 
Barriers and facilitators to health and home care access for asthmatic children 
- What do you think about the health and home care that asthmatic children receive?  
 
- Please tell me about the last time you had contact with an asthmatic child’s caregiver.  
 
- What do you expect from an asthmatic child and his/her caregiver when you are 
treating them?  
 
Perception of recurrent asthma attack risk assessment tool use  
- Do you think some people may have a greater risk of suffering an asthma attack? 
Why?  
 
- Do you think there is something you can do to reduce that risk? What things do you 
know do work and what other things have you heard do not work?  
 
- What do you think about this tool?  
 
- How would your attitude towards a child’s asthma change after obtaining the 
information this tool offers?  
 
- Do you think there is anything you could do to reduce a child’s risk of suffering new 
asthma attacks?  
 
- Anything else you would like to say? 
 
1. Interview guide
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1.2 Focus group discussions 
Initial Question 
What does the word ‘asthma’ mean to you? 
 
Asthma Attacks Perception 
- What do your child’s asthma attacks mean to you? 
 
- Please tell me about your child’s last asthma attack  
 
Recurrent Risk Perception 
- What does it mean to you that your child is ‘at risk’ of suffering a new asthma attack?  
 
- Please tell me about the last time you thought about the possibility of your child 
suffering a new asthma attack.  
 
Barriers and facilitators to health and home care access for asthmatic children 
- What do you think about the health and home care that asthmatic children receive?  
 
- Please tell me about the last time you had contact with a health care worker 
concerning your child’s asthma. 
 
- What do you expect from health care workers when you visit them for your child’s 
asthma?  
 
Perception of recurrent asthma attack risk assessment tool use  
- Do you think some people may have a greater risk of suffering an asthma attack? 
Why?  
 
- Do you think there is something you can do to reduce that risk? What things do you 
know do work and what other things have you heard do not work?  
 
- What do you think about this tool?  
 
- How would your attitude towards your child’s asthma change after obtaining the 
information this tool offers?  
 
- Do you think there is anything you could do to reduce your child’s risk of suffering 
new asthma attacks?  
 
- Anything else you would like to say? 
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2.1 In-depth interviews 
INFORMED CONSENT FORM  
 
UNIVERSIDAD INTERNACIONAL DEL ECUADOR 
CLINICAL, HEALTH AND LIFE SCIENCES FACULTY 
SCHOOL OF MEDICINE 
 
INFORMED CONSENT TO PARTICIPATE IN HUMAN BEING 
RESEARCH  
 
TITLE OF RESEARCH:                                  IN-DEPTH INTERVIEWS 
 
“Understanding the significance of acute asthma exacerbations in 
children and adolescents from the caregivers’ and health care 
workers’ perspective, in Esmeraldas, Ecuador: A Qualitative Study 
“ 
  
RESEARCH TEAM  
 
NAME ACADEMIC TITLE INSTITUTION CONTACT DETAILS 
Cristina Ardura 
García MD, MSc, MRes 
Liverpool School of Tropical 
Medicine,  
Tlf: 0997756251 
Email: crisardura@gmail.com 
Philip Cooper PhD Universidad Internacional  de Ecuador 
pcooper@sgul.ac.uk 
Natalia Romero 
Sandoval PhD 
Universidad Internacional  
de Ecuador 
nromero@internacional.edu.ec 
 
I- INTRODUCTION 
We are inviting you to participate in this research where we will study the 
experiences of asthmatic children’s carers and the health care workers, 
regarding the management and treatment of asthma. The purpose of this 
research is to explore the understanding of future risk of asthma attacks, 
and the best way to inform about it.  
Your decision to participate in this study is entirely voluntary. Take as much 
time as you need to take the decision and discuss it with other members 
of the family. This form includes a summary of the research, which we will 
analyse with you. If you decide to have your child to participate, you will 
receive a copy of this form. You may ask as many questions and request 
as many explanations as you need to any member of the study team about 
all the different study activities and procedures.  
 
II- PURPOSE OF THE STUDY 
We are carrying out this research because asthma is the most frequent 
chronic disease in children and we do not have much information regarding 
the experiences and understanding of asthma from the children’s carers 
2. Informed consent form
Appendix C 
 
299 
 
and health care workers’ point of view. In this study we will talk to 
asthmatic children’s carers and health care workers about their 
experiences regarding asthma, including management and treatment, and 
especially looking into the risk of suffering asthma attacks in the future. 
We will invite them to share their knowledge and perception with us so that 
we can find ways of helping them understand the importance of the disease 
and how to minimise their risk of asthma attacks.  
 
III- STUDY PARTICIPANTS 
Around 30-50 adults will participate in this study. 
 
IV- PROCEDURES 
You will take part in an in-depth semi-structured interview, guided by 
me, which will last for 30-60 minutes. 
At the start of the interview I will answer questions about the research 
that you might have. Then we will talk about how your experience 
regarding treatment and communication with families of asthmatic 
children during an acute attack, especially regarding the risk of future 
recurrent asthma attacks. These are the types of questions I will ask. We 
will not ask you to share personal stories or anything that you are not 
comfortable sharing. 
The interview will take place where ever it may suit you best. The entire 
interview will be tape-recorded, but no-one will be identified by name on 
the tape. The tape will be kept in a locked filling cabinet in the study 
office. The information recorded is confidential, and no one else except 
the study team involved in the project will be allowed to listen to the 
tapes.  
 
V- BENEFITS AND RISKS 
V- BENEFITS 
There will be no immediate and direct benefit to you, but your participation 
is likely to help us find out more about how to help asthmatic children and 
their carers understand more about asthma management and future risk 
of asthma attacks.  
 
VI- COSTS AND COMPENSATIONS 
There is a risk that you may feel uncomfortable talking about some of the 
topics. However, we do not wish for this to happen. You must know that 
you do not have to answer any question you feel are too personal or if 
talking about them makes you uncomfortable. 
Participants will not have to pay for anything. The study researchers will 
pay for all the costs and materials necessary for the study. You will not be 
provided with any payment to take part in the research.  
 
VII- PRIVACY AND CONFIDENTIALITY 
Your privacy is very important to us. We will keep all your information 
absolutely confidential and will only be accessed by the study team 
involved in the project, and not by any other members of your family or 
neighbours.  
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Once the study results are ready, they will be published in scientific 
journals or presented at scientific meetings, without including any names 
or identifiable information which will be kept in absolute confidentiality. 
The data collected will be entered into a computer and handled only by the 
project’s study team. 
 
 
VIII- VOLUNTARY PARTICIPATION AND WITHDRAWAL 
It is very important for you to understand that your participation in this 
study is voluntary, so you may decide not to participate. If you accept to 
participate, you may also drop out of the study whenever you wish to. 
There will be no negative consequences if you decide not to participate or 
if you drop out before the end of the interview. 
 
IX- OPTIONS TO QUESTIONS AND ANSWERS 
You may discuss with, ask or request information to any of the study team 
members. 
 
X. ETHICS COMMITTEE CONSULTANT FOR THE STUDY 
 
XI. NAME AND SIGNATURE OF PRINCIPAL INVESTIGATOR FOR THE 
STUDY 
Cristina Ardura Garcia  
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INFORMED CONSENT 
The study: “Understanding the significance of acute asthma 
exacerbations in children and adolescents from the caregivers’ and 
health care workers’ perspective, in Esmeraldas, Ecuador: A 
Qualitative Study“ has been explained to me. I understand the 
purpose of me participating in this study, and the risks and benefits of 
doing so. I have been informed of the study procedures and I accept 
the explanations I have received. I consent voluntarily to participate 
as a participant in this study. 
 
I_____________________________________________________
______________,  wish to participate voluntarily in this study and I 
give my authorisation to Universidad Internacional de Ecuador to use 
my information given  for the described purposes in the informed 
consent form. By signing this informed consent form I do not renounce 
any of my legal rights.  
 
 
 
____________________ ________________ 
Name of participant /Tutor                 Signature of participant /Tutor 
Date (Place, day/month/year) ____________________________ 
I confirm that the information give in this informed consent form was 
clearly explained and understood by the participant or tutor. The 
participant or tutor agree to participate voluntarily in this research 
study.  
 
 
 
____________________                                _________________ 
Name of Witness                                            Signature of witness 
Date (Place, day/month/year) ____________________________ 
 
 
 
 
____________________ ________________ 
Name of Researcher                                  Signature of researcher 
Date (Place, day/month/year) ____________________________ 
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2.2 Focus group discussions 
INFORMED CONSENT FORM  
 
UNIVERSIDAD INTERNACIONAL DEL ECUADOR 
CLINICAL, HEALTH AND LIFE SCIENCES FACULTY 
SCHOOL OF MEDICINE 
 
INFORMED CONSENT TO PARTICIPATE IN HUMAN BEING 
RESEARCH  
 
TITLE OF RESEARCH:                       FOCUS GROUP DISCUSSIONS 
 
“Understanding the significance of acute asthma exacerbations in 
children and adolescents from the caregivers’ and health care 
workers’ perspective, in Esmeraldas, Ecuador: A Qualitative Study 
“ 
  
RESEARCH TEAM  
 
NAME ACADEMIC TITLE INSTITUTION CONTACT DETAILS 
Cristina Ardura 
García MD, MSc, MRes 
Liverpool School of Tropical 
Medicine,  
Tlf: 0997756251 
Email: crisardura@gmail.com 
Philip Cooper PhD Universidad Internacional  de Ecuador 
pcooper@sgul.ac.uk 
Natalia Romero 
Sandoval PhD 
Universidad Internacional  
de Ecuador 
nromero@internacional.edu.ec 
 
X- INTRODUCTION 
We are inviting you to participate in this research where we will study the 
experiences of asthmatic children’s carers and the health care workers, 
regarding the management and treatment of asthma. The purpose of this 
research is to explore the understanding of future risk of asthma attacks, 
and the best way to inform about it.  
Your decision to participate in this study is entirely voluntary. Take as much 
time as you need to take the decision and discuss it with other members 
of the family. This form includes a summary of the research, which we will 
analyse with you. If you decide to have your child to participate, you will 
receive a copy of this form. You may ask as many questions and request 
as many explanations as you need to any member of the study team about 
all the different study activities and procedures.  
 
XI- PURPOSE OF THE STUDY 
We are carrying out this research because asthma is the most frequent 
chronic disease in children and we do not have much information regarding 
the experiences and understanding of asthma from the children’s carers 
and health care workers’ point of view. In this study we will talk to 
asthmatic children’s carers and health care workers about their 
experiences regarding asthma, including management and treatment, and 
especially looking into the risk of suffering asthma attacks in the future. 
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We will invite them to share their knowledge and perception with us so that 
we can find ways of helping them understand the importance of the disease 
and how to minimise their risk of asthma attacks.  
 
XII- STUDY PARTICIPANTS 
Around 30-50 adults will participate in this study. 
 
XIII- PROCEDURES 
You will take part in a discussion with 4-7 other participants. This 
discussion will be guided by me. 
The group discussion will start with me making sure that the participants 
are comfortable. I will also answer questions about the research that you 
might have. Then I will ask questions about asthma. We will talk about 
your experience regarding asthma, your beliefs and concerns relating to 
your risk of suffering an asthma attack. These are the types of questions 
we will ask. We will not ask you to share personal stories or anything that 
you/they are not comfortable sharing. 
The discussion will take place at the study office, and no one else but the 
people who take part in the discussion and I will be present during this 
discussion. The entire discussion will be recorded, but no-one will be 
identified by name on the tape. The digital recording will be kept in a 
locked filling cabinet and the digital file will be saved to a password-
protected computer. The information recorded is confidential, and no one 
else except the study team involved in the project will be allowed to 
listen to the recordings.  
 
V- BENEFITS AND RISKS 
I- BENEFITS 
There will be no immediate and direct benefit to you, but your participation 
is likely to help us find out more about how to help asthmatic children and 
their carers understand more about asthma management and future risk 
of asthma attacks.  
 
II- COSTS AND COMPENSATIONS 
There is a risk that you may feel uncomfortable talking about some of the 
topics. However, we do not wish for this to happen. You must know that 
you do not have to answer any question you feel are too personal or if 
talking about them makes you uncomfortable. 
Participants will not have to pay for anything. The study researchers will 
pay for all the costs and materials necessary for the study. You will not be 
provided with any payment to take part in the research. However, a light 
lunch will be provided for all the participants, as well as a small stipend to 
cover travel expense if needed. 
 
III- PRIVACY AND CONFIDENTIALITY 
Your privacy is very important to us. We will keep all your information 
absolutely confidential and will only be accessed by the study team 
involved in the project, and not by any other members of your family or 
neighbours.  
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We will ask you and others in the group not to talk to people outside the 
group about what was said in the group. We will, in other words, ask each 
participant to keep what was said in the group confidential. You should 
know, however, that we cannot stop or prevent participants who were in 
the group from sharing things that should be confidential. 
Once the study results are ready, they will be published in scientific 
journals or presented at scientific meetings, without including any names 
or identifiable information which will be kept in absolute confidentiality. 
The data collected will be entered into a computer and handled only by the 
project’s study team. 
 
 
IV- VOLUNTARY PARTICIPATION AND WITHDRAWAL 
It is very important for you to understand that your participation in this 
study is voluntary, so you may decide not to participate. If you accept to 
participate, you may also drop out of the study whenever you wish to. 
There will be no negative consequences if you decide not to participate or 
if you drop out before the end of the discussion. 
 
V- OPTIONS TO QUESTIONS AND ANSWERS 
You may discuss with, ask or request information to any of the study team 
members. 
 
X. ETHICS COMMITTEE CONSULTANT FOR THE STUDY 
 
 
XI. NAME AND SIGNATURE OF PRINCIPAL INVESTIGATOR FOR THE 
STUDY 
Cristina Ardura Garcia  
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INFORMED CONSENT 
The study: “Understanding the significance of acute asthma 
exacerbations in children and adolescents from the caregivers’ and 
health care workers’ perspective, in Esmeraldas, Ecuador: A 
Qualitative Study“ has been explained to me. I understand the 
purpose of my child participating in this study, and the risks and 
benefits of doing so. I have been informed of the study procedures 
and I accept the explanations I have received. I consent voluntarily 
for my child to participate as a participant in this study. 
 
I_____________________________________________________
______________,  wish to participate voluntarily in this study and I 
give my authorisation to Universidad Internacional de Ecuador to use 
my information given  for the described purposes in the informed 
consent form. By signing this informed consent form I do not renounce 
any of my legal rights.  
 
 
 
 
____________________ ________________ 
Name of participant /Tutor                 Signature of participant /Tutor 
Date (Place, day/month/year) ____________________________ 
I confirm that the information give in this informed consent form was 
clearly explained and understood by the participant or tutor. The 
participant or tutor agree to participate voluntarily in this research 
study.  
 
 
 
____________________                                _________________ 
Name of Witness                                            Signature of witness 
Date (Place, day/month/year) ____________________________ 
 
 
 
 
____________________ ________________ 
Name of Researcher                                   Signature of researcher 
Date (Place, day/month/year) ____________________________ 
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